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Abstract 
Dementia is a significant global health problem and has become a leading cause of 
morbidity and a functional decline in elderly people. This syndrome comes together with 
the behavioural and psychological symptoms of dementia, (BPSD), which more than half 
of people with dementia tend to encounter behavioural disturbances at any one point 
during the course of the disease, leading to several problems for those patients, caregivers, 
family members as well as healthcare systems. Due to a controversy of the management 
of BPSD at this time, it results in a variety of treatment options for BPSD sufferers. 
Currently, an economic evaluation of atypical antipsychotic drug use for behaviourally 
disturbed patients with dementia is not well explored. As a result, it is important to 
address this lack of knowledge as well as the paucity of economic evaluation studies 
associated with the cost-utility of atypical antipsychotics for the treatment of dementia 
patients.  
This thesis aims to use the cost-utility analysis to assess the economic impact of 
olanzapine compared with risperidone, for patients with BPSD in Thailand.  
The main stages applied for this analysis are as follows: firstly, the scope of the health 
economic evaluation was defined. Secondly, the models were developed in different 
schemes and justified the most appropriate model to apply for evaluating the treatment 
with olanzapine in comparison to risperidone, for patients with BPSD within a Thai 
setting. Then, the estimated monthly costs and utility weights of patients with BPSD and 
receiving olanzapine or risperidone were calculated from the primary data collected from 
two hospitals in Thailand. Finally, the cost-utility analysis of atypical antipsychotics for 
the treatment of patients with BPSD in Thailand was conducted from a societal 
perspective, over a five-year time horizon using a one-month cycle length.  
The results suggest olanzapine is more cost-effective than risperidone, in the treatment of 
a patient with BPSD from a societal perspective (ICER< THB 160,000).  
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Chapter 1: Introduction 
The introductory chapter outlines the following: 
• The background information associated with the situation of ageing populations 
both worldwide and in Thailand;  
• The situation of dementia, including cost-associated dementia, both worldwide 
and in Thailand;  
• Origins of the study;  
• The rationale of the study, research questions and research contributions; and   
• An overview of the structure of the thesis.  
 
1.1 Overview 
1.1.1 Ageing in Thailand and Worldwide  
Today the growth of ageing populations continues rapidly in many parts of the world. In 
2015, the prevalence of elderly people aged 65 and over was more than 8.5% of the 
world’s population. The percentage gender mix of these populations was predominately 
female compared with male and were associated with 9.5% and 7.5% of the world’s 
population respectively. By 2050, the forecast population of global elderly people will be 
more than 21% in 94 countries (He, Goodkind and Kowal 2016). The number of elderly 
people is estimated to be 1.56 billion, equivalent to 16.7% of the total population 
worldwide, (18.5% females and 14.9% males), by 2050 (U.S. Census Bureau 2013).  
In Asia, there were approximately 341 million people aged 65 and over in 2015 and the 
numbers of elderly people is expected to be 634 million by 2050 (He, Goodkind and 
Kowal 2016). This is a significant region having a major impact on the total number of 
elderly people worldwide (U.S. Census Bureau 2013, He, Goodkind and Kowal 2016).  
The current situation in Thailand shows the elderly population aged 60 and above has 
rapidly increased from 6.8% in 1994 to 14.9% in 2014 (National Statistical Office of 
Thailand 2014). In 2010, the percentage of people aged 60 years and over was 13.18% of 
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the total of the Thai population. This group is expected to increase by approximately 
5.94% by 2020, 13.38% by 2030 and 18.95% by 2040. It is especially noticeable that a 
greater proportion of the elderly people are female rather than male. In 2010 the gender 
mix was 55.1% females compared to 44.9% being males and these percentages are likely 
to remain the same over the next 10 years. Looking at the age ranges by 2040, elderly 
people aged 70-79 years and 80 years and older are predicted to rise, whereas the reverse 
is expected in people aged 60-69 years (Office of the National Economic and Social 
Development Board of Thailand 2013). Between 2010 and 2040, the trend of living 
habits, (way of life), of elderly Thai people is also changing from living in rural areas to 
urban areas and is expected to increase by nearly 20% by 2040 when compared to 2010 
(Office of the National Economic and Social Development Board of Thailand 2013, 
National Statistical Office of Thailand 2014). Furthermore, the National Statistical Office 
of Thailand (2014) reported that 18.8% of elderly people were living with their spouse, 
followed by 8.7% living alone in 2014. The major income sources of this group of people 
were 36.7% from their children, 33.9% from their earnings and 14.8% from the elderly 
allowance from the government. The increasing dependence in activities of daily living 
(ADL) of elderly people had progressively increased from 10.7% in 1994 to 22.3% in 
2014 and those were classified by ADL, into 79.5% of well status, 19.9% of home-bound 
status and 1.5% of bed-bound status (National Statistical Office of Thailand 2014). In 
addition, the estimated percentage of dependency in ADL of Thai older individuals will 
tend to increase from 26.23% in 2017 to 54.95% in 2037 (Bureau of Policy and Strategy 
of the Ministry of Public Health of Thailand 2016). Interestingly, the demographic 
transition of Thailand’s population is highlighted as being a completely aged society in 
2021 and a super-aged society within the next 20 years (Office of the National Economic 
and Social Development Board 2002, Office of the National Economic and Social 
Development Board 2011, National Statistical Office of Thailand 2014).  
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1.1.2 Dementia 
Currently, several components, such as health care services, medical technologies, 
pharmaceuticals, and other factors have been developed to enhance the longevity of the 
global population, leading to an increase in the numbers of ageing populations. In spite of 
that, the Non-Communicable Disease (NCDs) has increased and became a significant 
burden and has a substantial impact on several countries worldwide. Several studies 
reported that almost 42% of deaths in the global population are associated with NCD 
conditions (Lozano et al. 2012, GBD 2015 Mortality and Causes of Death Collaborators 
2016). Additionally, the Global Burden of Disease 2015 suggested approximately 72%, 
(39.2 to 40.5 million), of all global deaths, had been caused by NCDs since 2005 (GBD 
2015 Mortality and Causes of Death Collaborators 2016).  
Dementia is one of the significant NCDs in elderly people and it is devastating in many 
countries worldwide. This is a syndrome or a set of related symptoms associated with a 
decline of cognitive abilities or brain functioning. Alzheimer’s disease is classified as the 
most common form of dementia, but unfortunately the cause of this disease cannot be 
explained with any certainty (Chertkow et al. 2013, Alzheimer’s Association 2019, 
Alzheimer’s society 2019, NHS 2019). Vascular dementia, dementia with Lewy bodies 
and frontotemporal dementia are other examples of types of dementia, while mixed 
pathologies of dementia are more common than just one type (Jellinger 2006, World 
Health Organization 2012, Alzheimer’s Association 2019). However, all types of 
dementia are associated with loss of memory, a deficit in cognition and behavioural 
disturbances as the disease progresses. Thus, this means people with dementia are likely 
to develop more severe symptoms over time, according to the disease progression 
(Lawlor 2002, Knapp and Prince 2007).  
Based on the UN population statistics in 2001, experts estimated that more than 24 
million people aged 60 years and over had dementia (Ferri et al. 2005). In 2010, WHO 
reported that there were about 35.6 million patients with dementia, and the number of 
people with this disorder globally will double every 20 years, suggesting that there will be 
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65.7 million and 115.4 million by 2030 and 2050, respectively. A new case of people with 
dementia was recorded to occur on average every 4 seconds worldwide and globally new 
cases were predicted to be nearly 8 million on average each year (World Health 
Organization 2012). The figures for people with dementia in low and middle-income 
countries, (LMIC), were higher compared with their counterparts who live in the high-
income countries (Ferri et al. 2005, World Health Organization 2012). However, the 
increase in people with dementia was driven by the population growth and the population 
age of each country. The Global Burden of Disease 2015 also suggested that the 
neurological disorder situation had been rising to over 35% of all global deaths since 
2005. Notably, Alzheimer’s disease and other dementias were found to account for 
approximately 38.2% of global deaths between 2005 and 2015 (GBD 2015 Mortality and 
Causes of Death Collaborators 2016). Furthermore, an estimated survival time from onset 
was calculated at 4.6 years for people with dementia, whereas people with Alzheimer’s 
disease were predicted at 7.1 years (Fitzpatrick et al. 2005, World Health Organization 
2012).  
In Thailand, the prevalence of Thai people with dementia was 2.4% of people aged 45 
and over (Wangtongkum et al. 2008) and 3.3%- 8.1% of people aged 60 years and over 
(Jitapunkul et al. 2001, Jitapunkul, Chansirikanjana and Thamarpirat 2009, Aekphakorn et 
al. 2016). Alzheimer’s disease and vascular dementia were also reported as the two 
commonest sub-types of dementia in Thailand, accounting for 75% and 12.5% 
respectively, in adults aged 45 and over in Chiang Mai province (Wangtongkum et al. 
2008). In addition, based on Alzheimer’s disease and Related Disorder Association 
(ARDA), the number of people with dementia was estimated at 0.6 million in 2015 and 
this tendency will double by 2030. Then the number of people living with dementia in 
Thailand are projected to be 1.12 million in 2030 and 2.1 million in 2050 (Alzheimer’s 
Disease International and Alzheimer’s Australia 2014). Focusing on age groups, the 
highest percentage of elderly adults with dementia in Thailand was found in people aged 
80 years and over, accounting for 22.6%, followed by 8.0% in people aged between 70 
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and 79 years old and 4.8% in people aged 60-69 years (Aekphakorn et al. 2016). There is 
a tendency of levels of dementia to be higher in females than males (Aekphakorn et al. 
2009, Aekphakorn et al. 2016). However, the prevalence of undiagnosed dementia in 
Thailand was nearly 3-times as high when compared with Canada (Sternberg, Wolfson 
and Baumgarten 2000, Jitapunkul, Chansirikanjana and Thamarpirat 2009). In 2013, a 
retrospective study at Srinagarind Medical School, at the Srinagarind University hospital 
in Thailand, reported that 53.85% of atypical presentation and 46.15% of typical 
presentation of elderly patients with dementia attended the emergency department (ED). 
Thus, a significant factor of ED visits by the elderly are associated with the atypical 
presentation of dementia (Limpawatana et al. 2016). Based on a diagnosis by the 10th 
revision of the International Statistical Classification of Diseases and Related Health 
Problems, (ICD-10), in 2010, the rate of illness of inpatients with dementia in Thailand 
was 14.65 per 100,000 population, (9,403 people), (Strategy and Planning Division of the 
Ministry of Public Health 2011). In 2015, the rate of inpatients with dementia increased to 
16.41 per 100,000 population, (10,671 people). The predominance of inpatients having 
dementia also showed more females than males, (1.27 to 1 ratio), (Strategy and Planning 
Division of the Ministry of Public Health 2016). Additionally, dementia has increased as 
a cause in the death rate in the Thai population year on year. During the period 2012-
2016, the mortality rates of mental and behavioural disorders, including dementia, had 
continued to grow and accounted for 1.3 per 100,000 population in 2012, 1.4 per 100,000 
population in 2013, 1.6 per 100,000 population in 2014, 1.9 per 100,000 population in 
2015 and 2.1 per 100,000 population in 2016 (Strategy and Planning Division of the 
Ministry of Public Health 2016). Considering the outpatient identified with dementia in 
Thailand, the rate of diagnosis of people with mental and behavioural disorders, excluding 
Bangkok, was 37.64 per 1,000 of the population in 2005. However, the figure had almost 
doubled to 72.09 per 1,000 population in 2015 (Strategy and Planning Division of the 
Ministry of Public Health 2011, Strategy and Planning Division of the Ministry of Public 
Health 2016). In fact, the current situation regarding dementia in the Thai population is 
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likely to increase continuously, along with Thai society becoming an aged society 
(Senanarong et al. 2013). This will lead to a variety of problems for the healthcare 
systems in Thailand.  
1.1.3 The burden of Dementia in Thailand and Worldwide   
From a socioeconomic perspective, dementia is a significant factor affecting elderly 
people. Global costs were approximately $605 billion to society in 2010 (World Health 
Organization 2012). Based on the Global Burden of Disease, dementia was classed as 
ninth in the top ten rankings leading to disability-adjusted life year (DALY) burden in 
2010, accounting for 10 million DALYs (Prince et al. 2015). In 2010, the worldwide costs 
of dementia were the highest category in the social costs, followed by informal care costs 
and then direct medical costs. The total global informal care costs had increased from 
$252 billion in 2010 to $331 billion in 2015. Medical costs also showed significant 
changes, increasing by 3.5% from 2010 to 2015 (Prince et al. 2015).  
In Thailand, the major cost for persons with dementia was informal care, estimated at 
$854 million in 2015. There were $721 million of non-medical costs and $89 million of 
medical costs for this group of people. These costs were estimated from the 600,000 
people with dementia in 2015 (Alzheimer’s Disease International and Alzheimer’s 
Australia 2014).  
In conclusion, the situation of people with dementia globally along with those in Thailand 
is on an upward trend leading to several serious problems, such as substantially greater 
costs and caregiver burden, which significantly affects the patients, caregivers and 
families as well as healthcare systems.  
1.1.4 Origins of the study  
In people with dementia, behavioural and psychological symptoms of dementia (BPSD), 
behavioural disturbances or neuropsychiatric symptoms (NPS) are the most common 
conditions occurring as the disease progresses. Some studies also reported that the 
prevalence of behavioural disturbances in people with dementia was nearly four times 
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higher than people without dementia (Lyketsos et al. 2000, Lyketsos et al. 2002). 
However, comparing between the sub-types of dementia, there were modest noticeable 
differences in behavioural disturbances in people with Alzheimer’s disease and people 
with vascular dementia (Lyketsos et al. 2002). In addition, BPSD can be characterised 
into four main groups: mood disorders, sleep disorders, psychotic symptoms and agitation 
(Desai, Schwartz and Grossberg 2012), and those symptoms may also manifest in 
wandering, aggression, agitation, anxiety, depression, sleep disturbance, hallucinations 
and delusions (Finkel et al. 1996, Olin et al. 2002 and Feast et al. 2016). From the onset 
of cognitive symptoms, approximately 50-90% of people with dementia presented at least 
one symptom of behavioural disturbances at any one point in time (Lawlor 2002, 
Lyketsos et al. 2002, Angelini et al. 2007, Haibo et al. 2013, NSW 2013, Feast et al. 
2016). Furthermore, there were several studies which reported that apathy, agitation, 
depression, and anxiety were the commonest symptoms in people with dementia (Mega et 
al. 1996, Lyketsos et al. 2000, Lyketsos et al. 2002).  
In Thailand, a study showed 97.5% of Alzheimer-type dementia patients presenting 
neuropsychiatric symptoms (Phanasathit et al. 2010). The most frequent BPSD traits in 
Thai dementia patients were apathy, (71.0 %), aberrant motor behaviour, (61.3 %), sleep 
disturbances, (56.5 %), eating abnormalities, (51.6 %), and agitation/aggression, (45.2 %) 
(Charernboon and Phanasatit 2014).  
For the management of BPSD, both non-pharmacological and pharmacological 
interventions are currently applied. In general, non-pharmacological treatments are 
recommended as being the first-line approach for treating patients with BPSD. The 
pharmacological approach is only initiated when the first-line approach is not successful. 
However, an integrated treatment of both approaches is suggested for better management 
of BPSD (Azermai et al. 2012, Cerejeira, Lagarto and Mukaetova-Ladinska 2012).  
At present, there are various types of medications used for the management of 
complicated BPSD. The most common pharmacological treatments are antipsychotics, 
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antidepressants, mood stabilizers, benzodiazepines, as well as cognitive enhancers 
(Andrade and Radhakrishnan 2009, Tampi et al. 2011, Cerejeira, Lagarto and Mukaetova-
Ladinska 2012 and Azermai et al. 2012). Nevertheless, in general, antipsychotic drugs 
have been routinely prescribed for BPSD patients more than any other drug class 
(Andrade and Radhakrishnan 2009).  
In 2005, the U.S. Food and Drug Administration (US-FDA) launched an awareness 
programme for atypical antipsychotics1, (AAs), use among the elderly, due to a 1.7 
increase in the incidence of all-cause mortality risk (U.S. Food and Drug Administration 
2005). In 2008, the FDA also increased the warning to typical antipsychotics2 (U.S. Food 
and Drug Administration 2008). 
Accordingly, the trend of prescribing antipsychotics for the elderly dropped from 2.3% in 
2003 to 1.8% in 2011; however, the rate of prescribing atypical antipsychotics is 
reversing, with an escalation from 0.37% to 0.64% over the same period (Gallini et al. 
2014). Although there are the safety warnings of atypical antipsychotic use, these drugs 
are still commonly administrated to patients with BPSD (Chiabrando et al. 2010).  
To date, there are no available treatments approved by the US-FDA for people with 
BPSD, leading to controversial recommendations for the treatment of patients with BPSD 
in each country (Desai, Schwartz and Grossberg 2012). In general practice, physicians 
tend to prescribe antipsychotic drugs as the first-choice therapy for people with BPSD, 
albeit these drugs are off-label use to those patients. Generally, even if the newer 
                                                            
1 Atypical antipsychotics are also called second-generation antipsychotics, and neuroleptic drugs such as 
clozapine, amisulpride, aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, and risperidone 
(Meltzer, Matsubara and Lee 1989, Meltzer 2013, The Government of the United Kingdom (2005). 
 
2 Typical antipsychotics are also known as conventional, classical or first-generation antipsychotics such as 
chlorpromazine, haloperidol, flupentixol, prochlorperazine, sulpiride and trifluoperazine (Meltzer, 
Matsubara and Lee 1989, Meltzer 2013, The Government of the United Kingdom (2005). 
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antipsychotics, (atypical antipsychotics), are costlier than the older antipsychotic drugs, 
(typical antipsychotics), atypical antipsychotic drugs are likely to be more frequently used 
for the treatment of BPSD relative to the other ones. The reason is that atypical 
antipsychotics account for superior efficacy and with inferior adverse effects, especially 
to extrapyramidal symptoms, (EPSs), namely acute dyskinesia or dystonic reactions, 
tardive dyskinesia, Parkinsonism, neuroleptic malignant syndrome, akinesia, and 
akathisia, in the geriatric population (Blair and Dauner 1992, Lawlor 2002, Andrade and 
Radhakrishnan 2009).  
While a variety of atypical antipsychotic options for patients with BPSD are available in 
clinical practice, differences amongst these drugs are not well defined. Consequently, the 
cost-effectiveness of atypical antipsychotics for the treatment of those patients is a 
significantly critical issue that needs to be researched. The exploration of which drug is 
more cost-effective will indicate the best possible effective intervention for the treatment 
of BPSD patients and decrease the caregiver burden in providing care to those patients, as 
well as providing data to support policy-makers and healthcare system managers, and 
improving the QoLs of both patients and their caregivers. 
 
1.2 The rationale of the study 
It is estimated that 80% of the world’s elderly population by 2050 will live in less-
developed countries. Most middle-income countries are predicted to have double the 
numbers of older people by 2050 (United Nations 2017). Similarly, the characteristic of 
the Thai population had turned into an ageing society since 2005 and within the next 20 
years is predicted to be a super-aged society. Thus, ailments in the elderly, particularly 
dementia, will grow significantly, leading to problems across both the formal and 
informal health care systems in Thailand as well as worldwide.  
Behavioural and psychological symptoms of dementia are significantly coincident 
conditions, occurring in people with dementia. These symptoms are overwhelming not 
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only for the people who suffer from it, but also for their caregivers and families. They are 
also major causes of disability, mortality, long-term hospital stays, caregiver’s distress, 
productivity losses of their families or caregivers for patient care, and the quality of life of 
both patients and caregivers (Fauth and Gibbons 2014, Feast et al. 2016).  
Again, the guidelines of the management of BPSD have currently been under debate, 
leading to difficulties in developing clinical practices. Under the controversy of 
pharmacological approaches, atypical antipsychotics are frequently prescribed for BPSD 
patients, although the adverse effects and safety issues have been raised as genuine 
concerns.  
There are several reasons for undertaking this study as follows: firstly, there are several 
studies focusing on health economic evaluations for other dementia drug groups, namely 
cholinesterase inhibitors and memantine, for the treatment of dementia. There are also 
several studies of the cost-effectiveness analysis on atypical antipsychotics for treating 
schizophrenia. However, there is a paucity of studies focusing on atypical antipsychotics 
for patients with BPSD. A pharmacoeconomic study on this topic is then a significant 
necessity. To the researcher’s best knowledge, this will be the first study to explore and 
evaluate the cost-effectiveness of atypical antipsychotics in the comparison between 
olanzapine and risperidone, for the treatment of patients with BPSD, specifically in 
Thailand or Asia in general. Secondly, the increase in people with dementia year on year 
leads to a growth in the financial burden, (medical care costs, informal care costs, and 
societal costs), mainly affecting patients, caregivers, as well as healthcare systems. The 
study by Prince at el. (2015) reported that the average dementia-associated cost was 
higher than other chronic conditions, including depression, hypertension, diabetes, 
ischemic heart disease, stroke, and chronic obstructive pulmonary disease. Consequently, 
the burden of dementia, including BPSD, is inevitably a significant issue to healthcare 
systems across many countries, along with Thailand. Thirdly, there are variations in the 
prescription of atypical antipsychotics found in people with behavioural disturbances in 
Thailand. Risperidone is one of the atypical antipsychotics which is frequently prescribed 
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for those people because the drug is accommodated in the National List of Essential 
Drugs, (NLED), in Thailand as a reimbursable medicine (Rapeepatchai and Promma 
2015). On the other hand, olanzapine is a newer atypical antipsychotic drug compared 
with risperidone and is also commonly used in people with BPSD (Chanthawong et al. 
2012). However, olanzapine is more costly and is not provided in the NLED of Thailand. 
Thus, patients with BPSD have to pay for that drug treatment as out-of-pocket expenses, 
leading to restricted patient access to the treatment and their ability to receive the most 
suitable medication. Accordingly, the medical cost is a significant factor threatening the 
cost burden and decision making of the treatment to patients with BPSD, their caregivers, 
staff, and healthcare systems.  
 
1.3 Research Question and Objectives 
1.3.1 Research Question 
The main research question sets out to address:  
What is the cost-effectiveness of olanzapine relative to risperidone for the treatment of 
behavioural and psychological symptoms in patients with dementia in Thailand? 
1.3.2 Aim and objectives  
The overall aim of this study is to apply a cost-utility analysis to assess the economic 
impact of olanzapine in comparison to risperidone, for the treatment of behavioural and 
psychological symptoms in patients with dementia in Thailand. 
The specific objectives of the research focus on three main sections as follows:  
1. To use a decision-analytical model for assessing the costs and outcomes of 
interventions for the treatment of patients with BPSD 
2. To explore the costs and health utilities, (or utility weights), of interventions for 
the treatment of patients with BPSD; and 
3. To calculate the incremental cost-effectiveness ratio, (ICER, as presented in terms 
of cost per QALY), of the intervention of interest and the comparator. 
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1.4 Original Contribution 
The current controversial management associated with safety and efficacy of atypical 
antipsychotic drug use for BPSD and the lack of pharmacoeconomic research on atypical 
antipsychotics for BPSD pose an immense challenge for current clinical practices in 
treating dementia patients. To the researcher’s best knowledge, this will be the first study 
to evaluate the cost-effectiveness of atypical antipsychotics, (olanzapine versus 
risperidone), for the treatment of BPSD in the context of Thailand. The findings of this 
study will indicate the recommended effective treatment intervention for patients with 
BPSD and intentionally contribute to the decision making of physicians, patients, and 
caregivers, in planning and selecting the relevant treatment for BPSD sufferers. This 
study also considered the side effects and relapse rates of both drugs which allow the 
results to be as realistic as they could possibly be. Therefore, this data will be useful and 
may be replicated in other settings with similar circumstances. 
In addition, this study integrated pharmacological, epidemiological and health economic 
evaluation techniques. A decision-analytical framework has been conducted to evaluate 
the cost-effectiveness of olanzapine compared with risperidone in patients with BPSD in 
Thailand, based on a societal perspective. 
Aside from that, the study has identified a number of benefits that would accrue for 
patients, their caregivers, health professionals and health care providers in Thailand, in a 
philosophical sense. The obvious benefit for the patients is a more effective treatment of 
their condition, resulting in greater wellbeing. If the patient's overall health condition 
improves, this would also be reflected in the wellbeing of the caregivers, who would see 
an improvement in the condition of their charge, leading to better quality of life of both 
the patients and their caregivers. This also has a bearing on the treatment of those patients 
by health professionals, who may possibly benefit from lower stress levels as a direct 
improvement of their patients’ health. Additionally, there may well be a significant 
impact on the wider healthcare systems in Thailand, if there is a significant improvement 
in patient wellbeing which could result in an overall reduction in the true costs of care for 
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these patients, even if there was a direct increase in pharmaceutical costs in using a 
different drug in the treatment of these cases. Less pressure on the health system for 
related treatments for these patients may well result in an overall reduction in treatment 
costs which would be beneficial for the wider Thai population. 
 
1.5 The structure of the thesis 
In this chapter, the background information associated with an ageing population, 
dementia situations, BPSD situations, and dementia associated costs, both worldwide and 
in Thailand has been provided. In terms of the structure, the thesis will focus on the 
following points.   
Chapter 2: The literature review introduces the definition of dementia and BPSD, the 
management of BPSD, health economic evaluations, the model-based health economic 
evaluations in dementia, and the conceptual framework of this study.  
Chapter 3: Philosophical underpinnings are addressed. This chapter also describes the 
design and methodology of this study, including sample size, target population, data 
settings, data collection processes, data requirements and data sources as well as data 
analyses. In addition, the ethical considerations of the study are presented here. 
Chapter 4: The model development is based on data from literature reviews of model-
based economic evaluations in dementia. This chapter provides the stages of developing 
the different models and the use of data from a Thai setting, for application in these 
developed models. The most appropriate model has been selected to be adopted for the 
cost-utility analysis of olanzapine compared with risperidone, in the treatment of patients 
with BPSD in Thailand in Chapter 7.  
Chapter 5: Costs of the treatment of patients with BPSD in Thailand with atypical 
antipsychotics, (olanzapine or risperidone), are presented in this chapter. Based on the 
primary data collection from within a Thai setting, the findings initially present an 
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overview of patient and caregiver characteristics. Then, the characteristics of both patients 
and caregivers are displayed following the classification of patients by cognitive function 
and dependence. Also, the cost analyses are performed based on two different 
distributions as previously stated.  
Chapter 6: This chapter is associated with the measure of the health-related quality of life 
of patients with BPSD and treatment with olanzapine or risperidone using the EQ-5D-5L. 
The responses to questionnaires are translated into utility weights, (or utility values). The 
utility analyses are then presented by classifying patients by cognitive function and 
dependence. 
Chapter 7: This chapter presents the application of the cost-utility analysis of atypical 
antipsychotics for the treatment of BPSD in Thailand. The selected model is used to 
predict the expected costs and outcomes associated with olanzapine and risperidone 
treatment in Thai patients with BPSD aged 60 years and above, over a 5-year time period 
from a societal perspective. The data analyses display in terms of the incremental cost-
effectiveness ratio, (ICER), calculated by incremental costs and incremental quality-
adjusted life year gained (QALYs). Furthermore, the uncertainty analyses are presented 
here.  
Chapter 8: This part is associated with the conclusion of an overview of this thesis, the 
summary of the findings, a contribution to knowledge, policy implements, the strengths 
and limitations of this thesis and the post-research evaluation. Moreover, further research 
opportunities and publications are presented in this chapter.   
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Chapter 2: Literature Review 
Abstract 
Introduction: Rapid growth of the elderly worldwide has led to several problems, 
particularly health, economic, social, mental, and family problems. The most common 
health issue facing the elderly is dementia which is a chronic health condition. 
Behavioural and psychological symptoms of dementia are closely associated with patients 
and are unavoidable in this progressive disease. These symptoms have a significant 
impact on distressing and burdening caregivers. Antipsychotics are one group of 
medications which are widely used in practice for the treatment of BPSD. However, there 
is currently limited data on the health economic evaluation of antipsychotics in patients 
with BPSD.  
Aim: The objective of this chapter is to review issues associated with definitions of 
dementia and BPSD, the prevalence and economic impact of dementia, management of 
BPSD, efficacy of atypical antipsychotics for the treatment of BPSD, heath economic 
evaluations of atypical antipsychotics for dementia, and the modelling-based economic 
evaluations in dementia. 
Methods: Relevant published studies of dementia from several sources were identified to 
review the definitions, prevalence and economic impact, as well as management of the 
disease. On the efficacy data of atypical antipsychotics (focused on risperidone, 
olanzapine, quetiapine, and aripiprazole) those published in the English language were 
identified by searching of MEDLINE, PsycINFO, and the Cochrane Library of 
randomised controlled trial, placebo-controlled, double-blind, parallel-group trials 
comparing drugs with placebo, from 1994 through to July 2015. Regarding the models of 
health economic evaluations, MEDLINE and CRD database were searched from January 
1975 through to March 2018, written in English, on cost-minimisation analysis, cost-
benefit analysis, cost-effectiveness analysis, and cost-utility analysis, of pharmacological 
treatments in dementia.  
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Results: Dementia is a progressive brain disease associated with cognitive impairment. At 
any one point, people with dementia had experienced BPSD accounting for 50-90% 
within the disease progression, leading to a significant caregiver burden. Due to clinicians 
having limited treatment alternatives, antipsychotics are widely used in treating BPSD, 
although these drugs are marginally useful in the treatment of these people. A total of 
2,190 articles were reviewed on atypical antipsychotics for dementia. However, only 13 
studies were identified for an in-depth review. The evidence supported the efficacy of 
atypical antipsychotics in patients with BPSD, although the adverse events might offset 
their efficacy. Regarding model-based economic evaluations in dementia, of 1,118 
citations identified, 40 studies contributed data for the modelling used in the economic 
evaluations of dementia. Different model structures were found to apply in health 
economic evaluations in dementia. The grouping of models according to the disease 
progression, found that there were 16 model approaches. A Markov model was most 
commonly used for evaluation. The FTC conceptual framework and CERAD conceptual 
framework were the most used model structures applied to economic evaluation in 
dementia.  
Conclusions: Despite the concerns with the adverse events of atypical antipsychotics for 
dementia, these drugs remain beneficial to patients with BPSD. The patients need to be 
monitored when they are prescribed antipsychotic drugs for dementia. There was a 
paucity of studies using model-based health economic evaluations in dementia on patients 
with BPSD and being treated with antipsychotic medications. 
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2.1 Dementia and Behavioural and Psychological Symptoms of Dementia (BPSD) 
2.1.1 Definition of Dementia 
Dementia can be defined as a progressive brain disease associated with the impairment of 
brain function. The dysfunction involves cognition, personality, and a person’s intellect, 
for example: memory, thinking, language, learning ability, calculation, comprehension, 
judgement, and orientation. Thus, the deterioration of the brain in this way can have a 
significant impact on people living with the condition, as well as on society as a whole 
(World Health Organization 2012, Butler and Radhakrishnan 2011, Holmes 2012, 
National Institute for Health and Care Excellence 2006).  Alzheimer’s disease (AD) is the 
most common type of dementia, accounting for 50-70% of cases. Vascular dementia 
(VaD), dementia with Lewy bodies, and frontotemporal dementia (FTD) are also 
substantial categories of the disorder accounting for 20%, 10% and 2% cases, respectively 
(Butler and Radhakrishnan, 2011, Holmes 2012, NSW Health 2013). According to the 
World Health Organisation (2012), dementia can be classified into three stages: 
  •Stage 1 - the early dementia stage occurs in the first or second year of the 
condition;  
 •Stage 2 - the middle dementia stage occurs from the second to fourth or fifth 
year; and finally  
 •Stage 3 - the late dementia occurring in the fifth year and beyond. 
2.1.2 Definition of Behavioural and Psychological Symptoms of Dementia (BPSD) 
Behavioural and psychological symptoms of dementia (BPSD) are common symptoms of 
the disease, including neuropsychiatric symptoms, non-cognitive symptoms and 
behavioural disturbance (NSW Health 2013, Byrne, 2005). Diagnosis of BPSD has no 
formally specified approach; therefore, clinical magnitude is more subjective than 
objective in patients with dementia. The clinical symptoms of BPSD present themselves 
as: agitation, apathy, anxiety, depression, delusion, hallucination, disinhibition, aberrant 
motor behaviour, elation, irritability, and sleep and appetite changes (Cerejeira, Lagarto 
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and Mukaetova-Ladinska 2012, NSW Health 2013, Byrne 2005). At any one point in 
time, 50-90% people with dementia are likely to experience at least one symptom of 
disorder (Lawlor 2002, Angelini et al. 2007, NSW Health 2013). Additionally, BPSD 
tends to be more prevalent in the last stage of the disorder. As a result, these problems 
directly affect patients, caregivers and their families. These include, but are not limited to, 
distress among carers and patients, long term hospitalisation, drug abuse, and other health 
care costs (Cerejeira, Lagarto and Mukaetova-Ladinska 2012).  The decline in patients' 
and caregivers' quality of life is the more troublesome aspect of BPSD management rather 
than cognitive impairment. 
 
2.2 Prevalence and Economic Impact of Dementia 
Dementia is a worldwide problem resulting from the rapid increase in populations aged 
60 or above. The worldwide size of the over 60 years old population is estimated to be 2 
billion in 2050 (World Health Organization 2012). It is predicted that 6.7% of this older 
population are expected to have dementia which would equate to 135 million people (See 
Figure 2.1) (Alzheimer’s Disease International 2013). It can be seen that the condition has 
the potential to impact significantly on social and economic welfare worldwide. There are 
three different aspects of dementia costs namely: informal care costs, direct social costs, 
and direct medical costs (See Figure 2.2). These tend to vary in proportion according to 
each nation’s wealth (World Health Organization 2012). 
In Thailand, the number of the population over 60 years old was approximately 10 million 
in 2014 (National Statistical Office of Thailand 2014). The prevalence of dementia 
amongst Thai people aged 60 and above was 3.3-8.1% (Jitapunkul et al. 2001, Kalaria 
2008, Aekphakorn et al. 2016). The projection for 2050 suggests that there will be more 
than 1.2 million Thai people with dementia (Uddin Akter et al. 2012). It is clear that the 
demographic characteristics of the Thai population have changed and it is entering into an 
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ageing society. The increased numbers of people with dementia will therefore lead to 
various demands and problems on the healthcare systems and communities in Thailand.  
 
Figure 2.1: Increase in the number of people with dementia worldwide (2010-2050), 
showing original and updated estimates (Alzheimer’s Disease International 2013) 
 
Figure 2.2: Distribution of total societal costs (%) by World Bank Income level 
(World Health Organization 2012) 
2.3 Management of behavioural and psychological symptoms of dementia 
Generally, people with dementia may experience BPSD at any point during the 
progression of the illness, associated with poor outcomes for patients and caregivers. 
Also, the disorder is significantly troublesome in clinical practice. The guidelines for 
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management of BPSD, classified into non-pharmacological and pharmacological 
approaches are listed below:  
2.3.1 Non-pharmacological approaches   
Non-pharmacological approach was recommended as the first-line management for BPSD 
(NSW Health 2013, Scottish Intercollegiate Guidelines Network 2006, Tampi et al. 2011, 
Sadowsky and Galvin 2012, Azermai et al. 2012, The American Geriatrics Society 2011). 
The treatments were applied for behavioural disorders following the characteristics of 
symptoms. The most common approaches are environmental design, music therapy, light 
therapy, and carer education for behavioural disturbances (NSW Health 2013, Scottish 
Intercollegiate Guidelines Network 2006). For example, the stimulation/activities and 
simple tasks were introduced for apathy (Segal-Gidan et al. 2011, Opie, Rosewarne and 
O’Cornor 1999). Furthermore, Fujii et al. (2010) suggested that behavioural and 
psychological symptoms of caregivers (BPSC) resulted from BPSD, namely, the 
behaviour of caregivers was an important factor that would affect a relationship and the 
emotions of a patient.  
2.3.2 Pharmacological approaches  
Pharmacological methods will be necessary when non-pharmacological interventions are 
unsuccessful or there is no response to the BPSD treatment (NSW Health 2013, Scottish 
Intercollegiate Guidelines Network 2006). There are several classes of drugs that have 
been utilised for the management of BPSD. The categories are listed below: 
2.3.2.1 Anticonvulsants 
There are studies associated with carbamazepine, sodium valproate, and gabapentin for 
the treatment of behavioural symptoms related to patients with dementia. Of these the 
evidence showed that valproate was insufficient for the treatment of BPSD (Lonergan and 
Luxenberg 2009, Scottish Intercollegiate Guidelines Network 2006). Carbamazepine 
revealed short- term effectiveness for agitated behaviour (Tariot et al. 1998, Scottish 
Intercollegiate Guidelines Network 2006). Gabapentin alone and also combined with 
psychotropic drugs showed efficacy for the treatment BPSD, however more evidence is 
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required (Scottish Intercollegiate Guidelines Network 2006, Tempi, Ozkan and 
Williamson 2012, Yeh and Ouyyang 2012). On the basis of the data, anticonvulsant drugs 
were not recommended for the treatment BPSD associated with dementia (Konovalov et 
al. 2008, Scottish Intercollegiate Guidelines Network 2006).  
2.3.2.2 Cholinesterase inhibitors (ChEIs) 
At present, there is evidence accounting for the benefits of ChEIs. Rodda et al. (2009) 
showed a limitation of effectiveness data, but ChEIs can be used for BPSD in 
Alzheimer’s disease (National Institute for Health and Care Excellence 2015). The US-
FDA has approved donepezil, galantamine, and rivastigmine for treatment of symptoms 
of Alzheimer’s disease; however, the recommendations of ChEIs are inconsistent in 
guidelines (Azermai et al. 2012). If behavioural symptoms still persist during ChEIs use, 
alternative drug classes may be considered as therapeutic options (Sadowsky and Galvin 
2012).  
2.3.2.3 Antidepressants  
Depression symptoms are common in patients with dementia. Selective serotonin 
reuptake inhibitors (SSRI) were observed for efficacy on depression (Gauthier et al. 
2010). Citalopram and sertraline had commensurate efficacy on agitated behaviour 
relative to risperidone or haloperidol. However, there were several controversial 
guidelines to support antidepressants for behaviour disturbances, excepting comorbid 
depression in patient associated with dementia (Scottish Intercollegiate Guidelines 
Network 2006, Sink, Holden and Yaffe 2005, Azermai et al. 2012).  
2.3.2.4 Memantine or NMDA (N-methyl-D-aspartate) 
Memantine is currently the US-FDA approved drug for treatment of moderate to severe 
stages of Alzheimer’s disease (Sink, Holden and Yaffe 2005). Nevertheless, the 
recommendation for BPSD is disputed in guidelines. The SIGN guidelines addressed the 
insufficient evidence of memantine for management of patients with BPSD (Scottish 
Intercollegiate Guidelines Network 2006). In contrast, the NICE guidelines recommended 
memantine for non-cognitive symptoms in cases of moderate to severe stages and the 
 
 
22 
 
ineffectiveness of ChEIs and antipsychotics (National Institute for Health and Care 
Excellence 2015). 
2.3.2.5 Antipsychotics  
The classification of antipsychotics is divided into two classes: typical antipsychotics and 
atypical antipsychotics. All guidelines have consistency for introducing antipsychotics for 
treatment of patients with BPSD, in particular agitation, aggression, and psychosis 
(Azermai et al. 2012, National Institute for Health and Care Excellence 2015). Due to 
adverse effects, the NSW guidelines did not recommend conventional antipsychotics as a 
first-line drug (NSW Health 2013). Atypical antipsychotic drugs are commonly 
prescribed for BPSD rather than typical antipsychotics. Drouillard, Mithani and Chan 
(2013) noted that atypical antipsychotics were useful for managing BPSD in relation to 
agitation and aggression. However, before applying medications, patients should be 
investigated. Tampi et al. (2011) recommended that risperidone, aripiprazole and 
olanzapine should be considered as the first-line of the treatment of patients with BPSD. 
Aripiprazole, olanzapine, and risperidone showed statistically significant effects in the 
reduction of psychosis, agitation, and global behavioural symptoms in dementia (Maher et 
al. 2011).  
In conclusion, the management of BPSD should integrate both non-pharmacological 
treatments and pharmacological treatments. Non-pharmacological approaches should be 
introduced as initial strategies. When non-pharmacological interventions have no 
response, starting medication was appropriate. Notwithstanding, atypical antipsychotic 
drugs have a significant performance. These are considered to be first-line drugs for the 
treatment of psychotic disorders in elderly people with dementia due to their more 
effectiveness and having less adverse effects. Currently, although these are controversial 
for use concerning drug safety, the goal of pharmacological therapy is the reduction in the 
problematic disorders and not in eliminating symptoms. The concept of antipsychotic 
drugs is “start slow, go slow”. Thus, caregivers should take part in the decision-making of 
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the care map for patients with dementia. Also, pharmacological treatment should 
scrutinize the risk-benefits to patients and be considered on a case by case assessment.  
Since there are an extensive variety of antipsychotics prescribed for the treatment of 
patients associated with BPSD, in this proposed research, the researcher will focus 
exclusively on atypical antipsychotic drugs. 
 
2.4 Efficacy of Atypical Antipsychotic Drugs for Dementia 
A comprehensive literature search was undertaken in electronic databases. The literature 
search was focusing on efficacy of atypical antipsychotics for dementia. In this procedure, 
there were four main steps. Firstly, the key search terms were developed on the basis of 
the relevant topic. Secondly, titles were considered for screening using the inclusion and 
exclusion criteria (see below). If they met the criteria, they were then exported to 
RefWorks for further evaluation. Thirdly, the abstracts were scrutinised for inclusion and 
exclusion criteria, to confirm whether they met an engagement. Finally, an assessment 
and in-depth review identified whether they were for inclusion or exclusion. If they 
fulfilled the criteria, they were then included into the final stage. Studies in non-English 
language were excluded from the literature review. 
2.4.1 Literature Search for Efficacy of Atypical Antipsychotics for Dementia 
A literature search for efficacy of second-generation antipsychotic drugs for the treatment 
of dementia, in particular risperidone, olanzapine, quetiapine and aripiprazole was 
undertaken in electronic databases, including MEDLINE, PsycINFO, and the Cochrane 
Library. The literature search covered the period from 1994 up to July 2015. The search 
terms were broken down into the relevant topics following these criteria: 
a) Dementia and Alzheimer’s disease; 
b) Behavioural and psychological symptoms of dementia, BPSD and 
neuropsychiatric symptoms; 
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c) Atypical antipsychotics, Risperidone, Olanzapine, Aripiprazole and 
Quetiapine. 
The database search for the efficacy of atypical antipsychotic (risperidone, olanzapine, 
quetiapine and aripiprazole) drugs for dementia retrieved 2,190 articles from MEDLINE, 
PsycINFO, and the Cochrane Library. Of these 1,075 articles were retrieved from 
MEDLINE, 754 articles retrieved from PsycINFO and 361 articles from the Cochrane 
Library. The titles were screened using the inclusion and exclusion criteria. Of the 
original 2,190 articles, 2,063 were excluded due to their title. The remaining 127 articles 
were identified for further scrutiny. A further 81 articles were excluded after screening the 
abstracts. 46 articles still remained to undergo the next step. From the remaining 46 
articles, a further 26 were excluded due to duplication. 20 articles remained to undergo 
the next step which was screening the full paper. Six articles were excluded due to not 
meeting the outline criteria. Another one paper was excluded due to having no access to 
full-text paper. 13 articles then remained which were potentially relevant on which to 
undertake a full review. Finally, these articles were reviewed to synthesise the results on 
the efficacy of newer antipsychotic agents for the treatment of patients with dementia. 
Inclusion criteria:  
• Participants: people with dementia, people with behavioural and psychological 
symptoms of dementia; 
• Interventions: atypical antipsychotic, risperidone, olanzapine, quetiapine and 
aripiprazole for the treatment of dementia, Alzheimer’s disease, behavioural and 
psychological symptoms of dementia and neuropsychiatric symptoms; 
• Study designs: randomised controlled trial, placebo-controlled, double-blind, 
parallel-group trials comparing drugs with placebo; 
• Outcomes: Behavioural Pathology in Alzheimer’s disease Rating Scale 
(BEHAVE-AD), Clinical Global Impression (CGI) scale, Neuropsychiatric 
Inventory (NPI), Cohen-Mansfield Agitation Inventory (CMAI), Brief Psychiatric 
 
 
25 
 
Rating Scale (BPRS), Severe Impairment Battery (SIB), time for initial treatment 
to the discontinuation, and Mini-Mental State Examination (MMSE). 
 
Table 2.1 shows the summary of studies for the efficacy of atypical antipsychotics for 
dementia. 
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Table 2.1: The summary of studies for the efficacy of atypical antipsychotics for dementia  
Trials Populations Interventions Outcome assessment Result Conclusion 
De Deyn et al. 
(1999) 
-n=344 
-Patient with 
dementia 
-Mean age 81 
years 
-Flexible 
dosage regimen 
of risperidone 
or haloperidol 
was 0.25-2 mg 
twice daily 
Risperidone, 
haloperidol,  
or placebo 
-BEHAVE-AD total score 
-CMAI 
-CGI-S 
-Tolerability (including EPS 
rating scale) 
-Functional Assessment 
-MMSE 
-Adverse events 
 
-At the end point and week 12, the 
mean dose of risperidone (1.1 
mg/day) showed improvement on 
BEHAVE-AD total score (the score 
reduction was equal to or greater 
than 30% from baseline), but not 
significant when compared with 
placebo (p=0.19) 
-BEHAVE-AD aggression and 
CMAI aggression, CGI-S score 
showed significant reduction at 12-
week and the endpoint outcome 
-Patient with vascular dementia 
demonstrated statistically significant 
improvements on BEHAVE-AD 
aggression and CMAI aggression 
both the end point and 12-week 
Risperidone showed 
efficacy for the 
treatment of patient 
with AD associated 
with aggression 
(mean dosage 1.1 
mg/day)  
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Trials Populations Interventions Outcome assessment Result Conclusion 
-No significant difference on EPS 
between risperidone and placebo 
Brodaty et al. 
(2003) 
n=345 
-Patients 
diagnosed AD, 
Vascular 
dementia, 
mixed 
dementia, and 
aggressive 
behaviour 
Risperidone vs 
Placebo 
-CMAI 
-BEHAVE-AD rating scale 
-CGI-S and CGI-C 
 
 
 
Primary efficacy outcomes: 
-Significant result for CMAI total 
aggression score (p<0.001) of 
risperidone compared with placebo 
Secondary efficacy outcomes: 
-Improvement on CMAI subscale 
(total non-aggression, p<0.002) in 
risperidone vs placebo 
-Significant results on BEHAVE-AD 
total (p<0.001) and psychotic 
symptoms subscale (p=0.004) 
-Risperidone showed no significant 
reduction in BEHAVE-AD activity 
disturbance and diurnal rhythm 
disturbances (p=0.067, p=0.098, 
respectively) 
Risperidone showed 
efficacy for treating 
of patients with 
dementia with 
psychosis, aggression 
and agitation (mean 
dosage 0.95 mg/day) 
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Trials Populations Interventions Outcome assessment Result Conclusion 
At the endpoint, risperidone 
improved CGI-S and CGI-C  scale 
(p<0.001) 
-Risperidone and placebo showed no 
significant in ESRS at the endpoint 
(p=0.407) 
Street et al. (2000) n=206 
-the elderly 
with AD with 
psychosis 
and/or 
behavioural 
symptoms in 
nursing home 
-6-week 
-Fixed-dose 
olanzapine 5.0, 
10.0, and 15.0 
mg/day 
Olanzapine vs 
placebo 
Primary efficacy outcome: 
-NPI-NH Core Total 
(agitation/aggression, 
hallucinations, and delusions 
items)  
Secondary outcomes: 
-NPI/NH Total score  
-NPI-NH Psychosis total 
(Hallucinations and Delusions)  
-NPI-NH Occupational 
Disruptiveness score 
-BPRS total and subscale 
-MMSE 
-EPS 
Primary outcome: 
-Significant results on olanzapine 5 
and 10 mg/day  improving in NPI-
NH  Core Total (p<0.001 and 
p<0.006, respectively) compared 
with placebo 
Secondary outcomes: 
-Olanzapine 5 mg/day showed 
significant results for NPI/NH Total 
score (p=0.005), NPI-NH 
Occupational Disruptiveness score 
(p=0.008), BPRS total (p=0.005), 
BPRS positive subscale (p=0.05) 
Olanzapine 5 and 10 
mg daily resulted in 
effectiveness for the 
treatment of patients 
with AD with 
agitation, aggression, 
and psychosis 
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Trials Populations Interventions Outcome assessment Result Conclusion 
 -NPI-NH psychosis scale, NPI-NH 
agitation/aggression, BPRS 
anxiety/depression subscale were 
significant in both dosage 5 and 10 
mg/day of olanzapine 
-NPI-NH depression/dysphoria, 
MMSE, and EPS not significant in 
all treatment groups 
De Deyn et al. 
(2004) 
-n=652 
-Patients with 
AD with 
psychosis 
symptoms 
-10-week 
-Fixed dose 
olanzapine 1.0, 
2.5, 5.0, and 7.5 
mg/day 
Olanzapine vs 
placebo 
Primary Outcomes: 
-NPI-NH psychosis total score 
(sum of delusion, hallucination 
items) 
-CGI-C 
-CGI-S 
Secondary outcomes: 
-BPRS score 
-Occupational Disruptiveness 
Psychosis total score 
-MMSE 
-SIB 
-No significant results for primary 
efficacy outcomes between 
olanzapine and placebo 
-Repeated-measure analysis showed 
improvement in NPI-NH psychosis 
total score (sum of delusion, 
hallucination items, p<0.001) in all 
treated olanzapine relative to placebo 
-Repeated-measure showed 
significant effect for olanzapine 2.5 
and 7.5 mg/day relative to placebo 
(p=0.049 and p=0.030, respectively) 
-Olanzapine 2.5 and 
7.5 mg daily showed 
significant 
effectiveness in 
treating of patients 
with AD with 
psychosis 
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Trials Populations Interventions Outcome assessment Result Conclusion 
-SAS 
-AIMS 
-POMA 
-Olanzapine 2.5 mg/day improved 
on CGI-C score (p=0.030) relative to 
placebo 
-Occupational Disruptiveness 
Psychosis total and overall 
Occupational Disruptiveness  
favoured olanzapine 7.5 mg daily 
(p=0.021 and p=0.007, respectively) 
-BPRS score showed improvement 
in all treatment groups but not 
significant differences. 
-MMSE showed significant increase 
in use of olanzapine 2.5 mg/day 
(p=0.019) 
-Treatment groups resulted in no 
significant differences in SAS,  
AIMS, and POMA compared with 
baseline in each group 
Zhong et al. (2007) -n=333 Quetiapine vs 
placebo 
-PANSS 
-CGI-C 
Primary efficacy outcomes: -Quetiapine 200 
mg/day showed a 
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Trials Populations Interventions Outcome assessment Result Conclusion 
-Patients with 
dementia and 
agitation 
-Fixed-dose 
quetiapine 100,  
200 mg/day or 
placebo 
-10-week 
-Mean age 83 
years 
-NPI-NH 
-CMAI 
-Incidence of adverse events 
-MMSE 
-Quetiapine at dose 100 mg/day 
showed no difference compared with 
placebo 
-Quetiapine 200 mg/day changed in 
PANSS (LOCF, p=0.017 and OC, 
p=0.002) 
Secondary outcomes: 
-Significant results for CGI-C 
(LOCF, p=0.017 and OC, p=0.002), 
CGI-C response rate (LOCF, 
p=0.002 and OC, p<0.001)  in all 
treatment groups relative to placebo 
-No significances in NPH-NH total 
score, agitation, psychosis score, and 
occupational disruptiveness, and 
CMAI in treated group compared 
with placebo 
-MMSE was not change compared 
with baseline 
significance impact in 
patients with 
dementia related to 
agitation 
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Trials Populations Interventions Outcome assessment Result Conclusion 
-CVE showed no significant changes 
among treatment groups 
Tariot et al. (2006) -n=284 
-Patients with 
AD with 
probable 
psychoses 
-Mean age 83.2 
years 
-10-week 
-Quetiapine, 
haloperidol, 
and placebo 
Primary outcomes: 
-BPRS total score 
-CGI-S  
Secondary outcomes: 
-BPRS agitation factors subscale 
-NPI-NH agitation scores 
-MMSE 
-MOSEC 
-PSMS 
-SAS 
-AIMS 
 
Primary outcomes: 
No statistical significance in BPRS 
total score (quetiapine vs placebo, 
p=0.217, quetiapine vs haloperidol, 
p=0.354) and CGI-S 
(quetiapine vs placebo, p=0.577 
quetiapine vs haloperidol, p=0.887) 
Secondary outcomes: 
-Significant results for BPRS 
agitation factors subscale (quetiapine 
vs placebo, p=0.023)  
No significant differences in NPI-
NH agitation scores, MMSE in all 
treatment groups, except MOSEC 
,PSMS, and SAS not significant in 
quetiapine vs placebo 
(p=0.612,  p=0.198 and p=0.974 
respectively) 
-No significant 
differences of all 
treatment groups for 
patients with AD with 
psychosis  
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Trials Populations Interventions Outcome assessment Result Conclusion 
 
Paleacu et al. (2008) n=40 
-Patients with 
AD associated 
with BPSD 
-6-week 
Quetiapine vs 
placebo 
Primary efficacy outcomes: 
-NPI total score 
-CGI-C 
Secondary efficacy outcomes: 
-MMSE 
-SAS 
-AIMS 
 
-No significant reduction in NPI 
total score in quetiapine vs placebo 
compared with baseline 
-Significant change in CGI-C score 
at 6-week in quetiapine (p=0.009) -
Placebo showed no significance 
(p=0.048) relative to baseline 
-No significant differences in 
secondary outcomes between 
quetiapine and placebo 
-Quetiapine showed  
no significance 
difference for treating 
AD patient with 
psychosis compared 
with placebo 
Kurlan et al. (2007) n=40 
-Patient with 
dementia and 
parkinsonism 
-10-week 
Quetiapine vs 
placebo 
Primary outcome: 
-BPRS 
Secondary outcomes: 
-NPI Psychosis and agitation 
-MMSE 
-ADSC-CGIC 
-ADCS Activities of Daily Living 
Questionnaire  
-No significant results for the 
primary and secondary outcomes 
between quetiapine and placebo 
-No worsening of parkinsonism 
showed in quetiapine 
 
  
-Quetiapine had no 
efficacy for  
psychosis or agitation 
in patients with 
dementia and 
parkinsonism 
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Trials Populations Interventions Outcome assessment Result Conclusion 
De Deyn et al. 
(2005) 
-n=208 
-AD patients 
with psychosis 
-10-week 
-Mean age 81.5 
years 
Aripiprazole 
vs placebo 
Primary outcome: 
-NPI psychosis subscale 
Secondary outcomes: 
-NPI total 
-BPRS 
-CGI-S 
-CGI-I 
-MMSE 
-Adverse events report 
-EPS rating scale 
-Body weight 
Primary outcome: 
-No significance of aripiprazole on 
NPI psychosis subscale compared 
with placebo (p=0.0169) 
Secondary Outcomes: 
-Aripiprazole showed significant 
improvement on BPRS psychosis 
and BPRS core subscale compared 
with placebo (p=0.029 and p=0.042, 
respectively)  
No significant differences in NPI 
total, BPRS total, CGI-I, CGI-S, 
ASA, AIMS, and BAS 
-Aripiprazole and placebo were no 
significant differences in  EPS rating 
Scale 
-Aripiprazole and 
placebo showed no 
significant 
improvements in NPI 
psychosis subscale  
-Aripiprazole showed 
improvement in 
BPRS psychosis core 
subscale relative to 
placebo  
 
Streim et al. (2008) -n=256 
-AD patients 
with psychotic 
symptoms 
Aripiprazole 
vs placebo 
Primary endpoints: 
-NPI-NH psychosis score (sums 
of Hallucinations and Delusions) 
-CGI-S 
Primary efficacy outcomes: 
-No significant differences in 
primary outcomes, NPI-NH 
psychosis score (p=0.883) 
Aripiprazole was 
efficacious for 
agitation, anxiety, and 
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Trials Populations Interventions Outcome assessment Result Conclusion 
-10-week Secondary endpoints: 
-NPI-NH total score 
-BPRS total 
-BPRS psychosis 
-CMAI 
-Cornell scale 
-NPI-NH Psychosis Caregiver 
distress 
-NPI-NH Total Caregiver distress 
ADCS-ADL-SEV 
and CGI-S (p=0.198)  
Secondary efficacy outcomes: 
-Significant results for NPI-NH total 
score (p=0.009), BPRS total 
(p=0.031), CMAI (p=0.030), 
Cornell scale (p=0.006), and NPI-
NH Total Caregiver distress 
(p=0.003) 
 
depression but not 
psychosis 
Mintzer et al. 
(2007) 
n=487 
-AD patients 
with psychosis 
-Aripiprazole 
2.0, 5.0, and 10 
mg/day 
-Mean age 82.5 
years 
Aripiprazole 
vs placebo 
Primary outcomes at 10-week: 
-NPI-NH psychosis subscale score 
Secondary outcomes: 
-NPI-NH total score 
-CGI-S score 
-BPRS psychosis, core and total 
score 
-CMAI total score 
-MMSE score 
-CGI-I 
At 10-week primary endpoint:  
-Aripiprazole 10 mg/day was 
significant improvement in NPI-NH 
psychosis subscale (p=0.013) 
relative to placebo 
Secondary efficacy outcomes: 
-NPI-NH total score, aripiprazole 10 
mg/day showed statistically 
significant improvement in the 
aggression/agitation, anxiety, and 
-Aripiprazole 10 
mg/day showed 
significant efficacy 
for treatment of AD 
patients with 
psychosis, agitation, 
and aggression 
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Trials Populations Interventions Outcome assessment Result Conclusion 
 irritability, as well as 5 mg/day 
resulted in reduced 
aggression/agitation and anxiety 
compared with placebo 
-No significant improvement on 
aripiprazole 2 mg/day vs placebo 
-Aripiprazole 10 mg/day also 
showed significant differences on 
CGI-S (p=0.031), BPRS total score 
(p=0.030), BPRS core score 
(p=0.007), and CMAI (p=0.023) 
compared with placebo 
-Aripiprazole 5 mg/day was 
significant in BPRS and CMAI score 
compared with placebo 
-On dose 2 mg/day showed no 
significant differences of 
aripiprazole relative to placebo 
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Trials Populations Interventions Outcome assessment Result Conclusion 
-The dose-dependent was significant 
leading to increase in  
cerebrovascular events (p=0.03) 
Schneider et al. 
(2006) 
-n=421 
-AD patients 
with psychosis, 
aggression or 
agitation 
-Mean dose 
olanzapine 5.5 
mg/day 
-Mean dose 
quetiapine 56.5 
mg/day 
-Mean dose 
risperidone 1.0 
mg/day 
 
 
 
Olanzapine,  
risperidone, 
quetiapine vs 
placebo 
Primary outcome: 
-Time for initial treatment to the 
discontinuation 
Secondary outcomes: 
-CGI-C scale 
-Time to the discontinuation of 
treatment due to lack of efficacy 
-Time to the discontinuation of 
treatment due to adverse events, 
intolerability, or death 
 
- All treatments showed no 
significant differences in time to the 
discontinuation of treatment  
-Lack of efficacy with regard to time 
to the discontinuation of treatment 
was greater in olanzapine (22.1 
weeks) and risperidone (26.7 weeks) 
than quetiapine (9.1 weeks), and 
placebo (9.0 weeks) (p=0.002) 
-CGI-C scale showed no difference 
against all treatments (p=0.22) 
-Olanzapine and risperidone had a 
greater effect on Parkinsonism or 
extrapyramidal signs  than 
quetiapine or placebo 
-Sedation effect favoured placebo 
more than drug groups 
-Atypical 
antipsychotics 
showed adverse 
events outweighed 
benefits for AD 
patients with 
psychosis, aggression 
or agitation 
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Trials Populations Interventions Outcome assessment Result Conclusion 
 -Olanzapine group showed higher 
cognitive disturbance and psychotic 
symptoms than the three-remaining 
treatment groups 
Deberdt et al. 
(2005) 
-n=494 
-Patients with 
moderate to 
severe 
psychotic 
symptoms with 
dementia 
-Mean dose 
risperidone 1.0 
mg/day 
-Mean dose 
olanzapine 5.2 
mg/day 
 
Olanzapine, 
risperidone vs 
placebo 
Primary outcomes: 
-NPI Psychosis Total 
-CGI-severity of psychosis scale 
Secondary outcomes: 
NPI Total 
-BPRS 
-CMAI  aggression 
-PDS 
-Cornell Scale 
Primary outcome: 
-All treatment groups showed no 
significant difference in NPI 
Psychosis Total 
Secondary outcomes: 
NPI Total, CGI-S Psychosis, BPRS 
Total, CGI-S dementia, Cornell 
Total, PDS, and CMAI aggression 
showed no significant differences of 
both olanzapine and risperidone 
compared with placebo  
-Overall discontinuation favoured in 
placebo 
-Incidence of discontinuation due to 
adverse effects was the greater in 
olanzapine 
Olanzapine, 
risperidone, and 
placebo were showed 
no significant 
differences for 
treating of patients 
with moderate to 
severe psychotic 
symptoms with 
dementia  
 
 
 
39 
 
Trials Populations Interventions Outcome assessment Result Conclusion 
-Somnolence, urinary incontinence 
and hostility significantly presented 
in risperidone and olanzapine 
compared with placebo 
Abbreviations: Behavioural Pathology in Alzheimer’s disease Rating Scale (BEHAVE-AD), Clinical Global Impression (CGI) scale, Clinical Global Impression-Change 
scale (CGI-C) scale, Clinical Global Impression-Severity scale (CGI-S) scale Neuropsychiatric Inventory (NPI), Cohen-Mansfield Agitation Inventory (CMAI), Brief 
Psychiatric Rating Scale (BPRS), Severe Impairment Battery (SIB), time for initial treatment to the discontinuation, and Mini-Mental State Examination (MMSE), the 
Simpson-Angus Scale (SAS), the Abnormal Involuntary Movement Scale (AIMS), the Modified Performance-Oriented Mobility Assessment (POMA), the Progressive 
Deterioration Scale (PDS), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL-SEV), Extrapyramidal Symptoms Rating scale (EPS rating 
scale), the ADCS Clinical Global Impression of Change (ADSC-CGIC), Positive and Negative Syndrome Scale (PANSS), Last Observation Carried Forward (LOCF), 
Observed Cases (OC) 
 
 
40 
 
From the literature review, the published evidence has supported the efficacy of atypical 
antipsychotics for the treatment of patients with dementia associated with behavioural and 
psychological symptoms. 
However, the adverse events associated with atypical antipsychotics may offset efficacy for 
the treatment of BPSD. The serious side effects in senile dementia accounted for 
cerebrovascular events, extrapyramidal symptom, falls, somnolence, sedation, disinhibition, 
depression, incontinence, Parkinsonism, weight gain, orthostatic hypotension, dyskinesia and 
cognitive function impairment (Schneider et al. 2006, Tan et al. 2015). 
To sum up, despite, the US-FDA warning of using atypical antipsychotics due to increased 
incidence in cerebrovascular mortality of  1.5 -1.7 times in the elderly with dementia  in 
2005, the trend of prescribing atypical antipsychotic for patients with dementia was 
paradoxical. Atypical antipsychotics were significantly prescribed for the treatment of BPSD 
(Schulze et al. 2013, Mcllroy, Thomas and Coleman 2015).  Additionally, several published 
articles showed that second-generation antipsychotic drugs had modest efficacy for the 
treatment of behavioural and psychological symptoms, namely agitation, aggression, 
psychosis, depression, anxiety. However, the limited and conflicting evidence for efficacy of 
atypical antipsychotic drugs were debatable for introducing them to manage BPSD in patients 
with dementia. The efficacy of certain drugs may be offset by adverse events.  
Although this still needs to be a debate about atypical antipsychotics on their effectiveness 
and adverse events, these drugs are widely used for the treatment of behavioural disturbance 
related to geriatric dementia. This is because the severity of behavioural disturbance worsens 
following disease progression. This then has potential impacts on morbidity, caregiver’s 
general health, the burden of care, patient and caregiver distress, and risk of harm to patients 
and carers. Consequently, it is important to weigh the risks and benefits before making 
judgments regarding the treatment of behavioural problems in people with dementia. The 
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pharmacological approaches are important and these are recommended after non-
pharmacological methods fail, for the better management of the disease. Finally, despite the 
modest efficacy for the reduction of behavioural symptoms, the potential improvement of the 
condition has considerable impact on the quality of life for patients and caregivers.  
 
2.5 Health Economic Evaluations 
Economic evaluations of health care involve a comparative analysis of the costs involved and 
the relevant options implemented. The purpose of this type of analysis is mainly to allocate 
scarce resources rationally for optimal decision making (Drummond et al. 2005). Cost-
effectiveness analysis (CEA), which is in widespread use in economic evaluations of health, 
compares the costs and the outcomes of one intervention against alternative interventions. 
The effect in this type of analysis is measured in terms of life-years gained (LYG). By 
contrast cost-utility analysis (CUA) is a type of health economic evaluation adapted from 
CEA. The outcome of this analysis is reported on the basis of life-years gained adjusted by 
the utility value (QALYs). These quality adjusted life years (QALYs) reflect both the quality 
and the quantity of life gains (Drummond et al. 2005).  
The cost-effectiveness plane (See Figure 2.3) is a diagram that can be applied to economic 
evaluations when comparing new technologies with current technologies. The horizontal and 
the vertical axes represent the differences in effectiveness and cost of both the new treatment 
and the current treatment respectively. The four scenarios can be illustrated as follows: in 
quadrant II, the new treatment dominates the comparator, which means the new treatment is 
more effective and cheaper than the comparator. Conversely, the new intervention is more 
expensive and less effective in quadrant IV and the new treatment is dominated by the current 
treatment. In quadrant I, is the scenario generally found in health economic evaluation, 
whereby the new treatment is more effective and also more expensive than the current 
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treatment. The same applies in quadrant III, but the justification is consistent with the 
previous quadrant (Drummond et al. 2005).  
The comparison of two heath care programmes can be demonstrated in terms of the 
incremental cost-effectiveness ratio (ICER). This ratio represents the incremental cost over 
the incremental outcome, which identifies how much it is worth paying for additional health 
gains (Drummond et al. 2005). Conventionally, the lowest ratio is held to be the optimal 
decision. 
 
 
                                                                       + 
                                                                        
 
                                  -                                                                    + 
 
                                                                       - 
 
Figure 2.3: The cost-effectiveness plane 
2.5.1 Literature Search for Heath Economic Evaluations of Atypical Antipsychotics for 
Dementia 
A comprehensive literature search was undertaken in electronic databases. The literature 
search was focusing on health economic evaluation of atypical antipsychotics for dementia. 
The procedure was similar to the literature search for efficacy of atypical antipsychotics for 
dementia. 
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A literature search was undertaken in the electronic databases MEDLINE, the Centre for 
Reviews and Dissemination (CRD), and the National Health System Economic Evaluation 
Database (NHS EED). The literature search covered the period between 1995 and June 2015. 
Search terms were as follows:  
a) Cost-effectiveness, cost-analysis, cost-benefit, cost-utility; 
b) Dementia, Alzheimer’s disease; 
c) Risperidone, Olanzapine, Aripiprazole, Quetiapine. 
The database search for cost-effectiveness of atypical antipsychotics, including risperidone, 
olanzapine, quetiapine and aripiprazole for dementia, resulted in a total of 14 articles 
retrieved from MEDLINE, NHS EED, and CRD. The titles were screened for inclusion and 
exclusion criteria.  
The result found only two studies associated with the cost-effectiveness. One study focused 
on olanzapine for agitation and psychosis in Alzheimer’s disease, based on a Markov state-
transition model to estimate the cost-effective treatment. The conclusion showed olanzapine 
was cost-effective compared with an untreated group, for agitation and psychosis in AD in a 
community dwelling in the United States, using the perspective of the US health system. 
However, the limitation of this study was the variables to enter into the model derived from 
other studies. Another factor to consider is the estimation of health utilities which was 
deduced from schizophrenia studies (Kirbach et al. 2008).  
On the contrary, another study is the cost-benefit analysis in a randomized controlled trial of 
second-generation antipsychotics and placebo for treating psychosis, agitation, or aggression 
in AD, followed-up over 9 months. The finding demonstrated that risperidone, olanzapine 
and quetiapine showed no differences in effectiveness compared to placebo, in a community 
dwelling in United States (Rosenheck et al. 2007). 
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2.5.2 The extended literature search for health economic evaluations of atypical 
antipsychotics for dementia 
A comprehensive literature search of electronic databases was conducted on 16th September, 
2015. MEDLINE, the Centre for Reviews and Dissemination (CRD) (containing the National 
Health System Economic Database (NHS EED), the Database of Abstracts of Reviews of 
Effects (DARE), and Health Technology Assessment database were searched. Search terms 
were as follows: 
a) Costing, costs, finance, “economic evaluation”, pharmacoeconomic; 
b) Dementia, Alzheimer’s disease; 
c) Risperidone, Risperdal, Olanzapine, Zyprexa, Aripiprazole, Abilify, Quetiapine, 
Seroquel. 
Inclusion criteria:  
• Population: people with dementia, people with Alzheimer’s disease; 
• Interventions: risperidone, risperdal, olanzapine, zyprexa, aripiprazole, abilify, 
quetiapine, and seroquel; 
• Study designs: comparison in terms of cost, and cost and health outcome, costs; 
• Outcomes: QALYs, monetary costs, health benefits, health outcomes. 
A total of 25 articles were retrieved. Twenty articles were retrieved from MEDLINE. Three 
articles were retrieved from NHS EED, two retrieved from HTA and DARE. The titles were 
screened for inclusion and exclusion criteria. After screening the titles, 15 articles were 
excluded. A further seven articles were excluded after screening the abstracts, while another 
one was excluded due to being non-English language which left two articles remaining. 
However, these articles had already been identified from a former literature search for health 
economic evaluations of atypical antipsychotics for dementia. 
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2.5.3 Review for Modelling in Dementia 
Green (2007) reviewed the modelling method for cost-effectiveness analysis of Alzheimer’s 
disease. The results focused on four drugs which were most commonly used for the treatment 
of AD: donepezil, rivastigmine, galantamine, and memantine. Most of the models for 
evaluating the cost-effectiveness of donepezil used the Markov model. The models for 
rivastigmine used the Hazard model, introducing individual data of patients from clinical 
trials. Whereas, galantamine applied the Assessment of Health Economics in Alzheimer’s 
Disease (AHEAD) model for tracking the progression of disease. Most of the modelling for 
the economic evaluation of memantine used the Markov model.  
Green et al. (2011), a review of model-based economic evaluation in AD, findings showed a 
state-transition modelling, a Markov model, used in most studies for economic evaluation of 
disease progression in AD. The author also summarised the models of AD as follows: the 
McDonnell model, the Kinosian model, the Consortium to Establish a Registry in 
Alzheimer’s Disease-Clinical Dementia Rating (CERAD-CDR model-refer to Markov 
model), the CERAD-MMSE model, the Assessment of Health Economics in Alzheimer’s 
Disease model (AHEAD model), the memantine model, the Fenn and Gray model, the 
Kungsholmen-MMSE model, the CERAD-Severe Impairment Battery model (CERAD-SIB 
model, and the Predictors Alzheimer’s Disease Assessment Scale-Cognitive Function 
(ADAS-cog model). 
Pouryamout et al. (2012) studied a systematic review of cost-effectiveness analysis in 
patients with AD. The study demonstrated four main models used for economic evaluation. 
The models were the Markov model, microsimulation model, AHEAD model, and discrete-
event simulations.  
 As a result of the lack of pharmacoeconomic research of atypical antipsychotics on 
dementia, it is recommended to explore this significant problem. Although the atypical 
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antipsychotics for treatment in BPSD are still controversial in practical guidelines due to the 
efficacy and safety related to adverse events, they currently remain in general use in clinical 
practices and have a relatively adverse impact on the burden of care, and quality of life of 
patients and caregivers. There were several studies using a decision-analytic model to 
evaluate the cost-effectiveness on the use of atypical antipsychotics for schizophrenia. 
However, there were very few focusing on dementia. Additionally, there were other health 
economic evaluations for other classifications of drug groups for dementia, namely 
Cholinesterase Inhibitors, memantine, based on decision-analytic models. This study will be 
the first to explore and evaluate the cost-effectiveness of atypical antipsychotics drugs 
between olanzapine relative to risperidone, for treatment of behavioural and psychological 
symptoms, in patients with dementia in Thailand. 
 
2.6 Modelling-based economic evaluation in dementia  
The purpose of this review is to explore the existing decision-analytic models, which have 
been used to undertake economic evaluations in dementia. The results from a literature 
review identify the further development of the most appropriate model to apply with the cost-
effectiveness of atypical antipsychotics, for the treatment of behavioural and psychological 
symptoms of dementia in Thailand. 
2.6.1 Literature search for model-based economic evaluation in dementia 
A comprehensive literature search was undertaken in electronic databases. The literature 
search was performed using the following parameter: modelling in dementia. In this 
procedure, there were four main steps. Firstly, the key search terms were developed on the 
basis of the relevant topic. Secondly, titles were considered for screening using the inclusion 
and exclusion criteria. If they met the criteria, they were then exported to RefWorks for 
further evaluation. Thirdly, the abstracts were scrutinised for inclusion and exclusion criteria 
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to confirm whether they met the inclusion criteria. Finally, an assessment and in-depth 
review were conducted to identify whether the literature was for inclusion or exclusion. If 
they fulfilled the criteria, they were then included into the final stage.  
The literature search for model-based economic evaluation in dementia was undertaken in 
electronic databases, including MEDLINE, the Centre for Reviews and Dissemination of the 
University of York (CRD), the Database of Abstracts of Reviews of Effects (DARE), the 
NHS Economic Evaluation Database (NHS EED) and the HTA database (HTA). The 
literature search covered January 1975 up to March 2018. The search terms were broken 
down into the relevant topics as follows: 
a) Dementia or Alzheimer’s disease; 
b) Modelling or models or economic models; 
c) Assessment of health economics, economic evaluations (cost-minimisation 
analysis, cost-benefit analysis, cost-effectiveness analysis, and cost-utility 
analysis). 
The inclusion for the literature search was critically appraised using a PICO framework. The 
inclusion and exclusion criteria are listed below: 
Inclusion criteria: 
• Participants: people with dementia, people with Alzheimer’s disease; 
• Interventions and Comparators: interventions for people with dementia and people 
with Alzheimer’s disease which focused on the treatment of disease progression; 
• Study designs: decision-analytic models, statistical models; 
• Outcomes: economic evaluations (cost-minimization analysis, cost-benefit 
analysis, cost-effectiveness analysis, and cost-utility analysis). 
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Exclusion criteria: 
Articles were excluded when they did not match the inclusion criteria; and in particular if 
they were: 
• Abstracts, letters or commentaries; 
• Studies of cost of illness; 
• No access to full-text papers; 
• Non-English-language articles; 
• Review of articles. 
2.6.2 Data Extraction Strategy 
Initially, the database search retrieved in total 1,118 articles both from MEDLINE and the 
CRD database, respectively. The search resulted in 755 articles retrieved from MEDLINE 
and 363 articles from CRD.  
The initial total of 755 articles from the MEDLINE database underwent screening of the title 
against the inclusion and exclusion criteria. Of these, 616 articles were removed due to their 
title not meeting the inclusion criteria. The remaining 139 articles were identified for 
conducting further scrutiny. A further 101 articles were excluded after the abstract screening. 
The remaining of 38 articles progressed to a full review of the texts.  
From the CRD database, 363 articles were identified based on their titles. After a further 
scrutiny, 299 irrelevant articles based on their titles were removed, and the remaining 64 
articles abstracts were scrutinised. The result of abstract screening was that a further 28 
articles were excluded. The remaining 36 articles were identified to progress to the next step 
in the review process. However, 33 articles were excluded due to duplication, 3 articles 
remained which were potentially relevant and progressed to a full-text review. 
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As a result of scrutinising the two databases, 41 articles were identified as meeting the 
inclusion criteria and were retrieved for full-text reviews. After the articles had been 
identified for full text reviews, a paper was judged to be excluded if access to the full text of 
the paper was not available. Finally, a total of 40 articles were potentially identified to be 
reviewed in-depth, for the model in the treatment of patients with dementia. A literature 
review flowchart is presented in Figure 2.4. 
2.6.3 Results of the literature review 
The screening of the 1,118 article titles identified from MEDLINE and the CRD resulted in 
203 articles being retrieved for abstract consideration. After considering the exclusion 
criteria, a total of 40 were judged to meet the inclusion criteria for an in-depth review. 
Following a more detailed review of those articles, the main findings focused on the model 
for economic evaluation in dementia.  
Following on from the literature search, 40 articles modelled the disease progression in 
dementia. The majority of studies were based on Alzheimer’s disease (n = 39 out of 40). 
There was only one paper identified which was associated with vascular dementia. The 
Markov model was the most commonly used as the decision-analytic model to be employed 
for the disease progression of economic evaluations in dementia, in particular Alzheimer’s 
disease (n = 30 out of 40).  
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Figure 2.4: A comprehensive literature search for model-based economic evaluation in 
dementia  
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Most model-based economic evaluation in dementia included data analyses carried out in 
different time periods and these were classified into five different model structures: the 
Markov model, the Discrete Event Simulation (DES) model, the microsimulation, the 
decision tree, and the statistic model. The findings from the literature search are presented as 
follows: the overall analytical approaches are categorised model structures presented in Table 
2.2. The economic evaluation based on modelling is classified by year and by region 
presented in Table 2.3 and 2.4, respectively. 
Table 2.2: Summary of the decision-analytic models based on model structures used in 
the disease progression of dementia 
Model structure Reference 
1. Markov model Stewart, Phillips and Dempsey (1998), Jonsson et al. (1999), Neumann 
et al. (1999), O’ Brien et al. (1999), Getsios et al. (2001), Caro et al. 
(2002), Garfield et al. (2002), Ikeda, Yamada and Ikegami (2002), 
Migliaccio-Walle et al. (2003), Ward et al. (2003), Caro et al. (2004), 
Francois et al. (2004), Jones, McCrone and Guilhaume (2004), Green et 
al. (2005), Jonsson et al. (2005), Antonanzas et al. (2006), Gagnon et al. 
(2007), Teipel et al. (2007), Fuh and Wang (2008), Kirbach et al. (2008), 
Lopes-Bastida et al. (2009), Suh (2009), Rive et al. (2010), Hoogveldt et 
al. (2011), Lachaine et al. (2011), Pfeil, Kressig and Szucs (2012), Rive 
et al. (2012), Touchon et al. (2014), Hu et al. (2015), Zala, Chan and 
McCrone (2017) 
2.The Discrete Event 
Simulation (DES) 
Getsios et al. (2010), Guo et al. (2010), Hartz et al. (2012), Thibault et 
al. (2015) 
3. Microsimulation Weycker et al. (2007) 
4. Decision tree Henke and Burchmore (1997), Wong et al. (2009) 
5. Statistical model Fenn and Gray (1999), McDonnell et al. (2001), Nagy et al. (2010) 
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Table 2.3: Summary of the model types used to model the disease progression of 
dementia by year 
Model Type 1996-2000 2001-2005 2006-2010 2011-2015 2016-present 
 No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
1. FTC framework -AHEAD 
model based on Caro and 
colleague (2001) 
 7 1   
2. FTC framework-model 
structure based on Rive and 
colleague (2010) 
  1 1 1 
3. CERAD-CDR model structure 1 1 3   
4. CERAD-SIB model   1   
5. Model developed to evaluate 
memantine drug 
 3 2 1  
6. DES model   2 2  
7. Model based on Lachaine et al. 
(2011) 
   3  
8. McDonnell et al. (2001)  1    
9. Fenn and Gray (1999) 1     
10. Model based on the data from 
Kungsholmen project 
1  1   
11. Henke and Burchmore (1997) 1     
12. Nagy et al. (2010) based on 
the MMSE- and ADL- based 
model 
  1   
13. Wong et al. (2009)   1   
14. Stewart, Phillips and 
Dempsey (1998) 
1     
15. Hu et al. (2015)    1  
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Model Type 1996-2000 2001-2005 2006-2010 2011-2015 2016-present 
 No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
No. 
Referenced 
16. O’ Brien et al. (1999) 1     
 
The modelling based on the Markov model  
The model based on the FTC conceptual framework using the predictive equation of time to 
FTC developed by Caro and colleagues (2001) was widely used and modified in studies 
between 2001 and 2009. The model based on the FTC conceptual framework using the 
predictive equation of time to FTC developed by Rive et al. (2010) was applied in several 
studies conducted in 2010 to 2017. In addition, modelling based on the CERAD data using 
the CDR scale to assess the cognitive function of patients was applied in various studies of 
the economic evaluation of dementia during 1999 to 2009. The modelling used to evaluate 
the cost-effectiveness of memantine based on the Markov model was conducted in six studies 
between 2004 and 2011. There were also three studies based on Lachaine et al. (2011) 
conducted between 2011 and 2014. The project of Kungsholmen was adopted to Jonsson et 
al. (1999) and Teipel et al. (2007). Other models were the studies by O’ Brien et al. (1999) 
and Hu et al. (2015).  
The modelling based on the Discrete Event Simulation (DES) model, the decision tree model, 
the statistic model, and the microsimulation model 
Most studies associated with DES models were applied in 2010 to 2015. The decision tree 
model was adopted by two studies those of Henke and Burchmore (1997) and Wong et al. 
(2009), respectively. Fenn and Gray (1999), McDonnell et al. (2001) and Nagy et al. (2010) 
applied the statistic model in their studies. Only one model based on the CERAD study using 
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the SIB scale to measure the cognitive function was applied in the microsimulation model 
(Weycker et al. 2007).  
Table 2.4: Summary of the model types used to model the disease progression of 
dementia by regions 
Model Type Worldwide USA/Canada Europe Asia Multinational 
 
 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
1. FTC framework -AHEAD model 
based on Caro and colleague (2001) 
8 (20) 2 (25) 4 (50) 1 (12.5) 1 (12.5) 
2. FTC framework-model structure 
based on Rive and colleague (2010) 
3 (7.5)  3 (100)   
3. CERAD-CDR scale model 5 (12.5) 2 (40) 1 (20) 2 (40)  
4. CERAD-SIB model 1 (2.5) 1 (100)    
5. Model developed to evaluate 
memantine drug 
6 (15) 1 (20) 5 (80)   
6. DES model 4 (10) 1 (25) 3 (75)   
7. Model based on Lachaine et al. 
(2011) 
3 (7.5) 1 (33.3) 2 (66.7)   
8. McDonnell et al. (2001) 1 (2.5)  1 (100)   
9. Fenn and Gray (1999) 1 (2.5)  1 (100)   
10. Model based on the data from 
Kungsholmen project 
2 (5.0)  2 (100)   
11. Henke and Burchmore (1997) 1 (2.5) 1 (100)    
12. Nagy et al. (2010) based on the 
MMSE- and ADL- based model 
1 (2.5)  1 (100)   
13. Wong et al. (2009) 1 (2.5) 1 (100)    
14. Stewart, Phillips and Dempsey 
(1998) 
1 (2.5)  1 (100)   
15. Hu et al. (2015) 1 (2.5)   1 (100)  
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Model Type Worldwide USA/Canada Europe Asia Multinational 
 
 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
Referenced 
(%) 
16. O’ Brien et al. (1999) 1 (2.5) 1 (100)    
 
Based on the classification by region as seen in Table 2.4, the most often used was the model 
based on the FTC conceptual framework using the predictive equation of time to FTC 
developed by Caro and colleagues (2001) accounting for 20% out of all studies. 
Approximately 50% of the studies were conducted in Europe, followed by the US or Canada. 
The model based on the FTC conceptual framework using the predictive equation of time to 
FTC developed by Rive et al. (2010), was used to evaluate all the studies in Europe. 40% of 
the studies in the US and Asia employed the CERAD-CDR scale, whereas there was only one 
study that applied this model in Europe. The memantine and the Lachaine models were also 
used in studies in Europe accounting for 80% and 66.7%, respectively. There were only two 
studies based on the Kungsholmen project and these were conducted exclusively in Europe. 
75% of the studies based on the DES model were conducted in Europe. The remaining 
studies were undertaken in Europe and the USA or Canada (Henke and Burchmore 1997, 
Stewart, Phillips and Dempsey 1998, O’ Brien et al. 1999, Fenn and Gray 1999, McDonnell 
et al. 2001, Wong et al. 2009, Nagy et al. 2010), with one exception which was employed in 
Asia (Hu et al. 2015).  
The major interventions applied to the model-based economic evaluations in dementia were 
categorised as follows: 
1. Donepezil 
2. Galantamine 
3. Rivastigmine 
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4. Memantine 
5. Olanzapine 
6. Tacrine 
Additionally, the target groups of patients identified in the model-based economic 
evaluations in dementia are summarised as listed below: 
1. Mild to moderate Alzheimer’s disease patients; 
2. Mild to moderate Vascular dementia patients; 
3. Mild to moderately severe Alzheimer’s disease patients; 
4. Mild to moderate and moderate to severe Alzheimer’s disease patients; 
5. Mild to moderately severe and moderate to moderately severe Alzheimer’s 
disease patients; 
6. Moderate to severe Alzheimer’s disease patients; 
7. Moderately severe to severe Alzheimer’s disease patients; 
8. Moderate and severe Alzheimer’s disease patients; 
9. Agitation and psychosis Alzheimer’s disease patients; 
10. Moderate Alzheimer’s disease patients; 
11. Alzheimer’s disease patients not specified severity.   
2.6.4 A summary of the model-based economic evaluation in dementia 
Most studies of modelling in economic evaluations in dementia are focused on Alzheimer’s 
disease. There is only one study identified related to vascular dementia. The literature search 
shows that the modelling used in classifying dementia progression follows one of these 
models: 
1. Model based on the FTC conceptual framework; 
1.1 AHEAD-based model developed by Caro et al. (2001); the predictive equation of 
time to FTC was based on data from the study by Stern et al. (1997); 
 
 
57 
 
1.2 model structure developed by Rive et al. (2010); the predictive equation of time to 
FTC was based on Rive et al. (2010); 
2. Model based on the Consortium to Establish a Registry for Alzheimer’s disease 
(CERAD); 
2.1 Cognitive function was measured based on the Clinical Dementia Rating (CDR) 
scale: CERAD-CDR model; 
2.2 Cognitive function was measured based on the Severe Impairment Battery:  
CERAD-SIB model; 
3. Model developed to evaluate memantine drugs; 
4. The Discrete Event Simulation (DES) model; 
5. Model developed by Lachaine et al. (2011); 
6. Model developed by McDonnell et al. (2001); 
7. Model developed by Fenn and Gray (1999); 
8. Model based on the data from Kungsholmen project;  
9. Model developed by Henke and Burchmore (1997); 
10. Model developed by Nagy et al. (2010) based on the MMSE- and ADL- based model; 
11. Model developed by Wong et al. (2009); 
12. Model developed by Stewart, Phillips and Dempsey (1998); 
13. Model developed by Hu et al. (2015); 
14. Model developed by O’ Brien et al. (1999). 
The next section goes on to the findings of the model-based economic evaluation in dementia 
from the literature review.  
2.6.4.1 Findings of the model-based economic evaluation in dementia from the 
literature review 
Most studies of modelling in economic evaluations in dementia focused on Alzheimer’s 
disease, with one exception related to vascular dementia. The findings from the 
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comprehensive literature search are presented in Table 2.5 which is classified by model types 
and chronological order.  
2.6.4.1.1 Concept of model-based economic evaluations in dementia and model 
applications from the literature review 
According to the comprehensive literature review, the concept of modelling applied to 
economic evaluations in dementia are outlined below.  
2.6.4.1.1.1 Model based on the FTC conceptual framework 
The model-based the FTC conceptual framework according to the literature review in this 
thesis was classified into two main types as subsequently described.  
2.6.4.1.1.1.1 The Assessment of Health Economics in Alzheimer’s disease (AHEAD)-
AHEAD model using the predictive equation of time to FTC developed by Caro and 
colleagues (2001) 
The original model of the Assessment of Health Economics in Alzheimer’s disease 
(AHEAD) based on the need for full-time care (FTC) was initially developed by Caro et al. 
(2001). The model was used to estimate the disease progression of patients to the FTC 
requirement. FTC was the requirement that patients need a significant amount for care and 
supervision almost every day, regardless of the locus of care or who provided it. Further, the 
prediction to death was also estimated. The health states in the model consisted of not 
requiring FTC, FTC and death. Basically, the time spent in the different stages of AD was 
measured. The transition probabilities of requiring FTC were computed by the hazard 
function, based on the patient characteristics. Similarly, the Gompertz hazard functions were 
used to calculate the transition probabilities for patients moving from one state to death were 
based on the patient characteristics. The average delay to FTC was the difference in the 
expected time spent in the given state. The mean time of patients, based on different 
characteristics, was computed by the subtraction between both values. In addition, the 
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equation to predict the need for FTC was developed from data from the study by Stern and 
colleagues (1997), which was undertaken in USA, and modelled in 236 Alzheimer’s disease 
patients. The patients were followed-up for 7 years and the mean age of the patients was 73 
years, (this marked age was brought about to determine younger and older groups which 
were computed in the regression equations for needing FTC). The endpoints of follow-up of 
patients were the need of health related facility, (HRF), care and death.  The set of patient 
characteristics were important to the predictive equation to estimate disease progression over 
time, which correlates to the time to reach FTC. The presence of extrapyramidal symptoms 
(EPS), presence of psychotic symptoms, aged at the onset of disease, cognitive function, and 
duration of illness were found to be the significant factors of the equation. The coefficient of 
predictors were the EPS = -0.9419, psychotic symptoms = -0.4027, at young age of the onset 
of disease = -0.4848, cognitive function = 0.0724, and duration of illness = 0.0617, 
respectively. The cognitive function was measured in terms of the modified Mini-Mental 
State examination (mMMS), whereas the significant predictors of death were based on 
female gender, EPS, cognitive function, and duration of illness. The coefficient of the 
predictors of death were the female gender = 0.7046, EPS = -1.2825, cognitive function = 
0.0310, and duration of illness = 0.1052, respectively. To calculate the time to FTC need, the 
following two steps were undertaken (Caro et al. 2001). The first step was a calculation 
around the average hazards for reaching FTC and death. The equation was: 
 
𝜆 =  
− ln(1 − 𝐹)
(𝑡𝑖 − 𝑡𝑖−1)
 
 
where  𝜆 was the average hazard over the period, 
           𝐹 was the cumulative of proportion of patients with failure over period, 
          𝑡𝑖 was the time at failure  (𝑖) and 
          𝑡𝑖−1  was the previous time (𝑖 − 1).  
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In accordance with the index derived from the hazard model, the baseline hazard for 
index (𝜆
0
) was computed by: 
 
                                                                           𝜆0
𝑡  = 
𝜆𝑖𝑛𝑑𝑒𝑥
𝑡
𝑒−𝑖𝑛𝑑𝑒𝑥
 
 
The next step was to calculate the relationship between the baseline hazard and time. The 
equations were separated by aged group, defined into younger and older, the cut-off point 
being aged 73-year. The coefficients applied in the equation to calculate for risk over time 
were A = 0.0231, B = -1.8117, C = 0.0373, D = 0.1532, and E = -4.7903 for patients aged 73 
years and younger. Whereas the coefficients for the patient aged more than 73 years were A 
= 0, B = -0.6846, C = -6.4172, D = 0.0112, and E = 0.1413. Thus, the relation for risk over 
time was calculated by the equation:   
 
𝜆𝐹𝑇𝐶 = 𝑒
(𝐴𝑡+𝐵+𝐶 sinh(𝐷𝑡+𝐸)) 
 
where   sinh was the hyperbolic sine, 
                   𝑡  was the time and  
            A, B, C, D and E were coefficients as presented above.  
Then the regression equation was applied to estimate the hazard for other index values based 
on the Cox proportional hazard equation. The hazard for risk over time for any index scores 
was calculated for the time to FTC need using the equation below.  
 
                                                                           𝜆𝑖𝑛𝑑𝑒𝑥
𝑡  = 
𝜆0
𝑡
𝑒𝑖𝑛𝑑𝑒𝑥
 
 
In conclusion, the concepts of the AHEAD model, which was developed by Caro et al 
(2001), used the patient characteristics at a given point to predict the disease progression to a 
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level of requiring FTC. The health states in the model consisted of pre-FTC, FTC and death. 
The Cox proportional hazard models were used to predict the risk of FTC need and death of 
patients as a function of time as well as index scores that incorporated the various patient 
characteristics. The significant covariates to predict those requiring FTC were the presence of 
EPS, presence of psychotic symptoms, age at onset of disease, duration of illness, and 
cognitive score (mMMS). The prediction to death was based on EPS, duration of illness, 
female gender, and mMMS score. The mMMS was the modified Mini-Mental State 
examination.  
In addition, eight studies used the AHEAD model developed by Caro et al. (2001). Concepts 
of these models were the course of disease progression in terms of health states defined by 
the time until patients requiring FTC (Getsios et al. 2001, Caro et al. 2002, Garfield et al. 
2002, Migliaccio-Walle et al. 2003, Ward et al. 2003, Caro et al. 2004, Green et al. 2005, Suh 
2009).  
● Model type:  
 
All eight studies applied Markov models (Getsios et al. 2001, Caro et al. 
2002, Garfield et al. 2002, Migliaccio-Walle et al. 2003, Ward et al. 
2003, Caro et al. 2004, Green et al. 2005, Suh 2009). 
● The definition of disease 
severity:  
The need to FTC was used to define the disease severity in the model of 
all eight studies (Getsios et al. 2001, Caro et al. 2002, Garfield et al. 
2002, Migliaccio-Walle et al. 2003, Ward et al. 2003, Caro et al. 2004, 
Green et al. 2005, Suh 2009).   
● The study population:  
 
Most studies conducted in the mild to moderate Alzheimer’s patients 
(Getsios et al. 2001, Caro et al. 2002, Garfield et al. 2002, Migliaccio-
Walle et al. 2003, Ward et al. 2003, Caro et al. 2004). Two studies 
conducted in mild to moderately severe Alzheimer’s disease (Green et 
al. 2005, Suh 2009). 
● Interventions:  
 
The majority of studies conducted the treatment of galantamine 
compared with no pharmacological treatment (Getsios et al. 2001, Caro 
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et al. 2002, Garfield et al. 2002, Migliaccio-Walle et al. 2003, Caro et al. 
2004). However, the differences of dosage regimen of galantamine were 
applied. A comparison between galantamine (not identified dosage 
regimen) and no pharmacological treatment was found in studies by 
Caro et al. (2002) and Caro et al. (2004). Getsios et al. (2001) examined 
galantamine 24 mg/day versus no pharmacological treatment. Between 
galantamine 12 mg given twice daily in Alzheimer’s patient and no 
pharmacological treatment were compared in the study by Garfield et al. 
(2002). Migliaccio-Walle et al. (2003) conducted the comparison of 
galantamine 16 mg/day and 24 mg/day versus no pharmacological 
treatment. Galantamine 16 mg/day and 24 mg/day compared with no 
cholinesterase treatment were employed in the study by Ward et al. 
(2003). Between galantamine 24 mg/day plus usual care versus usual 
care were examined by Suh (2009). Green et al. (2005) studied 
donepezil, galantamine and rivastigmine compared with usual care. 
● The disease progression:  
 
The predictive equation was needed to predict time to FTC over time. 
The significant covariates to predict the need to FTC were presence of 
EPS, presence of psychotic symptoms, age at onset of disease, duration 
of illness, and cognitive score (mMMS).  
● Model structure:  
 
The health states in all models comprised three states: not requiring FTC 
(Pre-FTC), requiring FTC, as well as death (Getsios et al. 2001, Caro et 
al. 2002, Garfield et al. 2002, Migliaccio-Walle et al. 2003, Ward et al. 
2003, Caro et al. 2004, Green et al. 2005, Suh 2009). 
● Data sources:  
 
Seven studies used the predictive equation based on the longitudinal 
study, undertaken in USA, in 236 Alzheimer’s disease patients by Stern 
et al. (1997), to predict the time until patients needed FTC (Getsios et al. 
2001, Caro et al. 2002, Garfield et al. 2002, Migliaccio-Walle et al. 
2003, Ward et al. 2003, Caro et al. 2004, Green et al. 2005). The other 
applied the longitudinal studies in South Korea (Suh 2009). 
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For mortality probabilities, six out of eight studies used data from a 
longitudinal study, as mentioned above, to predict the transition 
probabilities of death, with two exceptions which used data from the 
prospective study (Green et al. 2005) and a longitudinal study in South 
Korea (Suh 2009). 
There were six studies using the RCT data for the treatment effect 
(Getsios et al. 2001, Caro et al. 2002, Garfield et al. 2002, Migliaccio-
Walle et al. 2003, Ward et al. 2003, Caro et al. 2004), while one study 
used the meta-analysis on RCT study (Green et al. 2005) and another 
study adopted data from longitudinal studies in South Korea (Suh 2009).  
● Time horizon and cycle 
length: 
Six studies conducted over a 10-year period modelled using a monthly 
Markov cycle (Getsios et al. 2001, Caro et al. 2002, Garfield et al. 2002, 
Migliaccio-Walle et al. 2003, Ward et al. 2003, Caro et al. 2004).  Two 
studies modelled a 5-year time horizon performing with a one month 
cycle length (Green et al. 2005, Suh 2009). 
● Healthcare Perspective of 
model: 
Caro et al. (2002) used the broad perspective and formal care in their 
studies, whereas Caro et al. (2004) applied the broad perspectives 
including social services. The public health payer was used in Garfield 
et al. (2002). A third party approach was employed in the studies by 
Migliaccio-Walle et al. (2003) and Suh (2009). The studies by Ward et 
al. (2003) and Green et al. (2005) were conducted from the perspectives 
of the National Health Service and Personal Social Service. 
● Costs data and Utilities: All eight studies included direct costs for cost data (Getsios et al. 2001, 
Caro et al. 2002, Garfield et al. 2002, Migliaccio-Walle et al. 2003, 
Ward et al. 2003, Caro et al. 2004, Green et al. 2005, Suh 2009). 
However, one study considered the additional out-of-pocket expenses 
for the patients’ assistant or paid caregiver, caregiver time-related costs, 
and caregiver’s lost productivity (Suh 2009). Costs associated with 
visiting patients were encompassed in the study by Green et al. (2005).  
 
 
64 
 
 Six studies used the Health Utilities Index Mark 2 (HUI:2) based on the 
cross-sectional study (Getsios et al. 2001, Caro et al. 2002, Ward et al. 
2003, Caro et al. 2004, Green et al. 2005, Suh 2009). Two studies were 
not identified (Garfield et al. 2002, Migliaccio-Walle et al. 2003). 
● Discount rates:   The discount rates for costs and benefits varied in the studies. A 3% 
discount rate in both costs and outcomes was conducted in three studies 
(Getsios et al. 2001, Migliaccio-Walle et al. 2003, Caro et al. 2004). One 
study used the discount rate for only costs at 3% (Garfield et al. 2002). 
Three studies applied a 6% and 1.5% for the discount rate, respectively, 
for costs and outcomes per annum (Ward et al. 2003, Green et al. 2005, 
Suh 2009). A discount rate at 5% in both costs and outcomes was 
employed in Caro et al. (2002). 
 
In conclusion, the AHEAD model, which was developed by Caro and colleagues (2001), was 
wildly used to apply to the assessment of health economics between 2001 and 2009. The 
Markov model was used to predict the time until patients reached FTC. The predictive 
equation developed based on data from the study by Stern et al. (1997) was used in most 
studies. The three main health states in the model were Pre-FTC, FTC, as well as death. 
Approximately 75% of all studies were conducted in patients with mild to moderate 
Alzheimer’ disease. Most studies examined the treatment of galantamine relative to no 
pharmacological treatment (62.5%). The randomized controlled trials were used as data 
sources for the effectiveness data. Varieties were found in perspectives, the discounted rates 
of costs and outcomes, as well as the time horizon of the model. Most studies applied the data 
from the study by Neumann et al. (1999) for the utilities, and was the most commonly 
applied in the models, being associated with 62.5% of the studies, (5 out of the 8 studies).   
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2.6.4.1.1.1.2 Model structure based on the FTC framework using the predictive equation 
of time to FTC development by Rive and colleague (2010) 
In 2010, Rive and colleagues attempted to develop a new predictive equation of time to FTC 
applying to the model based on the FTC conceptual framework. The model consisted of the 
three health states: pre-FTC, FTC and death. The core concept of the model was to predict 
the disease progression of the patient until requiring FTC. The baseline patient characteristics 
were derived from London and the South-East region, (LASER), which was a longitudinal 
epidemiological study conducted in 224 people with Alzheimer’s disease and their caregivers 
(Livingston et al. 2004). The new predictive equations were used to compute the transition 
probabilities from pre-FTC to FTC deriving from the LASER-AD cohort of 117 pre-FTC 
patients with a 54-month follow-up period.  Also, the predictive equations of disease 
progression were correlated to the key features of Alzheimer’s disease; including cognitive 
function, functional ability, and behaviour, which predicted the time to FTC based on 
patient’s three core elements at baseline. The cognitive function was measured using the 
Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog). The functional ability was 
defined by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale 
(ADCS-ADL). The behavioural aspect was assessed using the Neuropsychiatric Inventory 
(NPI). The predictive equations which were developed by Rive and colleagues are presented 
below: 
● To predict the time to FTC in patients with Alzheimer’s disease, the predictive equation 
was calculated by: 
 
𝑃𝑗 = 1 − exp (−exp (−11.1343 + 0.0330 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  
−0.0877 × 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 + 0.0377 × 𝑁𝑃𝐼𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒  
+0.8122 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗) − 2.4072 
× 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗)) × exp (3.3195 × ln (𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙𝑗))) 
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where the coefficient of baseline parameters were logarithms of time = 3.320, baseline 
ADAS-cog total score = 0.033, baseline ADCS-ADL total score = -0.088, baseline NPI total 
score = 0.038, ADAS-cog slope = 0.812, ADCS-ADL slope = -2.407, and intercept = -
11.134, 𝑗 was time interval, and 𝑃 was hazard function. 
● To estimate the monthly transition probability to FTC state was calculated by: 
 
𝑝𝑗𝑖
𝐹𝑇𝐶 = 1 − √(1 − 𝑃𝑗
𝑙𝑒𝑛𝑔𝑡ℎ(𝑗)
) 
 
where   𝑝𝑗𝑖𝐹𝑇𝐶  was monthly probability 
  𝑝𝑗    was probability for the time interval  j. 
● The equation to estimate monthly death probability: 
 
𝑆𝑖 = exp (−exp (−13.615) × 𝑡𝑖𝑚𝑒
exp(0.568)) 
 
where   𝑆𝑖  was monthly probability of death 
  𝑡𝑖𝑚𝑒  was in days from the model start. 
● Then, the probabilities of dying between two cycles were estimated from 
 
𝑃𝑖
𝑑𝑒𝑎𝑡ℎ = 1 − 𝑆(𝑖+1)/𝑆𝑖 
 
where  𝑃𝑖𝑑𝑒𝑎𝑡ℎ was death probability for the time interval i. 
Based on the equations as presented above, the disease progression over time of time to FTC 
was predicted by the rate of changes in cognition and functional ability (Rive et al. 2010). 
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Additionally, three studies used the model based on the FTC framework using the predictive 
equation of time to FTC development by Rive and colleague (2010). The model concepts 
were the course of disease progression in terms of health states defined by patients needing 
FTC (Rive et al. 2010, Rive et al. 2012, Zala, Chan and McCrone 2017).  
● Model type:  
 
All studies used the Markov model (Rive et al. 2010, Rive et al. 2012, 
Zala, Chan and McCrone 2017).  
● The definition of disease 
severity:  
The need to FTC was used to define the disease severity in the model 
(Rive et al. 2010, Rive et al. 2012, Zala, Chan and McCrone 2017).   
● The study population:  
 
Two studies examined patients with moderate to severe Alzheimer’s 
disease (Rive et al. 2010, Rive et al. 2012). Only one study was 
conducted using moderate to severe and mild to moderate in 
Alzheimer’s patients (Zala, Chan and McCrone 2017). 
● Interventions:  
 
The comparison of memantine to no pharmacological treatment or 
background therapy with cholinesterase inhibitors (ChEIs) was 
examined by the studies of Rive et al. (2010) and Rive et al. (2012). 
Comparisons of memantine versus ChEIs or no treatment, in moderate 
to severe Alzheimer’s in patients and ChEIs versus no treatment in mild 
to moderate in Alzheimer’s patients were examined by Zala, Chan and 
McCrone (2017). 
● The disease progression:  
 
The predictive equation was needed to predict time to FTC over time. 
The significant covariates to predict those requiring FTC were 
cognitive function, (as measured by ADAS-cog), functional ability (as 
assessed by ADCS-ADL), and behaviour (as defined by NPI) (Rive et 
al. 2010, Rive et al. 2012, Zala, Chan and McCrone 2017).  
● Model structure:  
 
 The health states in the models were pre-FTC, FTC and death (Rive et 
al. 2010, Rive et al. 2012, Zala, Chan and McCrone 2017). 
● Data sources:  
 
Two studies used data from longitudinal studies for the course of 
disease progression (Rive et al. 2010, Rive et al. 2012). One study 
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obtained data from a longitudinal study and RCTs (Zala, Chan and 
McCrone 2017).  
The probabilities of death were derived from longitudinal studies which 
were applied to all these studies and a meta-analysis on RCTs was also 
employed for the treatment effect in these studies (Rive et al. 2010, 
Rive et al. 2012, Zala, Chan and McCrone 2017).  
● Time horizon and cycle 
length: 
The model conducted over a 5-year period with a 1-month cycle length 
in all models (Rive et al. 2010, Rive et al. 2012, Zala, Chan and 
McCrone 2017). 
● Healthcare Perspective of 
model: 
There were differences in the perspective of the models. Rive et al. 
(2010) employed the model based on the National Health Service and 
Personal Social Services. The societal and healthcare system was used 
as viewpoints in the study by Rive et al. (2012). The National Health 
Service and Social care perspectives were applied by Zala, Chan and 
McCrone (2017). 
● Costs data and Utilities: All three studies included direct costs in the models (Rive et al. 2010, 
Rive et al. 2012, Zala, Chan and McCrone 2017). Only one study 
encompassed informal care, including caregiver lost productivity, in the 
cost data (Rive et al. 2012).  
Regarding utilities, one study used QoL-AD, HSQ-12 and Ferm’ D-test 
mapped to EQ-5D for the utility in the Pre-FTC state, whilst the utility 
on the FTC state was derived from the LASER-AD study (Rive et al. 
2010). One study was conducted in a similar fashion to the study by 
Rive et al. (2010) for the utility in the Pre-FTC state. For the utilities in 
the FTC state were based on the published studies by Rive et al. (2010) 
and Caro et al. (2002) (Zala, Chan and McCrone 2017). Another study 
was not clear (Rive et al. 2012).  
● Discount rates:   Costs and health outcomes were discounted using an annual rate of 
3.5% in two studies (Rive et al. 2010, Zala, Chan and McCrone 2017). 
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A discount rate of 3% was applied in both costs and benefits in the 
remaining study (Rive et al. 2012). 
 
To conclude, the model based on the FTC framework using the predictive equation of time to 
FTC development by Rive and colleague (2010), was used to apply to the assessment of 
health economics of dementia during 2010 and 2017. This model concept was used to predict 
the disease progression of patients until requiring FTC. The health states were defined as Pre-
FTC, FTC and death. Most studies were conducted in patients with moderate to severe 
Alzheimer’s disease and memantine was a substantial treatment that was evaluated in three 
different studies using this model. The transition probability of the pre-FTC to the FTC state 
was applied with a predictive equation based on the study by Rive et al. (2010), along with 
the transition probability of dying which was based on the LASER-AD cohort (Rive et al. 
2010, Rive et al. 2012, Zala, Chan and McCrone 2017). Cognition, function, and behaviour 
were the significant components to predict the time to FTC. In addition, the healthcare 
perspectives used in the models varied as stated above. The application of the discount rate of 
costs and outcomes ranged between 3% and 3.5%. 
2.6.4.1.1.2 Model based on the Consortium to Establish a Registry for Alzheimer’s disease 
(CERAD)  
In this thesis, the concept of modelling based on the CERAD framework following the 
literature review are classified into two approaches as described below.  
2.6.4.1.1.2.1 Cognitive function was measured based on the Clinical Dementia Rating 
(CDR) scale: CERAD-CDR model 
The study of the cost-effectiveness analysis was conducted on donepezil in comparison to no 
treatment in mild to moderate Alzheimer’s disease patients in the US (Neumann et al. 1999). 
A Markov model was used to simulate patients’ progression through the disease severity 
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stages and residential settings. Patients were classified into disease severities based on the 
Clinical Dementia Rating (CDR) scale, measured memory, orientation, judgement and 
problem-solving, community affairs, home and hobbies, and personal care, as follows: mild 
(CDR = 0.5 or 1), moderate (CDR = 2), and severe (CDR = 3). Also, these patients were 
assigned to two settings (community or nursing home) at each disease stage, however, the 
transition amongst the disease severity stages of patients were not conditional on their 
settings. The CERAD database was compiled from 1986 to 1995 by clinicians from 22 
medical centres in the US, who had investigated 1,145 patients with dementia. The database 
was used to estimate the state-to-state transition probabilities in which the modified survival 
analysis was applied. The transition probability from mild state to moderate state was 
computed by the number of the annual transitions or events divided by the total number of 
years spent in a mild stage. Similarly, the transition probability from the community to the 
nursing home was predicted by the identical method using the data from CERAD. The effect 
of donepezil was derived from a clinical trial. To calculate the effectiveness of the drug, 
patients were initially identified as being in a mild state, then using the Cox proportional 
hazards regression model, comparing the hazard ratio between the drug and placebo, to 
estimate the transition probabilities to the moderate state.  
The CERAD-CDR model has been widely used in the economic evaluation in dementia. Five 
studies applied the CERAD-CDR concept. The course of disease progression was mainly 
defined by the disease severity levels associated with cognitive function (Neumann et al. 
1999, Ikeda, Yamada and Ikegami 2002, Fuh and Wang 2008, Kirbach et al. 2008, Lopes-
Bastida et al. 2009).  
● Model type:  
 
All studies developed the Markov approach to characterise the 
progression of disease (Neumann et al. 1999, Ikeda, Yamada and 
Ikegami 2002, Fuh and Wang 2008, Kirbach et al. 2008, Lopes-
Bastida et al. 2009).   
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● The definition of disease 
severity:  
All five studies used the CDR scale to determine the levels of 
disease severity (Neumann et al. 1999, Ikeda, Yamada and Ikegami 
2002, Fuh and Wang 2008, Kirbach et al. 2008, Lopes-Bastida et al. 
2009).   
● The study population:  
 
Four out of five studies conducted in mild to moderate Alzheimer’s 
patients (Neumann et al. 1999, Ikeda, Yamada and Ikegami 2002, 
Fuh and Wang 2008, Lopes-Bastida et al. 2009). Only one study 
examined patients with agitation and psychosis in Alzheimer’s 
disease (Kirbach et al. 2008). 
● Interventions:  
 
Four out of five studies conducted donepezil compared with usual 
care or no pharmacological treatment (Neumann et al. 1999, Ikeda, 
Yamada and Ikegami 2002, Fuh and Wang 2008, Lopes-Bastida et 
al. 2009). One study examined olanzapine versus no drug treatment 
(Kirbach et al. 2008). 
● The disease progression:  
 
Three studies showed that the transition probabilities from stage-to-
stage, used levels of disease severity to simulate the disease 
progression (Ikeda, Yamada and Ikegami 2002, Fuh and Wang 
2008, Lopes-Bastida et al. 2009). Two studies used the disease 
severity probabilities and institutionalisation probabilities to 
estimate the patients’ progress through the different states 
(Neumann et al. 1999, Kirbach et al. 2008).  
● Model structure:  
 
The health states in the models of three studies associated with the 
levels of disease severity were mild, moderate, severe, as well as 
death (Ikeda, Yamada and Ikegami 2002, Fuh and Wang 2008, 
Lopes-Bastida et al. 2009). Two studies included the severity levels 
of the cognitive function (mild, moderate and severe), 
institutionalisation and death as health states in the model (Neumann 
et al. 1999, Kirbach et al. 2008). 
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● Data sources:  
 
Based on 1,145 dementia patients from the CERAD study, a 
longitudinal study was used to estimate the transition probabilities 
of the disease progression (Neumann et al. 1999, Ikeda, Yamada and 
Ikegami 2002, Kirbach et al. 2008, Lopes-Bastida et al. 2009). One 
study applied data from an observational study in Taiwan (Fuh and 
Wang 2008).  
For mortality probabilities, four studies also obtained data from the 
CERAD studies (Neumann et al. 1999, Ikeda, Yamada and Ikegami 
2002, Kirbach et al. 2008, Lopes-Bastida et al. 2009). Another study 
applied data from an observational study in Taiwan (Fuh and Wang 
2008).  
Four studies took the treatment effect data from RCTs (Neumann et 
al. 1999, Ikeda, Yamada and Ikegami 2002, Kirbach et al. 2008, 
Lopes-Bastida et al. 2009), with one study which used a longitudinal 
study in Taiwan (Fuh and Wang 2008).  
● Time horizon and cycle 
length: 
Two studies conducted a 2-year period with a 1-month Markov 
cycle (Ikeda, Yamada and Ikegami 2002, Lopes-Bastida et al. 2009). 
One study examined over a 5-year period with 1-year cycle length 
(Fuh and Wang 2008). One study employed an 18-month time 
horizon and a 6-week cycle length for the model (Neumann et al. 
1999). Another study used the lifetime period with a 6-month cycle 
length (Kirbach et al. 2008).  
● Healthcare Perspective of 
model: 
Three studies used the societal perspective as the viewpoint 
(Neumann et al. 1999, Fuh and Wang 2008, Lopes-Bastida et al. 
2009). One study was performed for the US health system (Kirbach 
et al. 2008). Another model was conducted from the payer 
perspective (Ikeda, Yamada and Ikegami 2002).  
● Costs data and Utilities: All studies encompassed direct costs (Neumann et al. 1999, Ikeda, 
Yamada and Ikegami 2002, Fuh and Wang 2008, Kirbach et al. 
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2008, Lopes-Bastida et al. 2009). However, one study included 
unpaid caregiving cost data (Neumann et al. 1999). Another study 
covered unpaid informal care (Fuh and Wang 2008).  
Regarding health utilities, two studies used HUI:2 instrument to 
describe the health states (Neumann et al. 1999, Fuh and Wang 
2008). One study applied HUI:3 in the Japanese version from a 
survey (Ikeda, Yamada and Ikegami 2002). One study adopted EQ-
5D based on the survey (Lopes-Bastida et al. 2009). Another study 
took utilities from a schizophrenia study and the study by Murman 
and Colenda (2005) (Kirbach et al. 2008).  
● Discount rates:   All studies discounted costs at 3% and quality of life benefits at 3% 
per annum (Neumann et al. 1999, Ikeda, Yamada and Ikegami 2002, 
Fuh and Wang 2008, Kirbach, et al. 2008, Lopes-Bastida et al. 
2009). 
 
In brief, the CERAD-CDR model used the Markov model to simulate the disease progression 
through the disease severity. Four out of five studies were conducted in mild to moderate 
Alzheimer’s patients to compare donepezil to usual care or no pharmacological treatment. 
Only one study was associated with olanzapine versus no drug treatment which examined 
patients with agitation and psychosis in Alzheimer’s disease. The main health states were 
classified to mild, moderate, severe, and death as defined by the CDR scale. However, the 
residential settings which were the community and the nursing home were also considered in 
the Markov model by Neumann et al. (2001) and Kirbach et al. (2008). The studies based on 
CERAD-CDR had differences in the perspective of study (i.e. the health system, payer, 
societal perspectives) and the time horizon of study (i.e. a 2-year period and lifetime). 
However, all studies were similar in the use of their discounting rate of costs and outcomes at 
3%. Regarding the health utilities, studies applied the values based on HUI, HUI:2, HUI:3, 
and EQ-5D instrument. 
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2.6.4.1.1.2.2 Cognitive function was measured based on the Severe Impairment Battery:  
CERAD-SIB model 
Weycker et al. (2007) developed a microsimulation to evaluate the cost-effectiveness of 
memantine and donepezil compared with donepezil only, in moderate to severe Alzheimer’s 
disease patients, on a monthly cycle over a lifetime horizon from a societal perspective. The 
model was constructed to predict the changes in disease progression in terms of the cognitive 
function, as measured by SIB score. However, based on the data applied in the model, several 
studies used MMSE or CDR scale for measuring the disease severity. Thus mapping between 
MMSE or CDR and SIB were needed to allow comparisons between the data. The transition 
probability was obtained from data from a longitudinal study. The impacts of memantine and 
donepezil treatments were taken from data from clinical trials. The transition probabilities to 
institutionalisation were captured based on a longitudinal study by Neumann et al. (1999). 
The probability of dying was based on the life table of the general US population, adjusted by 
age and gender. Then the relative risk of death of Alzheimer’s patients was employed to 
compute the mortality probabilities. The utility weights were derived from the Health 
Utilities Index Mark 3 (HUI:3) and CDR (disease severity). The CDR was mapped to MMSE 
and the result was finally transformed to SIB. The costs considerations were both formal and 
informal care services. The discount rate of the analysis was at 3% for both costs and 
outcomes per annum. 
2.6.4.1.1.3 Model developed to evaluate memantine drug  
Jones, McCrone and Guilhaume (2004) studied the cost-effectiveness of memantine 
compared with no pharmacological treatment, in moderately severe to severe Alzheimer’s 
disease patients in the UK. A Markov model was used to predict the outcomes from treating 
with memantine over a 2-year time horizon. The outcomes were time to dependency (as a 
primary outcome), time to institutionalisation, and quality-adjusted life years (QALYs) (as 
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secondary outcomes). The Markov states were based on the three domains:  cognitive 
function, physical dependency, and residential setting. The cognitive function was measured 
using Mini-Mental State Examination (MMSE). The MMSE defined the severities of disease 
as moderate state (MMSE>14), moderately severe state (MMSE =10-14), and severe state 
(MMSE<10). The standardised tool, Alzheimer’s Disease Cooperative Study-Activities of 
Daily Living (ADCS-ADL), was used to assess the abilities to perform daily activities. The 
physical dependency was divided into dependence and independence. The residential settings 
were defined into community or institutionalisation. Therefore, the health states in the model 
totalled 13 states based on multiplying the 3 states of the disease severity, 2 states of physical 
dependency, 2 states of residential setting plus the state of death. The transitions in the model 
calculated the severity, dependency, institutionalisation, and mortality transitions. The 
severity transition probabilities were based on the disease severity at the initiate cycle and on 
the treatment. The disease severity and the dependency at the initiate cycle and on the 
treatment were the significant parameters used to calculate the dependence transition 
probability. The transition probability of institutionalisation was dependent on the disease 
severity at the initiate cycle and on the treatment. The death probabilities were derived from 
the UK epidemiological study and were assumed to be similar values in both no treatment 
and treatment.   
In addition, six studies examined the treatment with memantine in patients with dementia. 
The concepts of this model were the course of the disease defined on the basis of disease 
severity, patients’ dependency, and with/without residential setting (Jones, McCrone and 
Guilhaume 2004, Francois et al. 2004, Jonsson 2005, Antonanzas et al. 2006, Gagnon et al. 
2007, Hoogveldt et al. 2011).   
● Model type:  
 
All studies used the Markov model (Jones, McCrone and Guilhaume 
2004, Francois et al. 2004, Jonsson 2005, Antonanzas et al. 2006, 
Gagnon et al. 2007, Hoogveldt et al. 2011).   
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● The definition of disease 
severity:  
Three studies used cognitive impairment, physical dependency, and 
care setting to predict the disease progression (Jones, McCrone and 
Guilhaume 2004, Francois et al. 2004, Jonsson 2005). The other 
studies relied on two domains: cognitive function and physical 
dependency (Antonanzas et al. 2006, Gagnon et al. 2007, Hoogveldt 
et al. 2011). The cognitive function was measured by MMSE scores 
in all studies (Jones, McCrone and Guilhaume 2004, Francois et al. 
2004, Jonsson 2005, Antonanzas et al. 2006, Gagnon et al. 2007, 
Hoogveldt et al. 2011). MMSE scores were classified into moderate 
(MMSE>14), moderately severe (MMSE=10-14), and severe 
(MMSE<10) in four studies (Jones, McCrone and Guilhaume 2004, 
Francois et al. 2004, Jonsson 2005, Antonanzas et al. 2006). Two 
study defined the disease severity as moderate (MMSE=10-19) and 
severe (MMSE< 10) (Gagnon et al. 2007, Hoogveldt et al. 2011). 
The physical dependency was classified into dependent and 
independent as assessed by ADCS-ADL or ADL or IADL (Jones, 
McCrone and Guilhaume 2004, Francois et al. 2004, Jonsson 2005, 
Antonanzas et al. 2006, Gagnon et al. 2007, Hoogveldt et al. 2011). 
The place of residence was associated with living in the community 
and living in an institution (Jones, McCrone and Guilhaume 2004, 
Francois et al. 2004, Jonsson, 2005).    
● The study population:  
 
Four studies were conducted in patients with moderately severe to 
severe Alzheimer’s disease (Jones, McCrone and Guilhaume 2004, 
Francois et al. 2004, Jonsson 2005, Antonanzas et al. 2006). While, 
two studies were conducted using moderate to severe Alzheimer’s 
patients (Gagnon et al. 2007, Hoogveldt et al. 2011).   
● Interventions:  
 
All studies compared the memantine treatment with no 
pharmacological treatment or standard care (Jones, McCrone and 
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Guilhaume 2004, Francois et al. 2004, Jonsson 2005, Antonanzas et 
al. 2006, Gagnon et al. 2007, Hoogveldt et al. 2011).  
● The disease progression:  
 
Severity transition probabilities were conditional upon patients’ 
disease severity at the beginning of the cycle and on the treatment. 
Dependency transition probabilities depended on the patients’ disease 
severity and levels of patients’ dependency at the beginning of the 
cycle and on the treatment. Institutionalisation transitions were 
associated with patients’ disease severity at the beginning of the 
cycle and on the treatment (Jones, McCrone and Guilhaume 2004, 
Francois et al. 2004, Jonsson 2005). Two studies were based on 
disease severity and dependency; severity transitions depended on the 
disease severity at the beginning of the cycle and on the treatment 
and dependency transitions relied on the disease severity and levels 
of dependency at the beginning of the cycle, and on the treatment 
(Antonanzas et al. 2006, Gagnon et al. 2007). Only one study showed 
that severity and dependency transitions were conditional on the 
levels of the patients’ disease severity and levels of patients’ 
dependency at the beginning of the cycle and on the treatment 
(Hoogveldt et al. 2011).   
● Model structure:  
 
In three studies, the health states in the model totalled 13 states based 
on multiplying three states of disease severity (moderate, moderately 
severe, and severe), two states of physical dependency (dependent 
and independent), two states of residential setting (community and 
institution) plus the state of death (Jones, McCrone and Guilhaume 
2004, Francois et al. 2004, Jonsson 2005). Seven health states 
associated with three levels of cognitive function (moderate, 
moderately severe, and severe) and two dependency states 
(dependent and independent), including death, were applied in one 
study (Antonanzas et al. 2006). Two studies employed five health 
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states accounting for two disease severity modes (moderate and 
severe), dependency (dependent and independent), and death 
(Gagnon et al. 2007, Hoogveldt et al. 2011). 
● Data sources:  
 
Regarding the severity transition probabilities, four studies used data 
from RCTs (Francois et al. 2004, Jones, McCrone and Guilhaume 
2004, Antonanzas et al. 2006, Hoogveldt et al. 2011). One study 
applied RCT and a longitudinal study (Jonsson 2005). The other was 
obtained data from RCT and open-label extension study (Gagnon et 
al. 2007).  
For the dependence probabilities, four of six studies adopted data 
from RCT study (Francois et al. 2004, Jonsson 2005, Antonanzas et 
al. 2006, Hoogveldt et al. 2011). One study employed RCT and a 
longitudinal study (Jones, McCrone and Guilhaume 2004). The 
remaining study used RCT and open-label extension study (Gagnon 
et al. 2007).  
For institutionalisation probabilities, two studies applied data from 
longitudinal studies for no pharmacological treatment and RCTs for 
the treatment (Jones, McCrone and Guilhaume 2004, Francois et al. 
2004). One study used data from a longitudinal study. The 
institutionalisation was not included in the models of three studies 
(Gagnon et al. 2007, Antonanzas et al. 2006, Hoogveldt et al. 2011).  
For the death probabilities, five studies adopted data from 
longitudinal studies (Francois et al. 2004, Jones, McCrone and 
Guilhaume 2004, Jonsson 2005, Gagnon et al. 2007, Hoogveldt et al. 
2011). The other used data from a cross-sectional study (Antonanzas 
et al. 2006).  
According to the treatment effects of memantine, two studies applied 
the treatment effect data from RCTs (Jonsson 2005, Antonanzas et al. 
2006). RCTs and an open-label extension study were used in three 
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studies (Francois et al. 2004, Jones, McCrone and Guilhaume 2004, 
Gagnon et al. 2007). One study adopted data from an open-label 
extension study (Hoogveldt et al. 2011). 
● Time horizon and cycle 
length: 
The models conducted a 2-year period in three studies (Jones, 
McCrone and Guilhaume 2004, Antonanzas et al. 2006, Gagnon et al. 
2007). The remaining studies covered a 5-year period (Francois et al. 
2004, Jonsson 2005, Hoogveldt et al. 2011). All studies employed a 
6-month cycle length to predict the disease progression of the model. 
● Healthcare Perspective of 
model: 
The National Health Service and Personal Services were the 
viewpoints (Jones, McCrone and Guilhaume 2004). In addition, the 
public’s payer perspective was used in the study by Jonsson (2005). 
The other studies used a societal perspective in the model (Francois 
et al. 2004, Antonanzas et al. 2006, Gagnon et al. 2007, Hoogveldt et 
al. 2011).  
● Costs data and Utilities: Direct costs were included in all studies (Jones, McCrone and 
Guilhaume 2004, Francois et al. 2004, Jonsson 2005, Antonanzas et 
al. 2006, Gagnon et al. 2007, Hoogveldt et al. 2011). However, 
Francois et al. (2004) encompassed informal care in the model. Costs 
associated with the monitoring of patients were included in the study 
by Jones, McCrone and Guilhaume (2004).  While, caregiver 
medication and indirect costs were considered in the study by 
Antonanzas et al. (2006). Gagnon et al. (2007), added caregiver time-
related costs in the model. Pharmacist fees, family care, and informal 
care were incorporated in one study (Hoogveldt et al. 2011).  
The utility weights were taken from a cross-sectional study using 
EQ-5D instrument (Jonsson 2005). QoL-AD mapped to EQ-5D from 
a longitudinal study was applied in Gagnon et al. (2007) and 
Hoogveldt et al. (2011).  
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● Discount rates:   The discount rate for costs and outcomes varied in all studies. Costs 
and health outcomes were discounted at 3.5% per annum in the study 
by Jones, McCrone and Guilhaume (2004). Francois et al. (2004) 
applied a discount rate of 5% for both costs and benefits. An annual 
discount rate of 3% was applied for costs in one study (Jonsson 
2005). Gagnon et al. (2007) also used a 5% discount rate for costs. 
Antonanzas et al. (2006) used a discount rate applied at 6% for both 
costs and benefits per annum. The last study employed a discount 
rate at 4% for costs and 1.5% for outcomes (Hoogveldt et al. 2011). 
 
To conclude, the Markov model was used in all of the studies. 50% of all studies considered 
the three domains: cognition, dependency, and care setting, while the other 50% covered only 
two domains: cognition and dependency. The target populations in most studies were 
moderately severe to severe patients. 60% of all studies used the societal perspective. The 
range of time horizons was 2-5 years. The discount rate for costs ranged from 3-6%. Also the 
discount rates of outcomes ranged from 1.5-6%. The utilities were based on EQ-5D and QoL-
AD mapped EQ-5D.  
2.6.4.1.1.4 The Discrete Event Simulation (DES) model  
A discrete event simulation was applied in the study of Getsios and colleagues in 2010 in the 
UK. To compare the costs and health outcomes of donepezil to no treatment, the study was 
conducted in mild to moderate Alzheimer’s patients from a health care payer and societal 
perspective over a 10-year period. The technique used was patient-level modelling to capture 
the disease progression and outcomes. The concepts of the model were as follows: first, 
patients were categorised by their characteristics. These categorised patients were cloned and 
assigned to interventions, namely, donepezil and no treatment. Then the patients were 
simulated and the patient characteristics were updated over time. Before progressing to the 
next event, patient profiles were updated based on disease severity, treatment status, 
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physician visits, death, and end of model. Three domains, defined as cognitive function, 
functioning ability, and behavioural, were the significant predictors used to measure disease 
severity. The cognitive function was measured in terms of MMSE. The physical functioning 
was assessed using ADL and IADL. As part of behavioural assessment, NPI was used as the 
indicator. The developed integrated equations were applied to estimate the change in MMSE, 
NPI, ADL, and IADL consecutively. The changes in cognitive function affected to NPI, 
ADL, and IADL. Therefore, the changes in IADL were influenced from the changes of ADL. 
The various data sources were taken to predict the disease progression and effectiveness of 
the treatment. The baseline characteristics of patients were taken from data from the clinical 
trials of donepezil and a longitudinal study. The Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) data was used to develop the equation and estimate the 
change in MMSE. Therefore, the NPI, ADL, and IADL were computed from the changes 
based on those equations. The premature treatment discontinuation employed data from the 
UK study (Lyle et al. 2008).  
Furthermore, four studies which were conducted using a discrete-event simulation (DES) 
approach were associated with the individual-patient characteristics. The model was 
conceptualised on the basis of correlations of disease severity, functional ability, and 
behavioural ability (Getsios et al. 2010, Guo et al. 2010, Hartz et al. 2012, Thibault et al. 
2015).  
● Model type:  
 
The framework of all studies was the DES model (Getsios et al. 
2010, Guo et al. 2010, Hartz et al. 2012, Thibault et al. 2015).  
● The definition of disease 
severity:  
Two studies simulated the disease progression of patients over time 
based on cognition (as measured by MMSE), behaviour (as 
measured by NPI scale), and function (as measured by ADLs and 
IADLs) (Getsios et al. 2010, Hartz et al. 2012). One study predicted 
the disease progression based on cognitive function (using ADAS-
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cog and MMSE), behavioural assessment (using NPI scale), and 
functional abilities (using the Disability Assessment of Dementia 
(DAD) scale) (Guo et al. 2010). The other study incorporated 
cognition (as assessed by SIB scale), behaviour (as assessed by NPI 
scale), and function (as assessed by ADLs and IADLs) in the model 
to predict the disease progression (Thibault et al. 2015).  
● The study population:  
 
Two studies conducted in patients with mild to moderate 
Alzheimer’s disease (Getsios et al. 2010, Guo et al. 2010). One 
study applied in mild to moderately severe and moderate to 
moderately severe Alzheimer’s patients (Hartz et al. 2012). The 
other study examined moderate to severe patients with Alzheimer’s 
disease (Thibault et al. 2015). 
● Interventions:  
 
The varieties of interventions were engaged in studies. Getsios et al. 
(2010) examined donepezil compared with no treatment. A 
comparison amongst galantamine, no treatment, and ginkgo biloba 
was conducted by Guo et al. (2010). One study compared donepezil 
with memantine or no treatment (Hartz et al. 2012). While, 
memantine extended release plus cholinesterase inhibitor compared 
with cholinesterase inhibitor monotherapy was studied by Thibault 
et al. (2015).  
● The disease progression:  
 
Two studies used the regression models to predict the changes of 
disease progression through MMSE, NPI, ADLs, and IADLs over 
time (Getsios et al. 2010, Hartz et al. 2012). One study applied the 
regression model to estimate the changes of the disease progression 
over time based on the ADAS-cog score which was mapped to the 
MMSE score. In addition, the MMSE score had significant impacts 
on the NPI scale, DAD scale, and other outcomes (Guo et al. 2010). 
Another study considered the changes in SIB scale, NPI scale, 
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ADLs, and IADLs over time in the progression of the disease 
(Thibault et al. 2015).  
● Model structure:  
 
The model functions were based on the following: at the beginning 
the patient’s categorised characteristics were created. Then identical 
copies were created for individual patients. The interventions were 
also assigned.  
When the model was simulated, the patient characteristics were 
updated over time to predict the disease progression through 
correlated changes in cognitive function, behaviour, and functional 
performance (Getsios et al. 2010, Guo et al. 2010, Hartz et al. 2012, 
Thibault et al. 2015).  
● Data sources:  
 
Three studies used data from RCTs and longitudinal studies for the 
baseline patient characteristics (Getsios et al. 2010, Guo et al. 2010, 
Hartz et al. 2012). One study adopted data from the RCT for 
baseline population characteristics (Thibault et al. 2015).  
Three studies derived mortality rates from life tables (Guo et al. 
2010, Hartz et al. 2012, Thibault et al. 2015), whereas one study was 
based on a longitudinal study (Getsios et al. 2010).  
For the treatment effect, two studies were based on data from RCTs 
(Getsios et al. 2010, Thibault et al. 2015). The other two studies 
applied data from RCTs and pooled data from clinical trials (Guo et 
al. 2010, Hartz et al. 2012) 
● Time horizon  Three studies conducted the models over a 10-year time horizon 
(Getsios et al. 2010, Guo et al. 2010, Hartz et al. 2012). One study 
employed for a 3-year period (Thibault et al. 2015).  
● Healthcare Perspective of 
model: 
Three studies were performed based on the healthcare payer or care 
insurance and societal perspective (Getsios et al. 2010, Hartz et al. 
2012, Thibault et al. 2015). One study only implemented from a 
healthcare insurance perspective (Guo et al. 2010).   
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● Costs data and Utilities: All studies included direct costs and costs associated with caregiver 
time (Getsios et al. 2010, Guo et al. 2010, Hartz et al. 2012, Thibault 
et al. 2015). One study covered costs of antipsychotic changes from 
the beginning of the treatment (Thibault et al. 2015). Three studies 
also encompassed costs for monitoring patients (Getsios et al. 2010, 
Guo et al. 2010, Hartz et al. 2012).  
Regarding utilities, two studies used data from a cross-sectional 
study using EQ-5D (Getsios et al. 2010, Hartz et al. 2012). One 
study adopted HUI from a cross-sectional study for measuring 
quality of life (Thibault et al. 2015).  
● Discount rates:   Two studies applied discount rates at 3% in both costs and benefits 
per annum (Hartz et al. 2012, Thibault et al. 2015). Costs and health 
outcomes were discounted using an annual rate of 3.5% in the study 
by Getsios et al. (2010). The other study used the discount rate at 
5% of for both costs and outcomes per annum (Guo et al. 2010). 
 
In brief, the models based on the DES used individual-patient data. The changes of disease 
progression were updated through MMSE, NPI, ADLs, IADLs, and DAD over time. There 
were differences in the target populations of all studies, however, a half of all studies were 
conducted in patients with mild to moderate Alzheimer’ disease. A 10-year time horizon was 
most commonly applied in the models. Most studies adopted healthcare payer, healthcare 
insurance, and societal as the viewpoints of studies. The EQ-5D, and HUI instruments were 
the most applied to the utility weights. The discount rates ranged from 3-5% of both costs 
and outcomes.  
2.6.4.1.1.5 Model based on Lachaine, et al. (2011) 
In Canada, the first cost-utility analysis of memantine plus ChEI compared with ChEI and 
memantine versus ChEI was undertaken by Lachaine et al. (2011). A 7-year Markov model 
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was constructed to predict the impact on time to institutionalisation in patients with 
Alzheimer’s disease. The model was developed on the basis of a study by Lopez and 
colleagues, who conducted an observational study in 943 probable Alzheimers’ patients 
assigned interventions using memantine plus ChEI, ChEI only and no treatment, to predict 
time to nursing home admission and death (Lopez et al. 2009). Societal and the Canadian 
health care system was the viewpoint. The health states in the model consisted of non-
institutionalisation, not admitted to the nursing home, institutionalisation, admitted to the 
nursing home, and death. The significant transition probabilities in the model were the 
probabilities of nursing home admission and dying. The transition probability of 
institutionalisation was taken from published studies (Lopez et al. 2009). The mortality 
probability was derived from the life table, adjusted for age and sex and specific-Alzheimer’s 
disease-related mortality.  
Additionally, three studies used models developed based on the study by Lachaine, et al. 
(2011). The model framework applied the patients’ placement status as defined by 
noninstitutionalised and institutionalised as the health states of disease progression (Lachaine 
et al. 2011, Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
● Model type:  
 
A Markov model was applied in all studies (Lachaine et al. 2011, 
Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).   
● The definition of disease 
severity:  
The severity of disease was defined by requiring nursing home 
admission or institutionalised in all studies (Lachaine et al. 2011, 
Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
● The study population:  All studies conducted in patients with Alzheimer’s disease (Lachaine 
et al. 2011, Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
● Interventions:  
 
The comparison of memantine and cholinesterase inhibitors to 
cholinesterase inhibitors alone was employed in two studies (Pfeil, 
Kressig and Szucs 2012, Touchon et al. 2014). Another study 
examined memantine plus cholinesterase inhibitors compared with 
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cholinesterase inhibitors and memantine versus cholinesterase 
inhibitors (Lachaine et al. 2011).  
● The disease progression:  
 
The transition probabilities of moving from one state to another state 
were used to predict the disease progression of the model (Lachaine, 
et al. 2011, Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
● Model structure:  
 
The model consisted of three health states: noninstitutionalised, 
institutionalized, and deceased in all three studies (Lachaine et al. 
2011, Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
● Data sources:  
 
The probabilities of transition of disease progression between the 
non-institutionalised to the institutionalised state in all three studies 
were based on a longitudinal study by Lopez et al. (2009) (Lachaine 
et al. 2011, Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
The probabilities of dying used data obtained from the life tables in 
two studies (Lachaine, et al. 2011, Touchon et al. 2014). One study 
used a longitudinal study to estimate the transition probability to 
death (Pfeil, Kressig and Szucs 2012).  
All studies adopted data from longitudinal studies for the treatment 
effect (Lachaine et al. 2011, Pfeil, Kressig and Szucs 2012, Touchon 
et al. 2014).  
● Time horizon and cycle 
length: 
Two studies were conducted over a 7-year period to predict time to 
institutionalisation and the cycle lengths of the model were defined as 
1-year (Lachaine et al. 2011, Touchon et al. 2014). Another study 
was conducted over a 5-year time horizon with one year defined as 
the Markov cycle (Pfeil, Kressig and Szucs 2012).  
● Healthcare Perspective of 
model: 
The societal and healthcare system perspectives were applied to all 
models (Lachaine et al. 2011, Pfeil, Kressig and Szucs 2012, 
Touchon et al. 2014). 
● Costs data and Utilities: Direct costs were included in all three studies (Lachaine et al. 2011, 
Pfeil, Kressig and Szucs 2012, Touchon et al. 2014). One study 
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considered the lost productivity of caregivers (Lachaine et al. 2011), 
whereas costs associated with informal care were encompassed in 
two studies (Pfeil, Kressig and Szucs 2012, Touchon et al. 2014).  
The health utility sources were taken from cross-sectional studies 
using HUI:2 as an instrument (Lachaine et al. 2011, Pfeil, Kressig 
and Szucs 2012, Touchon et al. 2014).  
● Discount rates:   Two studies applied a discount rate at 3% for both costs and 
outcomes (Pfeil, Kressig and Szucs 2012, Touchon et al. 2014), while 
one study used a 5% discounted rate of both costs and outcomes per 
annum (Lachaine et al. 2011). 
 
To sum up, the model applications based on the Lachine model used the Markov structure to 
predict the disease progression. The main health states were noninstitutionalised, 
institutionalised and deceased. Comparison of memantine and cholinesterase inhibitors to 
cholinesterase inhibitors alone were applied in most studies. The societal and healthcare 
system perspectives were used in all studies. Time horizon of models employed a 5-7 year 
period with cycle length of one year. Utility data based on HUI:2 was applied in all models. 
The range of the discount rate was at 3-5% per annum in both costs and outcomes.  
2.6.4.1.1.6 Model developed by McDonnell et al. (2001) 
McDonnell et al. (2001) investigated the impact of treatment in Alzheimer’s patients based 
on the regression-based simulation model. The model was developed to estimate the disease 
progression through the decline in cognitive function, as measured by the MMSE score, 
during the treatment. The Rotterdam study, in the Netherlands, was used as a data source 
associated with the patient’s demographic and disease history data. The analyses were 
conducted through the MMSE model and the institutionalisation model. The MMSE model, a 
random-effect, linear regression incorporating several parameters based on the Rotterdam 
study, was used to predict the change in MMSE score over time and MMSE at baseline. The 
 
 
88 
 
institutionalisation used the multinomial logistic regression to predict the movement amongst 
the residence states or death. In the institutionalisation model, the presence of caregivers, the 
place of residence at the initial time, and the probability of hospitalisation were included. The 
simulations were functioned as follows: at the beginning, the patient’s baseline distribution 
and regression functions were created based on the Rotterdam study. Then the patient’s 
profiles were copied and defined the patients groups as treated or untreated. The next event 
was the movement of patients between states based on the disease progression. When the 
disease progressed, the cognitive function was expected to decrease. Patients also moved 
from one state to another state of residence or death. The costs data were accumulated within 
the cycle lengths of the cohorts until a 10-year period or death occurring. In addition, the 
cohort was simulated 10,000 times to calculate the median results. The data sources of costs 
included direct costs derived from Netherlands, but informal care was not included. The 
discount rate was at 5% for costs and benefits.  
2.6.4.1.1.7 Model developed by Fenn and Gray (1999) 
Fenn and Gray (1999) conducted a model to evaluate the cost saving from rivastigmine 
compared to a placebo, in mild to moderate Alzheimer’s patients, in the UK over a 3-year 
time horizon. The concept of the model was the time in which patients moved to the more 
severe stages of the disease severity. The more severe states of the disease were correlated to 
the increase in costs, such as caregiver care costs as well as the risk to nursing home 
admission. Thus the survival analysis was applied to assess the benefits from the treatment 
for delaying the disease progression to the more severe stages. The disease progressing was 
defined by the disease severity using a MMSE score. The model health states consisted of 
mild (MMSE=30-21), moderate (MMSE=20-11), and severe (MMSE=10-1) with the MMSE 
score classification being based on expert opinion. The Weibull distribution for the hazard 
function was used to calculate the transition probabilities. Only costs of formal care were 
employed in the study, using the UK price index for hospital and community health services.  
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2.6.4.1.1.8 Model based on the data from Kungsholmen project 
Jonsson et al. (1999) was an original model conducting a Markov model to evaluate the cost-
effectiveness of donepezil and no treatment, in mild to moderate probable Alzheimer’s 
patients over a 5-year period. The model applied the cognitive function to defined states of 
disease using the MMSE score. The health states in model consisted of MMSE=30-27, 
MMSE=26-21, MMSE=20-15, MMSE=14-10, MMSE=9-0, as well as death. The baseline 
transition probabilities were derived from the observational study, Kungsholmen project, in 
Sweden (Jonsson et al. 1999). A total of 206 elderly patients diagnosed with dementia in the 
Kungsholmen study, were adopted to compute the probabilities. The effectiveness data of 
donepezil was taken from the clinical trial. The cost data were also obtained from the 
Kungsholmen study, including home help, accommodation, and medications.   
Furthermore, two studies adopted data from the Kungsholmen project to develop their model. 
The concept of this model was similar to the CERAD-CDR model which defined health 
states of the disease progression by levels of disease severity (Jonsson et al. 1999, Teipel et 
al. 2007).  
● Model type:  
 
Both studies conducted the cost-effectiveness analysis based on a 
Markov model framework (Jonsson et al. 1999, Teipel et al. 2007).   
● The definition of disease 
severity:  
The levels of disease severity were defined by cognitive function as 
measured by MMSE scores (Jonsson et al. 1999, Teipel et al. 2007).  
● The study population:  
 
Jonsson et al. (1999) conducted the study in people aged 75 years and 
over. Teipel et al. (2007) studied in patients with mild to moderate 
Alzheimer’s disease.   
● Interventions:  
 
Both studies examined the comparison of donepezil versus no 
treatment or placebo (Jonsson et al. 1999, Teipel et al. 2007).  
● The disease progression:  
 
The movement from one state to another in the model relied on the 
transition probabilities (Jonsson et al. 1999, Teipel et al. 2007). 
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● Model structure:  
 
The six health states were classified into MMSE 30-27, MMSE 26-
21, MMSE 20-15, MMSE 14-10, MMSE 9-0, as well as death 
(Jonsson et al. 1999). The other study applied mild, mild to moderate, 
moderate, severe and death as the Markov states in the model (Teipel 
et al. 2007). 
● Data sources:  
 
Without treatment, the transitions between the health states of the 
disease progression were based on longitudinal studies (Jonsson et al. 
1999, Teipel et al. 2007).  
The probabilities of mortality in both studies were taken from 
longitudinal studies (Jonsson et al. 1999, Teipel et al. 2007).  
The treatment effect data used data from RCTs in both studies 
(Jonsson et al. 1999, Teipel et al. 2007).  
● Time horizon and cycle 
length: 
One study was conducted over a 5-year period with 10 Markov 
cycles (Jonsson et al. 1999), while the other study was conducted 
over a 5-year time horizon with cycle length of one year (Teipel et al. 
2007). 
● Healthcare Perspective of 
model: 
The health insurance and nursing care insurance company 
perspectives were adopted in Teipel et al. (2007), while the model 
perspective was not identified in the study by Jonsson et al. (1999).  
● Costs data and Utilities: Both studies included direct costs (Jonsson et al. 1999, Teipel et al. 
2007). Costs associated with caregiver time were encompassed only 
in the study by Teipel et al. (2007).  
One study used utility data taken from a cross-sectional study as 
measured by HUI:2 (Teipel et al. 2007). Another study was not clear 
regarding health outcomes (Jonsson et al. 1999). 
● Discount rates:   The discount rate for costs was 3% in the study by Jonsson et al. 
(1999). The costs and outcomes were discounted at 5% per annum in 
the study by Teipel et al. (2007).  
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In conclusion, both studies were modelled based on the data from the Kungsholmen project. 
A Markov model was constructed to predict costs and outcomes. The cognitive function as 
measured by MMSE was used to define levels of disease severity. Also, the Markov states 
consisted of disease severity levels and death. Both studies compared donepezil with no 
treatment or a placebo and covered a 5-year period with different cycle lengths. The discount 
rate of costs ranged from 3-5%, while the outcome was discounted at 5%, but only identified 
in one study.    
2.6.4.1.1.9 Model developed by Henke and Burchmore (1997) 
Henke and Burchmore (1997) applied a decision tree model to evaluate the cost-effectiveness 
of tacrine in treating mild to moderate Alzheimer’s disease over the patient’s lifetime. The 
health states of the model were: the need for nursing home care and the no requirement for 
nursing home care. The assumption of this study was that the increase in functional 
dependency leads to an increase in the nursing home care. The data sources were derived 
from various studies. The probability of no treatment to nursing home care was taken from 
cohort studies. The transition probabilities of tacrine treatment were derived from RCT study. 
Also, the mortality was obtained from RCT. The cost data included the medical care, paid 
social services, and costs for monitoring patients. The perspective was from the public and 
private payers. The discount rate was at 5% per annum for costs and outcomes.  
2.6.4.1.1.10 Model developed by Nagy et al. (2010) based on the MMSE- and ADL- based 
model 
Nagy et al. (2010) investigated the cost-effectiveness of a rivastigmine patch and capsule in 
comparison to basic support care from the UK health and social care costs. This study was 
conducted over a 5-year period. This study used the MMSE score and the MMSE-ADL 
model to predict the disease progression. The discontinuation rates used data from an open-
label study. Data from a prospective study was applied for the mortality rate. According to 
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the MMSE-based model, this model employed data from the study by Stewart (1997) in a UK 
context, to develop the linear regression equation of the institutionalisation probability. 
Another model was constructed to incorporate ADL into the traditional MMSE-based model. 
However, there were no studies associated with the correlation between ADCS-ADL and the 
institutionalisation probability. Based on the study by McNamee et al. (2001), the MMSE and 
Townsend-ADL were used to estimate the probabilities of institutionalisation. Consequently, 
the mapping between ADCS-ADL and Townsend-ADL was applied. The utility weights 
were based on the Health Utilities Index version III (HUI:3) which were mapped by the 
clinical data, to compute the utility weights of the MMSE and MMES-ADL models. The 
regression function was then used to calculate utility values based on the MMSE score. 
Health and social care costs of institutionalisation from the UK were included in the model. 
Costs and outcomes were discounted using an annual discount rate of 3.5%.  
2.6.4.1.1.11 Model developed by Wong et al. (2009) 
According to Wong et al. (2009), a decision tree model was conducted to evaluate the cost-
effectiveness of ChEI (donepezil, galantamine, and rivastigmine) and memantine compared 
with a placebo, in vascular dementia cases, from a societal perspective. The ICER was 
calculated from the incremental cost per the decline in the ADAS-cog scale. A published 
systematic review was used as the probabilities of adverse events of each drug. The model 
timeframe was conducted over 24-28 months. The cost data were taken from the drug costs 
using the drug prescriptions and physician visits.  
2.6.4.1.1.12 Model developed by Stewart, Phillips and Dempsey (1998) 
In 1998, Stewart, Phillips and Dempsey conducted a Markov model to evaluate the treatment 
of donepezil over 5 years in the UK using 6-month cycles. The health states were classified 
into minimal, mild, moderate, severe, as well as death which correlated to the disease 
severity. This study adopted existing data from previously published studies. The transition 
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probabilities for people with no treatment were derived from a cohort study. The treatment 
effectiveness of donepezil was acquired from the RCT. The data from a cohort study and a 
historic prospective study were applied to calculate the mortality probability. The cost data 
were taken from cost packages of elderly people with cognitive impairment in the UK. Costs 
were discounted using an annual rate of 6% in this study. 
2.6.4.1.1.13 Model developed by Hu et al. (2015) 
The study by Hu and colleagues in 2015 constructed 6-monthly Markov cycles over a 5-year 
period to predict the clinical benefits of memantine which patients were starting at a 
moderate level compared with starting at a severe level in Alzheimer’s disease in urban 
China. The health states were based on dependency (independent and dependent) and 
agitation/aggression (non-agitated/aggression and agitation/aggression). Then a total of nine 
possible health states, including four health states in moderate stage, four health states in 
severe stage, as well as death were applied in the model. The dimensions of the disease 
progression were cognitive function (as measured by MMSE or ADAS-cog or SIB), 
dependency (as assessed by ADL), and agitation/aggression (as defined by NPI). Expert 
panels were used to determine the data sources for the dependency, agitation/aggression, and 
resource utilisation. Transition probabilities were taken from pooled data of clinical trials of 
memantine. The discontinuation rate was derived data from the RCT study of memantine in 
Alzheimer’s patients in China. The mortality rate was based on data from the general Chinese 
population and mortality risk was taken from data of the elderly with dementia in Shanghai. 
Hospitalisation, caregiver time-associated costs, and nursing homes were included in the cost 
data of the model. The discount rate of the analysis was at 3% per annum for both costs and 
outcomes.  
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2.6.4.1.1.14 Model developed by O’ Brien el al. (1999) 
O’ Brien et al. (1999) studied the cost-effectiveness of donepezil in comparison to usual care, 
in mild to moderate Alzheimer’s patients in Canada, over a 5-year period. The perspective in 
this study was the government payer and society. A Markov model was constructed to 
estimate the decrease in MMSE score over time. The levels of disease severity were defined 
by the MMSE score. Data from the Alzheimer’ disease cohort study in Alberta was used to 
classify people with probable AD into three subgroups at baseline as follows: MMSE=10-14, 
MMSE=15-20, and MMSE=21-26. Six health states were employed in the model, consisting 
of MMSE<10, MMSE=10-14, MMSE=15-20, MMSE=21-26, MMSE=27-30, as well as 
death. The transition probabilities of patients moving amongst the health states were taken 
from the clinical trial. The discontinuation rate was considered when the MMSE score was 
less than 10. The cost data were encompassed medications, dispensing fee, community 
services (i.e. homemaking, home-help, and in-home meals), and caregiver time-associated 
costs. This analysis applied a discount rate at 5% for costs and outcomes.
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 Table 2.5: Summary of the modelling approaches used to model the disease progression in economic evaluations in dementia 
Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Henke and 
Burchmore 
1997 USA Cost 
analysis 
Decision-
tree model 
Specific 
model 
-Loss of functional 
independence of 
people with AD 
associated with 
increasing in nursing 
home placement 
Mild-to-
moderate 
AD 
 
Tacrine vs no 
treatment 
Health states: 
nursing home 
placement and 
non-nursing 
home placement 
Stewart, 
Phillips, and 
Dempsey 
1998 UK CEA Markov 
model 
Specific 
model 
-Time in lower disease 
severity stages (as 
defined by MMSE 
score) 
AD patients 
aged 75 
years and 
over 
 
Donepezil 5 mg 
and 10 mg vs 
placebo 
Health states: 
minimal, mild, 
moderate, severe, 
and dead 
Fenn and 
Gray  
1999 UK Cost 
analysis 
Statistical 
model-
based 
survival 
analysis 
Specific 
model  
 
-Time in stages of 
disease severity (as 
measured by MMSE 
score)  
-Survival analysis, 
using the accelerated 
Mild to 
moderate 
AD 
Rivastigmine vs 
placebo 
Health states in 
the model: mild 
(MMSE=21-30), 
moderate 
(MMSE=11-20), 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
failure-time model 
with the Weibull 
distribution for the 
hazard function 
and severe 
(MMSE=1-10) 
Jonsson et 
al.  
1999 Sweden CEA Markov 
model 
Specific 
model based 
on the 
project of 
Kungsholme
n 
-Time in the stages of 
disease severity 
(as defined by MMSE 
score) 
Mild to 
moderate 
probable AD 
Donepezil vs no 
treatment 
Health states:  
MMSE=30-27, 
MMSE=26-21, 
MMSE=20-15, 
MMSE=14-10,  
MMSE=9-0 
and death 
Neumann et 
al. 
1999 USA CEA Markov 
model 
CERAD 
based on 
CDR scale 
(cognitive 
function 
measured as 
CDR)  
-Time in the stages of 
disease severity 
(as defined by CDR 
score) 
-CERAD cohort was 
used to estimate the 
state-to-state transition 
probabilities using a 
Mild to 
moderate 
AD 
Donepezil vs no 
treatment 
Health states: 
mild(comm/ 
NH), 
moderate(comm/
NH), 
severe(comm/ 
NH), and death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Cox proportional 
hazards regression 
model  
O’ Brien et 
al.  
1999 Canada CEA Markov 
model 
Specific 
model  
-Time in stages of 
disease severity (as 
defined by MMSE) 
Mild to 
moderate 
AD 
Donepezil 5 mg 
vs usual care 
Health states: 
MMSE <10, 
MMSE=10-14, 
MMSE=15-20, 
MMSE=21-26, 
MMSE=27-30, 
and death 
Getsios et al.  2001 Canada CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
-The Cox proportional 
hazard function used to 
predict time to require 
FTC 
 
Mild to 
moderate 
AD 
Galantamine 24 
mg/day vs no 
pharmacological 
treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
McDonnell 
et al.  
2001 Nether- 
lands 
CEA Statistical 
model-
based 
Specific 
model 
-Changes in MMSE, 
resident, and mortality 
Patient with 
dementia 
Treatment vs 
non-treatment 
-Four aspects: 
patient 
characteristics, 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
regression 
analysis 
-Two models used for 
analyses: one model 
based on MMSE score 
and the other model 
based on the 
institutionalisation and 
patients’ vital status  
 
clinical 
characteristics of 
disease, place of 
residence (living 
in community, 
home for the 
elderly, nursing 
home), and vital 
status of patients 
Caro et al.  2002 Nether- 
lands 
CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
-The Cox proportional 
hazard model used to 
predict time to require 
FTC  
 
Mild to 
moderate 
AD 
Galantamine vs 
no 
pharmacological 
treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
Garfield et 
al.  
2002 Sweden CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
-The Cox proportional 
hazard model used to 
Mild to 
moderate 
AD 
Galantamine 12 
mg twice daily vs 
no treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
predict time to require 
FTC  
 
Ikeda, 
Yamada and 
Ikegami 
2002 Japan CUA Markov 
model 
CERAD 
based on 
CDR scale 
(cognitive 
function 
measured as 
CDR) 
-Time in the stages of 
disease severity 
(as defined by CDR 
score) 
-CERAD cohort was 
used to estimate the 
state-to-state transition 
probabilities using a 
Cox proportional 
hazards regression 
model 
Mild to 
moderate 
AD 
Donepezil vs no 
treatment 
Four-health 
states in the 
model structure: 
mild, moderate, 
severe, and death 
Migliaccio-
Walle et al.  
2003 USA CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
 
Mild to 
moderate 
AD 
Galantamine 16 
mg/day and 24 
mg/day vs no 
treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Ward et al.  2003 UK CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
 
Mild to 
moderate 
AD 
Galantamine 16 
mg/day and 24 
mg/day vs no 
cholinesterase 
treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
Caro et al.  2004 Multi- 
national 
CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
 
Mild to 
moderate 
AD 
Galantamine vs 
no 
pharmacological 
treatment 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
Francois et 
al.  
2004 Finland CEA Markov 
simulation 
model 
Memantine 
model 
-Time to dependency, 
institutionalisation/nur
sing home 
 
Moderately 
severe to 
severe AD 
Memantine vs no 
pharmacological 
treatment 
Health states 
based on  the 
multiplicity of 
three severity 
states, two 
physical 
dependencies, 
and two 
residence 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
settings, and plus 
death 
Jones, 
McCrone 
and 
Guilhaume  
2004 UK CEA Markov 
simulation 
model 
Memantine 
model 
-Time to dependency, 
institutionalisation/nur
sing home 
 
Moderately 
severe to 
severe AD 
Memantine vs no 
pharmacological 
treatment 
Health states 
based on  
multiplying: 
three severity 
states, two 
physical 
dependencies, 
and two 
residence 
settings, and plus 
death 
Green et al.  2005 UK CEA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to need of FTC 
 
  
Mild to 
moderately 
severe AD 
Donepezil, 
galantamine, and 
rivastigmine vs 
usual care 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Jonsson 2005 Sweden CEA Markov 
simulation 
model 
Memantine 
model 
-Time to dependency, 
institutionalisation/nur
sing home 
Moderately 
severe to 
severe AD 
Memantine vs no 
pharmacological 
treatment 
Health states 
based on  the 
multiplicity of 
three severity 
states, two 
physical 
dependencies, 
and two 
residence 
settings, plus 
death 
Antonanzas 
et al. 
2006 Spain CEA Markov 
simulation 
model 
Memantine 
model 
 -Time to dependence Moderately 
severe to 
severe AD 
Memantine and 
standard care 
Health states in 
the model: 
multiplying of 
three severities, 
two 
dependencies, 
plus death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Gagnon et 
al. 
2007 Canada CEA Markov 
simulation 
model 
Memantine 
model 
-Time to dependence 
 
  
Moderate to 
severe 
Memantine vs 
standard care 
Health states 
based on 
multiplying of 
two severities, 
two 
dependencies, 
and death 
Teipel et al. 2007 German
y 
CEA Markov 
model 
Specific 
model based 
on the 
Kungsholme
n project 
-Time in stages of 
disease severity (as 
defined by MMSE 
score) 
Mild to 
moderate 
AD 
Donepezil 10 mg 
vs placebo 
Health states: 
mild, mild-
moderate, 
moderate, severe 
and death 
Weycker et 
al.  
2007 USA CEA Microsim
ulation 
model 
CERAD 
based on 
SIB   
(cognitive 
function 
measured as 
SIB)  
-To predict the 
changes in cognitive 
function (as measured 
by SIB score) 
-Regression model was 
used to map SIB to 
MMSE 
Moderate to 
severe AD 
Memantine + 
donepezil vs 
donepezil alone 
The states in the 
model defined 
into profound 
and terminal 
(MMSE=0-4), 
severe 
(MMSE=5-9), 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
 moderate 
(MMSE=10-14), 
and 
questionable/mil
d (MMSE=15-
23) and living in 
community  
Fuh and 
Wang  
2008 Taiwan CEA Markov 
model 
CERAD 
based on 
CDR scale 
(cognitive 
function 
measured as 
CDR) 
-Time in the stages of 
disease severity 
(as defined by CDR 
score) 
-The hazard ratios 
were used to estimate 
the transition 
probabilities between 
one state to another 
state during the drug 
treatment 
Mild to 
moderate A 
Donepezil and 
usual care 
Health states: 
mild, moderate, 
severe, and death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Kirbach et 
al.  
2008 USA CUA Markov 
model 
CERAD 
based on 
CDR scale 
(cognitive 
function 
measured as 
CDR) 
-Time in the stages of 
disease severity 
(as defined by CDR 
score) 
-CERAD cohort was 
used to estimate the 
state-to-state transition 
probabilities using a 
Cox proportional 
hazards regression 
model 
Patients with 
agitation and 
psychosis in 
AD 
Olanzapine vs no 
treated with 
olanzapine 
Heath states: 
mild, moderate, 
severe, 
institutionalized, 
and death 
-The 
institutionalised 
was classified 
separately as a 
health state 
Lopes-
Bastida et al.  
2009 Spain CEA Markov 
model 
CERAD 
based on 
CDR scale 
(cognitive 
function 
measured as 
CDR) 
-Time in the stages of 
disease severity 
(as defined by CDR 
score) 
-CERAD cohort was 
used to estimate the 
state-to-state transition 
probabilities using a 
Mild and 
moderate 
AD 
Donepezil vs no 
drug treatment 
The model states  
classified into 
mild, moderate, 
severe, and death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Cox proportional 
hazards regression 
model 
Suh  2009 Korea CUA Markov 
model 
FTC 
framework 
(AHEAD) 
-Time to FTC require 
 
 
Mild to 
moderately 
severe AD 
Galantamine 24 
mg/day + usual 
care vs usual care 
Health states in 
the model: Pre-
FTC, FTC, and 
death 
Wong et al. 2009 Canada CEA Decision 
tree 
Specific 
model 
-The decision model 
included the 
effectiveness and the 
probabilities of 
adverse events of each 
medication  
Mild to 
moderate 
vascular 
dementia 
Cholinesterase 
Inhibitors or 
memantine vs 
standard care  
Two states were 
defined into no 
adverse events 
and adverse 
events 
Getsios et al. 2010 UK CEA Discrete-
Event 
Simulatio
n (DES) 
Patient-level 
data 
-The individual-level 
data 
-The simulation based 
on the inter-
relationship of 
cognitive function 
Mild to 
moderate 
AD 
Donepezil vs no 
treatment 
Update of 
disease severity, 
treatment status, 
physician visit, 
death, and end 
of model 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
(MMSE), behavioural 
ability (NPI), and 
functional abilities 
(ADLs and IADL) 
Guo et al.  2010 German
y 
CBA Discrete-
Event 
Simulatio
n (DES) 
Individual 
patient 
simulation 
-The individual-level 
data 
-The simulation based 
on the inter-
relationship of disease 
severities (ADAS-cog 
and MMSE), 
behavioural abilities 
(NPI), and functional 
abilities (DAD) 
Mild to 
moderate 
AD 
Galantamine vs 
no treatment vs 
ginkgo biloba 
Update of 
disease severity, 
treatment status, 
physician visit, 
death, and end 
of model 
Nagy et al.  2010 UK CEA Statistical 
model-
based  
regression 
analysis 
 MMSE-
ADL model 
-Regression analysis 
used to calculate 
probability of 
institutionalisation  
Patients with 
probable 
Alzheimer’s 
disease 
Rivastigmine 
patch and 
capsule treatment 
vs best 
supportive care 
-MMSE model 
based on MMSE 
-MMSE-ADL 
model based on 
MMSE and ADL 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
-Two models: MMSE 
model and MMSE-
ADL model 
  
Rive et al.  2010 UK CUA Markov 
model 
FTC 
framework  
-Time to FTC required 
 
Moderate to 
severe AD 
Memantine vs no 
pharmacological 
treatment or 
background 
therapy with 
cholinesterase 
inhibitors 
(ChEIs) 
The model health 
states based on: 
Pre-FTC, FTC 
and death 
Hoogveldt et 
al. 
2011 Nether- 
lands 
CEA Markov 
simulation 
model 
Memantine 
model 
-Time to dependence 
 
Moderate to 
severe AD 
Memantine vs 
standard care 
Health states 
based on the 
multiple of two 
severities and 
two dependence 
states, plus death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Lachaine et 
al.  
2011 Canada CUA Markov 
model 
Specific 
model bases 
on data from 
Lopez et al. 
-Time to nursing home  
 
Patients with 
AD 
Memantine  +
Cholinesterase 
inhibitor vs 
Cholinesterase 
inhibitor alone 
Health states: 
noninstitutionalis
ed, 
institutionalized, 
and death 
Hartz et al. 2012 German
y 
CEA Discrete-
Event 
Simulatio
n (DES) 
Individual- 
patient 
simulation 
-The individual-level 
data 
-The simulation of 
disease progression 
based on the correlated 
changes in disease 
severities (MMSE), 
behavioural abilities 
(NPI), and functional 
abilities (ADLs and 
IADL) 
Mild to 
moderately 
severe and 
moderate to 
moderately 
severe AD 
Donepezil vs 
memantine or no 
tratment 
Update of 
disease severity, 
treatment status, 
physician visit, 
death, and end 
of model 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Pfeil, 
Kressig and 
Szucs 
2012 Switzer 
-land 
CUA Markov 
model 
Model based 
on the 
developed 
model by 
Lachaine et 
al. 
-Time to nursing home  
 
Patients with 
AD 
Memantine  +
Cholinesterase 
inhibitor vs 
Cholinesterase 
inhibitor alone 
Health states: 
home, nursing 
home, and 
decease  
Rive et al.  2012 Norway CUA Markov 
model 
FTC 
framework  
-Time to need of FTC 
 
Patients with 
moderate 
and severe 
AD 
Memantine vs no 
pharmacological 
treatment or 
background 
therapy with 
cholinesterase 
inhibitors 
(ChEIs) 
The model based 
on three health 
states: Pre-FTC, 
FTC and death 
Touchon et 
al.  
2014 France CEA Markov 
model 
Based on the 
model of 
Lachaine 
and 
colleague  
-Time to nursing home 
admission 
 
Patients with 
AD 
Memantine  +
cholinesterase 
inhibitor vs 
cholinesterase 
inhibitor alone 
The health states: 
non-
institutionalised, 
institutionalized, 
and deceased 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Hu et al.  2015 China Cost 
analysis 
Markov 
model 
Specific 
model 
-Time in health states 
of disease progression 
based on two disease 
severities (moderate 
and severe as 
measured by MMSE 
score or ADAS-cog or 
SIB), functional 
abilities (dependence 
and independence as 
measured by ADL), 
presence of 
agitation/aggression 
(agitation/aggression  
and non-
agitation/aggression as 
measured by NPI)  
Moderate 
and severe 
patient with 
AD 
Initiated 
memantine in 
moderate vs 
initiated 
memantine in  
severe 
Health states 
based on the 
multiplicity of 
two severities, 
two functional 
abilities, two the 
presence of 
agitation/aggressi
on, plus death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
Thibault et 
al.  
2015 USA CUA Discrete-
Event 
Simulatio
n (DES) 
Individual-
patient 
simulation 
-The individual-level 
modelling 
-The simulation of the 
disease progression 
based on SIB, NPI, B-
ADL, and I-ADL over 
time 
 
Moderate to 
severe AD 
Memantine 
extended release 
+ Cholinesterase 
inhibitor vs 
Cholinesterase 
inhibitor 
monotherapy 
Update of 
disease severity, 
treatment status, 
physician visit, 
death, and end 
of model 
Zala, Chan 
and 
McCrone  
2017 UK CUA Markov 
model 
FTC 
framework 
 
-Time to need of FTC 
 
Mild to 
moderate 
and 
moderate to 
severe AD 
-Moderate to 
severe: 
memantine vs 
Cholinesterase 
inhibitor (ChEIs) 
alone or no 
treatment 
-Mild to 
moderate: 
cholinesterase 
The model based 
on three health 
states: Pre-FTC, 
FTC and death 
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Study Year 
published 
Country Study 
type 
Model type   Model  
Framework 
Health outcomes Target 
populations 
Comparators Health States 
inhibitor (ChEIs) 
vs no treatment  
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Based on model-based economic evaluation in dementia, the comparison of strengths and 
limitations of each model is presented in Table 2.6. 
Table 2.6: Comparison of strengths and limitations of model-based economic evaluation 
in dementia 
Model Type Strength Limitation 
FTC framework -AHEAD 
model using a predictive 
equation to predict the time to 
FTC developed by Caro et al. 
(2001) 
1. Predict time to need of FTC 
required which is the significant 
factor affecting the costs of 
Alzheimer’s disease 
2. Consider several factors 
influencing the progression of 
disease, namely EPS, Psychotic 
symptoms, duration of illness, 
cognitive function (as measured by 
mMMS), and age at disease onset 
3. Feasible to apply both individual-
patient data or cohort data 
4. Feasible to compare outcomes of 
specific patients or disease 
conditions 
5. The model has been widely used 
in health economic evaluations of 
dementia 
1. The predictive equation uses 
mMMS score  
2. Differences in the cognitive 
assessment (MMSE or ADAS-
cog) need to be translated to 
mMMS, leading to concerns 
about the accuracy of cognitive 
score  
3. Functional performance is not 
captured in the equation 
4. According to the development 
of the predictive equations based 
on data from the study by Stern 
et al. (1997) in the US patients, 
there is a concern that the 
application of these equations in 
different contexts leads to 
unreliable data  
FTC framework- model using a 
predictive equation to predict 
the time to FTC developed by 
Rive et al. (2010) 
1. To predict time to need of FTC 
2. Incorporate the significant 
domains associated with 
Alzheimer’s disease to the 
predictive equation, including 
1. The equations were developed 
based on the LASER-AD cohort 
study in the UK, there is a 
concern that the application of 
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Model Type Strength Limitation 
cognitive function (ADAS-cog), 
functioning (ADCS-ADL), and 
behavioural (NPI) 
these equations in different 
contexts leads to unreliable data  
CERAD-CDR scale model 1. To predict time in stages of 
disease severity as measured by the 
CDR scale 
2. The state-to-state transition 
probabilities were derived data from 
CERAD cohort using a Cox 
proportional hazards regression model 
3. Feasible to adjust the transition 
probabilities by age, gender, and 
behavioural symptoms 
4. The model has been widely used 
in health economic evaluations 
1. CDR scale is a significant 
predictor in the model 
2. The rating on CDR scale is 
mainly based on the cognitive 
ability 
3. The transition probabilities 
were based on the CERAD 
database in the US, there is a 
concern that the application of 
these equations in different 
contexts may not be accurate 
with regards to patient 
characteristics 
CERAD-SIB model 1. To predict time in stages of 
disease severity as measured by the 
SIB scale 
2. Apply the regression analysis for 
mapping MMSE score, CDR scale 
and SIB score 
1. The mapping of MMSE score, 
CDR scale, and SIB score may 
raise an issue concerning the 
accuracy of the process 
 
Model developed to evaluate 
memantine drug 
1. To predict the delay 
institutionalisation and time to 
dependence 
2. The model categorises health 
states into disease severity, 
1. Data associated with treatment 
and no pharmacological 
treatment were obtained from 
RCT, use for the transition 
probabilities 
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Model Type Strength Limitation 
dependency, and with/without 
residential setting 
3. Transition probabilities between 
states are based on severity, 
dependency and care setting  
4. The model is applied to evaluate 
the treatment of patients in more 
severe states of disease  
2. The cognitive score is the 
important factor in the model, 
inasmuch as the severity 
transition, dependency transition 
and with/without 
institutionalisation transition 
were influenced by cognitive 
score at the beginning of the 
cycle 
DES model 1. The model simulates based on the 
patient-level information 
2. Incorporates important factors 
associated with the disease 
progression, including MMSE, NPI, 
ADL, IADL, and DAD 
3. The analysis is a much finer 
gradient and much more realistic 
over time 
1. Requires the patient-level data 
sets related to the availability of 
data 
2. May be concerns over the 
complexity of the model 
 
Model developed by Lachaine 
et al. (2011) 
1. To predict time to nursing home 
admission, leading to the most 
significant predictor affecting the 
costs of Alzheimer’s disease 
2. The development of model and 
parameters are based on 
observational studies in particular 
the study by Lopes et al. (2009) in 
the US 
1. The model is based on data 
from the study by Lopes et al. 
(2009) in the US, the application 
in different contexts needs to be 
a concern regarding patient 
characteristics 
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Model Type Strength Limitation 
Model developed by McDonnell 
et al. (2001) 
1. Apply statistical model-based 
regression analysis 
2. The model applies the patient 
characteristics, clinical 
characteristics, care settings, and 
mortality 
1. The model is based on data 
from the Rotterdam study in the 
Netherlands, the application in 
different contexts needs to be a 
concern regarding patient 
characteristics 
Model developed by Fenn and 
Gray (1999) 
1. To predict time in delaying the 
onset of more severe disease stages 
2. Apply the survival analysis as 
accelerated failure time model based 
on the Weibull distribution for the 
hazard 
1. The model is reliant on the 
cognitive score 
2. Specific patients due to patient 
data taken from the clinical trials 
of rivastigmine 
Model based on the data from 
Kungsholmen project 
1. To predict Time in stages of 
disease severity (as defined by 
MMSE score) 
2. The transition probabilities and 
mortality rate are based on the 
Kungsholmen project 
1. Cognitive function is a 
significant predictor in the model 
2. The model is based on data 
from Kungsholmen project in 
Sweden, the application in 
different contexts needs to be a 
concern 
Model developed by Henke and 
Burchmore (1997) 
1. The model is not complex due to 
using the decision tree 
2. The model is used to predict the 
reduction of costs from the 
institutionalised care 
1. A specific model for the 
tacrine treatment 
MMSE- and ADL- based model 1. The model is used to predict the 
probability of requiring 
institutionalisation 
1. May be concerns over the 
accuracy of the mapping between 
the ADCS-ADL scale and the 
Townsend-ADL scale for 
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Model Type Strength Limitation 
2. The ADL is incorporated into the 
MMSE model to predict health 
outcomes and costs 
calculating the transition 
probability of institutionalisation 
Model developed by Wong et 
al. (2009) 
1. The model is not complex due to 
using the decision tree 
2. The model is applied in vascular 
dementia 
3. The effectiveness and clinical 
probabilities of adverse events of 
medications are applied in the model 
1. The model is undertaken over 
a short period of time (24-28 
weeks) 
2. Only ADAS-cog is used for 
effectiveness data, leading to an 
underestimation in the capture of 
the executive function of patients 
with vascular dementia 
Model developed by Stewart, 
Phillips and Dempsey (1998) 
1. To predict time in stages of 
disease severity as measured by the 
MMSE scale 
1. Cognitive function is the only 
factor used to estimate the 
disease progression 
2. Model is specific for donepezil 
(Aricept®) treatment  
Model developed by Hu et al. 
(2015) 
1. To predict time in health states of 
disease progression  
2. The cognitive function (as 
measured by MMSE, ADAS-cog 
and SIB score), functional abilities 
(as defined by ADL) and presence 
of agitation/aggression (as defined 
using NPI) are incorporated in 
health states of the model 
1. The clinical management in 
the model is based on Delphi 
panel meetings by clinical 
experts in China 
2. The model focuses on an 
urban population in China 
 
Model developed by O’ Brien et 
al. (1999) 
1. To predict time in stages of 
disease severity (as assessed by 
MMSE score) 
1. Cognitive score is a significant 
factor to measure the 
improvement 
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Model Type Strength Limitation 
2. The model combined data from 
RCT and a cross-sectional study 
2. MMSE score is mapped into 
cost data 
 
 
2.7 Conclusion   
In summary, based on the literature review, Alzheimer’s disease is the most common type of 
dementia studied in the health economic evaluation area. There is only one study identified 
that is associated with vascular dementia. Based on the interventions, donepezil forms the 
majority of health economic studies in dementia being 25.5% from the total studies in this 
literature review. The other interventions used in studies on dementia are galantamine and 
memantine which account for 20% in both instances. Considering the model-based economic 
evaluation, most studies apply the Markov model to predict the disease progression (75%). 
Based on the FTC frameworks, the AHEAD model, developed by Caro et al. (2001), is the 
most common method used to categorise the progression of disease. The model structure 
consists of pre-FTC, FTC, and death. The “requiring FTC” is employed to estimate the 
effectiveness of interventions from the disease progression. The FTC conceptual framework 
used to evaluate health economics in dementia is divided into two approaches, since there are 
differences in the approaches to calculate the time to FTC need. The conventional study using 
the predictive equation of time to FTC developed by Caro et al. (2001). That study used the 
data based on the study by Stern et al. (1997), to develop the predictive equations to calculate 
the patient’s time to require FTC. From Stern and colleagues, the predictive equations to FTC 
incorporated various parameters, including the presence of EPS, presence of psychotic 
symptom, duration of illness, cognitive function, and age at disease onset. The mortality 
probability relied on the female gender, presence of EPS, cognitive function, and duration of 
illness. Furthermore, in the initial period, during 2001 to 2005, these equations were widely 
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used in the health economic evaluation. In the recent period from 2010 onwards, new 
predictive equations were developed to be used for computing the disease progression of the 
time of patients to requiring FTC (Rive et al. 2010). The model structure remained similar to 
the model structure from the study by Caro et al. (2001). Further, the new predictive equation 
integrated the three main characteristics of the Alzheimer’s disease progression to predict the 
time to FTC, as categorised into cognitive, functional, and behavioural assessment. The 
details of each method are as previously stated.  
In addition, another model framework, generally used in health economic evaluation in 
Alzheimer’s disease studies, is the CERAD model structure. This model was constructed 
based on the CERAD database. The health states in the model structure are the severities in 
the cognitive function predicting the disease progression as composed of mild, moderate, and 
severe. Further, the health state also included the absorbing state, as defined death, in the 
model. The cognitive function was assessed by the CDR scale. The transition probabilities of 
patient’s moving from one state to another state used the modified survival analysis to 
calculate based on the data from the CERAD database (Neumann et al. 1999). In the early 
period, most studies based on CERAD adopted the same fashion of the study by Neumann et 
al. (1999), in terms of applying the transition probabilities in their studies (Yamada and 
Ikegami 2002, Kirbach et al. 2008, Lopes-Bastida et al. 2009). On the basis of the model 
structure, another study applied data from the epidemiological cohort study to compute the 
transition probabilities (Fuh and Wang 2008). Another study used different instruments, 
namely SIB, to measure the level of cognitive function (Weycker et al. 2007). 
Other types of models used in health economic evaluations in dementia are: the discrete event 
simulation (DES), statistical analysis model, regression-based analysis model, decision tree, 
and microsimulation. The finding showed that DES has been adopted during the latter period 
since 2010. However, the decision-analytical model based on the Markov model stands out as 
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the one to use when compared against the other models in the health economic evaluation in 
dementia area.  
For interventions, the major studies of model-based economic evaluations in dementia were 
associated with anti-dementia medications, including acetylcholinesterase inhibitors, 
(donepezil, galantamine, and risvastigmine), and NMDA receptor antagonist (memantine). 
Based on data from the U.S. Food and Drug Administration (FDA), donepezil was the first 
drug approved in 1996 followed by rivastigmine in 2000. Galantamine and memantine were 
then approved in 2001 and 2003, respectively. The combination of donepezil and memantine 
was recently approved in 2014. The US-FDA data also indicated that there are delays in 
developing new anti-dementia treatments (Alzheimer’s Association 2017). Consequently, the 
tendency of economic evaluations in dementia is currently focusing on the diagnostic or the 
early detection of dementia.  
Considering the behavioural and psychological symptoms of dementia (BPSD), these 
symptoms are significant problems and have vital impacts on patients and caregivers 
experiencing this disorder. Non-pharmacological approaches are recommended for these 
BPSD patients. However, the pharmacological approaches are important to patients who have 
persistent symptoms. Although, antipsychotic drugs are widely used for patients with BPSD, 
in the real practice, these drugs are off-label use for those patients. Currently, there is only 
one model-based study which takes into account BPSD, in particular agitation, aggression, 
and psychosis, in an economic evaluation in dementia (Kirbach et al. 2008). This implies a 
shortage of studies in this field. Thus, further health economic evaluation studies of dementia 
should take into consideration patients with BPSD and their treatment.  
To conclude, the model-based economic evaluation in dementia from the literature review 
highlighted the strengths and weaknesses of the models identified, including the model 
conception, leading to further implementation and development of a suitable model to apply 
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for the economic evaluation in dementia. The conceptual framework of this thesis is 
displayed in Figure 2.5.  
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Figure 2.5: Conceptual framework of the thesis 
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Chapter 3: Methods 
Abstract 
Introduction: Behavioural and psychological symptoms of dementia (BPSD) are the most 
common problems of patients with dementia. These symptoms lead them to be a danger to 
themselves and their caregivers and a complication for the management of the disease. In 
addition, there are currently no US-FDA approved drugs for the treatment of those 
symptoms. This results in a wide range of treatment options that are available to 
behaviourally disturbed patients with dementia. In Thailand, the atypical antipsychotic group 
is one type of medication which has been widely used for the treatment of BPSD. However, 
there is a paucity of data on the health economic evaluations of these drugs. Thus, atypical 
antipsychotic use for the treatment of BPSD sufferers needs to be evaluated to provide useful 
information to decision-makers, namely, patients themselves, caregivers, patient’s families, 
physicians and health policy-makers.  
Aim: The objective of this chapter is to address the research methodology of the cost-
effectiveness of olanzapine in comparison to risperidone, for the treatment of patients with 
BPSD in Thailand. 
Methods: An analysis of the cost-effectiveness was constructed following these stages: 
firstly, the scope of the health economic evaluation was defined. Secondly, different models 
were developed for applying to the evaluations. Thirdly, the estimated monthly costs of 
patients with BPSD were calculated from the primary data collection in a Thai setting. Then, 
the utility weights were also measured from those patients and/or their caregivers. Finally, 
the analysis, reporting, presenting as well as a sensitivity analysis were conducted.  
Results: The five main stages that were applied for this study of olanzapine in comparison to 
risperidone of patients with BPSD in Thailand were: the defining scope of the evaluation;  
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developing models and selecting the most appropriate model to adopt in following stage of 
the cost-utility analysis of the atypical antipsychotic use for BPSD in Thailand; monthly costs 
and utility weights, using the cost and the EQ-5D-5L questionnaires, are then estimated; 
lastly, results of the cost-utility analysis together with sensitivity analyses are reported.  
Conclusions: By comparing olanzapine with risperidone, the cost-utility analysis will indicate 
the more cost-effective drug for the treatment of patients with BPSD in Thailand. The 
findings also have benefits to patients, caregivers and physicians in managing and planning 
the appropriate treatment for sufferers. Furthermore, policy-makers are able to use the data in 
deciding on the allocation of healthcare resources efficiently for these patients.   
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 Introduction 
Currently, a rapid rise in the elderly population is a major cause of a substantial number of 
people with dementia. By 2050, people aged over 60 years were estimated to be two billion 
globally and approximately 116 million of these will be people with dementia (World Health 
Organisation 2012). Behavioural and psychological symptoms of dementia (BPSD) are 
significantly relevant to people with dementia and these symptoms are the most common that 
occur during the progression of the disease, consequently leading to serious problems. 
Patients with a presence of BPSD have potential impacts on the burden of care, caregiver’s 
distress, and quality of life of both themselves and their caregivers. The presence of 
problematic behavioural symptoms in people with dementia is more difficult to cope with 
than cognitive changes (Kar 2009).  
In clinical practice, the management of BPSD is now complicated and troublesome. 
However, atypical antipsychotics are widely used for the management of these symptoms in 
BPSD patients, although there is a concern over the adverse effects that these drugs have. 
Whilst a variation of atypical antipsychotic use for treatment of patients with BPSD are 
available, they are not well defined. A difference in drug prices of those atypical 
antipsychotics might also influence the decision making of individual patients, caregivers as 
well as physicians, leading to a limitation in the prescribing of those drugs for patient care. 
Consequently, the exploration of the treatment BPSD with atypical antipsychotics is 
significantly important.  
To our knowledge, this is the first study to conduct a cost-utility analysis in comparison of 
atypical antipsychotics for the treatment of patients with BPSD, based on the decision-
analytic model from the societal perspective in Thailand. Cost and utility data is based on the 
data collected from BPSD patients in a Thai setting, using face-to-face interviews by cost and 
the EQ-5D-5L questionnaires. This study also takes into account adverse event-related costs 
and relapse-related costs of atypical antipsychotic use in those patients for the cost analysis. 
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The results of the study indicate the most cost-effective treatment in comparing between 
olanzapine to risperidone, for those patients with BPSD. In addition, this study also estimates 
the cost and health utility data of BPSD patients treated with olanzapine and risperidone. 
These useful data also help to support the relevant person in all matters relating to the 
planning and the management of the effective treatment option to BPSD patients. 
Consequently, the purpose of this chapter addresses the research methodology of the cost-
utility analysis in assessing the economic evaluation of olanzapine in comparison to 
risperidone, of behaviourally disturbed patients with dementia in Thailand.  
 
 Philosophical underpinnings of the research 
Philosophical underpinnings are significant to all researches exposing the ontological, 
epistemological, theoretical perspective, methodological approach and methods which the 
researchers choose to adopt in their researches.    
Ontology is the study of existence. Ontological assumptions are concerned with the nature of 
reality. The key ontological question is what is real (Saunders, Lewis and Thornhill 2006, 
Scotland 2012). When the researcher takes a position on an ontological perspective, it means 
that the researcher begins to choose the methodological decision-making which is based on 
beliefs, values, independent social reality, dependent social reality, or reality constructed by 
the social environment. The approach, (quantitative, qualitative or mixed methods), of the 
research will often be influenced by such ontological perspectives. In this thesis, the 
ontological perspectives are categorised into realism and idealism. Realism is the view that 
the reality is objective and it exists independently of the human mind. The idealism is 
contrasted, it is the view that the reality is subjective and it is constructed by the mental 
awareness of individuals.  
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Epistemology is the theory of knowledge. Epistemological assumptions are concerned with 
the way of knowing (Saunders, Lewis and Thornhill 2006, Scotland 2012). In seeking new 
knowledge, the epistemological perspective is an aid in informing the methodology of the 
research in terms of purposes and goals (Snap and Spencer 2003). Objectivism, 
constructivism and subjectivism are elements of epistemological terms in this thesis as 
subsequently outlined.  
The objectivists hold the view that the discovery of knowledge is based on an objective 
reality which is separately formed in the consciousness of the human (Scotland 2012). 
Objectivist epistemology also stands alongside the realism of the ontological position. 
Subjectivists believe that the reality is only based on the individual’s perceptions. Also, the 
subjectivists do not pursue the reality that exits out there in the world. Thus, the conclusions 
from subjectivism are drawn from the individual’s perceptions and the perspective of the 
subjectivists is consistent with the ontological position of idealism. Considering the 
constructivists, they attempt to reach a balance between objectivists and subjectivists. The 
constructivists hold the view that truths and meanings are their concepts. The meanings 
engage objects and subject meanings are developed based on individuals’ experiences 
(Creswell 2014).   
As indicated above, a relationship between ontology and epistemology is that the ontological 
perspective is about what is true of the world and epistemological perspective is about 
methods of figuring out those truths.  
According to ontological and epistemological assumptions, there are different theoretical 
perspectives which could be applied in research in general. Within realism and objectivism, 
the positivist approach emphasis is to establish universal laws or generalisations. The 
positivism focus more on a quantitative research, (observations and measurements of 
empirical data), than a qualitative research. Thus, positivism is also known as the scientific 
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method for undertaking research in science. Moreover, the positivists tend to belief in 
empiricism and do not try to explain or interpret the correlation of phenomena which have 
been observed. The statements of the positivists are descriptive and factual. The conclusion 
of those positivists has been produced through a deductive approach. The key strategies of 
the positivists approach are therefore found in experiments.  
The post-positivist approach has similar theme to the ontological and epistemological 
perspectives as in the positivist approach. However, post-positivists believe that the reality 
exists, but this reality cannot explain by an observation alone. They also accept that theories, 
backgrounds, knowledge and values of researchers can affect what is observed. From the 
post-positivists view, the most important is developing various measurements for 
observations and studying the behaviours and actions of humans. The laws or theories in the 
world need to be tested and refined in order to achieve a greater understanding of the world. 
Thus, the post-positivists begin with a theory and then collect data associated with such 
theory. Finally, they produce the revisions or additional investigations of tests (Creswell 
2014). This implies that the post-positivists do not pursue absolute truths of knowledge, 
whilst they do consider more on the impacts of biases associated with objectivity. Based on 
the post-positivists, the conclusions are derived through a deductive approach. 
Considering the critical realist approach, the critical realist holds the view that all 
observation is fallible and has some errors and that all truths are revisable. The human action 
could be changeable in reality. Additionally, both a description and an explanation of social 
phenomena are required for the critical realists and they focus on exploring the method to 
explain the regularities. Critical realism starts with an observation of relations from within 
social phenomena and then constructs the hypothetical relations of phenomena. Finally, 
exploration to demonstrate the real existence of those hypothesised relations is conducted. 
Due to all observation being fallible, it is important that critical realists attempt to apply 
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various measurements and observations in their research. A combination of quantitative and 
qualitative methodology is frequently conducted in this critical realist approach. Thus, 
inductive and deductive approaches, as combined in terms of a retroductive approach, are 
also applied for the understanding of both socially constructed and the impacts of such 
structures, leading to knowledge gained based on the critical realist approach (Henry et al. 
2005).  
The pragmatist approach focuses on tasks, activities, situations and consequences rather than 
preceding abstract theory. Pragmatism is conducted on the basis of what works and its 
usefulness, (solutions to problems). Further, the pragmatists seek to perceive the problems, 
they then attempt to apply all approaches available to obtain knowledge from those problems. 
The methods generally applied in the pragmatic approach are mixed methods.    
Regarding the interpretive approach, it is constructed to describe the social phenomena 
through the interaction between human consciousness and their world. The knowledge gained 
from this approach is likely to understand the differences in individuals as social actors. The 
importance of the interpretive approach is to enter into the social actors’ world to understand 
their world from their view points and then develop a theory from the social actor’s activities 
and transfer data to a social context. However, this knowledge is limited to the viewpoints of 
the individuals who participated in the study. Typically, the methods of open-ended 
interviews, focus groups, open-ended questionnaires and role-playing are applied to the 
interpretivists. It provides qualitative data and analyses are based on the researcher’s 
interpretations. Then the conclusions are obtained through an abductive approach. 
The aim of this thesis is to apply a cost-utility analysis to assess the economic impact of 
atypical antipsychotics for the treatment of patients with BPSD in Thailand using a decision-
analytic model. Thus, the theoretical underpinning of this thesis based on the cost-utility 
analysis is posed on a basis of the extra-welfarist approach whereby it incorporates utility 
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units in its outcomes, (as measured in terms of QALYs, a combination of years and quality of 
life gained through an intervention). Further, the extra-welfarist approach is based on the 
concept of the maximisation of the overall health behaviours (Edwards et al. 2013).  
To position the research and its philosophical underpinnings, the ontology perspective of this 
thesis explicitly highlights realism. Also, the epistemological perspective clearly focuses on 
the objectivism approach based on a post-positivist perspective, an empirical method as well 
as a deductive approach. The methods are consistently used in objectivism which mainly 
focus on the quantitative method.  
This positioning represents an appropriate approach in the thesis because it has benefits to 
identify: 
• a dominant effective treatment for patients with BPSD in a comparison of olanzapine 
to risperidone based on the cost-utility analysis using the decision-analytic model; and 
• how to assess the economic impact of atypical antipsychotics, (olanzapine and 
risperidone), for the treatment of patients with BPSD in Thailand. 
 
 
 Research methods 
As Flowchart 3.1 shows, the five main stages were performed for undertaking an economic 
evaluation in this thesis. More details of each stage are presented below.  
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Incremental Cost-Effectiveness Ratio (ICER) was calculated  
Discount rates based on the Health Intervention and 
Technology Assessment Programme (HITAP) in 
Thailand HITAP recommendation, Thailand 
Flowchart 3.1: Stages of the cost-utility analysis to assess the economic evaluation of 
olanzapine in comparison to risperidone for the treatment of behavioural and 
psychological symptoms of dementia in Thailand 
 
 
 
 
 
 
 
  
Stage 2  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Stages  
 
Data Requirements 
Developed models based on the 
literature review and defined criteria 
(Chapter 4) 
Defined criteria for the model development based 
on the literature review of model-based economic 
evaluation in dementia  
Data sources: Electronic Databases (MEDLINE, 
CRD, NHS EED, DARE and HTA) 
Define the scope of health economic 
evaluation (Chapter 3) 
A literature review 
Data sources: Electronic Databases (MEDLINE, 
PsycINFO, Cochrane Library, CRD, NHS EED, 
DARE and HTA) 
Main parameters of the model:  
● Transition probabilities  
● Cost data  
Data source: Primary collected data in a Thai 
setting 
● Health Outcomes: Clinical outcomes and utility 
weights 
Data sources: Electronic databases and the 
primary collected data in a Thai setting 
Comparison amongst different models 
regarding model characteristics, 
strengths and weaknesses (Chapter 4) 
Justification of the most appropriate 
model (Chapter 4) 
Stage 1  
 
 
 
133 
 
 
 
                  
 
 
 
    
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Utility measurements of patients with BPSD 
and being on atypical antipsychotics (Chapter 6) 
● Utility weights of patients classified by 
cognitive function 
● Utility weights of patients classified by 
physical dependence 
 
 
● Utility weight data  
● Thai Tariffs for the five-level version of EQ-5D 
Data source: Primary collected data in a Thai 
setting using the EQ-5D-5L questionnaire 
 
 
Outcomes of interest: 
1. The most appropriate model for applying the cost-utility analysis of atypical antipsychotics for the 
treatment for BPSD in Thailand (Chapter 4) 
2. Estimated costs of patients with BPSD who were treated with risperidone or olanzapine (Chapter 5) 
3. Estimated utility weights of patients with BPSD who were treated with risperidone or olanzapine 
(Chapter 6) 
Stage 3 
Data Requirements 
 
Data of costs: 
● Direct medical costs 
● Direct non-medical costs 
Data source: Primary collected data in a Thai 
setting using the cost questionnaire 
    
 
Cost analysis of patients with BPSD and being 
on atypical antipsychotics (Chapter 5) 
● Cost data of patients classified by cognitive 
function 
● Cost data of patients classified by physical 
dependence  
 
 
Stages 
Stage 4 
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Cost-utility analysis of atypical antipsychotics for the 
treatment of patients with BPSD in Thailand  
 
(Chapter 7) 
Collected cost data of olanzapine and 
risperidone: 
    ● Direct medical costs               
    ● Direct non-medical costs 
Data source: Primary collected data in a 
Thai setting using the cost questionnaire 
 
(Chapter 5) 
 
Health outcomes:  
    ● Clinical outcomes  
    ● Utility weights  
Data sources: Electronic databases and 
the primary collected data in a Thai 
setting using the EQ-5D-5L 
questionnaire  
 
 
The calculation of transition 
probabilities (Chapter 4) 
 
 
The calculation of Incremental Cost-Effectiveness Ratio (ICER)  
Discount rates  
Data source: the Health Intervention 
and Technology Assessment Programme 
in Thailand 
Outcomes of interest: 
1) ICER of olanzapine compared with risperidone 
2) The cost-effectiveness plane (CE plane) 
3) Indicating the most cost-effective drug for the 
treatment of BPSD patients in Thailand 
4) The cost-effectiveness acceptability curve (CEA 
curve) 
 
 
Sensitivity analyses (Chapter 7) 
                                        Stages                                                                                    Data requirements 
  
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage 5 
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 Stage 1: Defining the scope of the health economic evaluation  
The principal objective of the study was to examine the value for money of the treatment of 
BPSD patients with atypical antipsychotics. A cost-utility analysis was used to predict the 
expected costs and outcomes of atypical antipsychotics for the treatment of those patients 
with BPSD. Based on the current treatments of BPSD patients in Thailand, atypical 
antipsychotics are widely used, even though these drugs have no US-FDA approvals for their 
use in the treatment of patients with dementia. Consequently, this leads to a variety of 
atypical antipsychotic treatment options for patients with BPSD in a routine clinical setting. It 
was therefore necessary to conduct a cost-effectiveness of the atypical antipsychotic drugs, to 
explore the most cost-effective drug for the treatment of BPSD within a real setting in 
Thailand.  
Further, the scope of the evaluation of this study was defined based on a comprehensive 
literature search on the use of atypical antipsychotic drugs for the treatment of dementia (see 
Chapter 2). The finding found 13 studies which have been summarised in the following Table 
3.1. 
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Table 3.1: Summary of the effectiveness of atypical antipsychotics for the treatment of patients with dementia 
Study Intervention Risperidone Olanzapine Quetiapine Aripiprazole 
De Deyn et al. (1999) Risperidone, haloperidol,  or placebo /    
Brodaty et al. (2003) Risperidone vs Placebo /    
Street et al. (2000) Olanzapine vs placebo  /   
De Deyn et al. (2004) Olanzapine vs placebo  /   
Zhong et al. (2007) Quetiapine vs placebo   /  
Tariot et al. (2006) Quetiapine, haloperidol, and placebo   x  
Paleacu et al. (2008) Quetiapine vs placebo   x  
Kurlan et al. (2007) Quetiapine vs placebo   x  
De Deyn et al. (2005) Aripiprazole vs placebo    / 
Streim et al. (2008) Aripiprazole vs placebo    / 
Mintzer et al. (2007) Aripiprazole vs placebo    / 
Schneider et al. (2006) Olanzapine,  risperidone, quetiapine vs 
placebo 
/ /   
Deberdt et al. (2005) Olanzapine, risperidone vs placebo x x   
* (/) refers to effectiveness when compared between/amongst interventions and (x) refers to no significant differences between/amongst interventions  
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As the data shows above, olanzapine, risperidone and aripiprazole showed the most 
significant beneficial effects on the treatment of patients with BPSD.  
Considering the treatment of BPSD in Thailand, amongst those atypical antipsychotic 
drugs (olanzapine, risperidone, quetiapine and aripiprazole), olanzapine and risperidone 
were the most widely used for the treatment of those patients. According to retrospective 
studies, just over 50% patients with dementia at Srithanya Hospital have been prescribed 
risperidone and nearly 18% patients were assigned olanzapine to treat BPSD in 
Alzheimer’s and other types of dementia at Srinagarind Hospital (Chanthawong et al. 
2012, Rapeepatchai and Promma 2015).  
Moreover, only drugs approved in the National List of Essential Drugs (NLED) in 
Thailand are covered by the Universal Coverage scheme (UC), which is a foundation 
healthcare system or entitlement, for all patients within the Thai population.  
For risperidone, this drug was classed as an essential drug (ED) in NLED for the 
treatment of patients with BPSD. The expenditure on this medicine was then reimbursed 
under the UC scheme in Thailand.  
Olanzapine was the alternative drug that was compared with the current drug 
(risperidone) in the context of the treatment of BPSD in Thailand. This drug was chosen 
for evaluation in this study due to recommendations from the guidelines and its efficacy 
data from clinical trials for the management of behavioural problems in dementia, 
especially Alzheimer’s disease (Schneider et al. 2006, Scottish Intercollegiate Guidelines 
Network 2006, The American Geriatrics Society 2011, Azermi et al. 2012, Sadowsky and 
Galvin 2012, British Columbia 2012, Prasat Neurological Institute 2014). However, 
olanzapine was provided as a non-essential drug (non-ED) based on Thai NLED. 
Consequently, olanzapine-associated expenses for the treatment of BPSD patients were 
the patients’ responsibility as out-of-pocket expenses (Ministry of Public Health in 
Thailand 2013).  
Accordingly, the comparators of this study were defined as follows: 
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   1) The alternative treatment of patients with BPSD used olanzapine; 
  2) The current treatment of patients with BPSD used risperidone; 
The dosage regimens that were recommended by guidelines are presented below:  
                             Drugs             Dosage Regimen 
           Risperidone (Risperdal®)      ● Initial dosage: 0.25 mg/day  
     ● Maximum dosage: 0.5-2 mg/day  
           Olanzapine (Zyprexa®) 
 
     ● Initial dosage: 2.5 mg/day  
     ● Maximum dosage: 5 mg/day 
 
 Stage 2: Model development and application to health economic evaluation of 
the treatment with antipsychotics for behavioural and psychological symptoms of 
dementia in Thailand (Chapter 4) 
At this stage, there were several steps that were undertaken. Firstly, models were 
developed in different structures, reflecting the progression of the disease based on the 
comprehensive literature review (Chapter 2). The criteria for developing models were 
defined in Chapter 4. Secondly, a comparison amongst different developed models was 
conducted to identify the characteristics, strengths as well as weaknesses of each model. 
At step 2, the parameters of each model function for each developed model needed to be 
explicitly identified. Whilst the main parameters required for each model were transition 
probabilities, drug effectiveness, cost data and utility weights. The transition probabilities 
were the chance of patients changing from one health state to another as the disease 
progressed which was conditional on the model framework of each model. These might 
be derived from the calculations by the equations or available data from published studies. 
The effectiveness of the drugs was obtained from a literature review of published studies 
searched from 1994 up to July 2015. However, this data needed to be reviewed, 
considered and appraised to determine the quality of the evidence that was presented in 
the studies. For cost data and utility weights, these were received from the primary 
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collected data from patients with BPSD in Thailand (Chapter 5 and 6). The health 
outcome of each model was presented in terms of quality-adjusted life years (QALYs). 
Thus, the main outcome of this analysis was the cost per QALY gained or the incremental 
cost-effectiveness ratio (ICER) which was calculated as outlined below: 
 
                                      ICER     =   
Cost of Olanzapine - Cost of Risperidone 
QALY of Olanzapine - QALY of Risperidone
     
 
where:   ICER was an incremental cost-effectiveness ratio 
             QALY was the quality-adjusted life year 
In addition, the time horizon and discount rates for all developed models were conducted 
over a 5-year time period with a one-month cycle length. The discounted rate was 
calculated at 3% per annum of both costs and outcomes for all those models. These rates 
were recommended by the Health Intervention and Technology Assessment Programme 
(HITAP) in Thailand (The Health Intervention and Technology Assessment Program 
2014).  
After conducting the two steps as stated above, the last step of Stage 2 was that the 
different models would be justified based on model characteristics and the advantages and 
disadvantages of each model, (in Chapter 4), in order to select the most appropriate one to 
apply for further analysis (Chapter 7). 
The outcome of interest from this stage was:  
The selected model to adopt for the cost-utility analysis of olanzapine and 
risperidone, for the treatment of patients with BPSD in Thailand. 
 Stage 3: Estimation of costs based on the primary data collection in Thailand 
(Chapter 5) 
From a societal perspective, data on direct medical and non-medical costs were collected 
for economic evaluation and this was adjusted to take into account the Thai setting.  
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3.3.3.1   Direct medical costs consisted of the medication costs of olanzapine and 
risperidone, hospitalised costs, additional payments beyond the patient’s healthcare 
insurance coverage and comorbidity-related costs. Medication costs were referenced to 
data from the Drugs and Medical Supplies Information Centre (DMSIC), using the 
database of drug prices of the Ministry of Public Health in Thailand. 
Additionally, this study considered the safety of atypical antipsychotic drugs because a 
variety of atypical antipsychotic treatment options for BPSD were available. Although 
their efficacy was available for scrutiny, safety was just as significant a factor as the 
efficacy that should be considered in the treatment of patients. Generally, the adverse 
effects of atypical antipsychotics are often associated with extrapyramidal symptoms, 
somnolence, injury by falling, gait disturbance, oedema, urinary tract infection, weight 
gain, sedation, prolactin increase, and cerebrovascular events (Deberdt et al. 2005,  
Schneider et al. 2006, Tan et al. 2015). The impact of these adverse events had to be taken 
into account when considering the use of atypical antipsychotics for the treatment of 
patients with BPSD. Thus, costs of the potential adverse events of these drugs were also 
encompassed in the economic evaluations, to cover the aspect of the costs of care, the 
drug effectiveness and the quality of life for patients and caregivers, namely drug-related 
adverse events, additional medication use for the treatment of drug-induced adverse 
events, and adverse event-associated emergency department visits.  
Relapses are also a common event occurring during a course of treatment of patients with 
atypical antipsychotic drugs. Thus, relapse risk was also included to calculate the direct 
medical costs of drug-related relapse in the economic evaluation of BPSD patients in this 
study. 
3.3.3.2   Direct non-medical costs were applied to the patients' out-of-pocket 
expenses, the cost of informal care, paid caregiver time, the cost of transportation, the cost 
of accommodation, and the cost of extra food for patients.  
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All patients' costs, such as direct medical and non-medical costs, were collected at face-
to-face interviews, using the cost questionnaire completed by patients and/or caregivers. 
The processes of data collection of the costs data and cost analysis are presented in 
section 3.4. The cost questionnaire can be seen in Appendix 4. 
The outcome of interest from this stage is:  
The estimated costs of patients with BPSD who were treated with risperidone or 
olanzapine in Thailand. 
 Stage 4: Estimation of health-related quality of life weights based on the data 
collection in Thailand (Chapter 6) 
In this study, quality-adjusted of life years (QALYs) used as a health outcome which were 
mainly based on utilities. These values were collected during the face-to-face interviews 
with the patients or caregivers conducted in Thailand, using a preference-based health 
measure questionnaire (see Appendix 4). The data collection process of the health-related 
quality of life and utility analysis are shown in section 3.4.  
The outcome of interest from this stage is:   
The estimated utility weights of patients with BPSD who were treated with 
risperidone or olanzapine in Thailand. 
 Stage 5: Cost-utility analysis of atypical antipsychotics for the treatment of 
patients with behavioural and psychological symptoms of dementia and sensitivity 
analysis (Chapter 7) 
This study was a full economic evaluation, which compared both costs and outcomes of 
two interventions, (olanzapine or risperidone), for the treatment of BPSD. A decision-
analytic model was used to assess the costs and outcomes of treatments associated with 
the management of BPSD patients aged 60 years or above, over a 5-year time period with 
a cycle length of one month. In addition, both costs and outcomes were discounted at 3% 
per annum in this analysis.  
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As this stage focused on the application of the most appropriate model derived from Stage 
2. The ICER and the net benefit approach were also applied. Sensitivity analyses were 
also performed to handle the uncertainty of the parameters in the model. The cost-utility 
analysis is shown in section 3.5.  
The outcomes of interest from this stage are: 
1) ICER of olanzapine compared with risperidone; 
2) The cost-effectiveness plane (CE plane); 
3) An indication of the most cost-effective drug in comparison of olanzapine and 
risperidone, for the treatment of BPSD patients in Thailand; and 
4) The cost-effectiveness acceptability curve (CEAC). 
 
 Data collection for cost and utility analyses of patients with behavioural and 
psychological of dementia in Thailand 
 Study design 
The research question of this thesis is “What is the cost-effectiveness of olanzapine versus 
risperidone for the treatment of behaviourally disturbed patients with dementia in 
Thailand”. A justification of the study design in this thesis was then based on the criteria 
as follows: 
• Aims of research 
• Inclusion criteria of patients  
• Data settings 
• Time and budget management  
An observational study using a cross-sectional study 
The study aimed to undertake a comparison on the cost-effectiveness of existing drugs, 
(risperidone and olanzapine), used in patients with BPSD in Thailand, during the time 
period 2017. Costing and utility data in this study were based on the actual routine clinical 
practices.  
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This study explored the associated factors with dementia patients suffering from BPSD 
who are on atypical antipsychotic drugs, including the costs and utility during some point 
in 2017. Thus, the data were collected based on one interview with each patient during 
this time period and was not aimed at any follow up of the participants. Consequently, a 
cross-sectional study was then considered to be the most appropriate and was designed to 
undertake data collection of cost and utility data, at only one point in time by face-to-face 
interviews based on the routine clinical practices. This also relates to potentially 
providing actual data to inform patients, caregivers and physicians in designing, 
managing and choosing the relevant treatment for BPSD sufferers, as well as policy-
makers for a drug-reimbursement decision-making process. Further, to the researcher’s 
best knowledge, this was also the first study to survey the costs and the utility weights of 
the treatments with atypical antipsychotics for Thai patients with BPSD.  
 Sample size 
There were about 160 patients attending the neurological outpatient clinic weekly. As it 
was a cross-sectional study, the plan was to recruit between 40 and 50 patients in each 
group to detect the changes in their quality-adjusted life years (QALYs).  For the 
purposes of this study, the researcher considered a 20% non-response. Thus, 44 patients 
per group were recruited at the baseline; using the power of 0.8 with a significance level 
of 0.05 to detect a one point difference between the two groups with SD of 1.5. However, 
this study expected to have at least 36 patients per category to detect one unit change in 
QALY between the two categories.  
 Data settings 
Based on the aims of this study as previously mentioned, the selected data settings were 
justified from the criteria as listed below:  
• Hospitals where risperidone and olanzapine were used for the treatment of 
behaviourally disturbed patients with dementia aged 60 years and over;  
• A local supervisor; and 
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• Management of time and budget.  
Accordingly, Thammasat University Hospital and Khon Kaen Rajanagarindra Psychiatric 
Hospital were chosen for the data collection of costing and utility weights as they met all 
the above criteria. The details of the hospitals are described below. 
3.4.3.1   Thammasat University Hospital is a centre of excellence in health care, 
situated in Pathum Thani province in the central region of Thailand. This hospital has 
over 600 beds and serves an average of 2,000-3,000 outpatients per day. Patients with 
dementia or Alzheimer’s disease typically attend two main outpatient clinics, including 
the internal medicine and the psychiatric clinic, which provides an integrated service from 
multiple discipline staff, for follow-up on the progression of the disease in each patient. 
The internal medicine clinic opened on Mondays, Thursdays, and Saturdays. The clinic 
delivered a service between 8.30 am and 4.30 pm on Mondays and Thursdays and from 
9.00 am to 5.00 pm on Saturdays. The psychiatric clinic was open on Wednesdays and 
Thursdays between 8.30 am and 4.30 pm. In addition, the patients’ symptoms were the 
significant factors of the frequency of doctors’ appointments; namely 2-week, 1-month, 
1.5-month, 2-month, 3-month, or 6-month intervals. In this setting, Assoc. Prof. Dr 
Sombat Muengtaweepongsa, who was a specialist in neurology, (nerve), was the local 
supervisor (see Appendix 2). 
3.4.3.2   Khon Kaen Rajanagarindra Psychiatric Hospital is a tertiary care unit, 
situated in Khon Kaen province in the North Eastern region of Thailand. The hospital has 
372 beds and provides care for an average of 400 outpatients per day, covering patients 
from 4-province areas (Khon Kaen, Kalasin, Roi Et and Maha Sarakham). The outpatient 
department opened 8 hours per day between 8.30 am and 4.30 pm. The frequency of 
patient hospital visits was similar to those at Thammasat University Hospital.  
 Target population and data collection process 
Ethics approval was secured before data collection took place. A formal letter and 
research proposal were submitted to the data setting steering committee of Thammasat 
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University Hospital (Human Research Ethics Committee of Thammasat University, 
Faculty of Medicine) and Khon Kaen Rajanagarindra Psychiatric Hospital, as well as the 
Faculty Research Ethics Committee of the Centre for Health and Social Care Research of 
Sheffield Hallam University, for their approval of the agreement (see Appendix 3). The 
patient information sheet and the consent form were also submitted for approval by the 
ethical committees (see Appendix 4). 
Patients with behavioural and psychological symptoms of dementia were recruited from 
the outpatient departments in the excellence centre, (Thammasat University Hospital) and 
the tertiary care centre, (Khon Kaen Rajanagarindra Psychiatric Hospital). At each site, 
the local supervisor or healthcare providers were the gatekeepers in reviewing the medical 
records of patients diagnosed with dementia or Alzheimer’s disease and who contacted 
patients and their caregivers to make appointments for interviews for this study. Patients 
and their primary caregivers were contacted if they met the criteria set out to participate in 
the study. The inclusion criteria comprised patients aged 60 years and over (Aekphakorn 
et al. 2009) and having been diagnosed with dementia or Alzheimer’s disease and being 
on olanzapine or risperidone for at least the last two months, (during December 2016 to 
January 2017 and August 2017 to September 2017), before the interview. 
If patients with BPSD had some difficulties in making a decision to participate due to 
their disease conditions, primary caregivers were approached to be the informants instead 
of the patients for practical reasons. A primary caregiver was defined as the person who 
had lived with patients or visited to provide care to patients for at least eight hours per day 
and over three days per week for at least two months. Also, the caregiver should be a 
knowledgeable informant who could contribute to the assessment associated with the 
patient’s health and other patient information. In this study, dementia and Alzheimer’s 
disease and BPSD were defined according to the International Statistical Classification of 
diseases and related health problems (ICD-10: 10th revision, fifth edition, 2016) (World 
Health Organization 2015). Dementia and Alzheimer’s disease had been classified by the 
ICD-10 codes of which F00-F03 referred to dementia and disorders related to dementia 
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1) Ethical consideration:  
1.1 Ethical reviews  
1.1.1 University ethics committee  
1.1.2  Hospital ethics committees 
1.2 Documentation 
1.2.1 Information Sheet  
1.2.2  Consent form  
1.2.3  Research protocol  
2) Instrument/Questionnaires: 
2.1 TMSE: Thai Mental State Examination  
2.2 EQ-5D-5L (Thai version): EuroQol Group 
2.3 Costing Questionnaire: developed by researcher   
3) Sample size calculation:  a cross-sectional survey  
 
 
(including BPSD) and G30 referred to Alzheimer’s disease (World Health Organisation 
2015). In addition, the Thai Mental State Examination (TMSE) test was used to assess 
patients' cognitive status. If patients had their cognitive states assessed during the last six 
months, (August 2016 to January 2017 and April 2017 to September 2017 before the 
interview), the cognitive assessment was not required to be tested again. The scores from 
the assessment test during the last six months would be used as the patients’ cognitive 
status to classify their levels of disease severity (see Appendix 5). In addition, patients 
and caregivers were excluded if they did not meet criteria or were unable to answer the 
questionnaire. The data collection processes are presented in the flow diagram in 
Flowchart 3.2A, Flowchart 3.2B-1 Flowchart 3.2B-2, and Flowchart 3.2C. 
 
Flowchart 3.2: Flow diagram of the data collection process in this study: planning 
process, participant recruitment and data gathering   
 
 
 
 
 
 
 
 
Flowchart 3.2A: Planning process  
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Inclusion Criteria: 
Patients 
1) Patients aged 60 years and above* diagnosed with Dementia (ICD-10: F00-F03) or 
Alzheimer’s disease (ICD-10: G30) and being on olanzapine or risperidone for at least 
the last 2 months.  
 
Partners or caregivers   
1) A person who lived with or visited the patient for at least 8 hours per week over 3 days 
or more per week for the last 2 months, were encouraged to contribute to the assessment. 
 
Exclusion criteria: 
1) Patients, who had no partners or caregiver support and were unable to answer the 
questionnaire on their own.  
2)   
 
 
 
 
 
 
 
 
 
 
 
* The definition of an elderly person in Thailand is a person aged 60 and above (the Ministry of Social 
Development and Human Security 2003, Aekphakorn et al. 2009, Aekphakorn et al. 2016) 
Flowchart 3.2B-1: Step I - Process of participant recruitment 
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Contacting the doctor (the local supervisor) to ask permission for the data collection 
(by formal letter). Medical doctors or healthcare personnel were invited to become 
involved in the research as the gatekeepers to review the medical records of dementia 
or Alzheimer patients and to contact patients and caregivers to make appointments 
for interview at the hospital. 
The doctor reviewed the medical records over the last two months and recruited the 
patients to participate in the study. 
The patients and/or caregivers had received the research information sheet prior 
to the data collection appointment.  
 
Did patient decide to participate in research? End 
No 
Yes 
Appointment made with patients and/or caregivers for interviews at the 
hospital via contact with the doctor. 
 Patients and/or caregivers received and signed the consent forms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Flowchart 3.2B-2: Step I - Process of participant recruitment  
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Flowchart 3.2C: Step II - Process of data gathering  
 
 
 
Assessing patients’ cognitive functions 
Had been TMSE test > 6 months  Had been TMSE test ≤ 6 months 
Did the patients answer the question by themselves? 
 
No 
Direct interview with patients Passive interview with caregivers 
Instruments:       
 ● Cost questionnaire 
● EQ-5D-5L questionnaire 
 
      TMSE test 
Yes 
Yes 
Yes 
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 Cost and quality of life questionnaires  
Two questionnaires were used in this study, namely a costing questionnaire and quality of 
life questionnaire, both of which aimed to collect data associated with costs and utilities 
in BPSD patients being treated with risperidone and olanzapine in Thailand. More details 
are outlined below. 
3.4.5.1 Costing questionnaire 
The costing questionnaire was designed for study purposes to collect data regarding the 
costs of patients with BPSD and being treated with atypical antipsychotics, (olanzapine or 
risperidone), in Thailand.  
In designing the questionnaire in this study, firstly, the literature review was used to 
identify examples of the cost measurements associated with dementia and/or BPSD and 
healthcare resource utilisation. In addition, examples of those cost questionnaires were 
used to design the cost assessment in this study, especially studies associated with cost-
utility analyses in Thailand (Murman et al. 2002, Beard et al. 2006, Kirbach et al. 2008, 
Turongkavee et al. 2011, Rive et al 2010, Mohara, 2012, Thongsri et al. 2012, Lachaine et 
al. 2014). Secondly, question items were produced by reviewing existing guidelines, 
existing health economic evaluation studies as well as information from an education 
expert, a medical specialist and a dementia caregiver. Finally, the researcher developed 
the cost questionnaire based on all the available data from the processes as previously 
stated.   
The costing questionnaire consisted of three main parts as listed below: 
• Part 1: This part was associated with the general data of patients, including 
demographic data (gender, age, marital status, religion, education, current 
occupation, prior occupation, income sources, living area, residence, living 
arrangement, (a status of living), time since diagnoses with dementia, TMSE 
scores, comorbidity conditions, drug-related adverse events, patients’ health 
insurance system and patients’ activities of daily living.   
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• Part 2: This part focused on cost data, including outpatient- and inpatient-
associated costs, costs of other treatments, paid caregiver costs and informal care 
costs.  
For outpatient-associated costs, these comprised of the number of visits to the 
outpatient department, additional payments associated with outpatient visits, costs 
associated with drug-induced adverse events, (falls, constipation and 
extrapyramidal symptoms), comorbidity condition-associated costs, and additional 
costs for travel, extra accommodation and extra food due to outpatient visits in 
excess of their normal routine daily expenditure. 
For inpatient-associated costs, these encompassed the number of hospital 
admissions with dementia or symptom-related dementia events, average length of 
stay at hospital (days), additional payments associated with the hospital 
admissions and additional costs for travelling, extra accommodation and extra 
food due to the hospital admissions, but again only those in excess of their normal 
daily living expenses were included.   
Other costs such as having new equipment, including wheelchairs, walkers and 
patient beds, food and dietary supplements, (e.g. liquid diets for patients, ginseng, 
grape seed extract, spirulina, dietary fibre, Moringa capsules and extracted 
mangosteen juice), herbs, vitamins, other nutritional sources (e.g. Anlene®, 
sterilised milk, yoghurt milk, UHT milk, Lactasoy®, Milo® and Ovaltine®) and 
disposable adult diapers were also included.  
Paid caregiver costs were associated with out-of-pocket expenses or paying for the 
hire of caregivers or home helpers whose time was solely for providing care to 
patients with BPSD.  
For informal care costs, these were related to family members, relatives or friends 
who spent time in providing care to patients but were not paid for their provision 
of care to these patients. However, informal care costs were calculated as the same 
as for paid workers based on an opportunity cost method (Berg, Brouwer and 
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Koopmanschap 2004) (see more details in Chapter 5). This was also consistent 
with the cost estimation of informal care of people with dementia according to 
World Health Organization (2012).  
• Part 3: This part focused on the general data of caregivers as follows: gender, age, 
marital status, religion, education, current occupation, prior occupation, stopping 
work due to providing patients’ care, duration of stopping work to care for their 
patients, relationship with patients, hours spent caregiving for patients and the 
impacts of the patient’s illness on the caregivers due to providing care, classified 
into physical health conditions, (e.g. low back pain, knee pain, shoulder pain, 
muscle pain and quality of sleep) and mental health problems, (e.g. distress, 
anxiety, stress and depression).  
In addition, the instruments used to measure patients’ cognitive status, (if patients had no 
cognitive assessment during the last six months), and patients’ physical dependency in 
this study are explained below.   
3.4.5.1.1 Measuring patients’ cognitive status  
To measure a person’s cognitive status in Thailand, there are several instruments, 
including Thai Mental State Examination (TMSE), Mini-Mental State Examination: Thai 
version (MMSE-Thai 2002), the 7-minute test and Montreal cognitive assessment 
(MOCA) (Prasat Neurological Institute 2014). However, the Institute of Geriatric 
Medicine, Ministry of Public Health in Thailand, suggested that the TMSE and MMSE-
Thai 2002 could help for diagnosis, indicating the levels of disease severity of dementia 
and indicating the disease progression over time (Institute of Geriatric Medicine 2008).  
The MMSE-Thai 2002 was developed by the Thai Cognitive Test Development 
Committee (1999). This test was developed for one-to-one matching based on the MMSE 
test established by Folstein, Folstein and McHugh (1975). The MMSE-Thai 2002 
composed of 11 main items as follows: orientation for time (5 points), orientation for 
place (5 points), registration (3 points), attention/calculation (5 points), recall (3 points), 
naming (2 points), repetition (1 point), verbal command (3 points), written command (1 
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point), writing (1 point) and visuoconstruction (1 point). Eventually, the MMSE-Thai 
2002 yielded a maximum score of 30 (Institute of Geriatric Medicine 2008, Prasat 
Neurological Institute 2014).  
Alternatively, in 1993 the TMSE test was formed by the Train the Brain Forum 
Committee in Thailand and this test was also adapted from the MMSE test established by 
Folstein, Folstein and McHugh (1975). However, the TMSE test consisted of six main 
items as follows: orientation (6 points), registration (3 points), attention (5 points), 
calculation (3 points), language (10 points) and recall (3 points). The TMSE also 
contributed a maximum score of 30 (Institute of Geriatric Medicine 2008, Prasat 
Neurological Institute 2014).   
Both the TMSE and the MMSE-Thai 2002 instruments could be grouped into six domains 
as follows: complex attention, executive function, learning and memory, language, 
visuoconstructional-perceptual ability and social cognition (Prasat Neurological Institute 
2014). Both of the instruments are compared in the following Table 3.2.  
Table 3.2: Differences between the TMSE and MMSE-Thai 2002 
 TMSE MMSE-Thai 2002 
Presented Point Presented Point 
Social cognition     
Orientation of time ● 4 ● 5 
Orientation of place ● 1 ● 5 
The orientation of the 
person 
● 1   
Learning and memory     
Registration ● 3 ● 3 
Recall ● 3 ● 3 
Complex attention and 
executive function 
    
Attention and calculation ● 8 ● 5 
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 TMSE MMSE-Thai 2002 
Presented Point Presented Point 
Language     
Naming ● 2 ● 2 
Repetition ● 1 ● 1 
Verbal command ● 3 ● 3 
Written command ● 1 ● 1 
Writing   ● 1 
Comparison of things ● 1   
Visuoconstructional 
perceptual ability 
    
Visuoconstruction ● 2 ● 1 
Total score  30  30 
* (●) refers to the presence of items to measure cognition when compared between the TMSE and MMSE-
Thai 2002 
When comparing between the two instruments, scores from both tests studied in people 
aged 60 and over in Thailand showed in the same direction and it also found that the 
Pearson correlation coefficient of both tests was 0.904 (p<0.000) (Institute of Geriatric 
Medicine 2008). Further, 84.2% of medical staff reported that the MMSE-Thai 2002 was 
easy to administer, compared to the TMSE which only 38.5% found easy. Time spent to 
complete the tests in less than 10 minutes accounted for 23.1% for the MMSE-Thai 2002 
and 9.6% for the TMSE. Therefore, it was clear that the MMSE-Thai 2002 was quicker to 
complete when compared with the TMSE (Institute of Geriatric Medicine 2008).  
To measure patients’ cognitive states, the TMSE was chosen in this study. The reason was 
that the TMSE was the recommended cognitive assessment tool from both the clinical 
practice guidelines for dementia in Thailand and the Institute of Geriatric Medicine, as 
mentioned above. The test was also commonly used for screenings patients’ cognitive 
states in Thailand. In essence, the selection of a cognitive test also relied on clinical 
practices or policy at each hospital or setting.  
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Moreover, the classification of disease severity by TMSE scores in this study was based 
on MMSE scores from previous studies, (Perneczky et al. 2006, Bond et al. 2012), which 
were TMSE: 21-26 (mild dementia), TMSE: 10-20 (moderate dementia), and TMSE: <10 
(severe dementia).  
3.4.5.1.2 Measuring patients’ physical dependency based on Activities of Daily Living 
(ADL) 
Dementia is a leading cause of illness affecting elderly patients where each patient has a 
difference in levels of disease severity following the disease progression. The cognitive 
deterioration of patients is not only problematic to themselves but also impacts on 
caregivers who provide care to those patients.  
To measure the basic activities of daily living (bADL), there were various approaches 
used to assess the ability to perform ADL. However, Barthel Index and Katz Index of 
ADL were instruments which were widely used measurement tools providing useful 
information to differentiate between levels of dependence in Thailand (Table 3.3).   
The Barthel Index in the Thai version was developed by Jittapunkul et al. (1994) based on 
the original Barthel Index established by Mahoney and Barthel (1965). This instrument 
comprises 10 items, including feeding, grooming, transfer, toilet use, mobility, dressing, 
stairs, bathing, bowels and bladder. In addition, definitions of scoring the Barthel index 
(Thai version) are described as follows: 
• Feeding  
0 = Patient was unable to feed by himself/herself. 
1 = Patient needed some help such as cutting up the food and preparing devices 
such as a spoon and a fork.  
2 = Independent.  
• Grooming (e.g. washing face, combing hair, cleaning teeth and shaving within last 
24-48 hours) 
0 = Patients needed the help. 
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1 = Patient was able to do these activities as stated above by himself/herself, 
including preparing equipment.  
• Transfer (e.g. transferring in the same level floor, transferring to a bed, lying down 
on the bed, getting on and off the bed, changing their position to sit on the bed, 
transferring to sit a chair) 
0 = Patient was unable to transfer by himself/herself or needed to be lifted by two 
people. 
1 = Patient needed a great deal of help from an assistant to change position to 
sitting.  
2 = Patient needed minimal help from an assistant. For example, the patient 
needed to be supervised for safety or reminded of what to do.  
3 = Patient was able to transfer without help or supervision. 
• Toilet use 
0 = Patient was unable to use the toilet by himself/herself. 
1 = Patient needed some help in some steps of this activity.  
2 = Independent. For example, the patient could get on and off the toilet and clean 
themselves. 
• Mobility (moving within a room or home) 
0 = Patient was unable to move by himself/herself.  
1 = Patient used a wheelchair independently and was able to go around a room 
corner and through a door. 
2 = Patient needed some help to walk and move or needed to be supervised for 
safety or reminded of what to do.  
3 = Patient could independently move by himself/herself without help or 
supervision. 
• Dressing 
0 = Patient was able to put on and remove his/her clothing.  
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1 = Patient could dress by himself/herself accounting for 50% of dressing. The 
rest of the activity they needed some help to complete.  
2 = Independent.  
• Stairs (ascending and descending stairs) 
0 = Patient was unable to go up and down stairs.  
1 = Patient needed some help to do these activities. 
2 = Patient could ascend or descend himself/herself without help or supervision. If 
they used a walker or canes, they had to carry them going up or downstairs.  
• Bathing 
0 = Patient needed supervision to do this activity.  
1 = Patient was able to do all steps of bathing by himself/herself.  
• Bowels (continence of bowels over the last week)  
0 = Patient was uncontrollable his/her bowel movement. Some patients often need 
a suppository or an enema.  
1 = Patient was sometimes unable to control his/her bowels; however, this was 
less than once a week. 
2 = Patient was normally able to control his/her bowels.  
• Bladder (controlling bladder over the last week) 
0 = Patient was uncontrollable with his/her bladder. 
1 = Sometimes the patient was unable to control his/her bladder; however, this 
was less than once a week. 
2 = Patient was normally able to control his/her bladder. 
Based on the Katz Index of ADL, this consisted of six activities as follows: feeding, 
transferring, toileting, dressing, bathing and continence. The definitions of scoring were 
slightly adapted from Katz et al. (1970) and are presented below: 
• Feeding  
0 = needed partial or total help with feeding or required parenteral feeding. 
 
 
158 
 
1 = got food from the plate into the mouth without help, preparation of food might 
be done by another person. 
• Transferring 
0 = needed help in moving from bed to chair or required a complete transfer. 
1 = moved in and out bed or chair unassisted. Mechanical transferring aides were 
acceptable.  
• Toileting 
0 = needed help transferring to the toilet, cleaning self, or used bedpan or 
commode.  
1 = went to the toilet, got on and off, arranged clothes and cleaned genital area 
without help. 
• Dressing 
0 = needed help with dressing or needed to be completely dressed.  
1 = got clothes from closets and drawers and put on clothes and outer garments 
complete with fasteners. Might have help trying shoes. 
• Bathing 
0 = needed help with bathing more than one part of the body, getting in or out of 
bathtub or shower. Required total bathing.  
1 = bathed self completely or needed help in bathing only a single part of the body 
such as the back, genital area, or disabled extremity.  
• Continence 
0 = was partially or totally incontinent of bowel or bladder.  
1 = exercised complete self-control over urination and defecation. 
Table 3.3: Differences between the Barthel Index-Thai and the Katz Index of ADL 
 Barthel Index-Thai Katz Index of ADL 
Feeding ● ● 
Grooming ●  
Transferring ● ● 
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 Barthel Index-Thai Katz Index of ADL 
Toileting ● ● 
Mobility ●  
Dressing ● ● 
Stairs ●  
Bathing ● ● 
Bowels ● ● 
Bladder ● ● 
Total score 20 6 
* (●) refers to the presence of activities when compared between the Barthel Index-Thai and Katz Index of 
ADL 
For an interpretation of scores, the Barthel Index-Thai scores contributed four levels as 
follows: 0-4 points (a total dependence), 5-8 points (a severe dependence), 9-11 points (a 
moderate dependence), and more than 12 points (a mild dependence). The Katz Index of 
ADL scores were 6 points (independence), 4 points (a moderate dependence) and less 
than 2 points (a severe dependence) (Prasat Neurological Institute 2014). 
To measure patients’ functional ability, the Barthel Index-Thai and the Katz Index of 
ADL were widely used and recommended to assess ADL; however, the Barthel Index-
Thai was designed specifically as a Thai version. This scale was also applied to assess 
ADL in the elderly that provide helpful information regarding long-term care (LTC) 
conditions to a LTC management policy for older Thai people (National Health Security 
Office 2016). Thus, the Barthel Index-Thai was chosen as the tool to assess ADL of 
patients with BPSD in this study.  
3.4.5.2 Quality of life questionnaire 
As previously stated, this study used the QALYs as health outcomes in an evaluation. The 
concept of QALYs is a measure of outcome which captures both quality of life and 
quantity of life (Drummond et al. 2005, Gray et al. 2012). For more clarification, this is 
that individuals have experienced various health states over time where each health state 
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is weighted, correlating to a health utility score during that time. Consequently, the 
multiplication of the time spent in each health state by the health-related quality of life 
weight (HRQoL weight) associated with that health state is the calculation of the QALY 
(Drummond et al. 2005, Whitehead and Ali 2010, Gray et al. 2012). Based on this 
assumption, this indicates that HRQoL weights or utility values or utility weights are 
significantly substantial factors in producing QALYs.  
For technology appraisals, the QALY is frequently used in a cost-utility analysis. This is 
also recommended by several agencies, such as NICE in the UK, the Canadian Agency 
for Drugs and Technologies in Health (CADTH) in Canada, the Pharmaceutical 
Management Agency (PHARMAC) in New Zealand, The Pharmaceutical Benefit 
Advisory Committee (PBAC) in Australia and the Health Intervention and Technology 
Assessment Program (HITAP) in Thailand (National Institute for Health and Care 
Excellence 2013, The Health Intervention and Technology Assessment Program 2014, 
The Pharmaceutical Benefit Advisory Committee 2016, The Pharmaceutical Management 
Agency 2017, Canadian Agency for Drugs and Technologies in Health 2017). 
In addition, health-related quality of life was measured by several instruments including 
generic instruments and disease-specific instruments (Guyatt et al. 1989, Guyatt, Feeny 
and Patrick 1993, O’ Brien 1994, Drummond et al. 2005).  
Generic instruments were designed to use a wide range of treatments, populations and 
interventions. The measures of HRQoL by these scales are classified into two main 
techniques as follows: health profiles and utility measures (preference-based measures). 
Sickness Impact Profile (SIP), Nottingham Health Profile (NHP), Short Form health 
survey-36 (SF-36) as well as World Health Organization Quality of Life (WHOQOL-
BREF) were examples used to measure the health profiles of people. For utility weights, 
this could be scaled by direct and indirect methods for measurements of the preferences of 
individuals for their health outcomes. Standard Gamble (SG), Time Trade-Off (TTO), and 
Visual Analog Scale (VAS) were patterns which were the most commonly used in the 
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direct approaches. For indirect methods or multi-attribute health status classification 
systems with preference scores, there were SF-6D, Quality of Well-Being (QWB), Health 
Utilities Index (HUI), and EuroQOL (EQ-5D) which were favourable tools of this 
method. Disease-specific instruments were applied to specific diseases and sub-
populations. Thus, instruments used in this method were focused on particular uses in 
diseases or conditions (Guyatt et al. 1989, Guyatt, Feeny and Patrick 1993, O’ Brien, 
1994, Drummond et al. 2005).     
To measure the utility weights of BPSD patients being treating with risperidone or 
olanzapine in this study, the EQ-5D-5L instrument was chosen. The reasons for this were 
that the results from this tool provided utility weights which could be adopted for the aim 
of this study as a cost-utility analysis. The tool was also widely used to measure the 
HRQoL and recommended by several agencies, especially the HITAP in Thailand. 
Although there were some doubts about using this scale in applying the EQ-5D-5L 
instrument for use in patients with dementia, there were several studies reporting that this 
scale was valid and able to use for an assessment of the HRQoL in people with dementia 
(Wolfs et al. 2007, Jones, Edwards and Hounsome 2012, Diaz-Redondo et al. 2014, 
Aquirre et al. 2015, Yang et al. 2017). The disease-specific measure, such as the 
Dementia Quality of life Instrument (DQI), the Quality of Life in Late-Stage Dementia 
scale (QoL-AD), and Dementia Quality of Life (DEMQOL), had been developed to 
identify HRQoL in patients with dementia, but these instruments still did not apply for the 
utility measurement which was used to calculate for the QALY (Hounsome, Orrell and 
Edwards 2011, Missotten, Dupuis, and Adam 2016). Lastly, dementia-specific 
instruments are still limited in Thailand.   
Consequently, the quality of life questionnaire in this study used the EQ-5D-5L which 
was derived and permitted from the EuroQol Group. The EQ-5D-5L questionnaire was a 
Thai version. This instrument consisted of five domains, including mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression, and five levels of problems, 
including no problems, slight problems, moderate problems, severe problems and extreme 
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problems (EuroQol Group 2015). The conversion from EQ-5D-5L health states into index 
values was recommended to use data based on tariff or value sets of country-specific data. 
Thus, this thesis employed value sets based on the study in the Thai population (see more 
details in Chapter 6).  
In addition, the utility weights in this thesis were measured by the EQ-5D-5L. This 
instrument was only used in the targeted patients based on calculated sample size as stated 
above (see section 3.4.2), to evaluate health-related quality of life, at only one point in 
time during some point in 2017. These values were then used in the evaluation of the 
cost-utility analysis of olanzapine and risperidone use in patients with BPSD in Thailand, 
(see more details in Chapter 6). Moreover, the additional assessment to evaluate the 
improvement of the treatment was also conducted after first interviewing patients and/or 
caregivers by using the EQ-5D-5L. This was undertaken based on asking those patients or 
their caregivers by face-to-face interviews or a telephone interview at any point of time, 
which was at least five months to six months from the initial interview, using a 5-point 
Likert scale. The scales are described as follows: 1 = not at all improved, 2 = slightly 
improved, 3 = moderately improved, 4 = much improved and 5 = extremely improved. 
Results associated with this evaluation are presented in Appendix 6. 
3.4.5.3 Implement the questionnaire 
After developing the costings questionnaire for the purpose of this study, it was then 
examined by an education expert, a medical specialist, (a local supervisor in Thailand), 
and a dementia caregiver, which aimed to evaluate and refine the relevance of the 
questions in cost questionnaire.  
Owing to this being study a primary data collection tool in patients with BPSD and/or 
their caregivers an ethics approval was required before the process of data gathering could 
begin.  
To apply the questionnaire with patients suffering from BPSD and being treated with 
either risperidone or olanzapine and/or their caregivers at an outpatient clinic of 
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Thammasat University Hospital, Thailand, using a face-to-face interview process, patients 
and/or caregivers were recruited based on the participant recruitment process, (as 
considered from inclusion criteria in Flowchart 3.2B). If patients and/or caregivers 
decided to participate in this study, information sheets and consent forms were distributed 
to those informants. Signed consent forms of informants were needed before being 
interviewed by the researcher. The process then carried on the data gathering of the study 
as previously mentioned (see Flowchart 3.2C). 
There were two informants, one risperidone-treated patient with mild dementia and his 
caregiver and one moderate dementia patient’s caregiver of an olanzapine-treated patient. 
These were interviewed to complete the questionnaire both for the costing and quality of 
life data. Based on an information sheet the total time to accomplish the questionnaire 
was determined to be around 30-45 minutes. Interviewing both of the informants 
completed the interview within a defined time. The time needed interviewing the patient 
was nearly 45 minutes, whereas the caregiver was approximately timed at about 28 
minutes. Both informants could follow and respond to all of the items (the general data of 
the patient, costing and the general data of the caregiver). Interestingly, the patient with 
moderate dementia was unable to complete the questionnaire by himself, so his caregiver 
became the informant (as a proxy) instead of the patient. The major time-consuming 
aspect of the interviews was predominantly the part consisting of the costing 
questionnaire which was composed of more questions when compared with the other part. 
Whereas, a part of the EQ-5D-5L, (as measure health-related quality of life), was 
completed within a few minutes. In addition, all informants responded well to co-operate 
during the interviews.  
 Cost and utility analyses 
For calculating cost data, descriptive statistics, including percentage, arithmetic mean and 
standard deviation (SD), were conducted for a cost analysis of each drug treatment 
(olanzapine and risperidone) using Microsoft® Excel version 2013. All cost data were 
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presented in Thai baht, (THB), at 2017 values, (1£ = THB 45). A societal perspective was 
used as a viewpoint of this study. 
Furthermore, cost data analysis was also presented by the classifications of patients by 
cognitive function and physical dependence. The patients’ cognitive states were classified 
into mild dementia, moderate dementia and severe dementia. Pre full-time care (Pre-FTC) 
and full-time care (FTC) were used to classify patients by their dependent status. The 
FTC state in this study was defined as a patient’s requirement for care and supervision for 
the greater part of each day (Caro et al. 2001).  
According to utility measurements, a utility analysis was conducted in a similar fashion to 
the cost analysis. The percentage, the arithmetic mean and the SD were also calculated for 
the utility analysis of olanzapine treated patients and risperidone treated patients using 
Microsoft® Excel version 2013. The analysis of utility data was also separately reported 
by patients’ cognitive function and patients’ physical dependence following the criteria 
outlined above.  
 
 Cost-utility analysis  
Health economic evaluation methods are classified into four main techniques as presented 
below.  
A cost-minimisation analysis (CMA) is conducted to compare interventions (two or more 
alternative treatments) in which those interventions are assumed to have equivalent 
outcomes. Thus, the core purpose of this method is to consider only the minimisation of 
costs (Drummond 1998, Drummond et al. 2005, Gray et al. 2012).  However, the CMA 
technique is not characterised as a full health economic evaluation (Drummond et al. 
2005). Briggs and O’Brien (2001) also suggested that using this technique does not 
frequently encounter the right conditions regarding the equivalence of costs or outcomes 
of the interventions due to having an uncertainty of costs and outcomes in real situations. 
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The CMA is not then appropriate to employ for healthcare evaluations which should test a 
hypothesis of differentiating between costs and outcomes.  
A cost-effectiveness analysis (CEA) is one method which is widely used in health 
economic evaluations and is also under full health economic evaluation scheme. This 
method is based on the concept of an extra-welfare (Brouwer et al. 2008). The CEA 
undertakes a comparison between costs and outcomes, (effectiveness or efficacy) where 
these outcomes are measured as disease-specific outcomes or natural units of disease such 
as case detected, case prevented, a reduction of serum cholesterol (LDL-C), a reduction of 
blood pressure (mmHg), bone mineral density, disability avoided and life year gained 
(LYG). However, this approach is likely to be limited in comparing across different 
disease areas (Wanner and Hutton 1980, Drummond 1998, Drummond et al. 2005). 
Consequently, the CEA is classified as a technical efficiency measure (Shiell et al. 2002, 
National Information Center on Health Services Research and Health Care Technology 
2016). 
A cost-utility analysis (CUA) is based on the principal of extra-welfare (Brouwer et al. 
2008). The CUA is a similar concept to the CEA, yet this method compares between costs 
and utility-based outcome measurement as quality-adjusted life years (QALYs). The 
QALY accommodates both life years (quantity gained) and a quality of life (quality 
gained) and is the life year gained yielded from the intervention, adjusted by preferences 
for health outcomes of individuals on different health states. This method is classified as a 
full health economic evaluation. Some studies suggest the CUA is a subdivision of the 
CEA. Due to the outcomes of the CUA, it is classed as a generic measure and this allows 
the studies based on this method to compare a wide range of different disease areas 
(Drummond 1998, Drummond et al. 2005, Gray et al. 2012). Thus, this method is classed 
as a technical efficiency measure and an allocative efficiency measure (Shiell et al. 2002, 
National Information Centre on Health Services Research and Health Care Technology 
2016).  However, a study by Jakubiak-Lasocka and Jakubczyk (2014) reported the CUA 
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method is more time and resource consuming when compared with using the CEA 
method.  
A cost-benefit analysis (CBA) is a comparison of costs and outcomes approach in which 
the outcomes are defined in monetary terms. The principle of this method is based on 
social welfare (Brouwer et al. 2008) and also facilitates an allocative efficiency (Shiell et 
al. 2002, National Information Centre on Health Services Research and Health Care 
Technology 2016). This approach can then be used to compare a wide range of scopes, 
such as different programmes and different diseases and not focused only on healthcare 
aspects. A full health economic evaluation also covers the CBA method. However, the 
major restraint is that it is not simple to transform effects into monetary terms 
(Drummond 1998, Drummond et al. 2005).  
The different methods of health economic evaluations and comparisons of the strengths 
and weaknesses of each method are presented in the following Table 3.4 and Table 3.5, 
respectively.  
Table 3.4: Methods of health economic evaluations 
 Costs Outcomes 
Cost-minimisation analysis (CMA) Monetary units Equivalent outcomes 
Cost-effectiveness analysis (CEA) Monetary units Health outcomes in natural units (e.g. 
case prevented, mmHg blood 
pressure reduction, case successfully 
treated, case detected and LYG) 
Cost-utility analysis (CUA) Monetary units Utility-based outcomes (e.g. QALYs 
and DALYs) 
Cost-benefit analysis (CBA) Monetary units Monetary units 
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Table 3.5: Comparison of the strengths and weaknesses of each method of health 
economic evaluation 
 Strength Weakness 
Cost-minimisation analysis 
(CMA) 
● Outcomes of two or amongst 
treatments are equivalent 
● The comparison is based on 
only different costs of different 
interventions 
● Favouring in lower costs 
● Rare circumstances of an 
assumption whether outcomes 
of interventions are equivalent 
● Not a full health economic 
evaluation 
● Not appropriate to study in 
health economic evaluations 
Cost-effectiveness analysis 
(CEA) 
● A full health economic 
evaluation 
● Based on extra-welfare  
● A technical efficiency 
measure 
● The method is widely used in 
health economic evaluations 
● Outcomes are measured as 
effectiveness/efficacy for 
clinical evaluations (disease-
specific outcomes or natural 
units) 
● Less resource- and time-
consuming compared with the 
CUA 
● An interpretation of the 
results is a cost-effectiveness 
ratio (CER) and an incremental 
cost-effectiveness ratio (ICER) 
which ICER is the most widely 
used  
● Limits to compare across 
different disease areas.  
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 Strength Weakness 
● A minimised ICER is 
favourable 
Cost-utility analysis (CUA) ● A full health economic 
evaluation 
● Based on extra-welfare  
● A technical efficiency and 
allocative efficiency 
● The method is commonly 
used in health economic 
evaluations 
● Outcomes are measured in 
terms of QALYs 
● Allows comparison across 
different disease areas 
● Interpreting the result in terms 
of CER and ICER which ICER 
is the most commonly uses  
● A lower ICER is favourable 
● More resource- and time-
consuming 
● The method is mainly based 
on a questionnaire for 
measuring utility which might 
have over- or under-estimate 
utility weights 
 
Cost-benefit analysis (CBA) ● A full health economic 
evaluation 
● Based on social welfare 
● An allocative efficiency 
measure 
● Allows comparison to a wide 
range of areas such as 
programmes, diseases  
● Results are interpreted in 
terms of a cost to benefit ratio 
approach or a net benefit 
approach 
● The difficulty for translating 
effects to monetary terms 
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In summary, to measure the most cost-effective treatment between risperidone-treated 
BPSD patients and olanzapine-treated BSPD patients, a cost-utility analysis was chosen 
for this study. The reasons were that an outcome of this study is measured in terms of the 
quality-adjusted life year (QALY) which was most frequently used in health economic 
evaluations and also allowed the comparison with a wide range of disease areas. In 
essence, the CUA was also recommended by the HITAP in Thailand for health economic 
evaluations (The Health Intervention and Technology Assessment Program 2009, The 
Health Intervention and Technology Assessment Program 2014).  
Analysing the cost-effectiveness of a new treatment by comparison with a current 
treatment was based on an incremental analysis which uses differences in costs 
(incremental costs) and differences in outcomes (incremental outcomes) (Drummond et 
al. 2005, Gray et al. 2012). The result could possibly be in the four quadrants based on the 
cost-effectiveness plane (see Chapter 2, section 2.5).  
Where the new treatment was more costly than the current treatment and the outcome of 
the new treatment was also better than the existing treatment, it was necessary to perform 
a trade-off which would provide valuable information associated with an incremental cost 
relative to an incremental outcome or an incremental-effectiveness ratio (ICER). This 
would help decision-makers in their judgement of those interventions, on the basis of a 
cost-effective threshold, (CE threshold), of a country-specific data. Indeed, if the ICER 
was greater than the CE threshold, the new treatment was not considered to be cost-
effective when compared with the current treatment.   
 Base-case analysis 
At a base case or reference case analysis, the result of the cost-utility analysis was 
calculated in terms of an incremental cost-effectiveness ratio (ICER) as measured by 
incremental costs, (a difference in costs between treatment groups), divided by 
incremental outcomes, (a difference in quality-adjusted life years, (QALYs), of both 
treatments) (see the equation in section 3.3.2).  
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Following conventions used in policy making in Thailand, the CE threshold was set at 
THB 160,000 per QALY as a cut-point to consider with regards to a cost-effectiveness 
strategy which was defined by the Sub-committee of the NLEM of Thailand 
(Teerawattananon 2018). Thus, this value was exercised in this thesis as the CE threshold.  
 Sensitivity analyses 
Using the model-based on health economic evaluations, there was the uncertainty of the 
variables which were used in the model. Therefore, to consider the responsiveness of 
results to change in different parameters, sensitivity analyses needed to be conducted to 
test robustness of the results (see more details in Chapter 7). Both methods of a 
deterministic sensitivity analysis, using a one-way sensitivity analysis, and a probabilistic 
sensitivity analysis, (PSA), using a Monte Carlo simulation of simulating 1,000 times of 
parameters, were conducted in this study.  
In this thesis, the results from the PSA were presented by the cost-effectiveness 
acceptability curve, (CEAC). The CEAC was constructed based on the net monetary 
benefit approach. A range of willingness to pay, (ceiling ratio), for an additional QALY 
gained, was used to draw the proportion of estimating the net benefit values at the given 
willingness to pay, (WTP), threshold. The willingness to pay was the valuation of health 
benefit in monetary terms. More explicitly, this was that the maximum price which a 
consumer will definitely pay for the health benefit (Bertram et al. 2016). For evaluating in 
this thesis, the willingness to pay was defined as a range between THB 0 - 500,000.  
In addition, the CEAC was correlated between a range of cost-effectiveness thresholds or 
willingness to pay thresholds, (the horizontal axis, X), and the probability of the treatment 
being cost-effective at that threshold (the vertical axis, Y). The net monetary benefit, 
(NMB), method was calculated following the equation presents below (Drummond et al. 
2005). 
NMB     =   RT * (EA- EB) – (CA- CB) 
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where:   NMB was the net monetary benefit 
 RT was a willingness to pay (WTP) per unit of increased effectiveness (QALY) 
 CA was the cost of the intervention of interest 
 CB was the cost of current treatment 
 EA was the effectiveness of an intervention of interest 
 EB was the effectiveness of current treatment 
By interpreting if the net benefit values were greater than zero, these indicated if the 
treatment of interest was more cost-effective than the current treatment (Drummond et al. 
2005). Further, a curve deriving from this approach would present the probability of the 
cost-effectiveness of the treatment of interest compared with the current treatment, by 
incorporating the uncertainty of sampling the variation of costs and outcomes and the 
uncertainty of an acceptable level of cost-effectiveness ratio for a decision maker 
(Fenwick, Claxton and Sculpher 2001, Briggs, O’Brien and Blackhouse 2002, Fenwick 
and Byford 2005). 
Although the thesis was defined the CE threshold at THB 160,000 per QALY based on 
the Sub-committee of the NLEM of Thailand, the study by Thavorncharoensap et al. 
(2013) suggested a range of the willingness to pay for an additional QALY in Thailand 
was between THB 59,000-285,000 as reported in 2008. Hence, these values, adjusted to 
2017 currencies by the Consumer Price Index, (CPI), of Thailand, would be applied in 
this thesis to consider by what price society would be willing to pay to gain an additional 
QALY.  
From the sensitivity analyses, different assumptions of inputs used in an analysis were 
applied to test the sensitivity of the results and conclusions to such alterations. The 
sensitivity analyses also incorporated a wide range of plausible parameters for assessing, 
then these would be able to support more confidence of the results. Further, the sensitivity 
analyses had benefits to quantify parameters which had the potential impacts on the 
degree of accuracy of the results, leading to more appropriate decisions of the decision-
makers.   
 
 
172 
 
 Comparison of the research relative to the existing literature 
According to the comprehensive literature search between 1995 to June 2015 (see Chapter 
2, section 2.5.1), the findings found only two published studies conducting associated 
with health economic evaluations of atypical antipsychotics for dementia or Alzheimer’s 
disease. To position this study relative to those two existing studies, the comparison has 
been summarised in the following Table 3.6. Whilst the strengths and limitations of each 
published studies are also outlined in Table 3.7.  
Table 3.6: Comparisons of this study relative to other published studies on the cost-
effectiveness of atypical antipsychotics in the treatment of dementia or Alzheimer’s 
disease 
 Rosenheck et al. 
(2007) 
Kirbach et al. 
 (2008) 
This study 
Type of economic 
evaluation 
● Cost-benefit 
analysis 
● Cost-utility analysis ● Cost-utility analysis 
Economic evaluation 
approach 
● Alongside a clinical 
trial 
● Model-based 
economic evaluation 
(Markov model) 
● Model-based 
economic evaluation 
The study population  ● Eligible patients 
with AD type of 
dementia, who were 
ambulatory 
outpatients living at 
home or in assisted 
living, with MMSE 
scores from 5-26 with 
hallucination, 
delusion, aggression, 
or agitation  
● US adults aged 65 
years and over with 
AD with psychosis 
and/or agitation 
● Thai adults aged 60 
years and over with 
BPSD 
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 Rosenheck et al. 
(2007) 
Kirbach et al. 
 (2008) 
This study 
Intervention and 
Comparator 
● Risperidone vs 
olanzapine vs 
quetiapine vs placebo 
● Olanzapine vs no 
treatment  
● Olanzapine vs 
risperidone 
Costing data ● Primary data: total 
health care and 
medication costs 
based on follow-up for 
9 months 
● Costs data were 
based on proxy reports 
from patients’ 
caregivers  
● Secondary data: total 
costs (direct and 
indirect costs)  
● Direct costs for 
patients with AD with 
low and high levels of 
NPI were based on 
costing data from a 
cross-sectional study 
(Murman et al. 2002) 
multiplied by the 
proportions of 
expenditures from 
study by Jonsson et al. 
(2006) 
● Indirect costs for 
patients with AD with 
low and high levels of 
NPI were based on a 
cross-sectional study 
by Murman et al. 
(2002) 
● Primary data: direct 
medical and direct 
non-medical costs, 
including adverse 
event- and relapse-
associated costs based 
on a cross-sectional 
study 
Utility data ● Primary data: Health 
Utilities Index Mark 3 
(HUI:3) instrument 
based on follow-up for 
9 months 
● Secondary data and 
using utility data from 
Murman and Colenda 
(2005) adjusted by the 
information of 
● Primary data: EQ-
5D-5L instrument 
based on a cross-
sectional study 
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 Rosenheck et al. 
(2007) 
Kirbach et al. 
 (2008) 
This study 
● Utility weights were 
based on proxy reports 
from patients’ 
caregivers 
● Analysis required a 
single measure of 
HRQoL which 
reflected both health 
gains and health losses 
olanzapine treatment 
from the  
schizophrenia study to 
extrapolate for 
changes in the health 
utility weights for 
olanzapine 
● Utility weights were 
derived from 
examining the 
relationship between 
the Health Utilities 
Index (HUI) in 
patients with probable 
AD based on a cross-
sectional study by 
Neumann et al. (1999) 
and cognition, 
behaviour and 
functioning; however, 
they were unpublished 
data 
Outcome ● QALYs gained ● QALYs gained ● QALYs gained 
Time horizon and 
cycle length 
● The follow-up for 9 
months 
● Over a 13-year time 
period with a 6-month 
cycle length 
● Over a 5-year time 
period with a one-
month cycle length 
Perspective ● Economic 
perspective 
● The US health 
system perspective 
● A societal 
perspective 
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 Rosenheck et al. 
(2007) 
Kirbach et al. 
 (2008) 
This study 
Discount rates ● N/A ● At 3% of both costs 
and QALYs per 
annum 
● At 3% of both costs 
and QALYs per 
annum 
Abbreviations: AD, Alzheimer’s disease; BPSD, behavioural and psychological symptoms of dementia; 
NPI, the Neuropsychiatric Inventory; HRQoL, Health-related Quality of Life; N/A, not applicable 
Table 3.7: Comparison strengths and limitations of published studies on the cost-
effectiveness of atypical antipsychotics in the treatment of dementia or Alzheimer’s 
disease 
 Strength Limitation 
Rosenheck et al. (2007) ● Large sample size 
● Based on primary analysis 
which was follow-up for 9 
months 
● Based on highly controlled 
conditions 
● This cost-benefit analysis 
was conducted in accompany 
with the CATIE-AD study  
 
● A placebo did not reflect to 
real-world clinical practice 
which it was not offered as a 
treatment 
● The 9-month continued 
original treatment might raise 
an issue concerning the 
accurate of the treatment 
● A statistical power of the 
study, specially Phase 1-only 
results, might need to be a 
concern 
● 80% of patients discontinued 
initially assigned treatments 
before 9 months 
● Cost data were reported by 
caregivers 
Kirbach et al. (2008) ● The first cost-utility analysis 
of olanzapine compared with 
● Health utilities were derived 
from schizophrenia studies 
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 Strength Limitation 
no treatment for patients with 
AD with agitation and 
psychosis in the US using a 
decision-analytic method 
● There was a limitation of 
quality of studies associated 
with parameters used in the 
model.  
 
In summary, to the researcher’s best knowledge, this study is the first cost-effectiveness 
of atypical antipsychotic medications, (olanzapine and risperidone), in the treatment of 
Thai patients aged 60 years and over with BPSD based on a societal perspective. A 
decision-analytic model is used to predict the costs and outcomes over a period of 5 years 
with a one-month of each cycle length. The main outcome measure used was the cost per 
QALY gained, (or ICER). Costs data are also expressed as direct medical costs and direct 
non-medical costs and reported in 2017 Thai Baht (THB).  In addition, both costs and 
QALYs are discounted at 3% per annum. 
However, cost and utility data in this thesis are based on a cross-sectional study design. 
This can be helpful to supply results to answer the cost-effectiveness question of real 
clinical settings in Thailand. However, this approach is from a hypothesis-generating 
study and also limited by randomised comparisons. Data from this method should 
therefore be applied for designing further studies, namely larger confirmation studies. In 
addition, the interpretation of the results from this study needs to be viewed cautiously.  
 
 Ethical Considerations  
The study required ethics committee approval before any data collection could begin. A 
formal submission was made to the Centre for Health and Social Care Research of 
Sheffield Hallam University in the UK and both hospitals in Thailand. Ethics approval 
was granted by the Human Research Ethics Committee of Thammasat University (Faculty 
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of Medicine) in Thailand, in full compliance with international standards such as the 
Declaration of Helsinki, The Belmont Report, CIOMS Guidelines and the International 
Practice (ICH-GCH), the Human Research Ethics Committee of Khon Kaen 
Rajanagarindra Psychiatric Hospital in Thailand as well as the Faculty Research Ethics 
Committee of Centre for Health and Social Care Research of Sheffield Hallam University 
in the UK. The ethical issues considered are described below: 
1) Recruitment -The primary data collection was based on a cross-sectional study 
of patients with BPSD in Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital in Thailand. In the case that patients with 
dementia had difficulties in providing informed consent due to cognitive 
impairment, then caregivers, who had contact with these dementia patients, 
were approached to be the respondents to the survey on behalf of the patients.  
2) Confidentiality - All data were anonymised and kept confidential. The names 
and the identities of the individuals were concealed and kept in a separate file 
from the main dataset for analysis. The data were kept securely and only used 
by the researcher.  
3) Consent - This study was associated with the data collected from the patients 
and caregivers, so a consent form was applicable. However, participants could 
withdraw from the study at any time as needed. 
4) Risks and benefits - Information was sought from patients and their caregivers 
on their treatment. Therefore, there were no risks, harmful and/or discomforts 
to the individuals associated with this study.  
 
 Conclusion 
This study focuses more on the post-positivist ontological and epistemological 
assumptions by generating a model for health economic evaluation. The study also carries 
through five main steps, namely the defined scope of the evaluation, the model 
development, the cost analyses, the utility analyses, and the cost-utility analysis along 
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with sensitivity analyses. In addition, the questionnaires is conducted to explore costs and 
utility weights of behaviourally disturbed patients with dementia being treated with 
olanzapine or risperidone based on routinely delivered care in the Thai setting. 
Consequently, the following chapters will demonstrate research steps undertaken within 
each chapter in more details and also deal with the findings attained from these studies.  
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Chapter 4: Model development and application to health economic 
evaluation of the treatment with atypical antipsychotics for 
behavioural and psychological symptoms of dementia in Thailand 
Abstract 
Introduction: Atypical antipsychotics are widely used as a first-line pharmacological 
approach to treat patients with behavioural and psychological symptoms of dementia, 
even though these drugs are off-label use for those patients due to safety concerns. 
Currently, there is a lack of studies conducting economic evaluations of atypical 
antipsychotics for the treatment of BPSD patients, particularly economic evaluations 
using models. Hence, it is important to explore the existing model-based economic 
evaluations in dementia to apply for the treatment with atypical antipsychotic drugs of 
such patients.  
Aim: The objective of this chapter is to develop the models and identify the most 
appropriate model for the economic evaluation for olanzapine treatment compared with 
risperidone treatment of BPSD within the Thai circumstances. 
Methods: Model development of the BPSD treatment were based on the existing model-
based economic evaluations reviewed through the comprehensive literature search from 
electronic databases between January 1975 and March 2018. The selected models were 
defined based on the selection criteria, including common use in the health economic 
evaluation in dementia, applying to the disease progression of dementia, and their 
applicability and feasibility in a Thai context. Parameters were then incorporated into 
each model. These also included cost and utility data of patients with BPSD in Thailand 
which were assigned to health states that were relevant to the condition of interest. The 
characteristics of the different models were then compared in order to justify the selection 
of the most appropriate model within a Thai setting for adoption in further evaluations.  
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Results: Three different model structures, including the CERAD-based conceptual 
framework (Neumann et al. 1999), the full time care, (FTC), conceptual framework using 
the predictive equation for predicting the time to FTC developed by Caro et al. (2001), 
and the FTC conceptual framework using the predictive equation for predicting the time 
to FTC developed by Rive et al. (2010), were considered for assessment. Based on a 
comprehensive assessment, the FTC conceptual framework using the predictive equation 
developed by Rive et al. (2010) was favoured as the most suitable model to apply for an 
assessment of health economics in comparison of olanzapine to risperidone for BPSD 
treatment in Thailand.  
Conclusions: The model using the predictive equation for predicting the time to FTC 
developed by Rive et al. (2010) took into account core domains of dementia, including 
cognitive function, functional abilities and behaviour, in the predictive equation. This 
model had more benefits for estimating the disease progression of patients with dementia 
when compared with the other two models. Hence, the selected model will be applied for 
further cost-utility analysis of olanzapine compared with risperidone for behaviourally 
disturbed patients with dementia in Thailand.   
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4.1 Introduction 
Due to the rapid increase in the number of people with dementia globally over the past 
few decades, many countries are concerned about the consequential losses because of this 
disease; in particular costs of medical and formal care, informal care costs, and social care 
costs (World Health Organization 2012). Therefore, several segments, namely 
pharmaceutical companies, WHO and the Alzheimer’s Association, have attempted to 
develop new interventions against the disease progression and highlight the main points 
of the current situation (World Health Organization 2012, Alzheimer’s Association 2019, 
Alzheimer’s Society 2019). Clinical trials, modelling and risk factor predictions are 
examples of the improvements being undertaken to cope with the progression of the 
disease. The modelling technique is one of the most important approaches to simulate the 
progression of the disease in patients. This is widely used in studies associated with 
economic evaluations in dementia to predict the disease progression and estimate the 
long-term outcomes of the treatments (Hernandez et al. 2016). Consequently, model-
based analyses have been continuously developed to provide more accurate information 
regarding costs and effectiveness of the treatments or technologies used in this disorder. 
This also assists the decision making for patients, caregivers as well as policy-makers in 
developing a response to dementia within their particular healthcare systems.  
Behavioural and psychological symptoms of dementia are one of the most debilitating 
problems in people with dementia and have a significant economic impact to themselves, 
family members, caregivers, and healthcare systems. Currently, no treatments are 
approved by the US-FDA (Desai, Schwartz and Grossberg 2012, Zdanys et al. 2016). 
This leads to a wide range of drug options for the BPSD management. However, 
antipsychotic drugs, particularly atypical antipsychotics, are frequently used to treat these 
symptoms (Andrade and Radhakrishnan 2009, Chiabrando et al. 2010). Although these 
drugs are off-label treatment in dementia at this time, use of atypical antipsychotic drugs 
in patients with BPSD can be offered to control the symptoms, improve the quality of life 
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of both patients and caregivers and reduce the caregiver burden (Maher et al. 2011, 
Maglione, et al. 2011).  
To date, health economic evaluation of atypical antipsychotics for the treatment of BPSD, 
especially using a model-based techniques, is not well examined. There was only one 
study that applied the decision-analytic model, (Markov model), to evaluate the cost-
effectiveness of antipsychotic drugs for the treatment of agitation and psychosis in 
patients with Alzheimer’s disease (Kirbach et al. 2008). That solitary study investigated 
the comparison of olanzapine versus no treatment. The health states of the model 
comprised mild, moderate, severe symptoms of Alzheimer’s disease, nursing home as 
well as death. (Kirbach et al. 2008).  
Due to a lack of model-based economic evaluation of atypical antipsychotic use in 
patients with BPSD, it is necessary to explore a range of model developments. As a result, 
the main purpose of this chapter is to develop the modelling in different schemes and 
identify the most appropriate model to apply for evaluating the treatment with olanzapine 
in comparison to risperidone, for patients with BPSD within a Thai context. 
  
4.2 Methods  
In this chapter, the model development to indicate the most suitable model for adopting in 
an economic evaluation of olanzapine compared with risperidone for the treatment of 
patients with BPSD in Thailand were conducted in the following three main steps as 
outlined below.  
4.2.1 Step 1: Model development for health economic evaluation of the BPSD 
treatment in comparison of olanzapine to risperidone based on the literature review 
To begin with the existing model-based economic evaluation of dementia was critically 
reviewed through the comprehensive literature search from electronic databases, 
including the MEDLINE and the Centre for Reviews and Dissemination of University of 
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York (CRD) - the Database of Abstracts of Reviews of Effects (DARE), the NHS 
Economic Evaluation Database (NHS EED), and the HTA database (HTA). The literature 
search covered the period from January 1975 up to March 2018 (see Chapter 2, section 
2.6). 
Based on the literature review, critical data was taken to develop models. Then the criteria 
for the model development was defined to consider the suitability and feasibility within a 
Thai setting as outlined below. 
Inclusion criteria: 
a) The model types are widely used in the health economic evaluation in 
dementia; 
b) The model frameworks are generally applied for the disease progression of 
dementia; and 
c) The development of the model is applicable and feasible to be employed 
within a Thai context. 
Exclusion criteria: 
a) The model is used to simulate patient-level data;  
b) The model is used to estimate the events occurring over a short time period, 
(one year); 
c) The model is used for specific purposed study or specific data sets;  
d) Health states of the model included institutionalisation or nursing home. 
To develop models in this thesis, the model frameworks that met the inclusion criteria 
were adopted to build the different models in the cost-utility analysis of olanzapine versus 
risperidone for the treatment of patients with BPSD in Thailand. In addition, for those 
models to functions, parameters were needed and these are outlined below.  
a) Transition probabilities: The transition of patients to move from one state to 
another state of each model relied on probabilities which were derived from a literature 
review. If the probabilities were available from the published studies, these could be 
applied for the models. If the probabilities of transitioning were driven by the equations,  
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the factors used in calculating those equations were firstly considered from data of the 
Thai population or data collection in a Thai setting, in order to more closely reflect the 
actual circumstances of the routine clinical practice in Thailand. However, if data were 
not available from the Thai populations or Thai setting, data from published literature 
which were applicable and feasible to be used in the model were alternatively proposed.   
b) Clinical effectiveness data of treatments: The effectiveness data of drug 
treatments, (olanzapine or risperidone), were also obtained from data based on a 
comprehensive literature search of published studies covered from 1994 up to July 2015 
(see Chapter 2, section 2.4). If clinical data being assigned to the models were not 
provided by those reviewed studies, other studies relevant to the reviewed studies given 
clinical data be assigned to the models would be considered instead, such as Phase 1 
outcomes from the clinical trials.   
c) Cost data:  The costing data of patients with BPSD and being treated with 
olanzapine or risperidone used in the developed models were direct medical costs and 
direct non-medical costs. These costs data were collected from patients and/or patients’ 
caregivers from Thammasat University Hospital and Khon Kaen Rajanagarindra 
Psychiatric Hospital in Thailand, at only one point in time during some point in 2017 by 
face-to-face interviews using a cost questionnaire. However, indirect costs, namely costs 
of productivity losses, were not included for cost data purposes because all patients were 
either not working or retired. In addition, this thesis also took into account adverse event-
associated costs and relapse-associated costs due to atypical antipsychotic use for treating 
patients with BPSD. More details of cost analyses are presented in Chapter 5.   
d) Utility values:  The utility weights applied in the developed models were also 
derived from the data collection of patients with BPSD and treated with olanzapine or 
risperidone and/or the patients’ caregivers from the two hospitals as indicated above. The 
data were also captured at only one point in time during some point in 2017 by face-to-
face interviews using the EQ-5D-5L questionnaire. Furthermore, the individual responses 
to the questionnaire were then translated into the utility weights, (EQ-5D index utilities), 
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using the Thai value sets available for Thailand. More details of the utility analyses are 
presented in Chapter 6.  
e) Perspective of the model:  All developed models in this thesis were conducted 
from a societal viewpoint.  
f) Time horizon and cycle length:  A five-year time horizon was chosen for all 
developed models. This was because dementia is a chronically progressive disease and 
this also reflects the natural history of the disease. Additionally, a one month cycle length 
was also applied for all those models.  
g) Discount rates:  Both costs and health outcomes for all developed models were 
discounted using an annual rate at 3%. These rates were based on the recommendation of 
the guideline of health technology assessment in Thailand (The Health Intervention and 
Technology Assessment Program 2014).  
From this step, the next steps were a comparison and a justification amongst those models 
to select the most appropriate model to apply for further analysis of an economic 
evaluation (in Chapter 7). 
4.2.2 Step 2: Comparing the distinctive developed models  
This step, the developed models were compared to find out the most advantageous model 
based on the following points:  
a) Characteristics of the model structure of each model, (health states in the 
model); 
b) Characteristics of the progression of the disease of each model, (the transition 
probabilities of changing health states of patients from one state to another state);  
c) The clinical effectiveness data of the treatments which were applied in each 
model; and 
d) The results of an economic evaluation of the treatment of patients with BPSD 
with olanzapine compared with risperidone based on the different models.  
In addition, the findings from this step were used in the following step which was 
associated with a justification and decision of the most appropriate model.  
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4.2.3 Step 3: Justification and selecting the most suitable model for applying in the 
cost-utility analysis within a Thai setting 
In this step, the considerations for making the decision to select the most appropriate 
model are outlined below: 
a) The model was constructed to reflect the natural disease progression of 
dementia;  
b) The model was commonly used in an economic evaluation in dementia;  
c) Clinical effectiveness data used in the model was deemed to cover an 
assessment on all core domains relevant to the clinical course of dementia; and 
d) The model was recently developed for the economic evaluation in dementia. 
Finally, the most appropriate model was chosen based on all the previous steps as stated 
above in order to be adopted for further analysis of the cost-utility analysis of atypical 
antipsychotics for the treatment of patients with BPSD in Thailand.  
 
4.3 Results  
4.3.1 The model development for health economic evaluation of the BPSD treatment 
in comparison of olanzapine to risperidone based on the literature review 
Based on a comprehensive literature search on model-based economic evaluation in 
dementia, (see Chapter 2, section 2.6.1), the findings of model frameworks and type of 
models from 40 articles have been summarised in the following Table 4.1.  
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Table 4.1: Summary of the type of models and the model frameworks of model-based economic evaluation in dementia based on the 
comprehensive literature search  
Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
Henke and Burchmore 
(1977) 
  /   Specific model Nursing home placement 
and non-nursing home 
placement 
Stewart, Phillips, and 
Dempsey (1998) 
/     Specific model Minimal, mild, moderate, 
severe, and dead 
Fenn and Gray (1999)     / Specific model Mild, moderate and severe 
Jonsson et al. (1999) /     Specific model 
(based on 
Kungsholmen 
project) 
MMSE=30-27, 
MMSE=26-21, 
MMSE=20-15, 
MMSE=14-10,  
MMSE=9-0 and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
Neumann et al. (1999) /     CERAD Mild (comm/NH), 
moderate (comm/NH), 
severe (comm/NH), and 
death 
O’ Brien et al. (1999) /     Specific model MMSE <10, MMSE=10-
14, MMSE=15-20, 
MMSE=21-26, 
MMSE=27-30, and death 
Getsios et al. (2001) /     FTC framework  
(AHEAD) 
Health states in the model: 
Pre-FTC, FTC, and death 
McDonnell et al. (2001)     / Specific model Patient characteristics, 
clinical characteristics of 
disease, place of residence 
(living in community, 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
home for the elderly, 
nursing home), and vital 
status of patients 
Caro et al. (2002) /     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
Garfield et al. (2002) /     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
Ikeda, Yamada and Ikegami 
(2002) 
/     CERAD Mild, moderate, severe, 
and death 
Migliaccio-Walle et al. 
(2003) 
/     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
Ward et al. (2003) /     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
Caro et al. (2004) /     FTC framework  Pre-FTC, FTC, and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
(AHEAD) 
Francois et al. (2004) /     Memantine 
model 
The multiplicity of three 
severity states, two 
physical dependencies, 
and two residence settings, 
and plus death 
Jones, McCrone and 
Guilhaume (2004) 
/     Memantine 
model 
The multiplying of three 
severity states, two 
physical dependencies, 
and two residence settings, 
and plus death 
Green et al. (2005) /     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
Jonsson (2005) /     Memantine 
model 
The multiplicity of three 
severity states, two 
physical dependencies, 
and two residence settings, 
plus death 
Antonanzas et al. (2006) /     Memantine 
model 
The multiplying of three 
severities, two 
dependencies, plus death 
Gagnon et al. (2007) /     Memantine 
model 
The multiplying of two 
severities, two 
dependencies, and death 
Teipel et al. (2007) /     Specific model Mild, mild-moderate, 
moderate, severe and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
(based on 
Kungsholmen 
project) 
Weycker et al. (2007)    /  CERAD-SIB Profound and terminal 
(MMSE=0-4), severe 
(MMSE=5-9), moderate 
(MMSE=10-14), and 
questionable/ 
mild (MMSE=15-23) and 
living in community  
Fuh and Wang (2008) /     CERAD Mild, moderate, severe, 
and death 
Kirbach et al. (2008) /     CERAD Mild, moderate, severe, 
institutionalized, and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
(The institutionalised was 
classified separately as a 
health state) 
Lopes-Bastida et al. (2009) /     CERAD Mild, moderate, severe, 
and death 
Suh (2009) /     FTC framework  
(AHEAD) 
Pre-FTC, FTC, and death 
Wong et al. (2009)   /   Specific model No adverse events and 
adverse events 
Getsios et al. (2010)  /    Patient-level data Update of disease severity, 
treatment status, physician 
visit, death, and end of 
model 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
Guo et al. (2010)  /    Patient-level data Update of disease severity, 
treatment status, physician 
visit, death, and end of 
model 
Nagy et al. (2010)     / MMSE-ADL 
model 
-MMSE model based on 
MMSE  
-MMSE-ADL model 
based on MMSE and ADL 
Rive et al. (2010) /     FTC framework  
(based on a new 
predictive 
equation) 
Pre-FTC, FTC and death 
Hoogveldt et al. (2011) /     Memantine 
model 
The multiple of two 
severities and two 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
dependence states, plus 
death 
Lachaine et al. (2011) /     Specific model 
(based on Lopez 
et al.) 
Non-institutionalised, 
institutionalized, and death 
Hartz et al. (2012)  /    Patient-level data Update of disease severity, 
treatment status, physician 
visit, death, and end of 
model 
Pfeil, Kressig and Szucs 
(2012) 
/     Specific model 
(based on 
Lachaine et al.) 
Home, nursing home, and 
decease  
Rive et al. (2012) /     FTC framework  Pre-FTC, FTC and death 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
(based on a new 
predictive 
equation) 
Touchon et al. (2014) /     Specific model 
(based on 
Lachaine et al.) 
Non-institutionalised, 
institutionalised, and 
deceased 
Hu et al. (2015) /     Specific model The multiplicity of two 
severities, two functional 
abilities, two the presence 
of agitation/aggression, 
plus death 
Thibault et al. (2015)  /    Patient-level data Update of disease severity, 
treatment status, physician 
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Study Markov 
model 
The 
Discrete 
Event 
Decision 
tree 
Micro 
simulation 
Statistical 
model 
Model 
framework 
Health States 
 
visit, death, and end of 
model 
Zala, Chan and McCrone 
(2017) 
/     FTC framework   
(based on a new 
predictive 
equation) 
Pre-FTC, FTC and death 
Total 30 4 2 1 3   
* (/) refers to the type of the model-based economic evaluation of each study  
Abbreviation: Activity of Daily Living (ADL), Assessment of Health Economics in Alzheimer’s Disease (AHEAD), Consortium to Establish a Registry in Alzheimer’s 
Disease (CERAD), Community (Comm), Full-time care (FTC), Mini-Mental State Examination (MMSE), Nursing home (NH), Severe Impairment Battery (SIB)
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As the data shows above, a Markov model was the commonest model type which had been 
used in the health economic evaluations in dementia, particularly Alzheimer’s disease, 
accounting for 75% of all studies. Most model structures built to predict the disease 
progression were based on the FTC and the CERAD conceptual frameworks accounting for 
11 (27.5%), and 5 (12.5%) studies, respectively.  
According to the defined inclusion criteria as introduced above, (see section 4.2.1), and the 
literature review, the FTC conceptual framework and the CERAD conceptual framework 
using the Markov-based type were then identified to build the models in this thesis. There 
were three possible models, which met the inclusion criteria which were selected and 
developed for simulating the disease progression and applying the cost-utility analysis of 
olanzapine compared with risperidone in the treatment of patients with BPSD in Thailand. 
These models are outlined below.  
● The first model was based on the Consortium to Establish a Registry in 
Alzheimer’s Disease database, (CERAD-based model framework), (Neumann et al. 1999). 
The CERAD-based model used severity levels of cognitive function to define the health 
status of the model and predict the disease progression of patients. The Clinical Dementia 
Rating, (CDR), scale was used to assess the levels of disease severity. Thus, the health states 
of this CERAD-based model consisted of mild, moderate, severe, as well as death. The 
transition probabilities were also derived data from the CERAD database (Neumann et al. 
1999). 
● The second model was constructed based on the full-time care, (FTC), conceptual 
framework which was used to predict the patient’s disease progression until requiring FTC. 
This model was constructed on the basis of an Assessment of Health Economics in 
Alzheimer’s Disease, (AHEAD), using the predictive equation developed by Caro et al. 
(2001). The health states of the model consisted of not requiring FTC (Pre-FTC), FTC and 
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death. The FTC state was defined as the patient’s dependency status when care and 
supervision was required for the greater part of each day, regardless of the location of care 
(Caro et al. 2001). The transition from the Pre-FTC to FTC state was driven by a predictive 
equation from data obtained from the published study by Stern et al. (1997). The patient’s 
characteristics, including the presence of extrapyramidal symptoms (EPSs), the presence of 
psychotic symptoms, age at onset of disease, duration of illness and cognitive score, (as 
measured by modified Mini-Mental State examination, mMMS), were significant factors to 
predict the need for FTC of the predictive equation. Estimating the transition to death was 
dependent on female sex, the presence of EPS, cognitive function and the duration of illness 
(Stern et al. 1997, Caro et al. 2001).  
● The third model was conceptualised based on the FTC conceptual framework using 
a new predictive equation for predicting the time to FTC which was developed by Rive et al. 
(2010). The health sates comprised of Pre-FTC, FTC and death. The significant factors 
needed to predict the time to FTC are as follows: cognitive function, (as measure by ADAS-
cog), functional ability, (as measured by ADCS-ADL), and behaviour, (as measured by NPI).  
Table 4.2 shows the summary of possible models classified by model frameworks which 
have been used to develop the models for health economic evaluation of BPSD treatment in 
comparison of olanzapine to risperidone in this thesis. 
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Table 4.2: The possible models used for developing models for an economic evaluation 
of BPSD treatment in comparison of olanzapine to risperidone based on the inclusion 
criteria of the thesis, classified by model frameworks 
 CERAD framework 
(Neumann et al. 1999) 
FTC framework 
using the equation for 
predicting the time to 
FTC developed by 
Caro et al. (2001) 
FTC framework 
using the equation for 
predicting the time to 
FTC developed by 
Rive et al. (2010) 
Model type Markov model Markov model Markov model 
Health states Mild, moderate, severe 
and death  
Pre-FTC, FTC and 
death 
Pre-FTC, FTC and 
death 
Model concept The course of disease 
progression through 
stages of the disease 
severity 
The need for FTC The need for FTC 
Disease progression Transition probabilities 
between health states 
were estimated from 
the CERAD database, 
in the US (Neumann et 
al. 1999) 
A predictive equation 
for predicting the time 
to FTC developed by 
Caro et al. (2001)  
A predictive equation 
for predicting the time 
to FTC developed by 
Rive et al. (2010)  
Risk factors of 
progression to FTC 
N/A The presence of EPS, 
the presence of 
psychotic symptoms, 
age at onset of disease, 
duration of illness and 
cognitive score (as 
measured by mMMS) 
ADAS-cog, ADCS-
ADL and NPI 
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Abbreviation: Assessment of Health Economics in Alzheimer’s Disease (AHEAD), Alzheimer’s Disease 
Assessment Scale-Cognitive Function (ADAS-cog), Alzheimer’s Disease Cooperative Study-Activities of Daily 
Living (ADCS-ADL), Clinical Dementia Rating (CDR),  Consortium to Establish a Registry in Alzheimer’s 
Disease (CERAD), Extrapyramidal symptoms (EPS), Full-time care (FTC), Not applicable (N/A) 
 
Although there were other studies that used the Markov model for health economic 
evaluation in dementia, the model frameworks were constructed by incorporating nursing 
home or institutionalisation as the health states of the model (Francois et al. 2004, Jones, 
McCrone and Guilhaume 2004, Lachaine et al. 2011, Pfeil, Kressig and Szucs 2012, 
Touchoun et al. 2014). These might be inappropriate in a Thai context because the 
institutionalised setting or nursing home provision are not generally provided for the care 
process of people with dementia in Thailand. Thus, model frameworks, including nursing 
home or institutionalisation, were not considered in developing the models in this thesis. 
In addition, the developed models based on the defined inclusion criteria are displayed in the 
following sections.  
4.3.2 Characteristics of the developed models based on the inclusion criteria in this 
thesis 
According to the inclusion criteria, three different models were developed in this thesis, 
including the CERAD-based framework (Neumann et al. 1999), the FTC conceptual 
framework using the predictive equation for predicting the time to FTC developed by Caro et 
al. (2001) and the FTC conceptual framework using the predictive equation for predicting the 
time to FTC developed by Rive et al. (2010). The next section then goes on to more details of 
each developed model.  
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4.3.2.1 Model 1: The model based on the Consortium to Establish a Registry in 
Alzheimer’s Disease, (CERAD), conceptual framework  
The structure and concept of the model which were developed on the basis of the CERAD 
framework from the study by Neumann et al. (1999), data inputs of this model type, 
(including transition probabilities, clinical effectiveness data of drug treatments, costs and 
utility weights), results of the cost-utility analysis and limitation of the model type are 
subsequently outlined.  
4.3.2.1.1 Model structure and model concept of the CERAD-based model 
According to the CERAD-based framework, the structure and model concept of the 
developed model in this thesis are displayed below.    
4.3.2.1.1.1 The model structure of the CERAD-based model 
The model was constructed to simulate the natural history of Alzheimer’s patients across the 
different progressive disease states, in the form of a Markov model. The health states were 
developed to characterise the progress of the disease and were classified into mild, moderate, 
and severe states, according to the Clinical Dementia Rating scales, (CDR). These were a 
mild stage (CDR = 0.5 or 1), moderate stage (CDR =2), severe stage (CDR = 3), as well as 
the health state of death (Neumann et al. 1999).  
However, in this thesis the Thai version of the Mini-mental State Examination (TMSE) was 
used as a measure of cognitive function. The test was developed from the standard Mini 
Mental State Examination (MMSE) and was more appropriate to the Thai population. The 
study by the Institute of geriatric medicine of the Ministry of Public Health in Thailand 
(2008) reported that either the TMSE test or the MMSE test did not show a significant 
difference in the scores of a cognitive test (Institute of Geriatric Medicine 2008). Then, the 
different levels of the disease severity of cognitive function as measured by the TMSE scores 
were implied to be the same value as the MMSE scores. These scores classified the severity 
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levels as follows: a score of 21-26 was associated with a mild stage, a score of 10-20 with a 
moderate stage, and a score of <10 with a severe stage. For the purpose of this thesis, the 
mapping between MMSE score and CDR scale was also conducted to define the severity 
levels of the patient’s cognitive function following these parameters: MMSE=21-26 for mild 
(CDR scales of 0.5 or 1.0), MMSE=10-20 for moderate (a CDR scale of 2.0) and MMSE<10 
for severe stages (a CDR scale of 3.0) (Perneczky et al. 2006, Bond et al. 2012). In addition, 
the original model structure was initially developed by Neumann et al. (1999). Thereafter, the 
structure of such models was adapted to several studies in undertaking economic evaluations 
of Alzheimer’s disease (Ikeda, Yamada and Ikegami 2002, Fuh and Wang 2008, Lopez-
Bastida et al. 2009).  
However, the treatment of patients with BPSD was the focus of this thesis. Therefore, BPSD 
associated with patients requiring atypical antipsychotic drugs for their treatment were also 
incorporated into the health states of the model. The model structure outline is depicted in the 
following Figure 4.1.  
 
 
 
 
 
 
 
 
Figure 4.1: Outline view of the model structure based on the CERAD framework  
 
 
Moderate + BPSD 
   
  Severe + BPSD     Mild + BPSD 
         Death 
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4.3.2.1.1.2 The model concept and flow of the CERAD-based model 
At the beginning of the decision node, patients faced the possibility of treatment with one of 
the two available choices of drugs, either olanzapine or risperidone. Initially, the patient 
began using only one of the two drug therapies. As patients receiving treatments, there were 
four possible health states which the patients could be in mild, moderate, severe, or death.  
In this decision-analytic model, all patients were assumed to start at time zero. Consequently, 
the initial probabilities for the Markov states were 1, 0, 0 and 0 for the four health states 
associated with mild, moderate and severe, as well as death, respectively. In each cycle 
length of the model, patients could have a movement between these possible health states and 
this process occurred repeatedly. The transition of patients’ moving from one state to another 
depended upon the probabilities to simulate the progression of the disease through health 
states in the model over time. Thus, any change to another state was determined by the 
transition probabilities based on the effects of drug treatments. 
The concept behind the model structure was demonstrated as follows:  
• From the mild with BPSD state, there were four possible transition states of 
the severity of the disease, these being mild with BPSD, moderate with BPSD, 
severe with BPSD, and death. Some patients remained in the mild with BPSD 
state, whereas the rest moved through the other three possible pathway 
combinations of moderate with BPSD, severe with BPSD, and death as the 
disease progressed;  
• From the moderate with BPSD state, some patients moved from this to severe 
with BPSD and death, whereas others remained in the moderate with BPSD 
state;   
• From the severe with BPSD state, some patients remained in this state whilst 
others progressed to the death state; and  
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• Death state was the absorbing state. 
Further, the transition from the more severe disease stages back to the less severe stages was 
not allowed for in the model in this thesis. The Markov model was constructed to simulate 
patients’ progression through the levels of severity of cognitive function and to predict the 
costs and outcomes of the disease progression over time. As the cohorts cycle through the 
Markov model until the time horizon was reached, the costs and outcomes were accumulated 
for each cycle which then used to compute the incremental costs per quality-adjusted life year 
gained over a five-year time horizon, covering disease progression and reflecting the natural 
history of the disease. A societal perspective was the viewpoint of this model. Both costs and 
outcomes were discounted at 3% per annum.  
4.3.2.1.2 Data inputs of the model based on the CERAD framework 
In this thesis, the main parameters required for the developed model based on the CERAD 
framework are demonstrated below.  
4.3.2.1.2.1 Transition probabilities of the model based on the CERAD framework 
The transition probabilities for this model were retrieved from the published study conducted 
by Neumann et al. (2001) based on data from a Consortium to Establish a Registry for 
Alzheimer’s Disease, (CERAD), cohort, the longitudinal cohort study in 1,145 patients from 
22 medical centres in the US between 1986 and 1995 (Morris et al. 1989).  
The Markov cycle of this study was defined as one month.  However, the existing transition 
probabilities based on the CERAD database were expressed in the annual probabilities. Thus, 
the annual probabilities were converted to one-month transition probabilities according to the 
cycle length of the model.  
Based on the longitudinal study, the Cache County Dementia Progression Study examined 
335 cases of possible or probable Alzheimer's disease and found that the correlation of the 
neuropsychiatric symptoms, (NPS), were associated with the progression to severe 
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Alzheimer's disease and death (Peters et al. 2015). Thus, the transition probabilities between 
health states in this model were adjusted by the hazard ratios of behavioural disturbances, as 
assessed by the Behavioural Rating Scale for Dementia score, (BRSD), based on the data 
from the previous literature (Neumann et al. 2001).  
As the hazard ratios were the ratio of the rate it was not possible to apply these values 
directly for the transition probabilities or risks. On the basis of definitions, rates were the 
instantaneous potential for the occurrence of an event, indicated per the number of patients at 
risk. The value of rates varies from zero to infinity. As part of the probabilities, these were 
the values, describing the tendency of an event occurring over the given time period. The 
possible value was as between 0 and 1 (Briggs, Claxton and Sculpher 2011, Gray et al. 2012).  
For this reason, the functions used to convert between rates and probabilities were needed. 
Hence, the annual probabilities were initially transformed to the rates and adjusted by the 
behavioural symptoms-related hazard ratio. The rates were ultimately converted back to the 
monthly probabilities. The relation between rate and probability and the conversion from rate 
to probability and vice versa were provided below (Sonnenberg and Beck 1993). 
The conversion from rate to probability was calculated by:  
p = 1- exp(-rt) 
 
where   𝑝 was the probability, 
            𝑟 was the rate,  
     and  𝑡 was the time period of interest.  
Alternately, the conversion from probability to rate was produced by:  
𝑟 =  
−[ln(1 − 𝑝)]
𝑡
 
where   𝑟 was the rate, 
            𝑝 was the probability,  
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  and   𝑡  was the time period of interest.  
The estimated monthly transition probabilities, adjusted by the hazard ratios for behavioural 
symptoms, used to simulate the disease progression in the model is presented in Table 4.3. 
Table 4.3: Estimated monthly transition probabilities adjusted by the hazard ratios for 
behavioural symptoms from the CERAD cohort (Neumann et al. 2001) 
Monthly transition probabilities (stage to stage) Value 
     Mild + BPSD to Mild + BPSD # * 
     Mild + BPSD to Moderate + BPSD 0.04216 
     Mild + BPSD to Severe + BPSD 0.00610 
     Mild + BPSD to Dead 0.00090 
     Moderate + BPSD to Moderate + BPSD # * 
     Moderate + BPSD to Severe + BPSD 0.03691 
     Moderate + BPSD to Dead 0.00421 
     Severe + BPSD to Severe + BPSD # * 
     Severe + BPSD to Dead 0.01837 
         * The residual (#) refers to the remaining probability 
In this decision-analytic model, all patients were assumed to start at time zero in a mild state. 
The probabilities were used to define the transitions amongst the possible events during a 
cycle. For example, the transition probabilities of moving within a severe state and moving 
from a severe state to death were # and 0.01837 respectively.  
4.3.2.1.2.2 Clinical effectiveness data of olanzapine and risperidone treatments 
To date, no drugs have US-FDA approval for the treatment of behavioural and psychological 
symptoms of dementia or non-cognitive symptoms. Generally, antipsychotics are widely used 
to treat Alzheimer’s patients with agitation, aggression or psychosis (Leeuwen E et al. 2018). 
These drugs are also recommended for individuals with persistent symptoms. Several 
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previous studies indicated that the patients with neuropsychiatric symptoms had a shorter 
survival time from mild dementia to severe dementia than those without symptoms (Cohen-
Mansfield et al. 1999, Peters et al. 2015). Thus, the assumption of this study was that 
decreasing the neuropsychiatric symptoms was associated with delaying the more severe 
states of patients with dementia.  
The effectiveness data of this thesis were adopted from the large clinical trial- the Clinical 
Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease, (CATIE-AD), study. 
This trial examined the effectiveness of atypical antipsychotics in outpatients with 
Alzheimer’s disease between 2001 and 2004, a double-blind, placebo-controlled trial 
comprising 421 outpatients with agitation, aggression, or psychosis, across 42 sites in the US 
and follow-up to 36 weeks. The primary outcome was the time to the discontinuation of 
treatment for any reason, whereas the improvement on the Clinical Global Impression of 
Change (CGI-C) score at 12 weeks was the main secondary outcome. The average 
medication doses of olanzapine and risperidone in this study were 5.5 mg and 1 mg per day, 
respectively.  
The CGI-C score at 12 weeks showed that at least minimal progress with continued use of 
olanzapine was an 11.00% increase in score compared with the placebo. Also, this was found 
to be 8.00% of risperidone relative to the placebo (Schneider et al. 2006). As a result, this 
study used the change in the CGI-C score as the clinical effectiveness of medications, to 
predict the long-term outcomes from the treatments with each drug (olanzapine or 
risperidone).  
The neuropsychiatric symptoms also had an association with the mortality in patients with 
Alzheimer’s disease (Cohen-Mansfield et al. 1999, Peters et al. 2015). As Kales et al. (2012) 
suggested, a retrospective study in 33,604 patients with dementia based on the national data 
of Veterans Affairs between 1999 and 2008, olanzapine treated patients had lower mortality 
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rates than risperidone treated patients (RR 0.99, 95% CI 0.89–1.10), but it was not 
statistically significant. Then, the mortality rates between the two drugs were not included in 
the model.  
Further, the tendency of patients with Alzheimer’s disease with more severe neuropsychiatric 
symptoms, in particular, agitation, aggression, or psychosis, respond well to long-term 
antipsychotic treatment (Leeuwen E et al. 2018). Consequently, the assumption of this thesis 
was that drug effects were assumed to be constant over a five-year time horizon. The 
effectiveness data of olanzapine and risperidone used in the model is as described in Table 
4.4. 
Table 4.4: The clinical effectiveness data of olanzapine and risperidone for the CERAD-
based model 
Effectiveness data (CGI-C score 
change compared with placebo)    
Value Reference 
Risperidone (mean dose 1.0 mg per day) 8.00% Schneider et al. (2006) 
Olanzapine (mean dose 5.5 mg per day) 11.00% Schneider et al. (2006) 
 
4.3.2.1.2.3 Costs of patients with behavioural and psychological symptoms of dementia and 
being treated with atypical antipsychotics (olanzapine and risperidone) based on the data 
collected in Thailand 
A societal perspective was used in the study. The cost data were retrieved from two hospitals 
in Thailand: Thammasat University Hospital, which is located in Pathum Thani province and 
is an Excellence care centre, and Khon Kaen Rajanagarindra Psychiatric Hospital, a 
psychiatric hospital which is located in Khon Kaen province, is a tertiary care centre 
providing patient care covering four provinces in the Northeast region of Thailand. 
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For this thesis the cost data of patients with BPSD and receiving olanzapine or risperidone 
took into account only direct costs, including direct medical costs and direct non-medical 
costs, were used as the cost parameters in the model. The indirect costs, indicating the cost of 
illness and loss of productivity, were not included in this study because all patients were 
either not working or retired. During the course of treatment, patients with BPSD were 
expected to consume different levels of costs. The data of medical costs included the drug 
prices, (risperidone and olanzapine), for the treatment of BPSD, hospitalisation-associated 
costs, costs of treating drug-induced adverse events, costs of drug-associated relapse, 
additional costs for the treatments associated with this illness, and costs of comorbidity 
conditions. The direct non-medical care costs covered travel, additional food, 
accommodation, costs due to other treatment resources, paid caregivers, and costs of informal 
care. 
Cost data were obtained from patients and/or caregivers participating in the two phases: 
Phase I (from February to March 2017) and Phase II (between October and November 2017). 
Briefly, the inclusion criteria of patients who were recruited in this thesis are described 
below:  
1) Patients who had been diagnosed with Dementia or Alzheimer’s disease and being on 
olanzapine or risperidone for at least the last two months, and aged 60 years and 
above;  
2) Caregivers or partners defined as the person who had lived with or visited for 
caregiving for at least eight hours per week over three days or more per week for the 
last two months, were requested to contribute the assessment. Patients who did not 
have a partner or caregivers and were unable to answer the questionnaire on their own 
were excluded.  
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Cross-sectional data were collected on a sample of 82 patients and/or caregivers in a Thai 
setting, from the two hospitals as stated above, using face-to-face interviews to complete a 
dataset questionnaire. There were 41 patients of each of the risperidone and olanzapine 
groups. In addition, a total of 98.78% of the part of the questionnaire which focused on cost 
data were completed by the primary caregivers as proxy respondents in this study, (see more 
details in Chapter 5, in section 5.3.1).  
All costs in this study were expressed in Thai Baht at 2017 values, (1£ =THB 45). The 
estimated costs before 2017 were adjusted by using the Thailand Consumer Price Index 
based on the health components, (Bureau of Trade and Economic Indices of the Ministry of 
Commerce Thailand, 2018). The monthly cost parameters for the model are presented in 
Table 4.5. 
Table 4.5: Monthly cost parameters for the model, calculated based on data from 
Thammasat University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital, 
Thailand, in Thai Baht (THB) at 2017 values  
Cost Assumptions  Value [mean (SD)] Reference 
By health state   
Risperidone:   
                   Mild + BPSD 41,444.22 (17,037.35) Primary collected data 
                   Moderate + BPSD 46,470.29 (11,607.73) Primary collected data 
                   Severe + BPSD 53,038.90 (11,918.14) Primary collected data 
Olanzapine:   
                   Mild + BPSD 41,901.85 (16,879.63) Primary collected data 
                   Moderate + BPSD 48,368.34 (16,228.88) Primary collected data 
                   Severe + BPSD 52,901.64 (18,029.26) Primary collected data 
                 * Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
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4.3.2.1.2.4 Utility weights of patients with behavioural and psychological symptoms of 
dementia and being treated with atypical antipsychotics, (olanzapine and risperidone), 
based on the data collected in Thailand 
The quality-adjusted life year (QALY), a measure of quantity and quality of life (QoL), were 
used as the outcome measurement in this thesis. Then utility weights of an individual’s 
preference-based specific health states were required for estimating QALYs (Drummond et 
al. 2005). 
For this thesis, utility weights were derived from the data collection of patients and/or 
caregivers. The face-to-face interviews were conducted at the outpatient departments of both 
hospitals at only one point in time during some point in 2017. The patient recruitment and 
data collection process followed the cost data as previously stated above. Most of the EQ-5D-
5L questionnaires were completed by the primary caregivers as proxy respondents. The 
utility weights be assigned to health states that were relevant to the health states in the 
CERAD-based model were 0.59 for mild, 0.27 for moderate, and 0.26 for severe stages of 
dementia, of risperidone prescribed patients. As for the utilities of olanzapine treated patients, 
these were 0.62 for mild, 0.53 for moderate, and 0.39 for severe stages (see more information 
in Chapter 6). 
4.3.2.1.3 Results of the cost-utility analysis of the CERAD-based model 
Over a five-year time horizon prediction, olanzapine treatment for BPSD patients was 
predicted to result in a gain of 6.42 QALYs when compared with risperidone. The 
incremental cost was THB 36,311.41 from a societal perspective. Thus, the incremental cost-
effectiveness ratio (ICER) was estimated to be THB 5,656/QALY (Table 4.6).    
Using this result, olanzapine was considered to be a considerably more cost-effective 
treatment in comparison to risperidone, for the treatment of patients with BPSD. The 
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olanzapine treatment group had an increase of cost less than THB 160,000 per an increase of 
one QALY for patients with BPSD, based on the cost-effective threshold in Thailand. 
Table 4.6: Cost-utility analysis results of olanzapine relative to risperidone for the 
treatment patients with BPSD, (THB at 2017 values), from the model based on the 
CERAD framework 
Strategy Cost Incremental 
Cost 
Effectiveness Incremental 
Effectiveness 
ICER 
Risperidone 2,268,254.00  19.66   
Olanzapine 2,304,565.41 36,311.41 26.08 6.42 5,655.98 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
 
4.3.2.1.4 Limitation 
The CERAD-based model focused on the impact of treatment on the change in cognitive 
functions. The assumption was that neuropsychiatric symptoms, (NPS), related to the more 
severe dementia cases (as a predictor); therefore, the decrease in NPS from the drug 
effectiveness might delay patients moving to the more severe health states and/or death. This 
might not directly affect the cognitive function which defined the health states of the model. 
Another consideration was that the transition probabilities applying in this model were based 
on data from the CERAD database in the US. This might be of concern over the 
generalisability of the patient data. In addition, this thesis included only the adverse events 
which often occurred in the elderly due to the use of atypical antipsychotic drugs such as 
EPSs, constipation and falls. Any other events, namely somnolence, cardiovascular events, 
cerebrovascular events and death were not encompassed in costs of drug-induced adverse 
events in this thesis. Due to the lack of studies for relapse rates of atypical antipsychotic 
drugs for dementia treatment, this data was adopted from a schizophrenia study. Lastly, 
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utility weights were mainly based on caregiver ratings, leading to a concern over the 
interpretation of the data.  
 
4.3.2.2 Model 2: The model based on the FTC conceptual framework: the Assessment 
of Health Economics in Alzheimer’s Disease (AHEAD)-based model using a predictive 
equation for predicting the time to FTC developed by Caro et al. (2001) 
The structure and concept of the model on the basis of the AHEAD framework using the 
predictive equation to predict the time until patients required for FTC developed by Caro et 
al. (2001), data inputs of this model, (including transition probabilities, clinical effectiveness 
data of drug treatments, costs and utility weights), results of the cost-utility analysis and 
limitation of the model type are subsequently outlined.    
4.3.2.2.1 Model structure and model concept of the AHEAD-based model using the 
predictive equation for predicting the time to FTC developed by Caro et al. (2001) 
According to the AHEAD-based model, the structure and model concept of the developed 
model in this thesis are described below.    
4.3.2.2.1.1 The model structure of the AHEAD-based model using the predictive equation 
for predicting the time to FTC developed by Caro et al. (2001) 
This decision-analytic model based on the AHEAD model conducted on three possible health 
states of Pre-FTC, FTC and death, to predict the health and economic impact of the treatment 
in patients with Alzheimer’s disease. FTC was defined as the patient’s dependency status 
when care and supervision was required for the greater part of each day (Caro et al. 2001). 
The significant concept of this model was the disease progression until patients needed for 
FTC.  
In this thesis, the dependence of patients was measured by physicians and the Activities of 
Daily Living rating, (ADL). The Barthel Index-Thai was applied in the assessment. The 
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scores were categorised as follows: a score of 0-4 was associated with total dependence, a 
severe dependence was associated with a score of 5-8, a moderate dependence was associated 
with a score of 9-11, and a mild dependence was associated with a score of 12 and above 
(Prasat Neurological Institute 2014). Consequently, the FTC and Pre-FTC states were defined 
by a score of 0-8 and 9 and over, respectively. The model structure is depicted in Figure 4.2 
which was also adopted from several previous studies (Getsios et al. 2001, Caro et al. 2002, 
Garfield et al. 2002, Ward et al. 2003, Caro et al. 2004, Green et al. 2005, Suh 2009). 
However, this thesis focused on the treatment of patients with BPSD. Therefore, BPSD 
associated with patients requiring atypical antipsychotic drugs for their treatment were also 
incorporated into the health states of the model. 
4.3.2.2.1.2 The model concept and flow of the AHEAD-based model using the predictive 
equation for predicting the time to FTC developed by Caro et al. (2001) 
At the beginning of the model, the baseline patient distributions were assigned 
characteristics, (age, the presence of psychotic symptoms, the presence of EPS, cognitive 
level assessed by MMSE, and duration of disease).  
The concepts of the AHEAD-based model incorporated the patient characteristics at a given 
point to predict the disease progression to require FTC. The status of patients with 
Alzheimer’s disease was classified into three possible health states: Pre-FTC, FTC, as well as 
death. The following transitions were possible: 
• At Pre-FTC, some patients remained at the same state; some groups changed from 
Pre-FTC to FTC, and others moved from Pre-FTC to death; 
• At FTC state, there was a possibility of patients remaining in FTC, but there were 
also those who moved to death; and 
• Death was defined as an absorbing state. 
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The predictive equations based on the Cox proportional hazard models developed from a 
longitudinal study in the USA by Stern et al. (1997), were adopted to predict the risk of 
requiring FTC in the model (Caro et al. 2001). The significant covariates incorporated into 
the equations to estimate the time until requiring FTC, were the presence of EPS, the 
presence of psychotic symptoms, age at onset of disease, duration of illness, and cognitive 
score (defined as modified Mini-Mental State examination-mMMS).  
The probabilities of dying were obtained data from the epidemiological data of the Thai 
population and the relative risk of mortality in Alzheimer’s disease (Gambassi et al. 1999, 
The Thai working group on the burden of disease and injuries 2002). For this model, the 
Markov process was undertaken in one-month cycle lengths over a five-year time horizon, to 
cover disease progression and to reflect the natural history of the disease. This model was 
also conducted from a societal perspective. The discount rates applied were at 3% per annum 
for both costs and outcomes.  
 
 
 
 
 
 
 
Figure 4.2: Outline view of the model structure based on the AHEAD framework using 
the predictive equation developed by Caro et al. (2001) 
 
 FTC + BPSD 
  
Pre-FTC + BPSD 
Death 
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4.3.2.2.2 Data inputs of the AHEAD-based model using the predictive equation for 
predicting the time to FTC developed by Caro et al. (2001) 
The main parameters required for the developed model based on the AHEAD-based model 
using the predictive equation to predict the time to the FTC state are outlined below.  
4.3.2.2.2.1 Transition probabilities of the AHEAD-based model using the predictive 
equation for predicting the time to FTC developed by Caro et al. (2001) 
A predictive risk equation was developed based on longitudinal epidemiological data. The 
AHEAD model allowed for a risk index (Stern et al. 1997) and regression equations (Caro et 
al. 2001) to be incorporated in the model. 
As Caro et al. (2001) suggested, predictor indices were employed, based on the Cox 
proportional hazard analysis of disease progression, to judge the significant characteristics of 
those patients who might need FTC. Such characteristics include the presence of 
extrapyramidal symptoms (EPS), the presence of psychotic symptoms, young age at onset (≤ 
65 years), a modified Mini-Mental State Examination (mMMS) score, and the duration of 
illness. These coefficients were employed to calculate the risk index once patients had 
entered the model. Additionally, the regression equations distinguished between two groups 
of patients: those aged 73 years old and younger, and those over 73 years old. These age 
factors were considered in calculating the baseline risk over time. The predictor indices and 
the coefficients of the regression equations are also illustrated in Table 4.7. 
Table 4.7: Predictive risk equation to calculate the transition probabilities from the Pre-
FTC state to FTC state based on Caro et al. (2001) 
 Variables EPS PSY Age at 
Onset 
mMMS Duration 
of illness 
Risk index Coefficient -0.9419 -0.4027 -0.4848 0.0724 0.0617 
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 Variables EPS PSY Age at 
Onset 
mMMS Duration 
of illness 
Risk over time Coefficient A B C D E 
 ≤ 73 years 0.0231 -1.8117 0.0373 0.1532 -4.7903 
 > 73 years 0 -0.6846 -6.4172 0.0112 0.1413 
 
The equations to predict time to FTC: The transition probabilities from the Pre-FTC state to 
FTC state were calculated as follows: 
• The equation used to calculate the baseline risk over time: 
 
𝜆0
𝑡 = 𝑒(𝐴𝑡+𝐵+𝐶𝑠𝑖𝑛ℎ(𝐷𝑡+𝐸)) 
 
where 𝜆0𝑡    was the baseline risk over time 
             𝑠𝑖𝑛ℎ was the hyperbolic sine 
 A, B, C, D and E  were coefficients of the regression equation separately for patient 
aged 73 years old and younger and those over 73 years old 
• To compute the hazard over time using the equation:  
 
𝜆𝑖𝑛𝑑𝑒𝑥
t =
𝜆0
𝑡
𝑒𝑟𝑖𝑠𝑘𝑖𝑛𝑑𝑒𝑥
 
 
where 𝜆𝑖𝑛𝑑𝑒𝑥t  was the hazard over time (the transition probability from Pre-FTC to FTC) 
 𝜆0𝑡  was the baseline risk over time 
  the risk index was the coefficient of predictor indices 
The baseline characteristics of patients in this model are presented in Table 4.8. These values 
were then used to calculate the risk index of the model. However, the presence of EPS, the 
presence of psychotic symptoms, and an age of onset were assessed by the present (value=1) 
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or not present (value= 0), these predictors were limited to measure the difference in changes 
of their scores.  
Table 4.8: Characteristics of patients with BPSD and being treated with olanzapine or 
risperidone from the data collected in the Thai setting  
Model Inputs Value  References 
Baseline characteristics of patients   
Age (yr) [Mean (SD)] 78.35 (8.80) Primary collected data 
Presence of EPS [n (%)]  11 (13.41)  Primary collected data 
Presence of psychotic symptoms [n (%)] 82 (100.00)   Primary collected data 
MMSE [Mean (SD)] 15.50 (7.52) Primary collected data 
Duration of illness (yr) [Mean (SD)] 2.44 (1.76) Primary collected data 
 
The probabilities of death in this model:  The probabilities for transitioning to death were 
calculated by multiplying the relative risk (RR) of the mortality associated with each health 
state (Pre-FTC or FTC) and the probability of dying of the general Thai population as 
classified by age (The Thai working group on burden of disease and injuries 2002). The 
relative risks of mortality in patients with Alzheimer’s disease were taken from a previous 
study accounting for 1.45 in Pre-FTC and 3.03 in FTC, respectively (Gambassi et al. 1999). 
The estimated monthly probabilities of the mortality in the Thai population are presented in 
Table 4.9. In addition, the assumptions in this model are as follows: 1) drugs, (olanzapine and 
risperidone), had no impact on the mortality; and 2) drug benefits were constant over the 
defined time period of this model.  
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Table 4.9: Monthly probabilities of mortality in the elderly Thai population classified by 
age group 
Age group (years) Probability Reference 
60-64 0.00119 The Thai working group on the burden of  
65-69 0.00175 disease and injuries (2002) 
70-74 0.00267  
75-79  0.00423  
80-84  0.00667  
> 85  0.01000  
 
4.3.2.2.2.2 Clinical effectiveness data of olanzapine and risperidone treatments 
Due to off-label antipsychotic treatment of dementia, the effectiveness data of drugs are 
controversial. There were only two studies comparing olanzapine and risperidone treatment 
in dementia based on the comprehensive literature review (see Chapter 2, section 2.4). 
However, the outcomes of both studies were not assessed regarding cognitive function (as 
measured by MMSE, ADAS-cog or mMMS). Thus, the clinical effectiveness data for 
olanzapine and risperidone applying in this model were derived from the study by Sultzer et 
al. (2008), in which the outcomes of atypical antipsychotics drugs of that study were based 
on a study of Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease 
(CATIE-AD). The CATIE-AD cohort study examined 421 outpatients with Alzheimer’s 
disease and with psychosis, aggression, or agitation, randomly assigned under double-blind 
conditions to treatment with olanzapine, risperidone, quetiapine and a placebo, in 42 
locations in the US (Schneider et al. 2006). Both olanzapine and risperidone altered cognition 
levels at 12 weeks in Phase 1 of the CATIE-AD study. The changes in the cognitive score, as 
measured by the Mini-Mental State Examination (MMSE), were -0.10 for the olanzapine-
treated group and -0.80 for the risperidone-treated group, however, there were no significant 
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differences among patients receiving the active drug or placebo (Sultzer et al. 2008). Table 
4.10 shows the effectiveness data on the difference in MMSE for olanzapine and risperidone 
which were applied in the model.  
Table 4.10: Model inputs for the clinical effectiveness data of olanzapine and 
risperidone  
Effectiveness Data (change in MMSE 
score compared with placebo) 
Value References 
Olanzapine (mean dose 5.5 mg/day) 0.60 Sultzer et al. (2008) 
Risperidone (mean dose 1.0 mg/day) -0.10 Sultzer et al. (2008) 
 
In addition, the MMSE score from the effectiveness data had to be converted to mMMS 
because the predictive equation incorporated mMMS as a variable for calculating the 
transition probability to FTC. The relationship between the MMSE and mMMS was depicted 
as presented below (Stern et al. 1997):  
𝑚𝑀𝑀𝑆 = 1.73 𝑀𝑀𝑆𝐸 + 2.81 
 
where 𝑚𝑀𝑀𝑆   was the modified Mini-Mental State Examination 
 MMSE   was the Mini-Mental State examination 
 
4.3.2.2.2.3 Costs of patients with behavioural and psychological symptoms of dementia and 
being treated with atypical antipsychotics, (olanzapine and risperidone), based on the data 
collected in Thailand 
As table 4.11 shows, the cost data of each type of care were obtained from the collected data 
from two hospitals in Thailand. Patients and/or caregivers were asked to provide the cost data 
that patients had expended during their treatment course. Face-to-face interviews were 
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conducted in this thesis. The gathering of data processes, including the inclusion and 
exclusion criteria are as presented in Chapter 5 (sections 5.2.1 and 5.2.2).  
The cost data of this model also included the direct medical costs and direct non-medical 
costs which were similar to the costing data in the CERAD-based model. All costs used in 
the model were reported in 2017 financial year values (see more information in Chapter 5).  
Table 4.11: Monthly cost parameters for the model, calculated based on data from 
Thammasat University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital, 
Thailand, Thai Baht (THB) at 2017 values 
Cost Assumptions  Value [Mean (SD)] Reference 
By health state   
Risperidone:   
Pre-FTC 44,717.09 (14,573.74) Primary collected data 
FTC 53,167.03 (11,251.27) Primary collected data 
Olanzapine:   
Pre-FTC 44,347.28 (16,071.51) Primary collected data 
FTC 58,294.20 (19,227.41) Primary collected data 
               * Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
 
4.3.2.2.2.4 Utility weights of patients with behavioural and psychological symptoms of 
dementia and being treated with atypical antipsychotics, (olanzapine and risperidone), 
based on the data collected in Thailand 
 The utility weights applied in the AHEAD-based model using the predictive equation to 
estimate the need of FTC developed by Caro et al. (2001) were derived from a cross-sectional 
study in Thailand. The face-to-face interviews were conducted at the outpatient departments 
of both hospitals as previously stated at only one point in time during some point in 2017 
using the EQ-5D-5L. For patients receiving risperidone, the utility weights were 0.46 of the 
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Pre-FTC state and 0.12 of the FTC state, whereas the utility weights of patients treated with 
olanzapine were 0.63 and 0.23 of the Pre-FTC state and the FTC state, respectively (see more 
information in Chapter 6).  
4.3.2.2.3 Results of the cost-utility analysis of the AHEAD-based model using the 
predictive equation for predicting the time to FTC developed by Caro et al. (2001) 
In a comparison of olanzapine to risperidone, the incremental cost and effectiveness were 
THB 26,171.15 and 0.22 higher, respectively, in favour of olanzapine treatment. Based on a 
societal perspective over a five-year time horizon, the ICER at the base case scenario was 
THB 118,959.77 per QALY gained. (Table 4.12).  This indicated that olanzapine was more 
cost-effective compared with risperidone for the treatment of patients with BPSD at the 
ceiling cost-effective threshold in Thailand (THB 160,000). 
Table 4.12: Cost-utility analysis results of olanzapine relative to risperidone for the 
treatment patients with BPSD, (THB at 2017 values), from the AHEAD-based model 
using the predictive equation for predicting the time to FTC developed by Caro et al. 
(2001) 
Strategy Cost Incremental 
Cost 
Effectiveness Incremental 
Effectiveness 
ICER 
Risperidone 1,901,735.35  41.23   
Olanzapine 1,927,906.50 26,171.15 41.45 0.22 118,959.77 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
4.3.2.2.4 Limitation 
There are several points to be concerned with regarding the model developed based on the 
AHEAD-based model using the predictive equation to predict the time to FTC developed by 
Caro et al. (2001). Firstly, this model might raise concerns over the generalisability of the 
data used in the predictive equations which were developed based on an observational study 
of US patients. Secondly, cognitive function, as measured by mMMS score, used to apply in 
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the predictive equation to predict time to FTC need, thus error may have arisen in the 
conversion from the differences in cognitive scale (as measured by MMSE and ADAS-cog) 
to mMMS. Although the predictive equation incorporated several factors to estimate time to 
requiring FTC, the functional ability was not included. Further, the definition of FTC might 
be different in each setting. Also, the treatment effect applied to the equation was focused 
only on the cognitive function, whereas other aspects associated with the progression of the 
disease, namely behaviour and functional ability, were not considered. Further, the presence 
of psychotic symptoms in the equation was assessed in terms of yes or no, thus this did not 
differentiate between the effectiveness of antipsychotics. Next, this model adopted data from 
a schizophrenia study to calculate costs associated with relapses. Finally, the caregivers were 
the main respondents for completing the questionnaire, thus there should be concerns over 
the interpretation of the utility weights.  
 
4.3.2.3 Model 3: The model based on the FTC conceptual framework using a new 
predictive equation for predicting the time to FTC developed by Rive et al. (2010) 
The structure and concept of the model on the basis of the FTC conceptual framework using 
the predictive equation to predict the time until patients required for FTC developed by Rive 
et al. (2010), data inputs of this model, (including transition probabilities, clinical 
effectiveness data of drug treatments, costs and utility weights), results of the cost-utility 
analysis and limitation of the model type in this thesis are presented in the subsequent 
sections.  
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4.3.2.3.1 Model structure and model concept based on the FTC framework using a new 
predictive equation for predicting the time to FTC developed by Rive et al. (2010)  
According to the FTC-based framework using the predictive equation to predict the time until 
patients required for the FTC state, the structure and model concept of the developed model 
in this thesis are described below.    
4.3.2.3.1.1 The model structure of the model based on the FTC framework using the 
predictive equation for predicting the time to FTC developed by Rive et al. (2010) 
The model structure consisted of three possible health states: Pre-FTC, FTC and death. The 
FTC state was considered based on either the dependency status or locus of care of the 
patients. Both physical and functional abilities were used for assessing the patients’ 
dependence status. In this study, the physician’s assessment and the Activities of Daily 
Living rating (ADL) score were used to evaluate the dependence of patients as previously 
stated in the model using the predictive equation to estimate the need of FTC developed by 
Caro et al. (2001). The model structure is presented in Figure 4.3.  
However, this thesis focused on the treatment of patients with BPSD. Therefore, BPSD 
associated with patients requiring atypical antipsychotic drugs for their treatment were also 
incorporated into the health states of the model. 
4.3.2.3.1.2 The model concept and flow of the model based on the FTC framework using 
the predictive equation for predicting the time to FTC developed by Rive et al. (2010) 
The model concept was the patient’s need for FTC. The time to FTC was estimated by the 
predictive equation.  
A new predictive equation to predict time for requiring FTC was developed by Rive et al. 
(2010). The baseline characteristics of the patients were taken from a longitudinal 
epidemiological study-the London and the South-East region (LASER-AD), which 
investigated 224 people with Alzheimer’s disease and their caregivers (Livingston et al 
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2004). Based on the LASER-AD cohort, 117 pre-FTC patients were followed-up over a 54-
month period which was used to construct the equations in computing the transition 
probabilities from pre-FTC to FTC and the probabilities of death. Also, the three main 
dimensions of Alzheimer’s disease, including cognitive, functional, and behavioural 
performances, were incorporated into the equations to predict time to FTC. In addition, the 
cognitive function, functional ability, and behavioural performance were assessed by the 
Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog), the Alzheimer’s Disease 
Cooperative Study-Activities of Daily Living scale (ADCS-ADL), and the Neuropsychiatric 
Inventory (NPI), respectively. 
A Markov model was used to predict the progression of a patient with Alzheimer’s disease 
with three possible health states: Pre-FTC, FTC, as well as death. The following transitions 
were possible: 
• At the Pre-FTC state, some patients had the possibility of moving to the FTC or 
death, while others remained in the same health state; 
• At the FTC state, some patients remained in the FTC state, but there was also the 
possibility that some could move to death; and  
• Death was an absorbing state.  
The Markov process was undertaken using a one-month cycle length over a five-year time 
period, covering disease progression and reflecting the natural history of the disease. 
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Figure 4.3: Outline view of the model structure based on the FTC conceptual 
framework using the predictive equation for predicting the time to FTC developed by 
Rive et al. (2010) 
4.3.2.3.2 Data inputs of the model based on the FTC framework using the predictive 
equation for predicting the time to FTC developed by Rive et al. (2010) 
In the thesis, the main parameters required for the developed model based on the FTC 
framework using the predictive equation to predict the time to the FTC state are outlined 
below.  
4.3.2.3.2.1 Transition probabilities of the model based on the FTC framework using the 
predictive equation for predicting the time to FTC developed by Rive et al. (2010) 
A predictive risk equation was used to calculate the time to FTC. The main variables were 
ADAS-cog, ADCS-ADL, and NPI scores which reflected the three domains, cognition, 
functioning and behaviour, in Alzheimer’s disease (AD) (Rive et al. 2010). To compute the 
interval probabilities of reaching the FTC state, the predictive equation parameters at baseline 
were based on data from the LASER-AD cohort study (Table 4.13). The estimated length of 
time to FTC in patients with Alzheimer’s disease was based on the equations as follows: 
 FTC + BPSD 
Death 
  
Pre-FTC +BPSD 
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• The hazard function equation used to predict the length of time to FTC 
 
𝑝𝑗 = 1 − exp (− exp (−11.1343 + 0.0330 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 − 0.0877 × 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
+ 0.0377 × 𝑁𝑃𝐼𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 + 0.8122 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗)
− 2.4072 × 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗)) × exp(3.3195 × ln(𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙𝑗))) 
 
where    𝑝𝑗  was probability for the time interval j 
  𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒    was the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale at baseline 
  𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒   was the Alzheimer’s Disease Cooperative Study- 
Activities of Daily Living scale at baseline 
  𝑁𝑃𝐼𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒    was the Neuropsychiatric Inventory total score at baseline 
  𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑠𝑙𝑜𝑝𝑒 (𝑗)  was the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale for the time interval j 
  𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑠𝑙𝑜𝑝𝑒 (𝑗)  was the Alzheimer’s Disease Cooperative Study 
Activities of Daily Living scale for the time interval j 
• The estimation of the monthly transition probability to the FTC state was calculated 
by 
     𝑝𝑗𝑖
𝐹𝑇𝐶 = 1 − √(1 − 𝑃𝑗
𝑙𝑒𝑛𝑔𝑡ℎ(𝑗)
) 
 
where   𝑝𝑗𝑖𝐹𝑇𝐶    was the monthly probability 
  𝑝𝑗        was the probability for the time interval j 
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Table 4.13: Parameters at baseline deriving from the LASER-AD cohort study 
(Livingston et al. 2004) 
Characteristics Value 
ADAS-cog baseline 36.30 
ADCS-ADL baseline 45.00 
NPI baseline 18.54 
ADAS-cog slope 0.6116 
ADCS-ADL slope -0.7503 
 
The transition probabilities of death: The probabilities for transitioning to death in this model 
were estimated from the mortality rates of the epidemiological data of the general Thai 
population, multiplied with the relative risk (RR). The study by Gambassi et al. (1999) 
reported, the relative risks of patients dying from Alzheimer’s disease were 1.45 in the Pre-
FTC state and 3.03 in the FTC state. The monthly probabilities of dying for the general Thai 
population, classified by age group that were derived from the epidemiological data of the 
Thai working group on burden of disease and injuries (2002), were similar to the AHEAD-
based model using the predictive equation for predicting the time to FTC developed by Caro 
et al. (2001) (see in Table 4.9).  
4.3.2.3.2.2 Clinical effectiveness data of olanzapine and risperidone treatments 
Due to the controversial use of antipsychotics for the treatment of BPSD, the effectiveness 
data applied to the model using the predictive equation to predict the need of FTC developed 
by Rive et al. (2010) were derived from two studies. The effectiveness of treatments 
associated with the functional ability and the cognitive function were obtained from the 
Phase 1 outcomes of the CATIE-AD study, a double-blind randomly masked study (Sultzer 
et al. 2008). At 12 weeks in Phase 1 of the CATIE-AD study, the changes in the cognition 
scores, as measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale 
 
 
230 
 
(ADAS-cog), was 0.70 for olanzapine, 1.70 for risperidone and 1.30 for the placebo. 
However, these scores were not significantly different. The changes in the Alzheimer’s 
Disease Cooperate Study-Activities of Daily Living Scale total (ADCS-ADL) found -6.1 in 
patients treated with olanzapine, -1.10 of patient’s receiving risperidone and 0.50 of the 
placebo group. In addition, neuropsychiatric inventory total (NPI-total) scores were derived 
from a double-blind randomised controlled trial (RCT) by Deberdt et al. (2005). This study 
reported that the changes of NPI-total scores compared with placebo were 0.50 and 2.60 for 
olanzapine and risperidone, respectively. Table 4.14 provides the summary of drug 
effectiveness that used to calculate in the model.   
Table 4.14: Summary of the clinical effectiveness data of olanzapine and risperidone  
Variable Olanzapine Risperidone Reference 
Behavioural (NPI-total) 0.50 2.60 Deberdt et al. (2005) 
Functioning (ADCS-ADL) -6.60 -1.60 Sultzer et al. (2008) 
Cognition (ADAS-cog) -0.60 0.40 Sultzer et al. (2008) 
 
According to the LASER-AD cohort, the assessment was conducted at baseline, at 6-months 
and then every twelve months. Thus, the interval probabilities of reaching the FTC state were 
extrapolated over a five-year time horizon based on the assumption as to whether the risk to 
the FTC state was constant in each time interval (Table 4.15). The monthly probabilities of 
the need of the FTC state were then calculated using the equation presented above. The 
estimated monthly probabilities time to the FTC state of olanzapine and risperidone are 
shown in Table 4.16.  
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Table 4.15: Interval transition probabilities of reaching the FTC state of olanzapine 
treatment and risperidone treatment  
 Interval Olanzapine Risperidone 
P1 0-6 months 0.01275 0.00922 
P2 7-18 months 0.38880 0.29900 
P3 19-30 months 0.93167 0.85575 
P4 31-42 months 0.99973 0.99730 
P5 43-54 months 1.00000 0.99999 
P6 55-60 months 1.00000 1.00000 
 
Table 4.16: Monthly transition probabilities time to the FTC state of olanzapine 
treatment and risperidone treatment 
 
4.3.2.3.2.3 Costs of patients with behavioural and psychological symptoms of dementia and 
being treated with atypical antipsychotics (olanzapine or risperidone) based on the data 
collected in Thailand  
Cost data were derived from the directly gathered data of two hospitals in Thailand. The face-
to-face interviews were conducted using the cost questionnaire. Further, the processes of data 
collection and calculating costs were given previously (see more details in Chapter 5). Cost 
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data included direct medical costs and direct non-medical costs. In addition, both health 
states of the AHEAD-based model using the predictive equation for predicting the time to 
FTC developed by Caro et al. (2001) and the model using the predictive equation to predict 
time to FTC developed by Rive et al. (2010) had similarities, (Pre-FTC and FTC). Then, the 
costing data of the AHEAD-based model using the predictive equation developed by Caro et 
al. (2001) were also used in this model (see Table 4.11).  
For patients receiving risperidone, the monthly costs were THB 44,717.09 for the Pre-FTC 
state and THB 53,167.03 for the FTC state, whereas the monthly cost of patient treated with 
olanzapine were THB 44,347.28 and THB 58,294.20 for the Pre-FTC and FTC states, 
respectively. All costs used in this model were reported in 2017 financial year values (1£ = 
THB 45) (see more information in Chapter 5).  
4.3.2.3.2.4 Utility weights of patients with behavioural and psychological symptoms of 
dementia and treated with atypical antipsychotics (olanzapine or risperidone) based on the 
data collected in Thailand  
Again, the health states of the model using the predictive equation to predict the time to FTC 
developed by Rive et al. (2010) comprised of Pre-FTC, FTC and death. Thus, the utility 
weights used here were similar to the AHEAD-based model using the predictive equation to 
predict the time to FTC developed by Caro et al. (2001) as follows: 0.46 for the Pre-FTC 
state and 0.12 for the FTC state of patients receiving risperidone treatment and 0.63 for the 
Pre-FTC state and 0.23 for the FTC state of patients receiving olanzapine treatment. More 
details of the utility analyses are presented in Chapter 6.  
4.3.2.3.3 Results of the cost-utility analysis of the model based on the FTC framework 
using the predictive equation to predict the time to FTC developed by Rive et al. (2010) 
The total five-year cost for a patient with BPSD receiving treatment with risperidone was 
estimated at THB 1,918,257, while the cost for a patient with BPSD receiving treatment with 
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olanzapine was THB 2,015,958. The incremental cost was THB 97,701.31. The estimated 
QALYs were 10.81 and 15.45 for the risperidone and the olanzapine treatment groups 
respectively. The incremental QALYs between the two drugs was 4.64. Consideration of the 
cost-utility analysis of the model, the ICER yielded THB 21,039.45/QALY under the base 
case scenario (Table 4.17).  
Using this result, olanzapine was considered to be the most cost-effective treatment when 
compared with risperidone, in the treatment of patients with BPSD from a societal 
perspective, following the ceiling threshold of the cost-effectiveness in Thailand as 
previously stated.  
Table 4.17: Cost-utility analysis results of olanzapine relative to risperidone for the 
treatment patients with BPSD, (THB at 2017 values), from the model based on the FTC 
framework using the predictive equation to predict the time to FTC developed by Rive 
et al. (2010)  
Strategy Cost Incremental 
Cost 
Effectiveness Incremental 
Effectiveness 
ICER 
Risperidone 1,918,257.12  10.81   
Olanzapine 2,015,958.43 97,701.31 15.45 4.64 21,039.45 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
4.3.2.3.4 Limitation 
The applied the model based on the FTC framework using the predictive equation to predict 
the time to FTC developed by Rive et al. (2010) for the health economic evaluation study in 
dementia has limitations. Firstly, the patient baseline characteristics used data from the 
LASER-AD cohort, a longitudinal epidemiological study in the UK.  Secondly, predictive 
equations were also based on the same cohort. Thus, this model might raise some concerns 
over the generalisability of the data used in the new predictive equations. Thirdly, the drug 
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effects on the cognitive function used the MMSE score, thus the conversion from MMSE to 
ADAS-cog score might introduce some errors. Finally, caregivers were the major 
respondents providing a rating for the utilities, therefore the results need to be interpreted 
with caution.  
 
4.3.3 The comparisons of the three developed models  
By comparing amongst developed models, the finding are presented following the defined 
points, (see section 4.2.2), as outlined below. 
4.3.3.1 Disease severity and health states of the models 
According to the CERAD-based model, the health states of the model comprised of mild, 
moderate, severe as well as death. The disease severity was defined by severity levels of the 
cognitive function as measured by TMSE scores.  
The dependency status of patients was used to define the disease severity of the two other 
models of the FTC conceptual framework which was measured by activities of daily living 
(ADL) together with an assessment by physicians. Therefore, the health states of the models 
using the predictive equation to predict the need of FTC developed by Caro et al. (2001) and 
developed by Rive et al. (2010) were Pre-FTC, FTC and death.  
4.3.3.2 The disease progression and transition probabilities of the models 
In the CERAD-based model, the course of the disease according to severity levels was used 
as a concept of this model type. The stage-to-stage transition probabilities of this model used 
data from the CERAD cohort, a longitudinal database of 1,145 patients with dementia in the 
US between 1986 and 1995 (Morris et al. 1989).  
Regarding the model based on the FTC frameworks, the need for FTC was used as a concept 
of the disease progression of this model type. The FTC state was a requirement for a 
significant amount of time for care and supervision, regardless of the locus of care or who 
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provided the patients’ care. To estimate the time until patients needed FTC, the predictive 
equation developed by Caro et al. (2001) used data of patient characteristics undertaken in 
236 Alzheimer’s disease patients followed-up over 7-years in the US by Stern et al. (1997). 
This equation incorporated multiple characteristics, including the presence of EPS, presence 
of psychotic symptoms, duration of illness, age at the onset of disease, and cognitive 
function. The probability of dying was based on the mortality rates of the general Thai 
population.  
The predictive equation developed by Rive et al. (2010) used data obtained from the LASER-
AD cohort, a longitudinal epidemiological study conducted in 117 pre-FTC patients with 
Alzheimer’s disease with a 54-month follow-up period in the UK to estimate the time until 
patients needed of FTC. The predictive equation included the cognitive function (as measured 
by ADAS-cog scale), the functional performance (as assessed by the ADCS-ADL) and 
behavioural ability (as measured by NPI). The probabilities of death in the model used the 
mortality rates of the general Thai population.  
4.3.3.3 The clinical effectiveness data of the treatments applied to the model 
The CERAD-based model used the change in the Clinical Global Impression of Change 
(CGI-C) scale as the effectiveness of drug treatment.  
Although the model based on the FTC framework using the predictive equation to predict the 
time to FTC developed by Caro et al. (2001) incorporated multiple characteristics of patients 
in the predictive equation to predict time until patients needed for the state of FTC, the 
effectiveness data of treatments mainly depended upon the alteration of the cognitive 
function, particularly mMMS score.  
The model using the predictive equation for predicting the time to FTC developed by Rive et 
al. (2010) considered several aspects of the clinical effectiveness of drug treatments, 
including cognition, (ADAS-cog scale),  behaviour, (NPI), and functioning, (ADCS-ADL).  
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4.3.3.4 The results of an economic evaluation of the treatment of patients with BPSD 
with olanzapine compared with risperidone based on the different models 
All three developed models suggested olanzapine was a domonant treatment option for 
patients with behavioural and psychological symptoms of dementia in Thailand when 
compared with risperidone. However, the incremental cost-effectiveness ratio, (ICER as 
measured an incremental of costs and an incremental of QALYs), of each model had 
provided different results which the model using the predictive equation for predicting the 
time to FTC developed by Caro et al. (2001) had the highest ICER.  
Furthermore, the significant characteristics of each model are summarised in Table 4.18. A 
comparison of strengths and limitations of each model are also presented in Table 4.19.  
Table 4.18: Summary of the characteristics of each developed model 
Description CERAD 
framework 
(Neumann et al. 
1999) 
FTC framework 
using the equation 
developed by 
Caro et al. (2001) 
FTC framework 
using the equation 
developed by Rive 
et al. (2010) 
Disease severity characteristics    
CDR scale ●   
Dependence-need for FTC  ● ● 
Disease progression of modelling    
Discrete states ● ● ● 
TMSE scale ●   
Cognitive function  ● ● 
Functional performance   ● 
Behavioural characteristics  ● ● 
Presence of extrapyramidal 
symptoms 
 ●  
Age at disease onset  ●  
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Description CERAD 
framework 
(Neumann et al. 
1999) 
FTC framework 
using the equation 
developed by 
Caro et al. (2001) 
FTC framework 
using the equation 
developed by Rive 
et al. (2010) 
Duration of illness  ●  
The effectiveness data    
CGI-C ●   
Cognitive assessment  ● ● 
Functional assessment   ● 
Behavioural assessment   ● 
Utility weights    
EQ-5D-5L (a cross-sectional survey) ● ● ● 
* (●) refers to the presence of characteristics of each developed model when compared amongst developed 
models  
Table 4.19: Comparison of strengths and limitations of each developed model 
Model Strength Limitation 
The CERAD-based model ● Health states were based on 
the CDR scale. 
● Mild, moderate, severe and 
death were the health states in 
the model. 
● Transition probabilities were 
based on the CERAD cohort.  
● CGI-C used as effectiveness 
data of treatments. 
● Cost data included adverse 
event-associated costs and 
relapse-associated costs 
● Health states were discrete 
states, there is a concern 
regarding a limitation to 
represent how changes occur 
over time. 
● Transition probabilities were 
based on the CERAD database 
in the US, leading to a concern 
over the application in different 
contexts. 
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Model Strength Limitation 
● QALY was a measure of 
outcome. 
● Effectiveness data of 
treatment mainly depended on 
cognitive assessment. 
● Data of costing and utility 
weights in the model were 
based on a cross-sectional 
study, leading to a concern 
associated with a limitation in 
representing how costing and 
utility changes influence the 
disease progression of patients 
and the treatment. 
The AHEAD-based model 
using the predictive equation 
developed by Caro et al. (2001) 
● Health states were based on 
Pre-FTC, FTC and death. 
● Transition probabilities were 
based on the equation which 
included various characteristics 
of the patients.  
● Effectiveness data relied on 
the mMMS score. 
● Cost data included adverse 
event-associated costs and 
relapse-associated costs 
● QALY was a measure of 
outcome. 
● Health states were discrete 
states, there is a concern 
regarding a limitation in 
representing how changes occur 
over time. 
● Transition probabilities were 
based on the equation by Caro 
et al. (2001) using patient 
characteristics from the study by 
Stern et al. (1997), in the US, 
there is a concern over the 
application in different contexts. 
● Effectiveness data of 
treatment mainly relied upon 
cognitive assessment, 
particularly mMMS. The 
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Model Strength Limitation 
difference in the cognitive 
measurement needed to be 
changed to mMMS, leading to a 
concern over accuracy. 
● Functional performance was 
not considered in the predictive 
equation to predict time to FTC. 
● Data of costing and utility 
weights in the model were 
derived from a cross-sectional 
study. There is a concern over a 
limitation to perform how 
costing and utility changes 
influence the disease 
progression and the treatment. 
The model using the predictive 
equation developed by Rive et 
al. (2010) 
 
● Health states of the model 
were Pre-FTC, FTC and death. 
● Transition probabilities were 
based on the equation which 
included cognition, functioning 
and behavioural performances. 
These were reflected a multi-
dimension associated with the 
natural disease progression of 
dementia.  
● Several factors, including 
ADAS-cog scale, NPI score and 
● Health states were discrete 
states, there is a concern 
regarding a limitation to 
represent how changes over 
time occur. 
● Transition probabilities were 
based on the equation by Rive 
et al. (2010) which used data 
from the LASER-AD cohort in 
the UK, there is a concern over 
the application in different 
contexts. 
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Model Strength Limitation 
ADCS-ADL, were taken into 
account as effectiveness data.  
● Cost data included adverse 
event-associated costs and 
relapse-associated costs 
● QALY was a measure of 
outcome. 
● The most recently used model 
compared with the model-based 
CERAD framework and FTC 
framework using the equation 
developed by Caro et al. (2001)  
● Data of costing and utility 
weights in the model were 
based on a cross-sectional 
study. This might be associated 
with a limitation in producing 
how costing and utility changes 
affect the disease progression 
and the treatment. 
 
4.3.4 Justification of the most suitable model for applying to the cost-utility analysis of 
antipsychotics (olanzapine compared with risperidone) for the treatment patients with 
BPSD in Thailand 
According to the defined considerations criteria for making the decision to select the most 
appropriate model, (see section 4.2.3), the model using the predictive equation to predict the 
need of FTC developed by Rive et al. (2010) was selected as being the most suitable model to 
be applied to the economic evaluation of the treatment BPSD in the comparison of 
olanzapine to risperidone for the Thai population. There were several reasons as follows: 
firstly, the model had taken into account all significant dimensions, (cognitive, functional and 
behavioural abilities), which were more consistent with the natural disease progression of 
dementia to predict the progression of disease.  
Secondly, the model structure based on the FTC conceptual framework was widely used in 
studies of economic evaluation of dementia. 
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Thirdly, the clinical effectiveness of drug treatments to use in the model also considered all 
core components of the disease progression of dementia, including cognition, functioning and 
behaviour.  
Finally, the model using the predictive equation developed by Rive et al. (2010) is the most 
recently developed when compared with the CERAD-based model and the AHEAD-based 
model using the predictive equation to predict the time to FTC developed by Caro et al. 
(2001). 
 
4.4 Discussion 
Based on the literature review, most studies of model-based economic evaluation in dementia 
were associated with Alzheimer’s disease. The majority of models for economic evaluations 
in dementia used the Markov model to predict the outcomes and estimate the most cost-
effective treatment. Also, it can be seen from the review that the two most common model 
structures in order of frequency used in several studies were based on the CERAD conceptual 
framework and the FTC conceptual framework (Neumann et al. 1999, Ikeda, Yamada and 
Ikegami 2002, Fuh and Wang 2008, Kirbach et al. 2008, Lopes-Bastida et al. 2009, Getsios et 
al. 2001, Caro et al. 2002, Garfield et al. 2002, Migliaccio-Walle et al. 2003, Ward et al. 
2003, Caro et al. 2004, Green et al. 2005, Suh 2009). However, there were some studies 
which were conducted using the DES model, the microsimulation model, the decision tree 
model, and statistical model (Henke and Burchmore 1997, Fenn and Gray 1999, McDonnell 
et al. 2001, Weyker et al. 2007, Wong et al. 2009, Getsios et al. 2010, Guo et al. 2010, Nagy 
et al. 2010, Hartz et al. 2012, Thaibault et al. 2015).  
Following the review and the defined criteria to develop models, (see the methods section 
4.2.1), three different models are selected to predict the cost-utility analysis of the use of 
atypical antipsychotics in the treatment of BPSD patients. Three decision-analytic models are 
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developed based on the different concepts of the model-based economic evaluations in 
dementia, especially Alzheimer’s disease. One is adopted from the CERAD-based structure 
and two models use the FTC conceptual framework.  
Although two models based on the FTC conceptual framework, including the models using 
the predictive equation for predicting the need of FTC developed by Caro et al. (2001) and 
developed by Rive et al. (2010), have similarities regarding the health states, (Pre-FTC, FTC 
and death), the predictive equations to predict the time to FTC are significantly different 
between the two models. Based on Caro et al. (2001), the predictive equation for predicting 
the time to FTC takes into account two domains of patient’s cognition and behavioural 
symptoms, whereas the predictive equation for predicting the time to FTC developed by Rive 
et al. (2001) includes three domains associated with patient’s cognition, behavioural 
symptoms as well as functioning.     
 Moreover, all three models adopt data from different longitudinal epidemiology cohorts to 
use as sources for the calculation of state-to-state transition probabilities. Two models of the 
CERAD-based model and the model using the predictive equation to predict the time to FTC 
developed by Caro et al. (2001) obtain data from studies conducted in the US, whereas the 
other model using the predictive equation to predict the time to FTC developed by Rive et al. 
(2010) uses data from a study in the UK. 
There are different clinical effectiveness data of the treatments use in each model which these 
affect the transitioning between health states of the model. One model uses CGI-C, another 
model uses mMMS score and the other model considers ADAS-Cog, ADCS-ADL and NPI. 
Although the three developed models use different approaches, the results of cost-utility 
analyses of all models are similar, in that olanzapine is a cost-effective treatment for patients 
with BPSD in Thailand, when compared with risperidone. This is consistent with the study 
by Kirbach et al. (2008) in the US, conducted using the CERAD model as the model 
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structure. That study reported that olanzapine was a favourable treatment in Alzheimer’s 
patients with agitation and psychosis, compared with no treatment. However, it should be 
noted that there are concerns about the differences in methods, data inputs and healthcare 
provision for each country between the Kirbach’s study and this thesis.   
According to the comparison amongst the three models, the model using the predictive 
equation to predict the time to FTC developed by Rive et al. (2010) is chosen as the most 
suitable model. This is associated with the model having met all defined points for the 
considerations of this thesis, (see section 4.2.3). Moreover, it is important to note that the 
model using the predictive equation to predict the time to FTC developed by Rive et al. 
(2010) included assessments of the core domains of Alzheimer’s disease, (cognition, 
behaviour and functioning), to estimate the transition from the Pre-FTC state to the FTC 
state. This implies that the model using the predictive equation to predict the time to FTC 
developed by Rive et al. (2010) is more consistent with the natural history of the disease 
progression of dementia, in particular Alzheimer’s disease.     
However, the developed models in this chapter also have several limitations. Firstly, they are 
associated with the generalisability of data used in the transition probabilities for the health 
states of the models.  
Secondly, all three models are conducted using discrete states. This might limit their ability 
to represent how changes over time influence the disease progression for patients and their 
treatments.  
Thirdly, the costing data and utility weights of all models are conducted in a cross-sectional 
study, and this might limit their ability to represent how costing and utility changes influence 
the disease progression for patients and their treatments. Thus, the application of the selected 
model to the economic evaluation in dementia should be carried out and interpreted with 
caution.   
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To the researcher’s best knowledge, this is the first study to explore the model-based 
economic evaluations in a comparison between olanzapine and risperidone, for the treatment 
of patients with behavioural and psychological symptoms of dementia, based on existing and 
available data. This thesis also highlights the model using the predictive equation to predict 
the time to FTC developed by Rive et al. (2010) as the most suitable model to apply for an 
economic evaluation of the BPSD treatment with atypical antipsychotic drugs in Thailand. 
Therefore, this model was adopted for further cost-utility analysis of olanzapine compared 
with risperidone for the treatment of BPSD patients in Thailand (in the Chapter 7).   
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Chapter 5: Cost analyses of patients with behavioural and psychological 
symptoms of dementia in Thailand 
Abstract 
Introduction: Dementia is a progressive illness and has become the leading cause of 
morbidity and functional decline in elderly people. This illness involves with cognitive and 
non-cognitive symptoms. Whilst the non-cognitive symptoms or behavioural and 
psychological symptoms of dementia (BPSD) are a serious complication of people with 
dementia and these symptoms occur at some point during the patient’s illness. The mental or 
behavioural disturbances are substantial predictors associated with the burden to patients, 
their families, their caregivers, and healthcare systems and also profoundly affect the quality 
of life of relevant individuals. However, there is a lack of data on costings, especially in 
patients with BPSD and being treated with atypical antipsychotics.  
Aim: The objective of this chapter is to analyse the costs of patients with behavioural and 
psychological symptoms of dementia using different atypical antipsychotic drugs, 
(risperidone and olanzapine), in Thailand. 
Methods: A cross-sectional study was conducted, with face-to-face interviews and using 
questionnaires, from patients with BPSD and being treated with atypical antipsychotics, 
(olanzapine or risperidone), and/or patients’ caregivers to estimate costs associated with these 
patients. The data collections were undertaken in two phases: Phase I, (from February 2017 
to March 2017), and Phase II, (from October 2017 to November 2017), at Thammasat 
University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital in Thailand. Cost 
analyses included direct medical costs and direct non-medical costs of risperidone and 
olanzapine prescribed patients, classified by their cognitive function and dependence.   
Results: Average monthly costs in THB at 2017 values, (1£ = THB 45), per patient classified 
by cognitive function, were THB 41,444.22 for mild, THB 46,470.29 for moderate, and THB 
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53,038.90 for severe stages for those treated with risperidone and THB 41,901.85 for mild, 
THB 48,368.34 for moderate, and THB 52,901.64 for severe stages for those prescribed 
olanzapine. The severity of cognitive impairment was associated with the costs of those 
patients with the greater severity predicted at higher costs. Classifying patients by their 
dependence on care, the average monthly costs of risperidone treatment in 2017 THB were 
THB 44,717.09 and THB 53,167.03 per patient for not requiring full-time care, (Pre-FTC), 
and full-time care, (FTC), states respectively. For olanzapine treatment, the monthly costs per 
patient were THB 44,347.28 for the Pre-FTC and THB 58,294.20 for the FTC state. The 
higher costs correlated with the higher dependence of care for those patients. Co-morbidity 
conditions had a substantial impact on total direct medical costs per month of both 
classifications of patients by cognitive function and dependence, accounting for 9.1%-10.0%. 
Informal care was also a significant burden of both groups of classified patients, leading to a 
major proportion of direct non-medical costs for these patients and their caregivers, (62.4% - 
66.4%). Although the medication costs per month showed significant differences between 
patients treated with risperidone and those treated with olanzapine, the average monthly costs 
between two drug treatments of both different methods of categorised patients were not 
significantly different.   
Conclusions: The costs of patients with BPSD relate to the high burden of patients and their 
caregivers, especially in the later stages of dementia in which patients experience a 
progressive decline in cognitive function and performing activity of daily living, (ADL), 
tasks. Behavioural disturbances are also correlated with the higher costs of BPSD patients, 
causing significantly high costs due to the patients’ care. Thus, a reduction of disturbances of 
BPSD patients has a potential to decrease the burden on those patients, their families, their 
caregivers and healthcare systems.  
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5.1 Introduction 
Dementia is a chronic illness in relation to cognitive decline which intensives as the 
population ages. Cognitive deterioration not only affects patients with dementia, but also 
influences the care providers as well as society in general. Behavioural and psychological 
symptoms of dementia (BPSD), known as neuropsychiatric symptoms (NPS), or non-
cognitive symptoms, are common and frequently arise at any point of the disease progression 
in these patients. The symptoms are classified into different characteristics according to 
Neuropsychiatric Inventory (NPI) items as follows: psychotic (delusions or hallucinations); 
affective disorders (depression, agitation, anxiety, and irritability); and behavioural 
disturbances (apathy, disinhibition, aberrant motor behaviour, and euphoria). These 
symptoms are able to occur concurrently in people with dementia (Canevelli et al 2013). 
Some studies however used behavioural disturbances referring to symptoms associated with 
BPSD as previously stated (Mangone et al. 1993, Lyketsos 2000, Lyketsos et al. 2002, 
Kirbach et al. 2008, Mesterton et al. 2010, Bergvall et al. 2011). As previously stated, 50-
90% of patients with dementia tend to experience BPSD during the course of their illness 
(Lyketsos 2000, Lawlor 2002, Lyketsos et al. 2002, Cerejeira, Lagarto and Mukaetova-
Ladinska 2012, Torrisi et al 2016). The symptoms also increase according to the higher 
stages of disease severity. A study in rural Tanzania found a total of 88% of patients with 
dementia having at least one symptom of BPSD and 51% of those patients suffered from 
three or more symptoms of BPSD (Paddick et al. 2015). In Thailand, at least one current 
BPSD was reported by 90-100% of patients with Alzheimer’s disease (Charernboon and 
Phanasathit 2014, Taemeeyapradit, Udomittipong and Tepparak 2014). Although most 
patients with dementia manifested symptoms related to BPSD at some point in their illness, 
these disturbances vary in frequency and severity. Apathy, depression, and 
agitation/aggression were generally reported as the main behavioural disturbances occurring 
in those patients (Levy et al 1996, Lyketsos et al. 2000, Lyketsos 2001, Lyketsos et al. 2002, 
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Fauth and Gibbons 2014, Paddick et al. 2015, Zhao et al. 2016, Sousa et al. 2016). Whilst, 
the most problematic symptoms reported in Thailand were apathy, aberrant motor behaviour, 
irritability, sleep disorders and depression (Pinidbunjerdkool, Saengwanitch and 
Sithinamsuwan 2014, Charernboon and Phanasathit 2014, Taemeeyapradit, Udomittipong 
and Tepparak 2014). In addition, several studies suggested behavioural disturbances were 
significant problems in patients with dementia. These disturbances correlated to cognitive 
decline in patients with advanced stage and functional decline, leading to worse prognosis, 
increased caregiver distress, increased burden on caregivers, greater care costs, earlier 
institutionalization and decreased quality of life of both patients and their caregivers 
(Mangone et al. 1993, Lyketsos et al. 2000, Getsios et al. 2002, Allegri et al. 2006, Shaji et 
al. 2009, Mohamed et al. 2010, Pinidbunjerdkool, Saengwanitch and Sithinamsuwan 2014, 
Torrisi et al. 2016, Lanctot et al. 2017, Cheng 2017, Shikimoto et al. 2018).  
Due to the rapid growth of the number of people with dementia worldwide, care costs of 
these people, including people with BPSD are overwhelming, not only for the people who 
have it, but also for their families, their caregivers and healthcare systems (Canevelli et al 
2013). According to the Alzheimer’s Association (2015), there were nearly 15.7 million 
family caregivers in the US providing care for people with Alzheimer’s disease or other types 
of dementia. WHO reported the total societal cost of dementia was $604 billion globally in 
2010, consisting of direct medical costs, direct social costs, and costs of informal care; whilst 
a major part of these costs fell into the informal care (World Health Organisation 2012). In 
Sweden, the annual costs of patients with dementia, especially Alzheimer’s disease, were 
$23,400, $56,800 and $71,400 for mild, moderate and severe stages, respectively (Mesterton 
et al. 2010). In the Scandinavian, (Sweden, Denmark, Finland and Norway), Jonsson et al. 
(2006) showed that the costs for patients with dementia were 172,000 SEK per annum ($1 = 
8.09 SEK in 2003). Further, a range of costs per annual were 60,730 SEK to 374,962 SEK for 
mild to severe dementia. In addition, the costs of community care per annum were 26,662 
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SEK for other community care and 61, 222 SEK for special accommodation. Informal care 
costs were 6,338 SEK and 39,733 SEK per annual for lost production and lost leisure time, 
respectively. According to Ferretti et al. (2018), costs of patients with dementia per month in 
a cross-sectional study in Brazil, classified by the severity of disease, were $1,012.35 for 
mild, $1,683.18 for moderate and $1,372.20 for severe dementia. Ferretti, Nitrini and Brucki 
(2015) also reported the estimated monthly indirect costs of patients with dementia in Brazil, 
were $1,122, $1,508, and $1,644 for mild, moderate, and severe dementia, respectively. In 
Germany, a total cost of €38,165 per patient per annum was spent on informal care, which 
covered 81% of the societal costs for patients with mild and moderate dementia in a 
community setting (Schwarzkopf et al. 2011). Morris et al. (2015) reported that a patient 
diagnosed with Alzheimer’s disease and suffering from agitation in the UK had excess costs 
of more than £4,000 per annum which accounted for 12% of the health and social care costs. 
In Spain, the costs of informal care for patients with dementia were approximately €1,214 per 
month (Farre et al. 2016). A study by Akerborg et al. (2016) reported the average cost of 
patients who were diagnosed with dementia in Sweden was estimated to be €43,200 per year. 
Cognitive function, functional ability, and NPS were significant predictors affecting the total 
annual cost of those patients (Akerborg et al. 2016). The study by Ku, Pai and Shih (2016) 
described informal care costs being estimated at 42% and 43% of the total costs in patients 
with mild and severe dementia, respectively. Whilst the monthly cost of informal care in 
Thailand was in a range of THB 4,814-25,872 for a patient with Alzheimer’s disease 
(Turongkaravee 2008).  
As previously stated, the behavioural disturbances add substantially to people with the illness 
and to the burden on caregivers, therefore it is necessary to give attention to this problem to 
help tackle the difficulties they experience. Levy et al. (2012) suggested that a decrease in the 
caregiver burden was attributable to the management of BPSD.  Thus, the costs of care for 
patients with BPSD are a significant burden on household expenditures for patients 
 
 
250 
 
themselves and their caregivers since these symptoms relate to their quality of life and well-
being. These costs also have a great impact on policy makers in deciding and improving the 
distribution of resources properly for those patients. Consequently, the main objective of this 
chapter is to indicate the costs of patients with behavioural and psychological symptoms of 
dementia and being treated with atypical antipsychotics, (risperidone or olanzapine), in 
Thailand. 
 
5.2 Methods 
5.2.1 Target population 
Outpatients with BPSD at Thammasat University Hospital and Khon Kaen Rajanagarindra 
Psychiatric Hospital meeting the following criteria were recruited:  
• Aged 60 years and over (National Health Examination Survey in Thailand criteria, 
2008-2009)  
• Diagnosed with dementia (ICD-10: F00-F03) or Alzheimer’s disease (ICD-10: G30) 
according to the International Statistical Classification of diseases and related health 
problems, (ICD-10: 10th revision, fifth edition, 2016), (World Health Organization 
2015) and receiving olanzapine or risperidone for the treatment BPSD for at least the 
last two months, (during December 2016 to January 2017 and August 2017 to 
September 2017), before the interview.    
In cases where patients with dementia had difficulties in their decision making due to 
cognitive impairment or patients having difficulties and were unable to answer the cost 
questionnaire by themselves, caregivers were then approached and encouraged to 
participate as being the respondents to the survey on behalf of all those patients. 
However, the caregivers had to meet the following defined criteria to be included in the 
study which included: 
 
 
251 
 
• Primary caregivers who lived with the patients; or  
• Caregivers who visited to provide patient care for at least eight hours per day and had 
to provide the care for a minimum of three days per week for at least the last two 
months before the interview. 
For more information regarding the inclusion and exclusion criteria of the patients and 
respondents see Chapter 3 (section 3.4.4).  
5.2.2 Data settings and data collection process 
A cross-sectional study and face-to-face interviews were undertaken in the outpatient 
departments at these hospitals: Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital in Thailand in 2017 during February to March 2017 and 
October to November 2017.  
As previously mentioned in Chapter 3 (section 3.4.4), patients and/or their caregivers, who 
met the criteria and had received the information sheet were asked to decide whether to 
participate in the study. Consent forms were then administered to those who had agreed and a 
signed consent form was needed before beginning the interview. The interview process took 
approximately 30-45 minutes to collect sociodemographic factors of the patients, information 
about the caregivers, clinical status of patients, impact of caregiving on physical and mental 
health, and costs related to the treatment of BPSD.  
The data gathering process in all patients with dementia and/or their caregivers who 
consented to participate in this thesis was divided into two phases as follows:  
5.2.2.1 Phase I: The initial data collection was conducted between February and 
March 2017 focusing on Thammasat University Hospital. Based on this phase, a total of 49 
cases were included in the study. There were 31 cases of risperidone-treated patients in one 
group and 18 cases of the olanzapine-treated patients in another group. However, in this 
thesis, the targeted subjects were calculated to be at least 36 patients per group as mentioned 
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in Chapter 3 (section 3.4.2). Consequently, the number of patients in the study needed to be 
increased in each group for the following reasons: 
a) To have enough subgroups (in each arm) in the suggested models; 
b) To allow the development of an appropriate model and have precise 
outcomes; 
c) To provide population characteristics in a precise way; and 
d) To identify transition probabilities, risk factors and developing predictions 
accurately. 
5.2.2.2 Phase II: The additional data collection was undertaken between October and 
November 2017. The data settings in this phase were at Thammasat University Hospital and 
Khon Kaen Rajanagarindra Psychiatric Hospital. From this phase, a further 23 cases of 
patients using olanzapine treatment and a further 10 cases of risperidone treatment were 
included in this stage.  
Based on the data as stated above, a total of 82 patients and/or caregivers were the 
respondents from the data collections in Phase I and Phase II from the two hospitals. These 
were evenly divided into 41 patients of each group. The respondents consisted of 33 cases 
from Thammasat University Hospital and 8 cases from Khon Kaen Rajanagarindra 
Psychiatric Hospital for both drug-treated groups. Flowchart 5.1A-5.1C show the flow 
diagram of the data collection process.  
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Flowchart 5.1A-5.1C: Flow diagram of data collection from Thammasat University 
Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital in Thailand 
 
                      73 patients with dementia or Alzheimer’s disease aged ≥ 60 years and being on  
the two selected drugs, were analysed during the study period 
 
                                                                                                                             Investigated for exclusion criteria                 21 were excluded 
                                                               
                                                                                                                       52 patients were eligible for the study 
             3 missed the interview appointment date 
                                                               Patients for current study (n = 49) 
 
                     Risperidone group (n = 31)    Olanzapine group (n = 18) 
      
 
Flowchart 5.1A: Phase I- The data collection conducting between February and March 
2017 
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                             44 patients with dementia or Alzheimer’s disease aged ≥ 60 years and  
being on the two selected drugs, were analysed during the study period 
 
                                                             Investigated for exclusion criteria 
                                                                                                                                  4 were excluded 
                                                          40 patients were eligible for the study 
        2 missed an appointment date 
        5 lost to follow-up with doctors 
                                                             Patients for current study (n = 33) 
 
                               Risperidone group (n = 10)         Olanzapine group (n = 23) 
 
Flowchart 5.1B: Phase II- The additional data collection conducted between October 
and November 2017 
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                                 117 patients with dementia or Alzheimer’s disease aged ≥ 60 years and  
being on the two selected drugs were analysed during the study period 
 
                                                         Investigated for exclusion criteria 
                       25 were excluded 
                                                       92 patients were eligible for the study 
                          5 missed the appointment date 
                         5 lost to follow-up with doctors 
                                                                Patients for current study (n = 82) 
                                               
                             Risperidone group (n = 41)                Olanzapine group (n = 41) 
 
Flowchart 5.1C: An overall view of the data collection process of this study 
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5.2.3 Cost evaluation and analysis 
5.2.3.1 Sociodemographic characteristics of patients and caregivers 
Sociodemographic characteristics of patients were extracted, including gender, age, marital 
status, religion, education, current occupation, previous occupation, income, geographical 
area, residence, living arrangements, status of living, and health insurance coverage, were 
collected using a questionnaire. Regarding caregiver characteristics, these were collected 
using the same approach to that of patients. Thus, data included gender, age, marital status, 
religion, education, current occupation, previous occupation, patients’ relationship, duration 
of providing care, caregiving time per day, the status of caregivers’ living, and health 
problems due to providing care to those patients (see Appendix 4).  
5.2.3.2 Classification of costs 
Costs of patients with BPSD and receiving atypical antipsychotics (olanzapine or 
risperidone) were classified into two domains: patients’ cognitive function and patients’ 
dependence. 
5.2.3.2.1 Patients’ cognitive function 
Cognitive function was assessed using the Thai Mental State Examination (TMSE). Due to 
the TMSE being developed based on the Mini-Mental State Examination (MMSE) (Folstein, 
Folstein and McHugh 1975), the cognitive severity was then classified as follows: mild 
(TMSE 21-26), moderate (TMSE 10-20), and severe stages (TMSE <10), respectively 
(Perneczky et al. 2006, Bond et al. 2012).   
5.2.3.2.2 Classification by patients’ dependence 
The dependence of patients was assessed by activities of daily living (ADL) using the Barthel 
Index-Thai version. In the study, the scores were defined according to the Prasat 
Neurological Institute in Thailand (2014): 0-4 points = a total dependence, 5-8 points = a 
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severe dependence, 9-11 points = a moderate dependence and more than 12 points = a mild 
dependence (Prasat Neurological Institute 2014).  
Caro et al. (2001) suggested health states were classified into pre-full time care (Pre-FTC) 
and full-time care (FTC). FTC was defined as a patient’s dependency status when care 
provision or supervision was required for the greater part of each of the patient’s day, 
regardless of the location of care.  
To classify the patient’s dependence into Pre-FTC and FTC states, this thesis used the ADL 
together with the physicians’ assessments, based on the following scores: 0-8 points = the 
FTC state and more than 8 points = the Pre-FTC state. 
5.2.3.3 Types of cost estimations  
To estimate the costs of patients with BPSD and being treated with atypical antipsychotics 
from a societal perspective, cost definitions in this study were in line with the suggestions by 
Kobelt (2002) and the guideline of the health intervention and technology assessment in 
Thailand (The Health Intervention and Technology Assessment Program 2014).  
The direct costs were then categorised into direct medical costs and direct non-medical costs. 
The indirect costs associated with the loss of productivity were excluded because all patients 
aged 60 years and above were retirees and therefore there were no productivity costs to 
assess. Furthermore, patients with BPSD were expected to consume different levels of costs 
during the course of treatment. The costs were then classified as follows: 
5.2.3.3.1 Evaluation of direct medical costs  
The costs included in the analyses were those associated with the medication, (risperidone or 
olanzapine), for the treatment of BPSD, additional care costs due to outpatient visits, 
additional care costs due to hospitalisation, costs for treating drug-induced adverse events or 
side effect-related costs, relapse-related costs, and costs for treating comorbidities or 
comorbidity-associated costs. The multiplication of the quantified utilisation of types of care 
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by cost for each type was used to estimate direct medical costs. In addition, a unit cost 
referring to an average charge for health care services, including the outpatient department 
and the inpatient department, was derived from both hospitals as mentioned above. The 
details of the direct medical costs are outlined below:  
5.2.3.3.1.1 Medications for the treatment BPSD  
The medications were based on a daily treatment cost of risperidone (0.25-2 mg daily) and 
olanzapine (2.5-5 mg daily), considering the average dosage regimen from several studies 
(Schneider et al. 2006, Scottish Intercollegiate Guidelines Network 2006, the American 
Geriatrics Society 2011, Sittironnarit 2011, Azermai et al. 2012, Sadowsky and Galvin 2012, 
British Columbia 2012). For each patient, the mean medical cost per month was calculated by 
the multiplication of the drug price, (risperidone or olanzapine), and the total quantity used 
during a one month period. The drug price was obtained from the Drug and Medical Supplies 
Information Centre (DMSIC), which was supplied by the Ministry of Public Health in 
Thailand, (Ministry of Public Health in Thailand 2017). To estimate the mean total 
medication cost of each drug per month, the calculation was the sum of the total monthly 
costs of drug used divided by the total number of patients receiving such drugs.  
5.2.3.3.1.2 Costs associated with outpatient visits and hospital admissions 
The frequency of outpatient visits and length of stay at the hospital (LoS) related to dementia 
per month were quantified. Estimating the monthly cost of outpatient visits of each patient 
was calculated by multiplying the frequency of visits to the outpatient department per month 
and the unit cost of the outpatient for each hospital. The unit costs of Thammasat University 
Hospital were THB 2,737.29 as reported in 2012, (THB 2,874.15 as adjusted to 2017 values), 
for the internal medicine clinic and THB 6,761.20, (THB 7,099.26 as adjusted to 2017 
values), for the psychiatric clinic, respectively (Lapsuwansakul and Kunkum 2012). A unit 
cost of the outpatient clinic of Khon Kaen Rajanagarindra Psychiatric Hospital was 
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approximately THB 478 as reported in 2005, (THB 563 as adjusted to 2017 values), 
(Tangseree et al. 2005).  
For costs of hospital admissions, the monthly hospitalised cost per patient was calculated by 
multiplying the frequency of hospital admissions, length of stay (LoS) and the unit cost of 
inpatients. The cost of an overnight hospital stay per diem was obtained from the data of each 
hospital, accounting for THB 13,292.26 as reported in 2012, (THB 13,956.87 as reported in 
2017 values) at Thammasat University Hospital, and THB 17,956.00 as reported in 2005 
(THB 21,134.21 as reported in 2017 values) at Khon Kaen Rajanagarindra Psychiatric 
Hospital, respectively (Tangseree et al. 2005, Lapsuwansakul and Kunkum 2012). However, 
the costs, especially unit costs of both hospitals, were calculated in different time periods. 
These costs then needed to be adjusted to a 2017 value using the consumer price index (CPI). 
The CPI is a common tool used as a measure of inflation. Whereby, the inflation is used as an 
indicator of the changes in prices which were paid by consumers for goods or services over a 
set period of time (Gray et al. 2012). For instance, the unit cost of Thammasat University 
Hospital was compiled in the fiscal year 2012, therefore this was adjusted to the present value 
in 2017, as all costs of the thesis were being reported in year 2017 in Thai currency (Baht, 1£ 
= THB 45). The costs were then inflated to reflect a 2017 value based on the CPI of Thailand, 
reported in the healthcare section (Bureau of Trade and Economic Indices of the Ministry of 
Commerce Thailand 2018). For the conversion to a present value, the equations were 
outlined below: 
PV = price*IAF 
 
                                or                      PV = Price* 
CPIpresent
CPIpast
 
where  PV was a present value  
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           IAF was an inflation adjustment factor (the CPI in a given year divided by the CPI in 
the baseline year) 
           CPI present was the Consumer Price Index of the present year  
           CPI past was the Consumer Price Index of the past year. 
5.2.3.3.1.3 Additional payments 
Costs, including additional costs from the patient healthcare insurance of both outpatient 
visits and hospital admissions and the dementia-associated comorbidity, were included. The 
frequencies of outpatient visits and length of stay at the hospital (LoS) per month were 
quantified for calculating the additional costs or self-pay patients due to non-covered services 
by their healthcare insurance coverage. These costs were counted by multiplying additional 
payments and the frequency of outpatient visits or hospitalised per month of each drug.  
In addition, the cost of dementia-associated comorbidities, such as gout, osteoarthritis, 
hypertension, diabetes mellitus, hyperlipidaemia and stroke, was calculated based on the 
current medication used to treat comorbid conditions of each patient per month.  
5.2.3.3.1.4 Costs for treating drug-induced adverse events 
The adverse events from using olanzapine and risperidone were considered to calculate the 
costs for treating these events from such drugs. Antipsychotics-associated serious adverse 
events reported from published studies were anticholinergic events, (such as falls and 
constipation), weight gain, and extrapyramidal symptoms (EPSs) (Schneider et al. 2006, 
Maher et al. 2011, Riggs 2013, Ma et al. 2014, Tampi et al. 2016). Maglione et al. (2011) and 
Riggs (2013), reported the incidence of weight gain due to atypical antipsychotic use in the 
elderly was less than younger patients; thereby drug-induced weight gain was excluded in 
this analysis. Consequently, adverse event-associated costs in the study focused only on falls, 
constipation and EPS and these were calculated as follows: 
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I. Falls: The costs of managing drug-associated falls were estimated by the 
multiplication of three variables: the percentage of falling in elderly due to olanzapine or 
risperidone use, fall-required treatment in the elderly, and the costs of treatment due to falls. 
According to the study by Deberdt et al. (2005), that investigated a comparison of olanzapine 
and risperidone for the treatment of patients with BPSD, a double-blind, flexible-dose 
treatment in 494 patients with dementia and having moderate to severe psychotic symptoms, 
followed-up for 10-week periods from 64 sites across the US, the risk of falling was 
estimated to be 11.3% for patients treated with olanzapine, 9.2% for patients treated with 
risperidone, compared to 6.4% of those treated with a placebo. However, data from that study 
was not adopted in this thesis because the risk of falls was calculated from fall-associated 
costs deriving from primary collected data in a Thai setting. In this thesis, the fall-required 
treatment and costs of treating due to falls were taken from data from previous literatures 
which was in line with a previous study of a cost-benefit analysis of alternative and 
antipsychotic drug use for dementia in the UK (NHS Institute for Innovation and 
Improvement 2011). Rubenstein (2002) reported the fall-required treatment in the elderly 
people was estimated at 7.5%. An average cost of treatment due to falls in the elderly was 
approximately £2,264 per year as reported in 2010 by NHS Institute for Innovation and 
Improvement (2011). Thus, the cost of treating falls in this analysis was calculated to a 
monthly cost and then adjusted to a 2017 value using the GDP inflator (National Statistics of 
HM Government 2018). Purchasing Power Parity (PPP) was used to adjust for Thai Baht 
(THB) based on the data from the World Bank (World Bank Organisation 2018).  
  II. Constipation: Constipation management was based on laxative use 
according to the study by Martin et al. (2003) who investigated the adverse events of oral 
risperidone and oral olanzapine in long-term care patients with BPSD. That study found the 
increased percent for laxative use accounted for 1.8% of patients treated with risperidone and 
10.2% for patients treated with olanzapine. According to the study by Pekmezaris et al. 
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(2002), it reported that the cost for the treatment of constipation was $2.11 per day. 
Additionally, 49% of treatments were fleet enema and milk of magnesia (MOM) from a total 
of 31 elderly patients with chronic constipation. Thus, this thesis assumed that the 
management of constipation focused only on the milk of magnesia owing to this being the 
only drug approved in the National List of Essential Medicines (NLEM) of Thailand. The 
dosage regimen of milk of magnesia (MOM) for constipation treatment in the elderly was 
assumed to be 15-30 mg per day up to twice daily (Gandell et al. 2013, Sethi 2012). This is 
consistent with the clinical practice guideline for treating constipation in Thailand 
(Kittinouvarat, 2009 and Thai Neurogastroenterology and Motility Society, 2018). 
Consequently, the estimated cost for treating drug-induced constipation per month was 
calculated by multiplying the increased per cent for laxative use due to patients treated with 
olanzapine or risperidone, the mean days of laxative administration, and the medication cost 
for the laxative drug. Furthermore, the medical cost was obtained from the DMSIC in 
Thailand (Ministry of Public Health in Thailand 2018).  
  III. Extrapyramidal symptoms (EPSs): Costs for managing drug-induced EPS 
events were computed by multiplying the incidence of the treatment-emergent EPSs of each 
drug by costs of emergency room visits. According to a comparison of olanzapine to 
risperidone in the treatment of BPSD patients by Deberdt et al. (2005), this showed that the 
incidence of treatment-emergency EPSs was 49.6% for risperidone-treated patients, 35.6% 
for olanzapine-treated patients, and 29.5% for the placebo group. However, the incidence of 
drug-induced EPSs in this thesis’s analysis was based on primary collected data in a Thai 
setting. As the Canadian Psychiatric Association (2005) suggested, drug-induced EPS events 
tended to be managed by a physician’s visit either for reducing drug dosage or switching to 
other medications. This is similar to the clinical practice guideline of dementia in Thailand 
for management the adverse events of patients (Prasat Neurological Institute in Thailand 
2014). Thus, one extra physician visit per year was assumed in calculating the costs for 
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management of EPSs. In addition, this thesis assumed that the treatment-emergent EPSs 
would occur at the emergency service point. The unit cost of the emergency department from 
Thammasat University Hospital, adjusted to a 2017 value, was used to calculate this cost 
(Lapsuwansakul and Kunkum 2012).  
5.2.3.3.1.5 Costs of drug-associated relapse  
A frequency of behavioural and psychological symptoms in patients with dementia was more 
likely to increase mortality and morbidity in these patients (Peters et al. 2015). The treatment 
of patients with those symptoms should be concerned over the potential response to drugs. 
The consequence of the failure of the treatment was serious, leading to a greater risk of 
relapse of those patients. As a result, the relapse risks were taken into account to compute the 
cost analyses in this thesis. Although several guidelines recommended the short-term use of 
antipsychotic drugs to treat patients with BPSD, the management of these symptoms, 
including agitation, aggression, and psychosis, showed benefits in the long-term treatment, 
for those patients who had more severe BPSD or persistent symptoms according to the 
systematic review by Leeuwen E et al. (2018) and a retrospective, population-based cohort 
study in Ontario, Canada between 2009 and 2012 by Mast et al. (2016). For this reason, the 
relapses due to using olanzapine or risperidone were included in the cost analyses. The 
relapse-associated costs of patients were classified into those requiring hospitalisation and 
not requiring hospitalisation.  
  I. The relapse-associated costs requiring hospitalisation: To estimate relapse-
associated costs, these were calculated by multiplying the relapse rate of each drug, 
(hospitalisation rates associated with atypical antipsychotic adherence and hospitalisation risk 
ratios), the length of stay spent in hospital due to such relapses, relapse frequency and costs 
of admission.  
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The study by Schneider et al. (2006), a large double-blind, placebo-controlled trial in 421 
outpatients with Alzheimer’s disease with psychosis, aggression or agitation to compare 
effectiveness of risperidone, olanzapine, quetiapine and placebo in the US, suggested the 
number of patients discontinuing the treatment because of the lack of efficacy was found to 
be 39% of Alzheimer’s patients treated with olanzapine, 44% of Alzheimer’s patients treated 
with risperidone, and 70% of those Alzheimer’s patients using a placebo. However, 
antipsychotics are currently off-label use in dementia, leading to a lack of information with 
regard to the relapse risks of these patients. Thus, the relapse rates and lengths of stay at the 
hospital due to relapses adopted data from a schizophrenia study.  
For the treatment with atypical antipsychotics, adherence to the treatment was a significant 
factor, leading to increased hospital admissions and poor conditions of patients regarding the 
relapse of these patients (Haddad, Brain and Scott 2014). Thus, this thesis made the 
assumption that all patients were fully adherent to their treatments. For the annual rate of 
admission associated with patients with atypical antipsychotic being fully adherent to their 
treatment, data in this analysis were derived from the previous study of adherence to 
treatment with antipsychotic drugs for schizophrenia. Gilmer et al. (2004), who conducted 
data from 2,801 person-years of Medicaid Beneficiaries with schizophrenia during 1998 and 
2000 in San Diego County, USA, reported that the annual rate of admission associated with 
patients’ fully adherent to atypical antipsychotic treatment was estimated at 7.0%.  
In addition, data of the hospitalisation risk ratios were taken from the literature for 
effectiveness of antipsychotic drugs for patients with chronic schizophrenia. According to 
Lieberman et al. (2005), the large randomised, double-blind study in a total 1,493 patients 
with schizophrenia who were assigned to receive olanzapine, risperidone, perphenazine, 
quetiapine and ziprasidone conducted in 57 sites in the US or Clinical Antipsychotic Trials of 
Intervention Effectiveness study, (CATIE): Phase 1, the hospitalisation risk ratios of the two 
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medications of interest were 0.29-fold of olanzapine-treated patients and 0.45-fold of 
risperidone-treated patients, respectively. Thus, the relapse rates requiring hospitalisation of 
patients due to olanzapine or risperidone treatment in this thesis were 2% of olanzapine and 
3.2% of risperidone based on the multiplication of the adherence to treatment of patients and 
hospitalisation risk ratio of the drugs. This is in line with the cost-effectiveness study of oral 
olanzapine and other oral atypical antipsychotics in the treatment of patients with 
schizophrenia in the US (Furiak, et al. 2009).  
Moreover, the mean number of days spent in hospital per year used in this thesis obtained 
data from previous literature of olanzapine and risperidone use on the risk of psychiatric 
hospitalization of patients with schizophrenia in the US. Ascher-Svanum et al. (2004) 
reported the mean number of days spent in hospital per year was 9.9 days for patients 
receiving olanzapine and 14.5 days for patients receiving risperidone. Then these values were 
applied in calculating the mean number of days spent in hospital per year in this thesis. This 
is also in line with a cost analysis in a comparison of olanzapine, risperidone, quetiapine, 
ziprasidone and haloperidol, of the treatment of patients with schizophrenia in Thailand 
Kongsakorn et al. (2005).   
According to Kongsakorn et al. (2005), it was suggested patients with schizophrenia were 
assumed to have only one relapse per patient per year due to antipsychotic drug use for their 
treatment. This thesis used the same assumption regarding the number of relapses per patients 
per year as in Kongsakorn’s study.  
Furthermore, costs associated with hospital admission were obtained from data from 
Thammasat University Hospital, adjusted to 2017 values (Lapsuwansakul and Kunkum, 
2012).  
  II. The relapse-associated costs not requiring hospitalisation:  The proportion 
of inpatient-to-outpatient rates of relapse and physician’s visits were taken into account in the 
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calculation of relapse-associated costs not requiring hospitalisation. The assumption of the 
relapses requiring hospitalisation whether all patients were fully adherent with their 
treatments was also adopted for the relapses not requiring hospitalisation.  
According to Furiak et al. (2009), the cost-effectiveness study of olanzapine and other oral 
atypical antipsychotics for treating schizophrenia in the US, assumed that the proportion of 
relapse rates of inpatient-to-outpatient was assumed to be 1.0 for patients who were fully 
adherent to their treatment. Similarly, the study by Edwards et al. (2005) reported relapse 
rates for requiring hospital to not requiring hospital were 1.0 in patients with full adherence 
to their treatment. Therefore, this thesis has taken that value for calculating the proportion of 
inpatient-to-outpatient rates of relapse of patients using olanzapine or risperidone treatment. 
Subsequently, the relapse rates not requiring hospitalisation in this analysis were 2.0% and 
3.2% of olanzapine and risperidone, respectively, based on multiplying the relapse rates 
requiring hospitalisation of patients due to olanzapine or risperidone treatment and the 
proportion of inpatient-to-outpatient rates of relapse.  
Based on the clinical practice in Thailand, the management of patient’s relapses not requiring 
hospitalisation depended upon the physician’s visits for making a decision regarding the 
patient’s treatment. Thus, this thesis assumed that patients with BPSD and being treated with 
olanzapine or risperidone would require one extra physician’s visit per year according to the 
assumption of the schizophrenia study in Thailand, where patients with schizophrenia and 
treated with antipsychotics had one relapse per patient per year (Kongsakorn et al. 2005). 
Further, the cost for the physicians’ visit at a psychiatric department was obtained from 
Thammasat University Hospital, adjusted to 2017 values (Lapsuwansakul and Kunkum 
2012).  
Due to a lack of data associated with adverse events and relapses which were categorised 
according to the disease severity, (mild, moderate and severe stages), and patients’ 
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dependency, (Pre-FTC and FTC), of olanzapine and risperidone in the treatment of dementia, 
this thesis made the assumption that costs for treating adverse effects and costs for relapses 
due to olanzapine and risperidone treatments had the same values amongst patients with mild, 
moderate and severe stages and between those patients in the Pre-FTC and FTC stages.  
5.2.3.3.2 Evaluation of direct non-medical costs 
By estimating the direct non-medical costs, these covered patients’ out-of-pocket expenses, 
travel, additional food, accommodation, paid caregivers, and informal care. 
5.2.3.3.2.1 Costs of travel, accommodation and food 
These costs were quantified by multiplying the patients’ expenses for travel, accommodation 
and extra food, and the frequency of hospital visits of both outpatient visits and hospital 
admissions. 
5.2.3.3.2.2 Costs of other treatments 
Other treatments, namely vitamins, food supplements, milk, liquid diet, equipment for 
patients with dementia and disposable diapers, were also included for the cost analyses.  
In addition, caregiving time-associated costs in this thesis were classified into paid caregiver 
time and unpaid caregiver time, following the study by Clipp and Moore (1995). 
5.2.3.3.2.3 Costs of paid caregiving  
These costs were associated with out-of-pocket expenses for the hiring of caregivers or home 
helpers whose time was solely for providing care to patients.  
5.2.3.3.2.4 Costs of informal care or unpaid caregiving 
An opportunity cost method was used to estimate the value of unpaid caregiving for 
providing care to patients, based on the principle on whether the time spent in providing care 
could be earned as same as paid workers, using market wage rates (Berg, Brouwer and 
Koopmanschap 2004). Accordingly, costs of informal care were calculated using time spent 
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in patients’ care per day multiplied by the wage per hour. The respondents were asked to 
estimate the number of hours spent in care provision for patients per day. However, the 
number of hours counted toward caring for patients was maximised to 16 hours a day, 
excluding sleeping time. The hourly wage was calculated by the average Gross National 
Income (GNI) per capita per year, divided by working hours, at 52 weeks a year and 48 hours 
a week (Department of Labour Protection and Welfare 2018, The Health Intervention and 
Technology Assessment Program 2014). The GNI was used in this analysis as following the 
recommendation by the HITAP guideline in Thailand and the World Health Organisation 
(The Department of Immunization, Vaccines and Biologicals 2008, The Health Intervention 
and Technology Assessment Program 2014). The GNI per capita in Thailand was reported at 
THB 205,339.00 per year, based on data from the National Economic and Social 
Development Board, the Government of Thailand (Office of the National Economic and 
Social Development Board 2018). 
5.2.4 Data analyses  
Data on patients’ and caregivers’ sociodemographic and health characteristics, clinical 
assessments of patients, direct medical costs and direct non-medical costs due to dementia, 
were analysed by descriptive statistics, categorised according to the classification of patients, 
including cognitive function and dependence. The analysis produced the results in percent, 
mean and standard deviation which had been performed using Microsoft® Excel version 
2013. 
 
5.3 Results 
5.3.1 Patient and caregiver characteristics  
A total of 82 patients and/or patients’ caregivers from the outpatient departments of the two 
hospitals in Thailand were interviewed, with 41 patients receiving risperidone, and the 
remaining patients receiving olanzapine. Regarding the completed questionnaires, the section 
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on the characteristics of patients was completed by the primary caregivers, as proxy 
respondents, accounting for 97.56%, while the remaining percentage relates to one patient 
receiving risperidone with mild dementia and another one receiving olanzapine with mild 
dementia who completed the questionnaire in this section by themselves (2.44%). The section 
of cost data was completed by caregivers (98.78%) and one patient receiving olanzapine with 
mild dementia (1.22%). For the section of characteristics of caregivers, a total of 81 
caregivers had completed by themselves (100%), however one patient receiving olanzapine 
with mild dementia had no caregiver for providing care.   
5.3.1.1 Overall patient characteristics  
Table 5.1 shows the patient characteristics. Patients receiving risperidone were 
predominantly female gender (65.85%) and a mean age of 80.37 (± 1.28) years. For the 
olanzapine treated group, 73.17% of these patients were of the female gender with a mean 
age of 76.34 (± 1.41) years.  
The largest proportion of the patients’ educational level was primary school accounting for 
65.85% of the risperidone treated group and 58.54% of the olanzapine treated group.  
All patients in both treatment groups were retired. The main sources of income of both 
groups were supported by public funds and their children. Most patients receiving risperidone 
lived in the Bangkok metropolitan areas (56.10%), such as Pathum Thani and Nonthaburi. 
Conversely, a total of 56.10% of the olanzapine treated group lived in provincial areas, 
namely Phra Nakhon Si Ayutthaya, Khon Kaen and Maha Sarakham.  
None of the patients in both drug groups lived alone. As the risperidone treated group 
illustrated, most patients were living with their children (85.37%), followed by living with 
their spouse (31.71%). Similarly, the patients receiving olanzapine were 70.73% living with 
their children and 43.90% with their spouse. Most patients were diagnosed Alzheimer’s 
disease accounting for 87.8% of risperidone treated patients and 85.37% of olanzapine 
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treated patients. The diagnosis of unspecified dementia was 9.76% of the risperidone group, 
whilst it was found to be 12.2% in the olanzapine group. Mixed dementia had the lowest 
percentage of diagnosis in those patients accounting for 2.44% of both risperidone and 
olanzapine treated groups.   
The meantime of patients diagnosed with dementia was lower in the risperidone treated 
patients (2.34 years) compared with the olanzapine treated patients (2.63 years). Mean TMSE 
score was also lower in the risperidone treated group than the olanzapine treated group 14.2 
(±1.21) for the risperidone and 16.37 (± 1.17) for the olanzapine. These indicated that most 
patients of both treatment groups were suffering from moderate dementia.  
Main comorbidity conditions of patients of both treatment groups were hypertension, 
(56.10% of olanzapine treated patients and 51.22% of risperidone treated patients), followed 
by hyperlipidaemia, (34.15% of olanzapine treated patients and 24.39% of risperidone treated 
patients), and diabetes mellitus, (19.51% of olanzapine treated patients and 29.27% of 
risperidone treated patients). The percentage of patients with osteoarthritis in the risperidone 
treated group was nearly twice as high as the olanzapine treated group, accounting for 
14.63% and 7.32%, respectively. Other comorbidities, namely heart disease, liver disease, 
thyroid, arrhythmia, thalassemia, anaemia, pulmonary embolism, and gastrointestinal tract 
disease, showed a higher incidence in the olanzapine treated group than in the risperidone 
treated group, by 4.88%.  
The percentage of non-adverse events was 46.34% of risperidone treated patients and 19.51% 
of olanzapine treated patients. Sedation or drowsiness was the most frequent adverse event 
occurring in both treatment groups, accounting for 36.59% of the olanzapine group and 
31.71% of the risperidone group. Drug-induced EPSs, (dystonia, akathisia, and tardive 
dyskinesia), were found to be higher risks in the risperidone prescribed patients (19.50%) 
than those olanzapine prescribed patients (7.32%). The risk of falls in patients receiving 
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risperidone was twice as higher than in the olanzapine treated patients, accounting for 4.88% 
and 2.44%, respectively.  
The Civil Servants Medical Benefits Scheme (CSMBS) was the main health insurance 
coverage scheme of both drug groups. However, this was a lower percentage in the 
risperidone treated group (60.98%) compared with the olanzapine treated group (80.49%). 
Conversely, the Universal Coverage (UC) scheme had a higher proportion in the patients 
receiving risperidone accounted for almost 32% compared with only 4.88% in the olanzapine 
treated group. The out-of-pocket payments were predominantly in the olanzapine treated 
group compared with the risperidone group accounting for 14.63% and 7.32%, respectively.  
Table 5.1: Characteristics of patients from the data collection based on Thammasat 
University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital, in Thailand 
Characteristics Risperidone (N = 41) Olanzapine (N = 41) 
Patient   
Sex [n (%)]   
   Male  14 (34.15) 11 (26.83) 
   Female  27 (65.85) 30 (73.17) 
Age, year [mean (SD)] 80.37 (8.22) 76.34 (9.00) 
Marital status [n (%)]   
   Married  18 (43.90) 22 (53.66) 
   Widowed  21 (51.22) 18 (43.90) 
   Divorced/Separated  2 (4.88) 1 (2.44) 
Religion [n (%)]   
   Buddhism  41 (100.00) 39 (95.12) 
   Islam - 1 (2.44) 
   Christian - 1 (2.44) 
Education [n (%)]   
   Never attend school/lower primary education  6 (14.63) 2 (4.88) 
 
 
272 
 
Characteristics Risperidone (N = 41) Olanzapine (N = 41) 
   Primary education  27 (65.85) 24 (58.54) 
   Lower-secondary education 1 (2.44) 3 (7.32) 
   Upper-secondary education 1 (2.44) 4 (9.76) 
   Certificate/diploma 2 (4.88) 2 (4.88) 
   Bachelor’s degree 4 (9.76) 6 (14.63) 
Current occupation [n (%)]   
   Retired 41 (100.00) 41 (100.00) 
Income sources [n (%)]   
   Pension 7 (17.07) 8 (19.51) 
   Deposit/interest 1 (2.44) 1 (2.44) 
   Public fund 23 (56.10) 25 (60.98) 
   Spouse’s  - 6 (14.63) 
   Child’s  26 (63.41) 23 (56.10) 
   Other income 7 (17.07) 6 (14.63) 
Living area [n (%)]   
   Bangkok 3 (7.32) 6 (14.63) 
   Bangkok metropolitan 23 (56.10) 12 (29.27) 
   Countryside/Province 15 (36.59) 23 (56.10) 
Residence [n (%)]   
   Detached house 34 (82.93) 33 (80.49) 
   Townhouse, Town home 7 (17.07) 5 (12.20) 
   Shop house/Row house - 2 (4.88) 
   Other  - 1 (2.44) 
Living arrangement [n (%)]   
   House owner 16 (39.02) 20 (48.78) 
   Rental 1 (2.44) - 
   Resident 24 (58.54) 21 (51.22) 
Status of living [n (%)]   
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Characteristics Risperidone (N = 41) Olanzapine (N = 41) 
   Living with spouse  13 (31.71) 18 (43.90) 
   Living with child  35 (85.37) 29 (70.73) 
   Living with the third generation 5 (12.20) 15 (36.69) 
   Living with relatives 1 (2.44) 3 (7.32) 
   Others - 4 (9.76) 
Diagnosis [n (%)]   
Alzheimer’s disease 36 (87.80) 35 (85.37) 
Unspecified dementia 4 (9.76) 5 (12.20) 
Mixed dementia 1 (2.44) 1 (2.44) 
Time since diagnosed with dementia, year 
[mean (SD)] 
2.34 (1.71) 2.63 (1.82) 
Mean TMSE score [mean (SD)] 14.17 (7.75) 16.37 (7.46) 
Cognitive impairment [n (%)]   
   Mild  10 (24.39) 12 (29.27) 
   Moderate 15 (36.59) 19 (46.34) 
   Severe 16 (39.02) 10 (24.39) 
Non-comorbidity conditions [n (%)] 7 (17.07) 4 (9.76) 
Comorbidity conditions [n (%)]   
   Gout 2 (4.88) 2 (4.88) 
   Osteoarthritis 6 (14.63) 3 (7.32) 
   Asthma - 1 (2.44) 
   Chronic renal failure 1 (2.44) 2 (4.88) 
   Hypertension 21 (51.22) 23 (56.10) 
   Diabetes Mellitus  12 (29.27) 8 (19.51) 
   Hyperlipidaemia  10  (24.39) 14 (34.15) 
   Stroke 4 (9.76)  3 (7.32) 
   Cancer 2 (4.88) 1 (2.44) 
   Other comorbidities 8 (19.51) 10 (24.39) 
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Characteristics Risperidone (N = 41) Olanzapine (N = 41) 
Non adverse events [n (%)] 19 (46.34) 8 (19.51) 
Adverse events [n (%)]   
   Dystonia 4 (9.76) 2 (4.88) 
   Falls  2 (4.88) 1 (2.44) 
   Edema 3 (7.32) 3 (7.32) 
   Weight gained 1 (2.44) 9 (21.95) 
   Sedation/drowsiness 13 (31.71) 15 (36.59) 
   Other adverse events 6 (14.63) 1 (2.44) 
Health insurance coverage [n (%)]   
   Universal Healthcare scheme (UC) 13 (31.71) 2 (4.88) 
   Civil Servants Medical Benefits (CSMBS) 25 (60.98) 33 (80.49) 
   Out-of-pocket expense 3 (7.32) 6 (14.63) 
 
5.3.1.2 Overall Caregiver Characteristics 
As Table 5.2 shows, a total of 81 primary caregivers were investigated from 2 hospitals, with 
41 caregivers of patients receiving risperidone being the respondents and 40 caregivers of 
patients receiving olanzapine being the respondents. For the olanzapine group, there was one 
patient who had no caregiver in providing care to him.  
Regarding the caregiver characteristics, most caregivers were female, accounting for 75.61% 
of the risperidone group and 80.00% of the olanzapine group. The mean age of the caregivers 
showed no significant differences in accounting for 54.93 years in the risperidone group and 
53.03 years in the olanzapine group.  
The educational levels of caregivers of the risperidone group were 39.02% graduated with a 
bachelor’s degree, followed by 29.27% to primary education. Similarly, caregivers of the 
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olanzapine group were 32.5% achieving a bachelor’s degree level, followed by 27.50% 
achieving primary education level.  
For the current occupation, there were differences in both groups of caregivers. Caregivers of 
the risperidone group showed that 56.10% were unemployed. Conversely, 57.50% of 
caregivers of the olanzapine group were employed. However, the majority of caregivers were 
housewives, accounting for 41.46% of the risperidone treated group and 17.50% of the 
olanzapine treated group. It seems that almost 20% of caregivers in each group were the 
spouse, while at least 50% were daughters providing care to the patients in each group.  
In comparison to the olanzapine treatment, caregivers of the risperidone treated patients 
showed a significantly higher percentage of stopping work to provide care for the patients 
(20%). The mean duration time of stopping work to provide care to patients was 8.24 months 
in the risperidone group and 6.15 months in the olanzapine group. The mean time spent in 
patients’ care was not significantly different in both drug groups, accounting for 12.51 hours 
a day in the risperidone group and 12.87 hours a day to the olanzapine group.  
In addition, the impacts of the patient’s illness on caregivers due to patients’ care were 
classified into physical health conditions, (such as low back pain, knee pain, shoulder pain, 
muscle pain, and quality of sleep), and mental health problems, (such as distress, anxiety, 
stress, and depression). The physical health conditions in the risperidone group showed that 
nearly half of total caregivers had no problems due to providing care, accounting for 48.78%. 
Other physical health conditions in the risperidone group were found to be 7.32% with slight 
problem levels, 24.39% at moderate problem levels, 17.07% at severe problem levels and 
2.44% at extreme problem levels. Similarly, caregivers of the olanzapine group experiencing 
physical health conditions were associated with 52.50% having no problems, 15.00% having 
slight problems, 22.50% having moderate problems, and 10% having severe problems, but 
none were found in extreme problem levels. Regarding mental health problems, this found 
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that the percentage of no problems was similar to that of severe problems, accounting for 
29.27% in caregivers of the risperidone group. There were 10% of caregivers in the 
risperidone treated group having extreme problems. In caregivers of the olanzapine group, 
the highest proportion of mental health problems had similar percentages in both “no 
problems” and “slight problems” being 25%. There were approximately 10% of caregivers in 
the olanzapine treated group having extreme mental health problems. Furthermore, stress and 
sleep quality were significant impacts on caregivers in the risperidone treated group due to 
patients’ care, accounting for 68.29% and 53.66%, respectively. The remaining problems of 
caregivers in the risperidone treated group associated with caregiving were associated with 
musculoskeletal disorders (43.90%), distress (34.15%), depression (7.32%), and other health 
problems (2.44%). For caregiver in the olanzapine treated group, 65% of caregivers 
experienced stress and caregiver distress was found to be approximately 33.00%. The 
remaining problems of caregivers in the olanzapine treated group due to providing care were 
musculoskeletal disorders (30.00%), sleep quality (27.50%), depression (15.00%) and other 
health problems (7.50%).  
Table 5.2: Characteristics of caregivers from the data collection based on Thammasat 
University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital, in Thailand 
Characteristics Risperidone (N = 41) Olanzapine (N = 40) 
Caregiver   
Sex [n (%)]   
   Male  10 (24.39) 8 (20.00) 
   Female  31 (75.61) 32 (80.00) 
Age, year [mean (SD)] 54.93 (11.83) 53.03 (11.84) 
Marital status [n (%)]   
   Single 10 (24.39) 6 (15.00) 
   Married  27 (65.85) 30 (75.00) 
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Characteristics Risperidone (N = 41) Olanzapine (N = 40) 
   Widowed  1 (2.44) 4 (10.00) 
   Divorced/Separated  3 (7.32) - 
Religion [n (%)]   
   Buddhism  40 (97.56) 40 (100) 
   Islam - - 
   Christian 1 (2.44) - 
Education [n (%)]   
   Never attend school/lower primary     
   education  
- - 
   Primary education  12 (29.27) 11 (27.50) 
   Lower-secondary education 3 (7.32) 2 (5.00) 
   Upper-secondary education 3 (7.32) 10 (25.00) 
   Certificate/diploma 3 (7.32) - 
   Bachelor’s degree 16 (39.02) 13 (32.50) 
   Higher bachelor’s degree 4 (9.76) 4 (10.00) 
   Others -  
Current occupation [n (%)]   
   Unemployment 23 (56.10) 17 (42.50) 
   Employment 18 (43.90) 23 (57.50) 
Type of current occupation [n (%)]   
   Housewife/Househusband 17 (41.46) 7 (17.50) 
   Wage-earner 4 (9.76) 4 (10.00) 
   Farmer/Fisherman - 1 (2.50) 
   Self-employed/Owner 3 (7.32) 7 (17.50) 
   Government officer 3 (7.32) 6 (15.00) 
   State enterprise employee 1 (2.44) 2 (5.00) 
   Company employee 2 (4.88) 1 (2.50) 
   Retiree 7 (17.07) 9 (22.50) 
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Characteristics Risperidone (N = 41) Olanzapine (N = 40) 
   Others 4 (9.76) 3 (7.50) 
Previous occupation [n (%)]   
   Unemployment 24 (58.54) 26 (65.00) 
   Employment 17 (41.46) 14 (35.00) 
Stop work due to provide patient’s care 
[n (%)] 
8 (19.51) 5 (12.50) 
Duration of stopping work due to provide 
care, month [mean (SD)] 
8.24 (20.38) 6.15 (21.19) 
Relationship with patient [n (%)]   
   Spouse 8 (19.51) 8 (20.00) 
   Son 1 (2.44) 3 (7.50) 
   Daughter 25 (60.98) 20 (50.00) 
   Relatives/Cousin - 1 (2.50) 
   Niece/Nephew 1 (2.44) 1 (2.50) 
   Friend/Neighbour - - 
   Maid/Paid caregiver 3 (7.32) 6 (15.00) 
   Others 3 (7.32) 1 (2.50) 
Hours spent for caregiving patients 
[mean (SD)] 
12.51 (3.95) 12.87 (5.69) 
Physical problem [n (%)]   
   No problems 20 (48.78) 21 (52.50) 
   Slight problems 3 (7.32) 6 (15.00) 
   Moderate problems 10 (24.39) 9 (22.50) 
   Severe problems 7 (17.07) 4 (10.00) 
   Extreme problems 1 (2.44) - 
Mental problem [n (%)]   
   No problems 12 (29.27) 10 (25.00) 
   Slight problems 6 (14.63) 10 (25.00) 
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Characteristics Risperidone (N = 41) Olanzapine (N = 40) 
   Moderate problems 7 (17.07) 8 (20.00) 
   Severe problems 12 (29.27) 8 (20.00) 
   Extreme problems 4 (9.76) 4 (10.00) 
Overall health problems from providing 
care to patients [n (%)] 
  
   Depression 3 (7.32) 6 (15.00) 
   Stress 28 (68.29) 26 (65.00) 
   Distress 14 (34.15) 13 (32.50) 
   Quality of sleep 22 (53.66) 11 (27.50) 
   Musculoskeletal disorders 18 (43.90) 12 (30.00) 
   Others 1 (2.44) 3 (7.50) 
 
 
5.3.1.3 Patient and caregiver characteristics classified by cognitive function 
According to a classification of patients by cognitive function in this thesis, the disease 
severity was measured by TMSE scores which were categorised as follows: mild (TMSE=21-
26), moderate (TMSE=10-20), severe stages (TMSE<10). The profile of patients receiving 
risperidone were categorised according to severity being mild (24.39%), moderate (36.59%), 
and severe stages (39.02%) of the disease. The profile of patients receiving olanzapine were 
mild (29.27%), moderate (46.34%), and severe stages (24.39%).  
Table 5.3 shows that most risperidone treated patients were female, being 70%, 53.33%, and 
75% of those with mild, moderate and severe stages. Similarly, most patients treated with 
olanzapine were female accounting for 41.67%, 94.74%, and 70% of those with mild, 
moderate and severe stages, respectively.  
The range of mean ages of patients was 77.80-83.44 years for the risperidone treatment and 
73.58-78.94 years for the olanzapine treatment. The highest of the mean age of patients was 
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found in the risperidone group within the severe stage (83.44 years). Primary education was 
the predominant educational level in both treatment groups (61.68%). The highest percentage 
of educational levels of the risperidone treated patients showed 75.00% achieving a primary 
level of those within the severe stage. Similarly, achieving the primary level was the highest 
proportion of the educational level of the olanzapine treated patients within the severe stage 
(70.00%).  
The main source of income of the olanzapine treated patients within the severe stage was 
public funds (90%). In the risperidone treated group, the highest percentage of the source of 
income was from their children in the mild stage (80%).  
Patients living with their children were the highest percentage of all severity levels of both 
treatment groups, followed by those living with their spouse. All risperidone treated patients 
within the severe stage were living with their children. The highest percentage in the 
olanzapine group showed that 83.33% of patients within the mild stage of the disease lived 
with their children. In both the two treatment groups, none of the patients of all severity 
levels were living alone. 
Patients diagnosed with Alzheimer’s disease were the highest percentage within both 
treatment groups of which the risperidone treated patients were 36.59% within the severe 
stage, followed by 34.15% within moderate stage and 17.07% within mild stage. For the 
olanzapine group, patients diagnosed with Alzheimer’s disease accounted for 21.95% within 
the mild stage, 43.90% within the moderate stage and 19.52% within the severe stage.  The 
diagnosis regarding unspecified dementia was 7.31% with mild and 2.44%with moderate 
stages of the risperidone treated patients, whilst the olanzapine treated patients showed 7.32% 
within the mild stage, 2.44% within the moderate stage and 2.44% within the severe stage. 
Mixed dementia was found at only 2.44% in the severe stage of both risperidone and 
olanzapine treatments.   
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For patients treated with risperidone, time from the first diagnosis ranged between 2.06 – 
2.67 years with the longest time being found in cases at the moderate stage. In the olanzapine 
group, the range of time from the first diagnosis was 2.08-3.06 years and the longest time 
was found in patients within the moderate stage. Mean TMSE scores were 22.8 for the mild 
stage, 17.6 for the moderate stage, and 5.56 for the severe stage of the risperidone treated 
patients. Similarly, in the olanzapine group, there were 24.58 for mild, 16.78 for moderate 
and 5.7 for severe stages as measured by TMSE.  
The main comorbidity conditions were hypertension, hyperlipidaemia, and diabetes mellitus 
of all severity levels in both patient groups. In addition, hypertension was the highest 
percentage in the risperidone treated patients within the mild stage and in the olanzapine 
treated patients within the severe stage, accounting for 70%. Diabetes showed the highest 
percentage in patients within the moderate stage and receiving risperidone (33.33%). The 
dominance of hyperlipidaemia was shown in patients within a mild stage and being treated 
with olanzapine (41.67%). In the risperidone treatment group, stroke was found only in 
patients with a mild stage (26.67%). Whereas patients receiving olanzapine in the mild and 
moderate stages, incidences of having stroke were 16.67% and 5.26%, respectively.  
Most adverse events were sedation/drowsiness in both groups, with 50% of the risperidone 
treated patients within the severe stage and 42.11% of the olanzapine treated patients within 
the moderate stage. Extrapyramidal symptoms were found in 10% of mild, 13.33% of 
moderate, and 31.25% of severe stages in risperidone prescribed patients. There were also 
ESPs occurring in the olanzapine prescribed patients with 5.26% and 20% in moderate and 
severe stages, respectively. The highest percentage of drug-induced EPSs was found in the 
severe stage of both treatments. The incidence of falls was the highest risk at 13.33% of the 
moderate stage in patients receiving risperidone and 8.33% of the mild stage in the patients 
receiving olanzapine.  
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In terms of health insurance coverage, patients in the risperidone group within the moderate 
stage were covered by the UC scheme (53.33%), followed by patients within the mild stage 
(40.00%). Conversely, only two patients in the olanzapine group with mild and severe stages 
were covered under the UC scheme. The CSMBS was the greatest proportion of healthcare 
insurance schemes in both groups across all severity levels at 59.03% of the risperidone 
treatment group and 76.58% of the olanzapine treatment group. Most out-of-pocket expenses 
were in the olanzapine-treated patients with the severe stage (30.00%).  
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Table 5.3: Characteristics of patients from the data collection based on Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, in Thailand, classified by cognitive function 
Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
Patient [n (%)]    10  (24.39)    15    (36.59)      16  (39.02)      12    (29.27)     19   (46.34)   10  (24.39) 
Sex [n (%)]                         
   Male  3 (30.00) 7 (46.67) 4 (25.00) 7 (58.33) 1 (5.26) 3 (30.00) 
   Female  7 (70.00) 8 (53.33) 12 (75.00) 5 (41.67) 18 (94.74) 7 (70.00) 
Age, year [mean (SD)] 79.30 (6.34) 77.80 (9.68) 83.44 (7.14) 73.58 (8.85) 78.94 (8.57) 74.70 (9.48) 
Marital status [n (%)]              
   Married  2 (20.00) 9 (60.00) 7 (43.75) 11 (91.67) 7 (36.84) 4 (40.00) 
   Widowed  7 (70.00) 5 (33.33) 9 (56.25) 1 (8.33) 11 (57.89) 6 (60.00) 
   Divorced/Separated  1 (10.00) 1 (6.67) - - 1 (5.26) - 
Religion [n (%)]              
   Buddhism  10 (100.00) 15 (100.00) 16 (100.00) 12 (100.00) 18 (94.74) 9 (90.00) 
   Islam - - - - 1 (5.26) - 
   Christian  -  -  -  -  - 1 (10.00) 
Education [n (%)]              
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Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
   Never attend 
school/lower primary 
education  
1 (10.00) 3 (20.00) 2 (12.5) - 1 (5.26) 1 (10.00) 
   Primary education  7 (70.00) 8 (53.33) 12 (75.00) 4 (33.33) 13 (68.42) 7 (70.00) 
   Lower-secondary 
education 
- 1 (6.67) - 1 (8.33) - 2 (20.00) 
   Upper-secondary 
education 
- 1 (6.67) - 3 (25.00) 1 (5.26) - 
   Certificate/diploma - 1 (6.67) 1 (6.25) 1 (8.33) 1 (5.26) - 
   Bachelor’s degree 2 (20.00) 1 (6.67) 1 (6.25) 3 (25.00) 3 (15.79) - 
Current occupation [n 
(%)] 
             
  Retired 10 (100.00) 15 (100.00) 16 (100.00) 12 (100.00) 19 (100.00) 10 (100.00) 
Income sources [n (%)]              
   Pension 1 (10.00) 3 (20.00) 3 (18.75) 5 (41.67) 3 (15.79) - 
   Deposit/interest - - 1 (6.25) 1 (8.33) - - 
   Public fund 7 (70.00) 8 (53.33) 8 (50.00) 5 (41.67) 11 (57.89) 9 (90.00) 
   Spouse’s  - - - 3 (25.00) 3 (15.79) - 
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Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
   Child’s  8 (80.00) 8 (53.33) 10 (62.50) 5 (41.67) 11 (57.89) 7 (70.00) 
   Other income 1 (10.00) 3 (20.00) 3 (18.75) 1 (8.33) 2 (10.53) 4 (40.00) 
Living area [n (%)]              
   Bangkok - 1 (6.67) 2 (12.50) 2 (16.67) 1 (5.26) 3 (30.00) 
   Bangkok 
metropolitan 
6 (60.00) 9 (60.00) 8 (50.00) 4 (33.33) 6 (31.58) 2 (20.00) 
   Countryside/ 
Province 
4 (40.00) 5 (33.33) 6 (37.50) 6 (50.00) 12 (63.16) 5 (50.00) 
Residence [n (%)]              
   Detached house 9 (90.00) 12 (80.00) 13 (81.25) 10 (83.33) 16 (84.21) 7 (70.00) 
   Townhouse, Town 
home 
1 (10.00) 3 (20.00) 3 (18.75) 1 (8.33) 3 (15.79) 1 (10.00) 
   Shop house/Row 
house 
- - - 1 (8.33) - 1 (10.00) 
   Other  - - - - - 1 (10.00) 
Living arrangement [n 
(%)] 
             
   House owner 2 (20.00) 7 (46.67) 7 (43.75) 5 (41.67) 11 (57.89) 4 (40.00) 
 
 
286 
 
Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
   Rental - - 1 (6.25) - - - 
   Resident 8 (80.00) 8 (53.33) 8 (50.00) 7 (58.33) 8 (42.11) 6 (60.00) 
Status of living [n (%)]              
   Living with spouse  1 (10.00) 9 (60.00) 3 (18.75) 9 (75.00) 6 (31.58) 3 (30.00) 
   Living with child  8 (80.00) 11 (73.33) 16 (100.00) 10 (83.33) 12 (63.16) 7 (70.00) 
   Living with the third 
generations 
1 (10.00) 1 (6.67) 3 (18.75) 5 (41.67) 7 (36.84) 3 (30.00) 
   Living with relatives 1 (10.00) - - - 1 (5.26) 2 (20.00) 
   Others - - - 1 (8.33) 2 (10.53) 1 (10.00) 
Diagnosis [n (%)]          
Alzheimer’s disease       7 (17.07)      14 (34.15)       15  (36.59) 9 (21.95) 18 (43.90) 8 (19.52) 
Unspecified dementia       3  (7.31)        1  (2.44)                         - 3 (7.32) 1 (2.44) 1 (2.44) 
Mixed dementia - -         1   (2.44)  - -  1 (2.44) 
Time since diagnosed 
with dementia, year 
[mean (SD)] 
2.29 (1.88) 2.67 (2.26) 2.06 (0.85) 2.08 (1.24) 3.06 (2.13) 2.50 (1.72) 
Mean TMSE score 
[mean (SD)] 
22.80 (1.04) 17.6 (2.75) 5.56 (3.48) 24.58 (1.66) 16.78 (2.66) 5.7 (3.64) 
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Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
Non-comorbidity 
conditions [n (%)] 
- 3 (20.00) 4 (25.00) 1 (8.33) 2 (10.53) 1 (10.00) 
Comorbidity conditions 
[n (%)] 
             
   Gout 2 (20.00) - - 1 (8.33) 1 (5.26) - 
   Osteoarthritis 2 (20.00) 1 (6.67) 3 (18.75) - 3 (15.79) - 
   Asthma - - - - 1 (5.26) - 
   Chronic renal failure - 1 (6.67) - 1 (8.33) - 1 (10.00) 
   Hypertension 7 (70.00) 6 (40.00) 8 (50.00) 7 (58.33) 9 (47.37) 7 (70.00) 
   Diabetes Mellitus  2 (20.00) 5 (33.33) 5 (31.25) 2 (16.67) 3 (15.79) 3 (30.00) 
   Hyperlipidaemia  3 (30.00) 3 (20.00) 4 (25.00) 5 (41.67) 7 (36.84) 2 (20.00) 
   Stroke - 4 (26.67) - 2 (16.67) 1 (5.26) - 
   Cancer 2 (20.00) - - - 1 (5.26) - 
   Other comorbidities 1 (10.00) 3 (20.00) 4 (25.00) 4 (33.33) 5 (26.32) 1 (10.00) 
Non adverse events [n 
(%)] 
5 (50.00) 7 (46.67) 7 (43.75) 2 (16.67) 3 (15.79) 3 (30.00) 
Adverse events [n (%)]              
   Dystonia - 2 (13.33) 2 (12.5)  - 1 (5.26) 1 (10.00) 
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Characteristics Risperidone (N=41) Olanzapine (N=41) 
  Mild Moderate Severe Mild Moderate Severe 
   Falls  - 2 (13.33) - 1 (8.33) - - 
   Edema - 1 (6.67) 2 (12.5) 3 (25.00) - - 
   Weight gained  1 (6.67) - 3 (25.00) 5 (26.32) 1 (10.00) 
   Sedation/ 
drowsiness 
1 (10.00) 4 (26.67) 8 (50.00) 4 (33.33) 8 (42.11) 3 (30.00) 
   Other adverse events 1 (10.00) 1 (6.67) 4 (25.00) - - 1 (10.00) 
Health insurance 
coverage [n (%)] 
             
   Universal Healthcare 
scheme (UC) 
4 (40.00) 8 (53.33) 1 (6.25) 1 (8.33) - 1 (10.00) 
   Civil Servants 
Medical Benefits 
scheme (CSMBS) 
5 (50.00) 5 (33.33) 15 (93.75) 9 (75.00) 18 (94.74) 6 (60.00) 
   Out-of-pocket 
expense 
1 (10.00) 2 (13.33) - 2 (16.67) 1 (5.26) 3 (30.00) 
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According to Table 5.4, caregivers of the risperidone treated patients accounted for 24.39% 
of mild, 36.59% of moderate, and 39.02% of severe stages. In the olanzapine treated patient 
group, the caregiver percentages were 27.50% of mild, 47.50% of moderate, and 25.00% of 
severe stages. The range of mean ages of caregivers was 50.5-58.67 years in the risperidone 
group and 47.8-54.82 years in the olanzapine group.  
A total of 43.75% caregivers of the risperidone treated patients within the severe stage had 
achieved bachelor’s degree level, followed by 40% achieving a primary education of those 
caregivers of patients in the moderate stage and 40% achieving bachelor’s degree of those 
caregivers of patients in the mild stage. A bachelor’s degree was the greatest educational 
level of caregivers in the olanzapine treatment group caring for patients in the moderate 
stage, associated with 42.11%, followed by 40% achieving upper-secondary education of 
those caregivers of patients in the severe stage.  
A total of 70% caregivers of the risperidone group of patients within the mild stage were 
unemployment and 25% of those caregivers of this group of patients within the severe stage 
were retired. In the olanzapine group, 45.45% of caregivers of patients within the mild stage 
were unemployed. It was also found that 27.27% of those caregivers of the olanzapine treated 
patients within the mild stage had retired.   
Caregivers of the risperidone group of patients within the severe stage showed that they 
stopped working to provide care at 10.25 months since last paid employment. Patients’ 
daughters were the main caregivers in all levels of disease severity of both drug groups, 
accounting for 70% of the risperidone group and 54.55% of the olanzapine group within the 
mild stage. Time spent in providing care to patients showed no significant differences across 
all disease severity levels of both drug treatment groups. Time spent in patients’ care was 
mostly found in the severe stage of both the risperidone and olanzapine groups.  
 
 
290 
 
For both treatments, the care of patients within the severe stage had a significant impact on 
both the physical and mental health of their caregivers. Stress was the main problem for 
caregivers due to patients’ care accounting for 81.25% and 80% of the severe and mild stages 
of the patients receiving risperidone and 73.68% and 70% of the moderate and severe stages 
in the olanzapine group.  
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Table 5.4: Characteristics of caregivers from the data collection based on Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, in Thailand, classified by cognitive function 
Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
Caregiver [n (%)]    10  (24.39)      15    (36.59)      16   (39.02)      11   (27.50)      19   (47.50) 10 (25.00) 
Sex [n (%)]                         
   Male  1 (10.00) 5 (33.33) 4 (25.00) 2 (18.18) 5 (26.32) 1 (10.00) 
   Female  9 (90.00) 10 (66.67) 12 (75.00) 9 (81.82) 14 (73.68) 9 (90.00) 
Age, year [mean (SD)] 56.40 (9.79) 58.67 (14.41) 50.50 (9.25) 54.82 (12.41) 54.73 (11.93) 47.80 (10.53) 
Marital status [n (%)]          
   Single 3 (30.00) 2 (13.33) 5 (31.25) 2 (18.18) 2 (10.53) 2 (20.00) 
   Married  6 (60.00) 10 (66.67) 11 (68.75) 9 (81.82) 15 (78.95) 6 (60.00) 
   Widowed  - 1 (6.67) - - 2 (10.53) 2 (20.00) 
   Divorced/Separated  1 (10.00) 2 (13.33) - - - - 
Religion [n (%)]              
   Buddhism  9 (90.00) 15 (100.00) 16 (100.00) 11 (100.00) 19 (100.00) 10 (100.00) 
   Islam - - - - - - 
   Christian 1 (10.00) - - - - - 
Education [n (%)]              
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Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
Never school - - - - - - 
   Primary education  3 (30.00) 6 (40.00) 3 (18.75) 3 (27.27) 5 (26.32) 3 (30.00) 
   Lower-secondary 
education 
2 (20.00) - 1 (6.25) - - 2 (20.00) 
   Upper-secondary 
education 
1 (10.00) 1 (6.67) 1 (6.25) 3 (27.27) 3 (15.79) 4 (40.00) 
   Certificate/diploma - 2 (13.33) 1 (6.25) - - - 
   Bachelor’s degree 4 (40.00) 5 (33.33) 7 (43.75) 4 (36.36) 8 (42.11) 1 (10.00) 
   Higher bachelor’s 
degree 
- 1 (6.67) 3 (18.75) 1 (9.09) 3 (15.79) - 
   Others - - - - - - 
Current occupation [n 
(%)] 
            
   Unemployment 7 (70.00) 9 (60.00) 7 (43.75) 5 (45.45) 8 (42.11) 4 (40.00) 
   Employment 3 (30.00) 6 (40.00) 9 (56.25) 6 (54.55) 11 (57.89) 6 (60.00) 
Type of current 
occupation [n (%)] 
             
   Housewife/ 5 (50.00) 9 (60.00) 3 (18.75) 2 (18.18) 2 (10.53) 3 (30.00) 
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Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
Househusband 
   Wage-earner 3 (30.00) 2 (13.33) - 1 (9.09) 3 (15.79) - 
   Farmer/Fisherman - - - 1 (9.09) - - 
   Self-employed/Owner - 1 (6.67) 2 (12.50) 2 (18.18) 1 (5.26) 4 (40.00) 
   Government officer - 1 (6.67) 2 (12.50) 2 (18.18) 4 (21.05) - 
   State enterprise 
employee 
- - 1 (6.25) - 2 (10.53)  - 
   Company employee - 1 (6.67) 1 (6.25) - 1 (5.26) - 
   Retiree 2 (20.00) 1 (6.67) 4 (25.00) 3 (27.27) 4 (21.05) 2 (20.00) 
   Others  - 1 (6.67) 3 (18.75)  - 2 (10.53) 1 (10.00) 
Previous occupation [n 
(%)] 
             
   Unemployment 5 (50.00) 9 (60.00) 10 (62.50) 6 (54.55) 13 (68.42) 7 (70.00) 
   Employment 5 (50.00) 6 (40.00) 6 (37.50) 5 (45.45) 6 (31.58) 3 (30.00) 
Stop work due to provide 
patient’s care [n (%)] 
1 (10.00) 3 (20.00) 4 (25.00) 1 (9.09) 2 (10.53) 2 (20.00) 
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Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
Duration of stopping work 
due to provide care, 
month [mean (SD)] 
7.20   (22.77) 6.80 (16.50) 10.25 (23.12) 5.45 (18.09) 2.05 (6.64) 15.30 (38.22) 
Relationship with patient 
[n (%)] 
             
   Spouse 1 (10.00) 7 (46.67) - 4 (36.36) 3 (15.79) 1 (10.00) 
   Son - 1 (6.67) - - 2 (10.53) 1 (10.00) 
   Daughter 7 (70.00) 7 (46.67) 11 (68.75) 6 (54.55) 9 (47.37) 5 (50.00) 
   Relatives/Cousin - - - - - 1 (10.00) 
   Niece/Nephew - - 1 (6.25) 1 (9.09) - - 
   Friend/Neighbour - - - - -  
   Maid/Paid caregiver - - 3 (18.75)  - 4 (21.05) 2 (20.00) 
   Others 2 (20.00) - 1 (6.25)  - 1 (5.26)  - 
Hours spent for 
caregiving patients [mean 
(SD)] 
11.40  (4.88) 12.20 (3.63) 13.50 (3.61) 11.33 (5.97) 13.37 (4.75) 13.80 (7.15) 
The physical problem [n 
(%)] 
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Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
   No problems 7 (70.00) 7 (46.67) 6 (37.50) 7 (63.64) 9 (47.37) 5 (50.00) 
   Slight problems - 1 (6.67) 2 (12.50) 2 (18.18) 3 (15.79) 1 (10.00) 
   Moderate problems 1 (10.00) 5 (33.33) 4 (25.00) 2 (18.18) 6 (31.58) 1 (10.00) 
   Severe problems 2 (20.00) 2 (13.33) 3 (18.75) - 1 (5.26) 3 (30.00) 
   Extreme problems - - 1 (6.25) - - - 
The mental problem [n 
(%)] 
             
   No problems 3 (30.00) 8 (53.33) 1 (6.25) 4 (36.36) 4 (21.05) 2 (20.00) 
   Slight problems 2 (20.00) 1 (6.67) 3 (18.75) 3 (27.27) 4 (21.05) 3 (30.00) 
   Moderate problems 1 (10.00) 2 (13.33) 4 (25.00) 2 (18.18) 4 (21.05) 2 (20.00) 
   Severe problems 4 (40.00) 2 (13.33) 6 (37.50) 2 (18.18) 5 (26.32) 1 (10.00) 
   Extreme problems - 2 (13.33) 2 (12.50) - 2 (10.53) 2 (20.00) 
Overall health problems 
from providing care to 
patients [n (%)] 
8 (80.00) 11 (73.33) 15 (93.75) 7 (63.64) 17 (89.47) 8 (80.00) 
   Depression - 2 (13.33) 1 (6.25) 2 (18.18) 2 (10.53) 2 (20.00) 
   Stress 8 (80.00) 7 (46.67) 13 (81.25) 5 (45.45) 14 (73.68) 7 (70.00) 
   Distress 2 (20.00) 5 (33.33) 7 (43.75) 2 (18.18) 7 (36.84) 4 (40.00) 
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Characteristics Risperidone (N=41) Olanzapine (N=40) 
  Mild Moderate Severe Mild Moderate Severe 
   Quality of sleep 4 (40.00) 7 (46.67) 11 (68.75) 2 (18.18) 6 (31.58) 3 (30.00) 
   Musculoskeletal 
disorders 
2 (20.00) 7 (46.67) 9 (56.25) 1 (9.09) 5 (26.32) 6 (60.00) 
   Others - - 1 (6.25) 2 (18.18) - 1 (10.00) 
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5.3.1.4 Patient and caregiver Characteristics classified by patients’ dependency 
The patients’ physical dependency was defined by a physician’s assessment along with the 
Activities of Daily Living (ADL) score as measured by the Barthel Index (Thai version). 
Scores were categorised as follows: total dependence (score=0-4), severe dependence (score 
=5-8), moderate dependence (score=9-11), and mild dependence (score ≥ 12) (Prasat 
Neurological Institute, 2014). To classify patients’ dependence into Pre-FTC and FTC states, 
the Pre-FTC state (not requiring full-time care) was a score of 9 and over and the FTC state 
(requiring full-time care) was a score of 0-8. The FTC state was defined as patients requiring 
a significant amount of care and supervision almost every day, regardless of the location of 
the care or who provided it.  
Table 5.5 shows patient characteristics by classifying patients with dependence status. The 
risperidone treated patients were 65.85% of the Pre-FTC state and 34.15% of the FTC state, 
whilst in the olanzapine treated patients there were 73.17% of the Pre-FTC state and 26.83% 
of the FTC state. Most patients were predominantly female in both dependence states of both 
treatment groups.  
The risperidone treated patients had a mean age at 82.93 years in the FTC state and 79.04 
years in the Pre-FTC state. In the olanzapine treatment, there were no differences in the mean 
age of the patients between the two dependence states, being 76.20 in the Pre-FTC state and 
76.23 years in the FTC state.  
Primary school was the greatest proportion of patient educational levels of both the Pre-FTC 
and the FTC states within each treatment group.  
All patients in both dependency states of both treatments were retired. The main sources of 
income were from public funds and the patients’ children in patients with the Pre-FTC and 
FTC states of both treatment groups. The highest percentage of income of those patients in 
each group was from their children, accounting for 64.29% of the Pre-FTC state of the 
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risperidone group and 72.73% of the FTC state of the olanzapine group. Most patients in both 
dependence states of both treatment groups were living with their children. 
For risperidone treatment, patients who were diagnosed with Alzheimer’s disease were 
56.10% in the Pre-FTC state and 31.71% in the FTC state. For the olanzapine group, patients 
diagnosed with Alzheimer’s disease accounted for 60.98% in the Pre-FTC state and 24.39% 
in the FTC state. Whilst the unspecified dementia was 9.76% of risperidone treated patients 
in the Pre-FTC state, 9.76% of olanzapine treated patients in the Pre-FTC and 2.44% of 
olanzapine treated patients in the FTC state. Mixed dementia was found at only 2.44% of 
both treatment groups in the FTC state of risperidone and the FTC state of olanzapine.   
Mean time since the first diagnosis of dementia was 2.52 years in the Pre-FTC patients using 
risperidone treatment which was longer than patients in the FTC state by 0.52 years. For 
patients using olanzapine treatment, the mean time from the first diagnosis of dementia was 
3.73 years in the FTC state which was longer than the Pre-FTC state by 1.49 years.  
Hypertension was the main comorbidity in both dependence states of both patient groups. 
Diabetes and hyperlipidaemia had higher proportions in the risperidone treated patients 
within the FTC state compared with the Pre-FTC state. For the olanzapine treated patients, 
diabetes mellitus showed a higher percentage in the FTC state than the Pre-FTC state while 
hyperlipidaemia was lower in the FTC state than the Pre-FTC state.  
For the adverse effects, most patients in the FTC state of the olanzapine group had weight 
gain and sedation/drowsiness (36.36%). In the risperidone treated patients it was found that 
37.04% in the Pre-FTC state presented sedation/drowsiness. The risk of EPSs also occurred 
in the risperidone treated patients being 14.81% and 28.57% of the Pre-FTC and the FTC 
states respectively. In the olanzapine group, the EPSs were only found in the FTC state 
(27.27%). The risk of falls was 7.41% of the Pre-FTC state of patients treated with 
risperidone and 3.33% of the Pre-FTC state of olanzapine treated patients.  
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Civil Servants Medical Benefits was the prominent healthcare insurance of both the Pre-FTC 
and the FTC states in patients of both drug groups. Importantly, both dependence states of the 
olanzapine treated patients had a greater portion of out-of-pocket expenses compared with 
risperidone treated patients.  
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Table 5.5: Characteristics of patients from the data collection based on Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, in Thailand, classified by dependence 
Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
Patient [n (%)]     27  (65.85)     14  (34.15) 30  (73.17)     11 (26.83) 
Sex [n (%)]                 
   Male  10 (37.04) 4 (28.57) 8 (26.67) 3 (27.27) 
   Female  17 (62.96) 10 (71.43) 22 (73.33) 8 (72.73) 
Age, year [mean (SD)] 79.04 (8.59) 82.93 (7.02) 76.20 (8.53) 76.23 (10.61) 
Marital status [n (%)]         
   Married  10 (37.04) 8 (57.14) 18 (60.00) 4 (36.36) 
   Widowed  16 (59.26) 5 (35.71) 11 (36.67) 7 (63.64) 
   Divorced/Separated  1 (3.70) 1 (7.14) 1 (3.33) - 
Religion [n (%)]         
   Buddhism  27 (100.00) 14 (100.00) 29 (96.67) 10 (90.91) 
   Islam - - 1 (3.33) - 
   Christian - - - 1 (9.09) 
Education [n (%)]         
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Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
   Never attend school/lower primary 
education  
3 (11.11) 3 (21.43) - 2 (18.18) 
   Primary education  18 (66.67) 9 (64.29) 17 (56.67) 7 (63.64) 
   Lower-secondary education 1 (3.70) - 2 (6.67) 1 (9.09) 
   Upper-secondary education - 1 (7.14) 3 (10.00) 1 (9.09) 
   Certificate/diploma 1 (3.70) 1 (7.14) 2 (6.67) - 
   Bachelor’s degree 4 (14.81) - 6 (20.00) - 
Current occupation [n (%)]         
   Retired 27 (100.00) 14 (100.00) 30 (100.00) 11 (100.00) 
Income sources [n (%)]         
   Pension 5 (18.52) 2 (14.29) 7 (23.33) 1 (9.09) 
   Deposit/interest 1 (3.70) - 1 (3.33) - 
   Public fund 15 (55.56) 8 (57.14) 19 (63.33) 7 (63.64) 
   Spouse’s  - - 4 (13.33) 3 (27.27) 
   Child’s  17 (62.96) 9 (64.29) 15 (50.00) 8 (72.73) 
   Other income 4 (14.81) 3 (21.43) 4 (13.33) 2 (18.18) 
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Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
Living area [n (%)]         
   Bangkok 1 (3.70) 2 (14.29) 4 (13.33) 2 (18.18) 
   Bangkok metropolitan 17 (62.96) 6 (42.86) 9 (30.00) 3 (27.27) 
   Countryside/Province 9 (33.33) 6 (42.86) 17 (56.67) 6 (54.55) 
Residence [n (%)]         
   Detached house 24 (88.89) 10 (71.43) 24 (80.00) 9 (81.82) 
   Townhouse, Town home 3 (11.11) 4 (28.57) 5 (16.67) - 
   Shop house/Row house - - 1 (3.33) 1 (9.09) 
   Other  - - - 1 (9.09) 
Living arrangement [n (%)]         
   House owner 7 (25.93) 9 (64.29) 17 (56.67) 3 (27.27) 
   Rental 1 (3.70) - - - 
   Resident 19 (70.37) 5 (35.71) 13 (43.33) 8 (72.73) 
Status of living [n (%)]         
   Living with spouse  7 (25.93) 6 (42.86) 14 (46.67) 4 (36.36) 
   Living with child  21 (77.78) 14 (100.00) 22 (73.33) 7 (63.64) 
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Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
   Living with the third generations 3 (11.11) 2 (14.29) 11 (36.67) 4 (36.36) 
   Living with relatives 1 (3.70) - 2 (6.67) 1 (9.09) 
   Others - - 2 (6.67) 2 (18.18) 
Diagnosis [n (%)]       
Alzheimer’s disease 23   (56.10) 13  (31.71) 25 (60.98) 10 (24.39) 
Unspecified dementia 4   (9.76) - 4 (9.76) 1 (2.44) 
Mixed dementia - 1     (2.44) 1 (2.44)  - 
Time since diagnosed with dementia, year 
[mean (SD)] 
2.52 (2.03) 2.00 (0.78) 2.24 (1.69) 3.73 (1.79) 
Mean TMSE score [mean (SD)] 17.19 (6.29) 8.36 (7.11) 17.6 (6.13) 13.00 (9.85) 
Non-comorbidity conditions [n (%)] 5 (18.52) 2 (14.29) 4 (13.33) - 
Comorbidity conditions [n (%)]         
   Gout 2 (7.41) - 1 (3.33) 1 (9.09) 
   Osteoarthritis 3 (11.11) 3 (21.43) 2 (6.67) 1 (9.09) 
   Asthma - - 1 (3.33) - 
   Chronic renal failure - 1 (7.14) 1 (3.33) 1 (9.09) 
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Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
   Hypertension 14 (51.85) 7 (50.00) 15 (50.00) 8 (72.73) 
   Diabetes Mellitus  6 (22.22) 6 (42.86) 5 (16.67) 3 (27.27) 
   Hyperlipidaemia  6 (22.22) 4 (28.57) 12 (40.00) 2 (18.18) 
   Stroke 2 (7.41) 2 (14.29) 2 (6.67) 1 (9.09) 
   Cancer 2 (7.41) - - 1 (9.09) 
   Other comorbidities 5 (18.52) 3 (21.43) 8 (26.67) 2 (18.18) 
Non adverse events [n (%)] 9 (33.33) 10 (71.43) 5 (16.67) 3 (27.27) 
Adverse events [n (%)]         
   Dystonia 2 (7.41) 2 (14.29) - 2 (18.18) 
   Falls  2 (7.41) - 1 (3.33) - 
   Edema 2 (7.41) 1 (7.14) 3 (10.00) - 
   Weight gained 1 (3.70) - 5 (16.67) 4 (36.36) 
   Sedation/drowsiness 10 (37.04) 3 (21.43) 11 (36.67) 4 (36.36) 
   Other adverse events 4 (14.81) 2 (14.29) - 1 (9.09) 
Health insurance coverage [n (%)]         
   Universal Healthcare scheme (UC) 9 (33.33) 4 (28.57) - 2 (18.18) 
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Characteristics Risperidone (41) Olanzapine (41) 
 Pre-FTC FTC Pre-FTC FTC 
   Civil Servants Medical Benefits scheme 
(CSMBS) 
15 (55.56) 10 (71.43) 26 (86.67) 7 (63.64) 
   Out-of-pocket expense 3 (11.11) - 4 (13.33) 2 (18.18) 
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Table 5.6 shows the caregiver characteristics based on a classification of patients by 
dependence. Caregivers of the risperidone treated patients were 65.85% of the Pre-FTC state 
and 34.15% of the FTC state. For the olanzapine treated group, caregivers were 72.50% of 
the Pre-FTC state and 27.50% of the FTC state. Caregivers in both dependence states of each 
treatment group were predominantly female. The mean age of caregivers of the Pre-FTC and 
the FTC states of both drugs ranged from 48.45-55.74 years.  
Most caregivers had a primary education level and some a bachelor’s degree level in both 
dependence states and both drug groups. By comparing current occupation and previous 
occupation status, this showed that the increased unemployment of caregivers was only found 
in the Pre-FTC state of the risperidone group by 3.70%.  
Caregivers in the FTC state of the risperidone group had the highest percentage of stopping 
work due to patients’ care (21.43%). The main caregivers of both dependence states and both 
drug groups were their daughters.  
The illness of patients in the Pre-FTC state of both treatment groups had less impact on the 
physical health problems of their caregivers accounting for 59% compared with the FTC 
state. Only patients in the FTC state of the risperidone treatment group showed that patients’ 
illness had extreme problems affecting the physical health conditions of their caregivers. 
Examining the mental health problems, the risperidone treated group within the Pre-FTC 
state showed that the illness of patients had severe problems affecting their caregivers 
accounting for 37.04%. Conversely, more than half of caregivers of the olanzapine treatment 
within the FTC state showed that the patients’ illness had no impact on their mental health. In 
addition, the extreme problems of caregiver’s mental health due to providing care were found 
within the risperidone treatment (21.43% and 3.70% of the FTC and Pre-FTC states, 
respectively) and within the olanzapine group (18.18% and 6.90% of the FTC and the Pre-
FTC states, respectively). Stress was a significant problem for most caregivers. The highest 
 
 
307 
 
percentage of caregiver stress was found in the Pre-FTC state of both the risperidone and the 
olanzapine treated patients, associated with 70.37% and 72.41%, respectively.  
 
 
308 
 
Table 5.6: Characteristics of caregivers from the data collection based on Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, in Thailand, classified by dependence 
 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
Caregiver 27         (65.85)     14    (34.15)       29   (72.50)      11   (27.50) 
Sex [n (%)]                 
   Male  7 (25.93) 3 (21.43) 7 (24.14) 1 (9.09) 
   Female  20 (74.07) 11 (78.57) 22 (75.86) 10 (90.91) 
Age, year [mean (SD)] 55.74 (12.71) 53.35 (10.19) 54.76 (10.45) 48.45 (14.45) 
Marital status [n (%)]         
   Single 7 (25.93) 3 (21.43) 4 (13.79) 2 (18.18) 
   Married  17 (62.96) 10 (71.43) 22 (75.86) 8 (72.73) 
   Widowed  1 (3.70) - 3 (10.34) 1 (9.09) 
   Divorced/Separated  2 (7.41) 1 (7.14) - - 
Religion [n (%)]         
   Buddhism  26 (96.30) 14 (100.00) 29 (100.00) 11 (100.00) 
   Islam - - - - 
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 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
   Christian 1 (3.70) - - - 
Education [n (%)]         
   Never attend school/lower primary 
education     
        
   Primary education  9 (33.33) 3 (21.43) 7 (24.14) 4 (36.36) 
   Lower-secondary education 2 (7.41) 1 (7.14) 1 (3.45) 1 (9.09) 
   Upper-secondary education 2 (7.41) 1 (7.14) 6 (20.69) 4 (36.36) 
   Certificate/diploma 1 (3.70) 2 (14.29) - - 
   Bachelor’s degree 11 (40.74) 5 (35.71) 12 (41.38) 1 (9.09) 
   Higher bachelor’s degree 2 (7.41) 2 (14.29) 3 (10.34) 1 (9.09) 
   Others         
Current occupation [n (%)]         
   Unemployment 16 (59.26) 7 (50.00) 13 (44.83) 4 (36.36) 
   Employment 11 (40.74) 7 (50.00) 16 (55.17) 7 (63.64) 
Type of current occupation [n (%)]         
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 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
   Housewife/Househusband 12 (44.44) 5 (35.71) 4 (13.79) 3 (27.27) 
   Wage-earner 3 (11.11) 1 (7.14) 3 (10.34) 1 (9.09) 
   Farmer/Fisherman - - 1 (3.45) - 
   Self-employed/Owner 1 (3.70) 2 (14.29) 5 (17.24) 2 (18.18) 
   Government officer 2 (7.41) 1 (7.14) 5 (17.24) 1 (9.09) 
   State enterprise employee - 1 (7.14) 2 (6.90) - 
   Company employee 1 (3.70) 1 (7.14) 1 (3.45) - 
   Retiree 5 (18.52) 2 (14.29) 7 (24.14) 2 (18.18) 
   Others 3 (11.11) 1 (7.14) 1 (3.45) 2 (18.18) 
Previous occupation [n (%)]         
   Unemployment 15 (55.56) 9 (64.29) 19 (65.52) 7 (63.64) 
   Employment 12 (44.44) 5 (35.71) 10 (34.48) 4 (36.36) 
Stop work due to provide patient’s care 
[n (%)] 
5 (18.52) 3 (21.43) 4 (13.79) 1 (9.09) 
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 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
Duration of stopping work due to provide 
care, month [mean (SD)] 
7.63 (21.15) 9.43 (19.51) 8.00 (24.45) 1.09 (3.62) 
Relationship with patient [n (%)]         
   Spouse 7 (25.93) 1 (7.14) 6 (20.69) 2 (18.18) 
   Son 1 (3.70) - 3 (10.34)   
   Daughter 14 (51.85) 11 (78.57) 15 (51.72) 5 (45.45) 
   Relatives/Cousin - - 1 (3.45) - 
   Niece/Nephew 1 (3.70) - - 1 (9.09) 
   Friend/Neighbour         
   Maid/Paid caregiver 2 (7.41) 1 (7.14) 3 (10.34) 3 (27.27) 
   Others 2 (7.41) 1 (7.14) 1 (3.45)   
Hours spent for caregiving patients 
[mean (SD)] 
12.04 (3.94) 13.42 (3.96) 13.21 (5.09) 13.18 (6.63) 
The physical problem [n (%)]         
   No problems 16 (59.26) 4 (28.57) 17 (58.62) 4 (36.36) 
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 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
   Slight problems 1 (3.70) 2 (14.29) 5 (17.24) 1 (9.09) 
   Moderate problems 6 (22.22) 4 (28.57) 6 (20.69) 3 (27.27) 
   Severe problems 4 (14.81) 3 (21.43) 1 (3.45) 3 (27.27) 
   Extreme problems - 1 (7.14) - - 
The mental problem [n (%)]         
   No problems 8 (29.63) 4 (28.57) 4 (13.79) 6 (54.55) 
   Slight problems 4 (14.81) 2 (14.29) 10 (34.48)  - 
   Moderate problems 4 (14.81) 3 (21.43) 6 (20.69) 2 (18.18) 
   Severe problems 10 (37.04) 2 (14.29) 7 (24.14) 1 (9.09) 
   Extreme problems 1 (3.70) 3 (21.43) 2 (6.90) 2 (18.18) 
Overall health problems from providing 
care to patients [n (%)] 
21 (77.78) 13 (92.86) 24 (82.76) 8 (72.73) 
   Depression 1 (3.70) 2 (14.29) 4 (13.79) 2 (18.18) 
   Stress 19 (70.37) 9 (64.29) 21 (72.41) 5 (45.45) 
   Distress 8 (29.63) 6 (42.86) 11 (37.93) 2 (18.18) 
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 Characteristics Risperidone (41) Olanzapine (40) 
  Pre-FTC FTC Pre-FTC FTC 
   Quality of sleep 14 (51.85) 8 (57.14) 7 (24.14) 4 (36.36) 
   Musculoskeletal disorders 7 (25.93) 11 (78.57) 5 (17.24) 7 (63.64) 
   Others 1 (3.70) - 2 (6.90) 1 (9.09) 
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5.3.2 Costs 
Cost data were classified into two different approaches based on patients’ cognitive function 
and patients’ dependence status as outlined below.  
5.3.2.1 The distribution of costs by patients’ cognitive function 
In Table 5.7, TMSE scores were used as a measure of patient cognitive function, to classify 
patients according to severity into mild, moderate and severe stages of the disease. More 
details can be seen in section 5.3.1.3.  
5.3.2.1.1 Direct medical costs 
The medication cost per month was nearly15-fold higher of the olanzapine treated patients 
than those of risperidone treated patients. The highest cost of medications was associated 
with the patients with the severe stage of olanzapine and risperidone treated groups, being 
THB 1,076.30 and THB 76.31, respectively. Medications prescribed per month were THB 
63.43 for mild and THB 74.41 for moderate stages of risperidone treated patients and THB 
981.39 for mild and THB 1,033.66 for moderate stages of olanzapine treated patients.  
There were 0.44-0.50 physician visits per month for the risperidone treated patients, whereas 
the olanzapine patients showed fewer physician visits at 0.39-0.47 per month. The greatest 
proportions of additional payments due to outpatient visits were found in patients with the 
mild stage, (THB 2,419 for the risperidone treated group and THB 1,758.33 for the 
olanzapine treated group), when compared with those who had moderate, (THB 1,972.67 for 
the risperidone treated group and THB 1,359.47 for the olanzapine treated group), and severe 
stages, (THB 762.19 for the risperidone treated group and THB 1,360 for the olanzapine 
treated group), for both the risperidone and olanzapine groups.  
Compared with the risperidone group, the olanzapine treated patients had a greater frequency 
of hospital admissions. Also, the patients with the moderate stage showed the highest lengths 
of stay in hospital, accounting for 3 days for the risperidone treated group and 2.53 days of 
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the olanzapine treated group. Further, the risperidone treated patients with a moderate stage 
incurred the highest cost of additional payments due to hospital admissions accounting for 
THB 5,366.67.  
The highest comorbidity associated costs of both treatment groups were found in patients 
within the severe stage of the risperidone group (THB 5,746.20) and patients within the 
moderate stage of the olanzapine group (THB 4,955.63). When comparing amongst the levels 
of disease severity, patients within the moderate stage and treated with risperidone had the 
lowest cost due to comorbidity conditions (THB 2,958.33 per month). Conversely, the 
highest cost was found in the moderate stage of the olanzapine group, at THB 4,955.63 per 
month.  
For the costs of drug induced adverse events, the olanzapine treated patients had a lower cost 
of falls compared with the risperidone treated patients by THB 7.05 per month of each 
cognitive severity stage. Conversely, the olanzapine treated patients showed a higher cost of 
treatment due to drug induced constipation compared with those risperidone treated patients. 
Costs of treatment associated with drug induced EPSs were lower in the olanzapine treated 
group than those in the risperidone treated group at approximately THB 8 per month.  
The costs of relapses requiring the hospitalisation of patients being treated with risperidone 
and patients undergoing olanzapine treatment were THB 393.24 and THB 167.80, 
respectively. Also, costs of relapses not requiring hospitalisation showed that patients using 
olanzapine were approximately THB 7 lower than those patients using risperidone, (THB 
18.93 for the risperidone group and THB 11.83 for the olanzapine group).  
As presented above, costs associated with adverse events and relapses were higher for 
individuals receiving risperidone than those individuals using olanzapine by THB 246.49. 
The monthly direct medical costs of the patients using risperidone were THB 5,095.03 for the 
mild stage, THB 4,437.31 for the moderate stage, and THB 5,327.03 for the severe stage. For 
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the olanzapine users, the monthly direct medical costs were THB 6,044.10, THB 5,569.29, 
and THB 5,855.27 for patients with mild, moderate, and severe stages, respectively. 
5.3.2.1.2 Direct non-medical costs 
For direct non-medical costs, including travel, food and accommodation of both physician 
visits and hospital admissions, the mean cost was higher in the risperidone group than the 
olanzapine group accounting for THB 5,537.28 and THB 4,450.73, respectively. In addition, 
the highest cost of each treatment was found in patients within the moderate stage.  
Other treatment costs were highest in the risperidone treated patients within the moderate 
(THB 2,892.00), followed by severe (THB 2,243.25) and mild stages (THB 2,109.00). 
Similarly, the olanzapine treated patients had the greatest cost for moderate (THB 1,852.63), 
followed by severe (THB 1,740.00) and mild stages (THB 1,445.83).  
Paid caregiver-associated costs were correlated with the severity levels of cognitive 
impairment. Thus, patients within severe stage were found to have the highest expense per 
month when compared against other severity stages. For the risperidone group, the mean cost 
of paid caregivers per month of all severity was THB 7,981.43. According to severity, these 
were for severe (THB 10,985.63), moderate (THB 7,650.67), and mild stages (THB 
5,308.00). Likewise, the mean cost of paid caregivers per month of the olanzapine treated 
patients was THB 7,674.68. These were for severe (THB 10,401.00), moderate (THB 
7,000.53), and mild stages (THB 5,622.50).  
The mean informal care cost per month was higher in the olanzapine treated group than the 
risperidone treated group, with costs of THB 31,647.33 and THB 30,522.17, respectively. 
Cognitive deterioration was a significant predictor relating to informal care costs. Less 
impaired cognitive functions had lower costs of informal care of patients.  
Accordingly, a mean direct non-medical cost per month showed a higher proportion in the 
risperidone group, compared with the olanzapine group by THB 130.29. The total non-
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medical costs per month were estimated at THB 42,031 for the risperidone treated group and 
THB 41,901 for the olanzapine treated group.  
5.3.2.1.3 Monthly costs of patients, classified by the cognitive severity, associated with 
the treatment BPSD 
The mean total cost of patients receiving risperidone was THB 46,984.87 per month. Based 
on cognitive severity, the monthly costs were THB 41,444.22 for mild, THB 46,470.29 for 
moderate, and THB 53,038.90 for severe stages of dementia for the risperidone treated 
patients. For patients receiving olanzapine, the mean total cost was THB 47,723.94 per 
month. The monthly costs for mild, moderate, and severe stages of the olanzapine treated 
patients were THB 41,901.85, THB 48,368.34, and THB 52,901.64, respectively.  
Table 5.7: Parameters of costs, classified by cognitive severity in patients with dementia 
based on the data collected from Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, Thailand, in Thai Baht (THB) in 2017 
Type of costs  Mild Stage Moderate Stage Severe Stage 
Direct medical costs    
   Medication use (per month, 
THB) [mean (SD)] 
   
      Risperidone treatment 63.43 (36.94) 74.41 (24.20) 76.31 (31.40) 
      Olanzapine treatment 981.39 (568.75) 1,033.66 (655.02) 1,076.30 (533.76) 
   Outpatient department (OPD)    
   The frequency of physician                
visits of patient (per month) 
[mean (SD)] 
   
      Risperidone treatment 0.50 (0.32) 0.44 (0.30) 0.50 (0.30) 
      Olanzapine treatment 0.47 (0.22) 0.39 (0.25) 0.47 (0.28) 
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Type of costs  Mild Stage Moderate Stage Severe Stage 
   Additional healthcare 
insurance coverage of OPD per 
visit, THB [mean (SD)]  
   
      Risperidone treatment 2,419.00 (3,828.32) 1,972.67 (2,976.42) 762.19 (1,065.51) 
      Olanzapine treatment 1,758.33 (4,219.10) 1,359.47 (3,433.10) 1,360.00 (1,364.18) 
   Inpatient department (IPD)    
   The frequency of hospital 
admission (per month) [mean 
(SD)] 
   
      Risperidone treatment 0.01 (0.03) 0.04 (0.09) - 
      Olanzapine treatment 0.04 (0.01) 0.04 (0.08) 0.01 (0.03) 
   Length of stay at the hospital, 
day (per admission) [mean 
(SD)] 
   
      Risperidone treatment 0.70 (2.21) 3.00 (7.92) - 
      Olanzapine treatment 1.67 (4.25) 2.53 (5.64) 2.20 (6.96) 
   Additional healthcare 
insurance coverage of IPD per 
admission, THB [mean (SD)] 
   
      Risperidone treatment 2,100.00 (6,640.78) 5,366.67 (15,684.92) - 
      Olanzapine treatment 2,500.00 (8,660.25) 463.16 (1,616.65) 880.00 (2,782.80) 
   Cost of comorbidity (per 
month, THB)  
[mean (SD)] 
   
      Risperidone treatment 4,110.00 (3,047.52) 2,958.33 (3,380.31) 5,746.20 (4,456.06) 
      Olanzapine treatment 4,252.75 (6,231.32) 4,955.63 (4,637.72) 4,102.50 (3,818.37) 
   Adverse events (per month, 
THB)  
   
 
 
319 
 
Type of costs  Mild Stage Moderate Stage Severe Stage 
   Falls [mean (SD)]    
      Risperidone treatment 14.10 (0.00) 14.10 (0.00) 14.10 (0.00) 
      Olanzapine treatment 7.05 (0.00) 7.05 (0.00) 7.05 (0.00) 
   Constipation [mean (SD)]    
      Risperidone treatment 0.24 (0.00) 0.24 (0.00) 0.24 (0.00) 
      Olanzapine treatment 1.68 (0.00) 1.68 (0.00) 1.68 (0.00) 
   Extrapyramidal symptoms 
(EPS) [mean (SD)] 
   
      Risperidone treatment 13.35 (0.00) 13.35 (0.00) 13.35 (0.00) 
      Olanzapine treatment 5.01 (0.00) 5.01 (0.00) 5.01 (0.00) 
   Relapses (per month, THB)    
   Relapse requiring 
hospitalisation [mean (SD)] 
   
      Risperidone treatment 393.24 (0.00) 393.24 (0.00) 393.24 (0.00) 
      Olanzapine treatment 167.80 (0.00) 167.80 (0.00) 167.80 (0.00) 
   Relapse not requiring 
hospitalisation [mean (SD)] 
   
      Risperidone treatment 18.93 (0.00) 18.93 (0.00) 18.93 (0.00) 
      Olanzapine treatment 11.83 (0.00) 11.83 (0.00) 11.83 (0.00) 
Total direct medical cost (per 
month, THB) [mean (SD)] 
   
   Risperidone treatment 5,095.03 (2,599.93) 4,437.31 (2,720.76) 5,327.03 (2,415.49) 
   Olanzapine treatment 6,044.10 (5,366.58) 5,569.29 (2,193.90) 5,855.27 (2,602.49) 
Direct non-medical costs    
   Non-medical costs (travel, 
food, accommodation) of OPD    
(per month, THB) [mean (SD)] 
   
      Risperidone treatment 1,564.68 (473.54) 2,658.85 (2,534.71) 2,327.29 (1,172.77) 
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Type of costs  Mild Stage Moderate Stage Severe Stage 
      Olanzapine treatment 1,453.81 (551.57) 2,197.46 (1,052.39) 1,782.68 (798.54) 
   Non-medical costs (travel, 
food, accommodation) of IPD 
(per admission, THB) [mean 
(SD)] 
   
      Risperidone treatment 1,621.42 (5,127.39) 5,085.93 (14,400.20) - 
      Olanzapine treatment 3,168.86 (7,425.50) 2,971.42 (9,960.53) 1,777.95 (5,622.38) 
   Other treatment (per month, 
THB) [mean (SD)] 
   
      Risperidone treatment 2,109.00 (3,454.16) 2,892.00 (2,874.04) 2,243.25 (2,150.14) 
      Olanzapine treatment 1,445.83 (1,462.79) 1,852.63 (2,250.52) 1,740.00 (1,938.61) 
   Paid caregiver (per month, 
THB) [mean (SD)] 
   
      Risperidone treatment 5,308.00 (4,690.26) 7,650.67 (4,074.83) 10,985.63 (3,697.95) 
      Olanzapine treatment 5,622.50 (4,322.09) 7,000.53 (5,315.40) 10,401.00 (2,424.30) 
   Informal care (per month, 
THB) [mean (SD)] 
   
      Risperidone treatment 28,136.34 (12,046.31) 30,110.82 (8,957.34) 33,319.35 (8,921.65) 
      Olanzapine treatment 27,970.86 (15,406.77) 32,993.49 (11,727.35) 34,058.63 (17,636.68)  
Total direct non-medical cost 
(per month, THB) [mean (SD)] 
   
   Risperidone treatment 36,349.19 (16,806.37) 42,032.98 (11,379.14) 47,711.87 (11,449.53) 
   Olanzapine treatment 35,857.75 (17,289.18) 42,799.05 (14,655.77) 47,046.37 (17,821.80) 
Total costs (per month, THB) 
[mean (SD)] 
   
   Risperidone treatment 41,444.22 (17,037.35) 46,470.29 (11,607.73) 53,038.90 (11,918.14) 
   Olanzapine treatment 41,901.85 (16,879.63) 48,368.34 (16,228.88) 52,901.64 (18,029.26) 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
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Figures 5.1-5.3 show the distribution of total costs, costs of treatment with risperidone and 
costs of treatment with olanzapine according to a classification of patients by cognitive 
function. From the distribution of total costs, this showed that direct medical costs of 
olanzapine treated patients were higher than risperidone treated patients, accounting for 
12.20% and 10.54%, respectively. Conversely, the olanzapine treated group had lower direct 
non-medical costs compared with the risperidone treated group, accounting for 87.80% and 
89.46%, respectively. Focusing on the distribution of costs of patients using risperidone 
treatment, significant part of the costs attributable to dementia were costs relating to unpaid 
caregivers or informal care (64.96%), followed by paid caregiver costs (16.99%) and non-
medical costs associated with transportation, extra food and extra accommodation (11.79%); 
whilst the lowest proportion was found in medication costs per month accounting for 0.15%. 
For patients using olanzapine treatment, the greatest proportion of costs was also in the 
informal care (66.37%), followed by paid caregiver costs (16.08%) and non-medical costs 
associated with transportation, extra food and extra accommodation (9.33%). However, in 
this olanzapine treated group, the lowest percentage was found in costs for treating adverse 
events (0.41%). The proportion of medication costs per month of olanzapine treated patients 
was 2.16%. Comparing the proportion of comorbidity conditions associated costs, 
risperidone treated patients had a slightly lower percentage compared with olanzapine treated 
patients, associated with 9.09% and 9.30%, respectively. Regarding other treatment costs, 
costs of additional healthcare insurance associated with outpatient visits and costs of 
additional healthcare insurance associated with hospital admissions, patients receiving 
olanzapine had lower percentages of these costs compared with patients receiving 
risperidone. Costs of additional healthcare insurance associated with outpatient visits were 
3.66% and 3.13% of risperidone treated and olanzapine treated patients, respectively. Whilst 
costs of additional healthcare insurance associated with hospital admissions were 7.95% of 
the risperidone group and 2.68% of the olanzapine group. When considering costs associated 
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with other treatments, 5.14% was for patients receiving risperidone and 3.52% for those 
receiving olanzapine.  
 
Figure 5.1: Distribution of total costs (%) classified by drugs and by patients’ cognitive 
function 
 
Figure 5.2: Distribution of type of costs (%) of risperidone classified by patients’ 
cognitive function  
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Figure 5.3: Distribution of type of costs (%) of olanzapine classified by patients’ 
cognitive function 
5.3.2.2 The distribution of costs by patients’ dependence 
The classification of patients by physical dependence used the patients’ activities of daily 
living, (as measured by ADL scores), along with a physician’s assessments. Thus, patients 
were classified into two different dependence states as follows: Pre-FTC state and FTC state. 
More details can be seen as previously stated (in section 5.3.1.4). As Table 5.8 shows, cost 
parameters are based on the dependence of patients.  
5.3.2.2.1 Direct medical costs 
The mean monthly medication cost was higher in olanzapine treated patients than those 
risperidone treated patients, accounting for THB 1,105.63 and THB 73.38, respectively. 
Patients within the FTC state of both the olanzapine and risperidone treated groups had more 
monthly medication costs compared with the patients within the Pre-FTC state.  
The frequency of physician visits per month of patients was not different between the patients 
receiving risperidone and those patients receiving olanzapine. However, additional payments 
due to outpatient visits were different between the two states of each treatment group. In the 
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risperidone-treated patients, the costs were THB 2,002.96 for the Pre-FTC state and THB 
849.64 for the FTC state. Conversely, patients with the olanzapine treatment in the FTC state 
had higher additional payments of physician visits than those Pre-FTC patients, being THB 
2,190.91 and THB 1,214.33, respectively.  
Regarding hospital admissions, approximately 1% of patients of both the olanzapine and 
risperidone treated groups with the Pre-FTC state tended to be admitted per month. These 
were found to be 4% of the patients receiving risperidone and 8% of those receiving 
olanzapine within the FTC state. The mean length of stay (LoS) was lower in the patients 
receiving risperidone than those patients receiving olanzapine, accounting for 1.22 days and 
2.68 days, respectively. The longest LoS was found in the olanzapine treated patients within 
the FTC state (3.73 days). The mean additional payments associated with hospital admissions 
showed a higher cost in the risperidone group relative to the olanzapine group by THB 
362.15.  
Comorbidity associated costs related to the functional abilities of the patients within the FTC 
state who had more monthly costs of comorbidity conditions compared with the Pre-FTC 
state. For the risperidone treated patients, the difference of comorbidity associated costs for 
the Pre-FTC and the FTC states was approximately THB 702. Similarly, the olanzapine 
treated patients within the FTC state had THB 2,644.98 higher costs of comorbidities 
compared with those patients in the Pre-FTC state.  
For adverse events, the risperidone treated patients had higher costs of falls compared with 
the olanzapine treated patients for both the Pre-FTC and the FTC states accounting for THB 
14.10 and THB 7.05, respectively. The difference of mean monthly costs associated 
constipation was THB 1.44 between the Pre-FTC state and the FTC state of both treatments. 
Costs associated EPSs were predominantly in patients treated with risperidone compared 
with those patients treated with olanzapine. For the risperidone treated patients, costs of drug 
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induced EPSs were approximately THB 13.35 per month for both the Pre-FTC and the FTC 
states. The costs of the olanzapine treated group were THB 5.01 per month for both the Pre-
FTC and the FTC states.  
Regarding relapse associated costs, the mean monthly cost of relapses requiring 
hospitalisation was lower in the patients treated with olanzapine than those patients treated 
with risperidone for both the Pre-FTC and the FTC states by THB 225.44. Similarly, the 
olanzapine treated patients had lower costs of the relapse not requiring hospitalisation when 
compared with those risperidone treated patients by THB 7 per month for both the Pre-FTC 
and the FTC states.   
Based on the data as stated above, total direct medical costs per month for the patients 
prescribed risperidone were THB 4,324.47 for the Pre-FTC state and THB 5,627.54 for the 
FTC state. For the patients receiving olanzapine, direct medical costs for both the Pre-FTC 
and the FTC states were THB 4,782.94 and THB 9,905.50 per month, respectively.  
5.3.2.2.2 Direct non-medical costs 
The mean monthly cost was THB 4,391.66 for patients treated with risperidone and THB 
6,541.86 for the patients treated with olanzapine.  
Costs of other treatments of patients receiving risperidone were THB 3,567.29 for the FTC 
state and THB 1,867.41 for the Pre-FTC state. Patients receiving olanzapine showed similar 
costs associated with other treatments as those patients receiving risperidone, being THB 
3,190.91 for the FTC state and THB 1,161.67 for the Pre-FTC state. Additionally, the 
risperidone treated patients had a higher cost of other treatments compared with the 
olanzapine treated patients.  
Regarding the costs of paid caregivers, these costs were relevant to the patient’s functional 
abilities. Patients with more dependence were more likely to have higher costs of paid 
caregivers. For the risperidone treated patients, the monthly costs associated with paid 
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caregivers were THB 9,382.86 for the FTC state and THB 7,861.11 for the Pre-FTC state. 
The olanzapine group was THB 6,189.67 and THB 10,800.00 for the Pre-FTC and FTC 
states of paid caregiver-associated costs per month.  
Costs of informal care showed that the patients in the olanzapine group had a higher mean 
cost compared with the patients in the risperidone group, where these costs differed by THB 
594.82 per month. Informal care costs also related to the functional abilities of patients. The 
FTC state was noted for higher costs in comparison to the Pre-FTC state of both treatment 
groups.  
As presented above, patients treated with olanzapine and those treated with risperidone 
showed slightly significant differences with regard to the mean direct non-medical costs per 
month, which were THB 43,966.06 of the risperidone group and THB 43,976.52 of the 
olanzapine group.  
5.3.2.2.3 The monthly cost of patients, classified by patients’ dependence, associated 
with the treatment of BPSD 
Based on the classification of patients by dependence, a higher monthly cost was found in the 
patients receiving olanzapine compared with those patients receiving risperidone by THB 
2,378.68. For patients using risperidone treatment, monthly costs for the Pre-FTC and the 
FTC states were THB 44,717.09 and THB 53,167.03, respectively. Whilst, THB 44,347.28 
was the monthly cost for the Pre-FTC state and THB 58,294.20 for the FTC state of patients 
using the olanzapine treatment.  
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Table 5.8: Parameters of costs, classified by dependence in patients with dementia based 
on the data collected from Thammasat University Hospital and Khon Kaen 
Rajanagarindra Psychiatric Hospital, Thailand, in Thai Baht (THB) in 2017  
Type of costs  Pre-FTC State FTC State 
Direct medical costs   
   Medication use (per month, THB) [mean (SD)]   
      Risperidone treatment 70.51 (34.13) 76.24 (21.12) 
      Olanzapine treatment 939.29 (588.38) 1,271.97 (544.42) 
   Outpatient department (OPD)   
   The frequency of physician visits of patient (per 
month) [mean (SD)] 
  
      Risperidone treatment 0.43 (0.29) 0.57 (0.30) 
      Olanzapine treatment 0.39 (0.22) 0.55 (0.31) 
   Additional healthcare insurance coverage of OPD 
per visit, THB [mean (SD)] 
  
      Risperidone treatment 2,002.96 (3,187.04) 849.64 (1,130.96) 
      Olanzapine treatment 1,214.33 (2,843.98) 2,190.91 (4,287.47) 
   Inpatient department (IPD)   
   The frequency of hospital admission (per month) 
[mean (SD)] 
  
      Risperidone treatment 0.01 (0.02) 0.04 (0.09) 
      Olanzapine treatment 0.01 (0.04) 0.08 (0.12) 
   Length of stay at the hospital, day (per admission) 
[mean (SD)] 
  
      Risperidone treatment 1.37 (5.88) 1.07 (2.73) 
      Olanzapine treatment 1.63 (5.42) 3.73 (5.69) 
   Additional healthcare insurance coverage of IPD 
per admission, THB [mean (SD)] 
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Type of costs  Pre-FTC State FTC State 
      Risperidone treatment 3,000.00 (12,086.23) 1,464.29 (4,352.12) 
      Olanzapine treatment 340.00 (1,618.13) 3,400.00 (9,066.42) 
   Cost of comorbidity (per month, THB) [mean 
(SD)] 
  
      Risperidone treatment 4,087.41 (3,222.32) 4,789.58 (5,020.62) 
      Olanzapine treatment 3,832.20 (3,667.20) 6,477.18 (7,108.94) 
   Adverse events (per month, THB)   
   Falls [mean (SD)]   
      Risperidone treatment 14.10 (0.00) 14.10 (0.00) 
      Olanzapine treatment 7.05 (0.00) 7.05 (0.00) 
   Constipation [mean (SD)]   
      Risperidone treatment 0.24 (0.00) 0.24 (0.00) 
      Olanzapine treatment 1.68 (0.00)  1.68 (0.00) 
   Extrapyramidal symptoms (EPS) [mean (SD)]   
      Risperidone treatment 13.35 (0.00) 13.35 (0.00) 
      Olanzapine treatment 5.01 (0.00) 5.01 (0.00) 
   Relapses (per month, THB)   
   Relapse requiring hospitalisation [mean (SD)]   
      Risperidone treatment 393.24 (0.00) 393.24 (0.00) 
      Olanzapine treatment 167.80 (0.00) 167.80 (0.00) 
   Relapse not requiring hospitalisation [mean (SD)]   
      Risperidone treatment 18.93 (0.00) 18.93 (0.00) 
      Olanzapine treatment 11.83 (0.00) 11.83 (0.00) 
Total direct medical cost (per month, THB) 
[mean (SD)] 
  
   Risperidone treatment 4,324.47 (2,030.91) 5,627.54 (3,003.93) 
   Olanzapine treatment 4,782.94 (1,938.46) 9,905.50 (7,990.77) 
Direct non-medical costs   
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Type of costs  Pre-FTC State FTC State 
   Non-medical costs (travel, food, accommodation) 
of OPD (per month, THB) [mean (SD)] 
  
      Risperidone treatment 2,173.87 (1,992.12) 2,433.69 (1,112.33) 
      Olanzapine treatment 1,795.05 (738.14) 2,106.62 (1,289.50) 
   Non-medical cost (travel, food, accommodation) 
of IPD (per admission, THB) [mean (SD)] 
  
      Risperidone treatment 2,618.66 (10,825.31) 1,557.10 (4,707.30) 
      Olanzapine treatment 592.65 (3,246.08) 8,589.39 (13,671.29) 
   Other treatment (per month, THB) [mean (SD)]   
      Risperidone treatment 1,867.41 (2,466.27) 3,567.29 (2,939.93) 
      Olanzapine treatment 1,161.67 (1,248.56) 3,190.91 (2,672.25) 
   Paid caregiver (per month, THB) [mean (SD)]   
      Risperidone treatment 7,861.11 (5,372.65) 9,382.86 (2,397.09) 
      Olanzapine treatment 6,189.67 (4,548.64) 10,800.00 (3,561.29) 
   Informal care (per month, THB) [mean (SD)]   
      Risperidone treatment 29,708.61 (9,716.47) 33,143.06 (9,763.31) 
      Olanzapine treatment 31,508.35 (13,713.54) 32,532.95 (16,364.21) 
Total direct non-medical cost (per month, THB) 
[mean (SD)] 
  
   Risperidone treatment 40,392.62 (14,412.45) 47,539.49 (10,245.71) 
   Olanzapine treatment 39,564.34 (15,404.85) 48,388.70 (18,511.68) 
Total costs (per month, THB) [mean (SD)]   
   Risperidone treatment 44,717.09 (14,573.74) 53,167.03 (11,251.27) 
   Olanzapine treatment 44,347.28 (16,071.51) 58,294.20 (19,227.41) 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
 
Figures 5.4 to 5.6 show the distributions of total costs, costs of treatment with risperidone and 
costs of treatment with olanzapine according to a classification of patients by dependency. 
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For total costs, the percentages of direct medical costs and direct non-medical costs of 
patients using risperidone treatment were 10.17% and 89.83%. For patients using olanzapine 
treatment, there were 14.31% of direct medical costs and 85.69% of direct non-medical costs. 
Considered by drug treatment, the main proportion of risperidone treated patients was 
informal care (64.21%), followed by paid caregiver costs (17.62%) and comorbidity 
condition associated costs (9.07%). The non-medical costs associated with transportation, 
extra food and extra accommodation in the risperidone group was 8.97%. For olanzapine 
treated patients, the highest percentage was found in informal care (62.39%), followed by 
paid caregiver costs (16.55%) and non-medical costs associated with transportation, extra 
food and extra accommodation (12.75%). In the olanzapine group, costs associated with 
comorbidity conditions was 10.04%. When considering costs of other treatments and 
additional payments associated with hospital admissions, patients using the risperidone 
treatment had a higher percentage compared with those patients using the olanzapine 
treatment. These were 5.55% of costs for other treatments and 4.56% of additional payments 
associated with hospital admissions of patients receiving risperidone. For patients receiving 
olanzapine, there were 4.24% of costs for other treatments and 3.64% of additional payments 
due to hospital admissions. However, additional payments associated with outpatient visits 
were higher in the olanzapine treated group than the risperidone treated group, accounting for 
3.32% and 2.91%, respectively. The percentage of medication costs per month was 0.15% of 
patients receiving risperidone and 2.15% of patients receiving olanzapine. For costs of 
treating adverse events, this showed that patients using the risperidone treatment had a higher 
percentage compared with patients treated with olanzapine, accounting for 0.90% and 0.38%, 
respectively.   
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Figure 5.4: Distribution of total costs (%) classified by drugs and by patients’ 
dependence 
 
 
Figure 5.5: Distribution of type of costs (%) of risperidone classified by patients’ 
dependence 
 
0.15%
0.90%
2.91%
4.56%
5.55%
8.97%
9.07%
17.62%
64.21%
Medication use
Adverse events
Additional healthccare insurance:OPD
Additional healthcare insurance:IPD
Other treatment
Travel, food, accommodation
Morbidity
Paid caregiver
Unpaid caregiver
Risperidone
10.17% 14.31%
89.83% 85.69%
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
Risperidone Olanzapine
Direct medical  costs Direct non-medical costs
 
 
332 
 
 
Figure 5.6: Distribution of type of costs (%) of olanzapine classified by patients’ 
dependence 
 
5.4 Discussion  
This chapter has reported the costs of patients with behavioural and psychological symptoms 
of dementia in Thailand. Cost analyses are classified by patients’ cognitive function and by 
patients’ physical dependence.  
When considering a classification of patients by their cognitive function, the findings show 
that costs of patients per month are increased following more severity stages of cognitive 
function of both treatment groups. Patients within the severe stage have the highest costs 
compared with the mild and moderate stages. Moreover, patients within severe stage have the 
highest direct non-medical costs, especially costs associated with paid caregivers and 
informal care, compared with the other stages of mild and moderate. Based on the findings 
(Table 5.7), the proportion of the direct medical cost of both treatment groups is only 11-12% 
of the total costs, whilst a significant part of the cost is the direct non-medical costs, being 
88-89% of total costs. Moreover, informal care costs are a significant part, leading to a 
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greater cost to those patients, accounting for 65-66% of the total costs of the treatments. This 
is consistent with the study by Permsuwan, Niwatananun and Pimkrai (2013), that conducted 
the cost-utility analysis of donepezil for the treatment of Alzheimer’s disease in Thailand, 
reported patients with the severe stage have the highest costs, (THB 13,896 per month), 
compared with the mild stage, (THB 6,254 per month), and the moderate stage, (THB 7,736 
per month). However, the monthly costs in each severity state from Permsuwan, 
Niwatananun and Pimkrai (2013) are lower than this thesis. That is because the cost data 
from Premsuwan and colleagues did not included non-medical costs due to transportation, 
extra food and accommodation, costs associated with other treatments and costs due to paid 
caregivers, whereas this thesis includes all of these costs. Moreover, it should be highlighted 
that Permsuwan, Niwatananun and Pimkrai (2013) conducts an analysis in general 
Alzheimer’s disease patients, whilst this thesis focuses on patients with BPSD and receiving 
olanzapine or risperidone.  
For hospital admissions, none of the patients within the severe stage and receiving 
risperidone had a hospital admission. This might be because those patients had no 
exacerbation of BPSD such as aggressiveness, hallucinations, and delusions when compared 
with patients with mild and moderate stages. By contrast, several studies reported that BPSD 
are correlated with the level of the disease severity of dementia, especially in Alzheimer’s 
disease. An increase in behavioural disturbances is frequently found in the late stage of the 
disease (Shimabukuro, Awata and Matsuoka 2005, Hashimoto et al. 2015).   
Additionally, patients within the severe stage and using risperidone have the lowest cost of 
additional payments for physician visits in comparison to patients having mild and moderate 
stages. These might be associated with the difference in healthcare insurance scheme 
proportions of those patients. For the risperidone treated patients within the severe stage, the 
healthcare insurance is approximately 6% under the Universal Coverage scheme, (UC 
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scheme), and 94% under the Civil Servants Medical Benefit Scheme, (CSMBS), whereas the 
patients with mild and moderate stages are 40-53% under the UC scheme and 33-50% under 
the CSMBS and 10-13% out-of-pocket expenses, respectively. In general, the additional costs 
of patients are associated with medical procedures, doctor fees, and non-essential drugs, (the 
NEDs are not covered by the healthcare insurance schemes for the Thai population), where 
these costs might be not covered by patients’ healthcare insurance scheme. Amongst 
healthcare insurance schemes in Thailand, the CSMBS tends to have more healthcare benefits 
relative to the UC scheme where the CSMBS is THB 12,767.06 per capita per year and the 
UC scheme is THB 2,592.89 per capita per year (The Comptroller General’s Department of 
the Ministry of Finance in Thailand 2018, the National Health Security Office of the Ministry 
of Public Health in Thailand 2018, the Budget Bureau of the Office of the Prime Minister of 
Thailand 2018). Consequently, patients under the UC scheme are likely to have more 
additional payments compared with the CSMBS. Further, additional costs for admissions 
vary for both drug groups. These expenditures are associated with costs of special rooms, 
equipment and medical procedures which are relied on during the length of stay, (LoS), at 
hospital and patients’ healthcare insurance schemes.  
Regarding physician visits, based on both treatments, patients with mild and severe stages 
have a similar frequency of physician visits per month and these patients tend to have more 
physician visits when compared with patients within the moderate stage. This is consistent 
with Ferretti et al. (2018), who examined direct and indirect costs of dementia in Brazil, 
suggested that Alzheimer’s patients with mild and severe stages have a similar frequency of 
specialised physician visits per month and these patients are likely to have more specialised 
physician visits when compared with patients within the moderate stage. However, it is in 
contrast with the study by Jonsson et al. (2006) which investigated costs of care for patients 
with Alzheimer’s disease according to the level of cognitive impairment, as measured by 
MMSE, in Sweden, Denmark, Norway and Finland. Jonsson’s study reported that patients 
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with the moderate stage have the highest mean specialist physician visits per year compared 
with the other stages.  
When considering costs of additional payments due to physician visits, there are differences 
amongst studies because these costs are depended on several factors, such as the provisions 
of healthcare systems by the government, medication accommodated in NLED and other 
expenditures not covered by patients’ healthcare insurance of each country.  
Focusing on comorbidity conditions, the risperidone treated patients within the moderate 
stage show the lowest costs for the treatment of comorbidities compared to those patients 
within the mild and severe stages. This might be associated with those patients in the 
moderate stage in the risperidone group have fewer comorbidity conditions and lower rates of 
osteoarthritis, hyperlipidaemia and hypertension, leading to lower costs of comorbidity 
condition treatment than the other groups.  
Further, the direct non-medication costs of hospital admissions vary across all cognitive 
severity levels of both drug groups. These might be associated with the differences in costs of 
transportation and food for their caregivers. Most caregivers spend more money on food and 
their transportation between home and the hospital, when patients are admitted into the 
hospital.  
Compared with patients with mild and severe stages and treated with risperidone, the highest 
cost of other treatments is found in moderate dementia patients. These costs might be 
associated with the patients having new wheelchairs, dietary supplements, (e.g. nutritional 
liquid diets), other sources of nutrition, (e.g. sterilised dairy milk, UHT milk, UHT yoghurt 
milk, Anlene®, and Lactasoy®), vitamins, and disposable adult diapers.  
To summarise, based on a classification of patients by cognitive function, the total direct 
medical cost of the risperidone treated patients is lower than those olanzapine treated patients 
by THB 870. When excluding costs associated with adverse events and relapses, this shows 
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that the olanzapine treated patients have higher total direct medical cost compared with the 
risperidone treated patients by THB 1,116. As a result, this implies adverse events and 
relapses are significant factors affecting the direct medical costs of patients. In addition, the 
severity levels of cognitive function have a substantial impact on direct non-medical costs 
and total costs for all patients. This indicates that an increase in costs of patients is directly 
correlated with more cognitive impairment of those patients. Consistently, several studies 
reported that neuropsychiatric symptoms (NPSs) in patients with dementia are correlated 
with declining cognitive function and an increase in the caregiver burden (Hux et al. 1998, 
Mohamed et al. 2010, Sansoni et al. 2013, Reed et al. 2014, Ku et al. 2016). Accordingly, it 
can be inferred that behavioural disturbances are significant predictors, leading to greater 
direct non-medical costs, especially for paid caregivers and informal care, in patients with 
dementia.  
When considering a classification of patients by their dependence, the total mean monthly 
costs show no significant differences between patients treated with risperidone and those 
treated with olanzapine. The direct non-medical costs are associated with 86-90% of total 
costs. In addition, informal care is also highlighted at 62-64%, whereas the direct medical 
costs are approximately 10-14% of the total costs.  
Patients receiving risperidone treatment within the Pre-FTC state have more additional costs 
for hospital admissions compared with those patients within the FTC state. This might be 
associated with the different proportions of healthcare insurance between two dependence 
states. The risperidone treated patients within the Pre-FTC state account for 33% under the 
UC scheme, 56% under the CSMBS, and 11% out-of-pocket expenses, whereas the patients 
with the FTC state are 29% under the UC scheme and 71% under the CSMBS. Regarding the 
UC scheme in Thailand, some costs are not covered by this healthcare scheme, such as 
special rooms and some medical procedures (National Health Security Office, the Ministry of 
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Public Health in Thailand 2018). Thus, the patients might have to pay those costs by 
themselves (as out-of-pocket expenses). These additional costs for the risperidone treated 
patients within the Pre-FTC state are approximately 15% higher than those FTC patients. For 
the olanzapine treatment, patients within the FTC state have higher additional costs 
associated hospitalisation than those patients within the Pre-FTC state. These might be 
associated with patients with the FTC state of the olanzapine treatment having more 
frequencies of hospital admissions and longer stays in hospital than those Pre-FTC patients. 
According to the frequency of hospital admissions of olanzapine treatment, this is in line with 
the findings from the study by Turongkaravee et al. (2011). Turongkaravee and colleagues, 
who conducted a cost-utility analysis of acetylcholine inhibitors in the treatment of 
Alzheimer’s disease in Thailand, reported patients in the FTC state had a 53% higher 
frequency of admission compared with patients in the Pre-FTC state.  
Comparing the direct non-medical costs for hospitalisation, risperidone treated patients 
within the Pre-FTC have a higher cost than those patients with the FTC state due to these 
patients having longer overnight stays in hospital than the other patient groups. Similarly, 
patients using olanzapine treatment within the FTC state have a higher hospitalisation 
associated cost compared with those patients within the Pre-FTC state because these FTC 
patients have a 2.3-fold higher LoS than the other state. Also, the FTC patients of the 
olanzapine treatment have more than an 8-fold frequency of hospital admissions compared 
with the patients within the Pre-FTC state.  
In a comparison of the comorbidity-associated costs, both treatment groups show that 
increased costs are associated with the greater dependence state of patients. Thus, it implies 
that the patients within the FTC state of both the risperidone and olanzapine groups have 
higher percentages of comorbidities compared with those patients within the Pre-FTC state.  
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Regarding other treatment costs, paid caregivers and informal care, these costs also increase 
with the greater dependence of patients. Accordingly, this infers that the total direct medical 
costs and direct non-medical costs are dependent upon the functional dependence of the 
patients. The total costs show a similar fashion where these are likely to be higher in patients 
with greater dependence. This is consistent with the study by Turongkaravee et al. (2011) 
which reported that costs of paid caregivers and informal care in Thailand are higher in 
patients within the FTC state than those patients within the Pre-FTC state. However, 
Turongkaravee and colleagues conducted the study in the Thai elderly with dementia in a 
Thai University hospital and was not focused on patients with BPSD and being treated with 
atypical antipsychotics.  
In brief, with regard to a classification of patients by their dependence, the total costs of 
patients show a THB 2,378.68 difference between the treatment groups. Medication costs, 
additional payments beyond patient healthcare coverage schemes, the frequency of hospital 
admissions, LoSs, comorbidity-associated costs, and costs associated with adverse events and 
relapses are important factors, leading to the cost discrepancy between the two treatment 
groups. Although direct non-medical costs are the greater part of the total costs of patients 
with BPSD, these costs are not significantly different between the risperidone treated and the 
olanzapine treated patients. Focusing on the total direct medical costs, the risperidone treated 
patients have lower costs than the olanzapine treated patients. The costs associated with 
adverse events and relapses are higher in the patients receiving risperidone than those patients 
receiving olanzapine. This indicates that the risperidone treated patients are associated with 
higher drug induced adverse effects and have more relapse rates than those olanzapine treated 
patients. However, the proportion of comorbidity conditions is higher in the patients 
receiving olanzapine than those patients receiving risperidone, leading to a greater cost of 
comorbidity treatment associated costs in the olanzapine group. When considering the total 
direct non-medical costs, these costs are directly associated with more impairment in 
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activities of daily living. Several studies consistently suggest patients with BPSD are 
correlated with increasing dependence and caregiver burden (Mangone et al. 1993, Getsios, et 
al. 2002, Allegri et al. 2006, Miyamoto, Tachimori and Ito 2010, Mohamed et al. 2010, 
Cerejeira, Lagarto and Mukaetova-Ladinska 2012, Pinidbunjerdkool, Saengwanitch and 
Sithinamsuwan 2014, Reed et al. 2014, Lanctot et al. 2017). Consequently, behavioural 
disturbances are the significant predictors affecting the direct non-medical costs, especially 
paid caregivers and informal care, in patients with dementia.  
Using to two different approaches for classifying patients, (by cognitive status and physical 
dependence), the direct medical costs and the direct non-medical costs of the olanzapine and 
risperidone treated patients have similar results. The medication cost per month is a 
significant difference between patients treated with risperidone and those treated with 
olanzapine. The lower direct medical costs and direct non-medical costs are found in patients 
using risperidone compared with patients using olanzapine in both methods of classification. 
Also, informal care has highlighted an impact on socio-economic conditions of patients and 
their families. These are in line with reporting from WHO, that costs of informal care are 
associated with 40-65% in lower-middle-income countries and upper-middle-income 
countries, whilst the direct medical costs contribute only 23-32% in those countries (World 
Health Organisation 2012).  
For adverse events and relapses, costs associated with falls, EPSs, relapses requiring 
hospitalisation, and relapses not requiring hospitalisation, they are higher in patients using the 
risperidone treatment than those patients treated with olanzapine, with the exception of 
constipation. This might be because the patients using risperidone treatment have a higher 
percentage in occurrence of EPSs, falls and relapses when compared with the olanzapine 
treatment. Consequently, these also imply that the risperidone treated patients are associated 
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with higher drug induced side effects and more relapse rates than those olanzapine-treated 
patients.  
For adverse events associated with falls, the findings in this thesis are contrary with previous 
published studies which reported olanzapine treated patients had a higher incidence of falls 
compared with risperidone treated patients (Deberdt et al. 2005, Schneider, Dagerman and 
Insel 2006 and Schneider et al. 2006). The findings in this thesis shows a higher incidence of 
falls in risperidone treated patients compared with olanzapine treated patients. According to 
Derberdt, et al. 2005, the risk of falls was higher in olanzapine treated patients than 
risperidone treated patients where risk differences between active drugs and placebo 
accounted for 4.9% and 2.8%, respectively. Conversely, the findings based on the patient 
data collection in Thailand found that olanzapine treated patients were at lower risks of falls 
than risperidone treated patients, accounting for 2.44% and 4.88%, respectively.  
Considering extrapyramidal symptoms, the findings from this thesis are consistent with 
several studies, including the RCT and a meta-analysis of the RCTs which reported that the 
EPSs are significantly higher in patients using risperidone treatment compared with those 
patients using the olanzapine treatment (Deberdt et al. 2005, Schneider, Dagerman and Insel 
2006 and Ma et al. 2014). For drug induced EPSs, the differences in incidence of treatment-
emergency EPSs between active drugs and placebo were 20.10% of risperidone treated 
patients and 6.10% of olanzapine treated patients (Derberdt et al. 2005). Consistently, the 
incidence of drug-induced ESPs from the data collected in the Thai setting were 19.50% of 
the risperidone treated patients and 7.32% of olanzapine treated patients. However, the 
CATIE-AD study by Schneider et al. (2006) suggested that extrapyramidal signs had the 
same percentage in both risperidone and olanzapine treated patients.  
Interestingly, this thesis is the first study to investigate the costs of patients with BPSD using 
olanzapine or risperidone in a Thai setting which includes costs associated with relapses 
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requiring hospitalisation and relapses not requiring hospitalisation and the costs associated 
with adverse events, (falls, EPSs and constipation), due to atypical antipsychotic use for 
treating BPSD.   
The cost analyses presented in this chapter have several limitations. Firstly, atypical 
antipsychotics are off-label use in dementia (Maglione et al. 2011). Thus, there are a lack of 
studies of atypical antipsychotics associated with drug induced adverse events within the 
different cognitive severity levels, dependence levels and drug-associated relapses, for the 
treatment of dementia patients. Consequently, costs of drug-induced adverse events and 
relapses are assumed to have similar values for all the patients’ cognitive severity levels 
(mild, moderate, and severe stages) and all patients’ dependence (Pre-FTC and FTC states). 
The relapse rates are associated with greater risks of the return of behavioural and 
psychological symptoms of patients, leading to an increase in costs of medication, outpatient 
services and inpatient services. Paid caregivers and informal care are associated with the NPS 
of patients, leading to caregiver burden and increasing costs of care (Torrisi et al. 2016, 
Cheng 2017, Lanctot et al. 2017, Shikimoto et al 2018). Thus, this study takes into account 
the relapses to estimate for costs. However, the relapse rate data are adopted from a study of 
schizophrenia. Therefore, these costs might be an over or underestimation of the actual costs 
of patients with BPSD being treated by atypical antipsychotics, (risperidone or olanzapine). 
Based on reporting in several previous studies, there are several adverse events that occur due 
to antipsychotic drug use in elderly people with dementia (Schneider et al. 2006, Maher et al. 
2011, Riggs 2013, Ma et al. 2014, Tempi et al. 2016). However, only three significant 
adverse events (falls, constipation and EPSs) are included in this cost analysis. Thus, costs 
associated with adverse events are likely to be underestimated due to the hidden costs of 
other adverse events. In addition, the treatment of constipation in this thesis is focused on 
magnesium hydroxide, (Milk of Magnesia or MOM), because this drug is recommended as a 
suitable treatment for elderly people and also is provided in NLED of Thailand. Therefore, 
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constipation treatment-associated costs may result in an undervaluation of cost data due to 
drug-induced constipation.  
Secondly, indirect costs of lost productivity have not been included due to all patients in this 
thesis have retired and/or are not working.  
Another limitation is that this study was conducted as a cross-sectional study, thus the data 
are limited in its ability to represent how NPS changes, influencing the costs of providing 
care to patients over time.  
To the researcher’s best knowledge, this thesis is the first study to explore the costs of 
patients with BPSD and receiving atypical antipsychotic drugs, (risperidone or olanzapine), 
in which adverse events and relapses are taken in account for the analysis for costs in 
Thailand or in general. The thesis also highlights costs of BPSD patients and receiving 
atypical antipsychotic drugs by classifying patients with cognitive severity and dependence 
status. However, this is based on a view of the dearth of evidence on costs of patients with 
BPSD and treated with olanzapine or risperidone. The findings in this thesis are also specific 
to healthcare system in Thailand. Therefore there might be concerned over a generalisability 
when these results are exercised in different circumstances. Furthermore, cost analyses in this 
chapter were focused only on the descriptive analysis. A further study associated with the 
costs of patients with BPSD should take into account other adverse events, such as gait 
disturbance, urinary tract infection, prolactin increase and cerebrovascular events, and 
indirect costs due to productivity loss of patients not included in this thesis. Taking these 
factors into account might lead to different aspects of costs being highlighted and also impact 
on the decision-making of patients, caregivers and physicians on the treatment of BPSD 
patients. 
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Chapter 6: Utility analyses of patients with behavioural and 
psychological symptoms of dementia in Thailand 
Abstract 
Introduction: Behavioural and psychological symptoms of dementia (BPSD) are major 
problems in patients with dementia. Dealing with BPSD has much more difficulties, therefore 
these symptoms are leading to individual suffering and impact on the caregiver burden as 
well as healthcare systems. The development of BPSD is also associated with a reduction in 
quality of life of patients and their caregivers because it is a major source of distress for 
patient themselves and relevant to family caregivers. Currently, a guideline for the treatment 
of BPSD remains uncertain; however, atypical antipsychotic drugs are often used in a clinical 
practice for BPSD patients. Owing to a paucity of data on health-related quality of life 
weights, (utility weights), of patients with BPSD received atypical antipsychotics, then it is 
challenging to ascertain an accurate picture at present.  
Aim: The objective of this chapter is to assess the utility weights of patients with BPSD and 
being treated with atypical antipsychotics, (risperidone or olanzapine), in different their 
disease stages, (mild, moderate and severe stages), and different their dependence status (Pre-
FTC and FTC states).  
Methods: In two hospitals, Thammasat University Hospital and Khon Kaen Rajanagarindra 
Psychiatric Hospital in Thailand, a cross-sectional study was conducted based on 82 
outpatients with BPSD and being treated with atypical antipsychotics, by face-to-face 
interviews using the EQ-5D-5L instrument. The data gathering was performed in two phases 
as follows: Phase I - from February 2017 to March 2017 and Phase II- from October 2017 to 
November 2017. In cases where the patients were not able to participate in the process their 
caregivers were approached to respond on their behalf. Responses to the questionnaire were 
converted into a utility score, (between a zero to one score), using Thai value sets. Utility 
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analysis of risperidone prescribed and olanzapine prescribed patients was performed based on 
patient classifications by cognitive function and dependence.  
Results: The mean EQ-5D-derived utility weights for the risperidone treated patients were 
0.59 in mild, 0.27 in moderate, and 0.26 in severe stages of dementia, whereas for olanzapine 
treated patients they were 0.62 in mild, 0.53 in moderate, and 0.39 in severe stages of 
dementia based on a classification of patients by cognitive function. The levels of cognitive 
impairment were associated with the utility weights of the patients. Patients with more severe 
cognitive impairment were likely to have a lower utility weight compared with patients with 
less cognitive impairment. For the classification of patients by their dependence, the utility 
weights of risperidone prescribed patients were 0.46 in the Pre-FTC state and 0.12 in the FTC 
state and olanzapine prescribed patients were 0.63 in the Pre-FTC state and 0.23 in the FTC 
state. The higher utility weights correlated with the lower level of the dependence of patients.   
Conclusions: Major BPSD complications are associated with decreased HRQoL in both 
patients and their caregivers. Utility weights estimated from this chapter are incorporated for 
health outcomes and can be used in cost-utility analysis of patients with BPSD and being 
treated with atypical antipsychotics to aid decision-making of stakeholders, including 
patients, caregivers, physicians and policy-makers, for planning and selecting the relevant 
treatment and resource allocation decisions for those BPSD sufferers.  
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6.1 Introduction 
Dementia is a chronic disease causing significant problems across the world due to a rapid 
growth in the number of ageing people (World Health Organisation 2012). The management 
of dementia is complicated because of non-cognitive symptoms or behavioural and 
psychological symptoms of dementia, namely psychosis, agitation, aggression and emotional 
change, which almost 50-90% of people with dementia have experienced during the course of 
their illness (Cerejeira, Lagarto and Mukaetova-Ladinska 2012, Tible et al. 2017). The 
presence of BPSD are more frustrating to deal with than the actual cognitive deterioration 
and also lead to potentially reduced health-related quality of life in patients and caregivers 
(Hersch and Falzgraf 2007, Tible et al. 2017). By comparison, individuals with BPSD have a 
lower quality of life than those without BPSD (Hurt et al. 2008).  
To measure the health-related quality of life, two main methods are applied: disease-specific 
instruments and generic instruments. The generic instruments comprise of health profiles and 
utility measures (Guyatt et al. 1989, Drummond et al. 2005). With regard to disease-specific 
instruments, Alzheimer Disease Related Quality of Life (ADRQOL), Dementia Quality of 
Life Instrument (D-QoL), Quality of Life in Late-stage Dementia scale (QUALID), the 
Quality of Life in Alzheimer's Disease (QOL-AD) and DEMQOL, these are examples of 
dementia-specific instruments (Ready and Ott 2003, Ettema et al. 2005, Moyle and Murfield 
2013, Perales et al. 2013). 
The types of instruments to measure health profiles are the Sickness Impact Profile (SIP), the 
Nottingham Health Profile (NHP), the Short Form health survey-36 (SF-36) and the World 
Health Organization Quality of Life (WHOQOL-BREF) (Hunt et al. 1980, Bergner et al. 
1981, Ware et al. 1992, the WHOQOL Group 1998, Drummond et al. 2005). For utility 
measures, these consist of direct and indirect methods. The Standard Gamble (SG), the Time 
Trade-Off (TTO), the Visual Analog Scale (VAS) are patterns of direct instruments (Von 
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Neumann and Morgenstern 1944, Torrance, Thomas and Sackett 1972, Torrance 1986, 
Drummond et al. 2005). Indirect methods are multi-attribute utility instruments, such as the 
Quality of Well-Being (QWB), the Health Utilities Index (HUI), the EQ-5D and the SF-6D. 
The values from these instruments are converted to produce utility weights, (sometimes 
known as weights, utilities, utility values, health utilities, quality of life scores or health-
related quality of weights), in which the scores range between zero and one, (zero denoted 
death and one perfect health) (Guyatt et al. 1989, O’ Brien 1994, Kaplan and Anderson 1988, 
The EuroQol Group 1990, Torrance et al. 1995, Feeny et al. 1995, Kaplan and Anderson 
1996, Brazier et al. 2002, Herdman et al. 2011, EuroQol Group 2015).  
The utility weights are applied by multiplying with the quantity of life, (duration), which 
produces the quality-adjusted life years (QALYs) which is widely used as a measure of 
incremental effect in economic evaluations of medical interventions, in particular the cost-
utility analysis (CUA). Estimating QALYs then requires utility weights for given health 
states that are relevant to the conditions of interest (Drummond et al. 2005, McIntosh and 
Luengo-Fernandez 2006). 
For health economic evaluation by cost-utility analysis, the EQ-5D is recommended by 
several agencies including the National Institute of Health and Clinical Excellence, (NICE), 
in the UK, The Pharmaceutical Benefits Advisory Committee, (PBAC), in Australia and the 
Health Intervention and Technology Assessment Program of Thailand (HITAP), in Thailand.   
The literature review of model-based economic evaluation in dementia (Chapter 2, section 
2.6), based on the CERAD conceptual framework, the cost-effectiveness studies of donepezil 
in Alzheimer’s disease by Neumann et al. (1999) and Fuh and Wang et al. (2008) took the 
health utilities from Neumann et al. (1999). The study by Neumann et al. (1999), conducted a 
cross-sectional study of 528 caregivers of patients with Alzheimer’s disease in the US 
between July 1996 and February 1997 using HUI:2 by proxy respondents, reported that the 
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utility weights were 0.68, 0.54 and 0.37 for mild, moderate and severe stages respectively. 
The utility weights in the cost-effectiveness analysis of donepezil in Alzheimer’s disease by 
Lopes-Bastida et al. (2009) were 0.5249 in the mild stage, 0.1818 in the moderate stage and -
0.2014 for the severe stage, based on the cross-sectional study in outpatients with 
Alzheimer’s disease in the Canary Island, in Spain by proxy respondents using the EQ-5D 
and a Spain value set for converting to utility weights. The cost-effectiveness analysis of 
donepezil treatment in Alzheimer’s disease conducted by Ikeda, Yamada and Ikegami (2002) 
reported the utility weights were 0.33, 0.16 and 0.22 for mild, moderate and severe stages 
based on the survey in the elderly people with dementia in Japan using HUI:3 by proxy 
respondents. According to Kirbach et al. (2008), a cost-utility analysis of olanzapine in the 
treatment of agitation and psychosis in patients with Alzheimer’s disease obtained utility data 
from Murman and Colenda (2005). The Murman and Colenda’s study investigated the 
relationship between the utility weights from Neumann et al. (1999) and the assessment of 
cognition, functioning and behavior and then the utility weights were reported as 0.54, 0.43 
and 0.29 for mild, moderate and severe stages in patients with Alzheimer’s disease and 
showing the presence of problematic behavioural disturbances (Murman and Colenda 2005).  
From the economic evaluation based on the FTC conceptual framework, five studies of cost-
effectiveness evaluations of the use of galantamine in Alzheimer’s disease and one of an 
analysis of the cost-effectiveness of donepezil, galantamine, rivastigmine and usual care in 
Alzheimer’s disease (Green et al. 2005) derived utility weights from Neumann et al. (1999) 
as previously mention above. The utility weights were 0.6 of the Pre-FTC state, (from 
Alzheimer’s patients with mild and moderate stages), and 0.34 of the FTC state, (from 
Alzheimer’s patients with severe, profound and terminal stages). According to the cost-
effectiveness of the use of memantine in Alzheimer’s disease by Rive et al. (2010), the utility 
weights of the Pre-FTC stage was based on the mapping of the EQ-5D and the Twelve-Item 
Health Status Questionnaire (HSQ-12), the Ferm’s D-test and the quality of life scale in 
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Alzheimer’s disease (QoL-AD), using the UK value set for translating to utility weights and 
then calculated by an equation. The mapping was also exercised for the utility weights of the 
FTC state based on the FTC sub-group of patients with moderate to severe classification in 
the LASER-AD study in the UK and the utility weights were reported as 0.336 of the FTC 
state (Rive et al. 2010).  
Currently, there is a dearth of studies evaluating the HRQoL of patients with BPSD and being 
treated with antipsychotic drugs using a preference-weighted instrument. Only one study by 
Rosenheck et al. (2007) reported that an assessment of HRQoL in Alzheimer’ patients 
receiving atypical antipsychotics, namely risperidone, olanzapine and quetiapine, compared 
with a placebo, was conducted alongside a clinical trial in the US and used the Health 
Utilities Index Mark 3 (HUI-3) as the instrument.  
However, this thesis aimed to conduct an economic evaluation using a decision-analytic 
model, (known as a Markov model). Then the utility weights associated with each health 
state, corresponding to the health-related quality of life weights for given health states, were 
needed to be incorporated in calculating health outcomes of this thesis, as measured in terms 
of quality-adjusted life years (QALYs). In addition, it is important to note that the health-
related quality of life measurement of patients treated with olanzapine or risperidone 
according to the health states of the developed models based on the CERAD conceptual 
framework and the FTC conceptual framework is not well explored.  
As a result, the purpose of this chapter is intentionally to assess the utility weights, as 
measured by EQ-5D-5L, of patients with BPSD and treated with atypical antipsychotics 
(risperidone or olanzapine). The results from this chapter will be further adopted in the 
calculation of QALYs for a cost-utility analysis of atypical antipsychotics, (risperidone 
versus olanzapine), for patients with BPSD in Thailand.  
 
 
349 
 
6.2 Methods 
6.2.1 Target population  
Patients with BPSD aged 60 and over from two outpatient departments at Thammasat 
University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital were included. For 
more details of the inclusion and exclusion criteria of participants in this thesis see Chapter 3, 
(section 3.4.4), where they are presented.   
6.2.2 Data settings and data collection process 
The data settings took place at two hospitals in Thailand as stated above. The process was 
undertaken in two phases: Phase I (from February to March 2017) and Phase II (between 
October and November 2017). More details of the data setting were described in chapter 3, 
(section 3.4.3).  
Before initiating the data collection process, ethics approval was secured (see Appendix 3). A 
cross-sectional study was then undertaken to investigate the utility weights of patients with 
BPSD and being treated with olanzapine or risperidone. Face-to-face interviews were 
conducted at only one point in time during some point in 2017 using the recent EQ-5D-5L 
instrument in a Thai version, with patients and/or their caregivers. Then patients and/or their 
caregivers who met the criteria, were asked to participate in the study. Generally, patients 
with BPSD had difficulties concerning judgement due to their condition of cognitive 
impairment. Therefore, caregivers were asked to complete the quality of life questionnaire 
instead as proxies. The consent form was then given to those participants who had agreed to 
participate in the study. The interview was then undertaken in which patients and/or their 
caregivers were interviewed for approximately 30-45 minutes in total, including the 
completion of the cost questionnaire. However, the part about the quality of life questionnaire 
was completed within a few minutes.   
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6.2.3 Data analysis  
Data on utility weights of patients receiving olanzapine or risperidone were analysed by 
descriptive statistics, categorised according to the classification of patients, including 
cognitive function and dependence. The analysis produced the results in percentage, mean 
and standard deviation which were performed using Microsoft® Excel version 2013. 
 
6.3 Results 
6.3.1 Patient characteristics and caregiver characteristics 
Utility weights were derived from the data collection of patients and/or caregivers. The face-
to-face interviews were conducted at the outpatient departments of both the Thammasat 
University Hospital and the Khon Kaen Rajanagarindra Psychiatric Hospital, Thailand. The 
recruitment of patients in the study was based on the same inclusion criteria as the cost data, 
as stated in Chapter 5 (section 5.2.1). The data collections were similarly conducted from two 
phases as the cost data Chapter 5 (section 5.2.2), but the utility weights were done based on 
one interview. Utility weights were collected on a sample of 82 patients with Alzheimer’s 
disease and/or caregivers. Only one patient (1.22%) with the mild stage of dementia and 
being treated with olanzapine and 81 caregivers (98.78%) completed the EQ-5D-5L 
questionnaire measures of health-related quality of life.  
Based on the gathered data using the EQ-5D-5L instrument, value sets from the Thai 
population were applied to estimate individual utility weights as shown in Table 6.1 
(Pattanaphesaj 2014).  
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Table 6.1: Value sets of health dimensions based on the Thai population (Pattanaphesaj 
2014) 
Health dimension Coefficient 
Mobility (MO)   
1                        0 
2 0.056 
 3 0.114 
4 0.231 
5 0.307 
Self-care (SC)   
1                        0 
2 0.033 
3 0.108 
4 0.225 
5 0.254 
Usual activities (UA)   
1                        0 
2 0.043 
3 0.075 
4 0.165 
5 0.207 
Pain/discomfort (PD)   
1                        0 
2 0.040 
3 0.068 
4 0.233 
5 0.266 
Anxiety/depression (AD)   
1                        0 
2 0.032 
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Health dimension Coefficient 
3 0.097 
4 0.202 
5 0.249 
 
6.3.2 Utility weights of patients with behavioural and psychological symptoms receiving 
risperidone or olanzapine for at least two months, according to cognitive function 
Patients in this chapter were classified by cognitive function according to mild, moderate and 
severe stages. More details are presented in Chapter 5 (section 5.3.1.3)  
Table 6.2 shows the distribution of responses of the five dimensions by the level of problems 
according to patients’ cognitive function. The profile of patients receiving risperidone were 
categorised according to severity in percentage terms being, mild (24.39%), moderate 
(36.59%), and severe stages (39.02%) of the disease. The profile of patients receiving 
olanzapine were mild (29.27%), moderate (46.34%), and severe stages (24.39%).  
Amongst the risperidone group in the mild stage, about 80.00% of patients were having 
problems with mobility, 70.00% with self-care, 80.00% with usual activities, 90.00% with 
pain/discomfort and 80.00% with anxiety/depression.  
Patients within the moderate stage and being treated with risperidone, between 6.67% and 
26.67% of patients in this group reported having no problem with mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression respectively. However, more than four in 
five of patients in this group also reported problems with mobility, self-care, usual activities 
and pain/discomfort being, ranging between 86.67% and 100%. Only 73.33% of these 
patients had reported having problems with anxiety/depression.  
Considering patients within the severe stage and being treated with risperidone, the range of 
those reporting no problems was 6.25% to 18.75%. Patients in this group reported their 
having problems with mobility (87.50%), self-care (93.75%) and usual activities (93.75%), 
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followed by pain/discomfort (93.75%) and anxiety/depression (81.25%), leading to those 
patients having a low health-related quality of life. 
For those patients treated with olanzapine the health-related quality of life measures were as 
follows. In the mild stage the percentages of patients who reported having no problem with 
mobility were (25.00%), self-care (58.33%), usual activities (50.00%), pain/discomfort 
(25.00%) and anxiety/depression (33.33%). More than half of the patients in this group 
reported having problems with mobility, usual activities, pain/discomfort and 
anxiety/depression which ranged between 50.00% and 75.00%. 
Olanzapine treated patients within the moderate stage reported having problems with 
mobility at (84.21%), self-care (52.63%), usual activities (78.95%), pain/discomfort 
(78.95%) and anxiety/depression (89.47%).  
In total 90.00% of olanzapine treated patients in the severe stage had problems with mobility, 
80.00% with self-care, 90.00% with usual activities, 80.00% with pain/discomfort and 
80.00% with anxiety/depression. 
The responses from the five dimension of the EQ-5D-5L questionnaire were then combined 
with Thai value sets for the EQ-5D-5L to convert the information into utility weights, 
(health-related quality of life weights), of individuals reflecting the benefits of living in each 
health state, as measured between zero and one. The mean utility weights of patients 
receiving risperidone classified by cognition, (as be assigned to health states), were 0.59 
mild, 0.27 moderate and 0.26 severe stages. Patients under olanzapine treatment were 0.62 
mild, 0.53 moderate and 0.39 severe stages of their utilities. Based on classifying patients by 
cognitive function, the overall utility weights of patients receiving olanzapine had higher 
values across all severity levels when compared with the risperidone group.  
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Table 6.2: Distribution of levels of perceived problems in each of the dimension of the 
EQ-5D-5L descriptive system and utility weights of patients with BPSD receiving 
risperidone or olanzapine for at least two months, according to cognitive function 
The dimension of the EQ-
5D-5L  
Risperidone (N=41) Olanzapine (N=41) 
 Mild 
(n=10) 
Moderate 
(n=15) 
Severe 
(n=16) 
Mild 
(n=12) 
Moderate 
(n=19) 
Severe 
(n=10) 
 n % n % n % n % n % n % 
Mobility             
Level 1  2 20.00 - - 2 12.50 3 25.00 3 15.79 1 10.00 
Level 2 3 30.00 2 13.33 - - 1 8.33 2 10.53 2 20.00 
Level 3 2 20.00 4 26.67 4 25.00 3 25.00 7 36.84 1 10.00 
Level 4 3 30.00 5 33.33 7 43.75 5 41.67 5 26.32 2 20.00 
Level 5 - - 4 26.67 3 18.75 - - 2 10.53 4 40.00 
Self-care             
Level 1  3 30.00 2 13.33 1 6.25 7 58.33 9 47.37 2 20.00 
Level 2 4 40.00 - - 1 6.25 1 8.33 2 10.53 1 10.00 
Level 3 2 20.00 3 20.00 4 25.00 1 8.33 4 21.05 2 20.00 
Level 4 - - 4 26.67 4 25.00 1 8.33 1 5.26 1 10.00 
Level 5 1 10.00 6 40.00 6 37.50 2 16.67 3 15.79 4 40.00 
Usual activities             
Level 1  2 20.00 1 6.67 1 6.25 6 50.00 4 21.05 1 10.00 
Level 2 1 10.00 - - 1 6.25 1 8.33 4 21.05 1 10.00 
Level 3 3 30.00 2 13.33 3 18.75 - - 2 10.53 2 20.00 
Level 4 3 30.00 4 26.67 1 6.25 4 33.33 4 21.05 1 10.00 
Level 5 1 10.00 8 53.33 10 62.50 1 8.33 5 26.32 5 50.00 
Pain/Discomfort             
Level 1  1 10.00 1 6.67 1 6.25 3 25.00 4 21.05 2 20.00 
Level 2 3 30.00 2 13.33 2 12.50 5 41.67 8 42.11 2 20.00 
Level 3 5 50.00 8 53.33 7 43.75 2 16.67 5 26.32 4 40.00 
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The dimension of the EQ-
5D-5L  
Risperidone (N=41) Olanzapine (N=41) 
 Mild 
(n=10) 
Moderate 
(n=15) 
Severe 
(n=16) 
Mild 
(n=12) 
Moderate 
(n=19) 
Severe 
(n=10) 
 n % n % n % n % n % n % 
Level 4 1 10.00 3 20.00 6 37.50 2 16.67 2 10.53 2 20.00 
Level 5 - - 1 6.67 - - - - - - - - 
Anxiety/Depression             
Level 1  2 20.00 4 26.67 3 18.75 4 33.33 2 10.53 2 20.00 
Level 2 4 40.00 1 6.67 2 12.50 6 50.00 8 42.11 3 30.00 
Level 3 2 20.00 7 46.67 5 31.25 - - 5 26.32 2 20.00 
Level 4 2 20.00 2 13.33 4 25.00 2 16.67 3 15.79 3 30.00 
Level 5 - - 1 6.67 2 12.50 - - 1 5.26 - - 
Utility weight [mean  
(SD)] 
0.59 
(0.20) 
0.27 
(0.26) 
0.26 
(0.25) 
0.62 
(0.34) 
0.53 
(0.30) 
0.39 
(0.35) 
* Level 1 (no problems), level 2 (slight problems), level 3 (moderate problems), level 4 (severe problems), and 
level 5 (extreme problems) 
6.3.3 Utility weights of patients with behavioural and psychological symptoms receiving 
risperidone or olanzapine for at least two months, according to dependence  
In this chapter, the definition of patients’ physical dependency used is given in Chapter 5 
(section 5.3.1.4) in which patients are divided into the Pre-FTC and FTC states. 
Table 6.3 shows that the total of risperidone treated patients were 65.85% in the Pre-FTC 
state and 34.15% in the FTC state. For olanzapine treated patients, there were 73.17% in the 
Pre-FTC state and 26.83% in the FTC state. 
In total 85.19% of the risperidone group in the Pre-FTC state had problems with mobility, 
77.78% with self-care, 85.19% with usual activities, 88.89% with pain/discomfort and 
81.48% with anxiety/depression. 
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For the FTC state and being treated with risperidone, all patients had problems with mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression, reflecting their low health-
related quality of life. However, 71.43% of patients in this group had a problem with 
anxiety/depression.  
Patients with the Pre-FTC state and receiving olanzapine reported having problems with 
mobility (76.67%), self-care (43.33%), usual activities (63.33%), pain/discomfort (70.00%) 
and anxiety/depression (86.67%).  
In the FTC state and treated with olanzapine, all patients reported problems of health-related 
quality of life with mobility, usual activity and pain/discomfort. Whilst 90.91% of those 
patients had a problem with self-care and 63.64% had a problem with anxiety/depression, 
reflecting their low health-related quality of life.  
Mean utility weights of patients using risperidone treatment classified by dependence, (as 
given health states), were 0.46 of the Pre-FTC state and 0.12 of the FTC state whilst for the 
olanzapine treated patients the values were 0.63 of the Pre-FTC state and 0.23 of the FTC 
state. Based on classifying patients by dependence, the overall utility weights of patients 
receiving olanzapine had higher values across all severity levels when compared with the 
patients receiving risperidone.  
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Table 6.3: Distribution of levels of perceived problem in each of the dimension of the 
EQ-5D-5L descriptive system and utility weights of patients with BPSD receiving 
risperidone or olanzapine for at least two months, according to dependence status 
The dimension of the EQ-5D-5L Risperidone (N=41) Olanzapine (N=41) 
 Pre-FTC 
(n=27) 
FTC  
(n=14) 
Pre-FTC 
(n=30) 
FTC  
(n=11) 
 n % n % n % n % 
Mobility         
Level 1  4 14.81 - - 7 23.33 - - 
Level 2 5 18.52 - - 5 16.67 - - 
Level 3 8 29.63 2 14.29 10 33.33 1 9.09 
Level 4 10 37.04 5 35.71 8 26.67 4 36.36 
Level 5 - - 7 50.00 - - 6 54.55 
Self-care         
Level 1  6 22.22 - - 17 56.67 1 9.09 
Level 2 5 18.52 - - 4 13.33 - - 
Level 3 8 29.63 1 7.14 7 23.33 - - 
Level 4 4 14.81 4 28.57 1 3.33 2 18.18 
Level 5 4 14.81 9 64.29 1 3.33 8 72.73 
Usual activities         
Level 1  4 14.81 - - 11 36.67 - - 
Level 2 2 7.41 - - 5 16.67 1 9.09 
Level 3 7 25.93 1 7.14 3 10.00 1 9.09 
Level 4 7 25.93 1 7.14 7 23.33 2 18.18 
Level 5 7 25.93 12 85.71 4 13.33 7 63.64 
Pain/Discomfort         
Level 1  3 11.11 - - 9 30.00 - - 
Level 2 4 14.81 3 21.43 9 30.00 6 54.55 
Level 3 16 59.26 4 28.57 8 26.67 3 27.27 
Level 4 4 14.81 6 42.86 4 13.33 2 18.18 
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The dimension of the EQ-5D-5L Risperidone (N=41) Olanzapine (N=41) 
 Pre-FTC 
(n=27) 
FTC  
(n=14) 
Pre-FTC 
(n=30) 
FTC  
(n=11) 
Level 5 - - 1 7.14 - - - - 
Anxiety/Depression         
Level 1  5 18.52 4 28.57 4 13.33 4 36.36 
Level 2 7 25.93 - - 15 50.00 2 18.18 
Level 3 7 25.93 7 50.00 4 13.33 3 27.27 
Level 4 5 18.52 3 21.43 6 20.00 2 18.18 
Level 5 3 11.11 - - 1 3.33 - - 
Utility weight [mean (SD)] 0.46 (0.26) 0.12 (0.13) 0.63 (0.30) 0.23 (0.22) 
*Level 1 (no problems), level 2 (slight problems), level 3 (moderate problems), level 4 (severe problems), and 
level 5 (extreme problems); Pre-FTC (not requiring for full time care); FTC (requiring for full time care) 
 
6.4 Discussion 
In this thesis, the findings are challenging in measuring the health utilities, (or utility 
weights), of patients with behavioural and psychological symptoms of dementia and being 
treated with atypical antipsychotics, (risperidone or olanzapine), according to their cognitive 
function, (mild, moderate and severe stages), and dependency, (the Pre-FTC and FTC states), 
using the EQ-5D-5L. Based on the two treatments, the findings contribute ten values of 
utility weights for given different health states of patients as follows: the risperidone treated 
patients with the mild stage; the risperidone treated patients with the moderate stage; the 
risperidone treated patients with the severe stage; the risperidone treated patients with the 
Pre-FTC state; the risperidone treated patients with the FTC state; the olanzapine treated 
patients with the mild stage; the olanzapine treated patients with the moderate stage; the 
olanzapine treated patients with the severe stage; the olanzapine treated patients with the Pre-
FTC state; and the olanzapine treated patients with the FTC state. 
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Considering the completed questionnaires, they were in the majority of cases, completed by 
patients’ primary caregivers as proxies during the face-to-face interviews. However, it is 
unavoidable in patients with BPSD due to them having difficulties in making realistic and 
accurate judgements related to their conditions.  
When considering the classification of patients by cognitive function, patients with BPSD in 
the mild stage receiving risperidone reported more problems in all dimensions than those 
receiving treatment with olanzapine. In the moderate stage, patients with BPSD receiving 
risperidone reported more problems than those receiving the treatment with olanzapine in the 
dimensions of mobility, self-care, usual activities and pain/discomfort, while in the 
anxiety/depression dimension it was the opposite. Furthermore, patients with BPSD in the 
severe stage and receiving risperidone reported more problems in self-care, usual activities, 
pain/discomfort and anxiety/depression dimensions, whereas the mobility dimension was 
reversed with the olanzapine patients. This implies that patients with BPSD in the mild, 
moderate and severe stages receiving olanzapine had a better HRQoL than those patients 
receiving risperidone, leading to the higher utility weights of the olanzapine group compared 
with the risperidone group.     
When considering the classification of patients by dependence, patients with BPSD in the 
Pre-FTC state receiving risperidone reported more problems than those receiving the 
olanzapine treatment in the mobility, self-care, usual activities and pain/discomfort 
dimensions, while in the anxiety/depression dimension it was different with the olanzapine 
group reporting more problems. Patients with BPSD in the FTC state receiving risperidone 
reported more problems than those receiving the olanzapine treatment in all dimensions. This 
indicates that patients with BPSD in the Pre-FTC and FTC states receiving olanzapine had a 
better HRQoL than those patients receiving risperidone, leading to the higher utility weights 
of the olanzapine group compared with the risperidone group.     
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In addition, the findings in this thesis also indicate that the more advanced stages of cognition 
impairment and the more dependence status are significantly correlated with much lower 
scores of the utility weights in patients with BPSD and treated with olanzapine or 
risperidone. A possible explanation is that both patients in the late stage of dementia and 
patients with dementia in the FTC state had experienced serious memory disturbances, 
resulting in poor conditions in self-care, change in mobility, unable to recognise, change in 
personality, behavioural changes, emotional changes and needed more assistance (WHO 
2012).  
Furthermore, the findings associated with the utility weights in this thesis are consistent with 
previous studies conducting an assessment of HRQoL in patients with dementia, in particular 
Alzheimer’s disease, where those previous studies reported that a lower HRQoL was 
correlated with the higher dependence status of those patients and the greater severity of 
cognitive impairment (Neumann et al. 1999, Ikeda, Niwata and Igarashi 2001, Murman and 
Colenda 2005). However, it should be noted that there are differences in the target 
populations, the cognitive test in evaluating cognitive function, the instrument in measuring 
HRQoL, the settings of the studies as well as country-specific healthcare systems amongst 
those published studies and this thesis.  
The utility analyses presented in this chapter have several limitations to note. Firstly, owing 
to the utility data not being conducted in a longitudinal assessment, thus there are 
uncertainties in monitoring changes in utility scores influenced by the treatment. Regarding 
utility data derived from a cross-sectional survey using the EQ-5D, this might be associated 
with a limitation of the thesis to know how changes over time were due to the two drugs. 
This thesis might be unable to answer how long patients benefit from drugs after taking them 
and the time until patients had discontinued drugs for any reason, namely lack of efficacy, 
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intolerability and undesirable effects. Also, current utility weights might be due to other 
conditions, such as the improvement of co-conditions of patients. 
Secondly, some limitations should be noted because the respondents in the interviews might 
not properly be representative of the population of patients with BPSD, due to the utility 
weight data in this thesis being based on the data collected from two hospital in Thailand, 
(Thammasat University Hospital and Khon Kaen Rajanagarindra Psychiatric Hospital).    
Thirdly, the findings are focused on outpatients with BPSD and being on risperidone or 
olanzapine, its generalizability to patients with BPSD in nursing home or institutionalisation 
is unknown. 
Additionally, it is important to note that the EQ-5D-5L instrument is not a dementia-specific 
instrument, therefore it might not have captured other conditions of interest.  
Finally, the questionnaires were mainly completed by caregivers as proxy respondents. 
Several studies reported that the proxy-rating scale under the assessment of HRQoL in people 
with dementia were affected by several factors, including caregiver burden, caregivers’ 
anxiety, caregivers’ distress, caregivers’ depression, patients’ functioning, severity of 
dementia and neuropsychiatric symptoms. These factors were significant impacts on lower 
HRQoL scores rated by the caregivers (Karlawish et al. 2001, Markowitz et al. 2003, Bryan 
et al. 2005, Samus et al. 2006, Naglie 2007, Valimaki et al. 2009, Naglie et al. 2011, Black et 
al. 2012, Sheehan et al. 2012, Orgeta et al. 2013, Gräske, Meyer and Wolf-Ostermann 2014). 
However, it is imperative to consider proxy respondents instead patients with cognitive 
impairment and behavioural disturbances for the HRQoL assessment. Thus, it is necessary to 
interpret the utility weights from this study with caution.  
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In conclusion, the utility data in this thesis are directly derived from patients with BPSD 
and/or their caregivers in the actual clinical setting. To the best of my knowledge, this study 
can be highlighted as the first study to conduct the health utility weights in patients with 
BPSD and being treated with atypical antipsychotics, (risperidone or olanzapine), using the 
EQ-5D-5L instrument. The study also highlights utility weights by classifying patients with 
cognitive severity and physical dependence. Further, the finding could be adopted in the cost-
utility analysis of atypical antipsychotics for the treatment of patients with BPSD. 
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Chapter 7: The application of the cost-effectiveness of olanzapine in 
comparison to risperidone for the treatment of patients with 
behavioural and psychological symptoms in dementia in Thailand 
Abstract 
Introduction: Dementia has been highlighted as a significant burden of several countries 
which are becoming ageing societies, including Thailand. This syndrome comes together 
with the behavioural and psychological symptoms of dementia (BPSD) which nearly all 
patients of those with dementia tend to encounter at any one point during the course of 
disease. These symptoms are related to several problems for those patients, caregivers and 
family members, resulting in a lesser quality of life as well as a higher incidence of both 
economic and clinical burdens for those people. To date, no treatments have been approved 
for the treatment of BPSD by the US FDA leading to a variety of treatments for those 
patients. However, antipsychotics, (especially atypical antipsychotics), have been widely 
used and recommended by many experts as a first-line therapy to treat BPSD in clinical 
practice, although these drugs are off-label use for patients with BPSD due to a concern over 
drug safety. Furthermore, the newer atypical antipsychotics are likely to be costlier than the 
older ones, leading to a restriction on a physician’s decision to prescribe these drugs for 
patients suffering from BPSD. This also has a significant impact on patients and their 
caregivers when deciding on the management of BPSD sufferers. Thus, this economic 
evaluation may provide the information potentially to enable decision makers in making a 
better-informed decision in this area.  
Aim: The aim of this chapter is to examine the cost-effectiveness of olanzapine versus 
risperidone in dementia patients with behavioural and psychological symptoms in Thailand.   
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Methods: An existing Markov model based on a critical review through the comprehensive 
literature search (Chapter 2) and a justification for the most appropriate model for a Thai 
setting (Chapter 4), was adapted to simulate the disease progression of patients with dementia 
with behavioural disturbances until their need for full-time care (FTC). The time to the FTC 
state was estimated by a predictive equation developed by Rive et al. (2010). The model was 
conducted to assess the expected costs and outcomes associated with olanzapine compared 
with risperidone for Thai patients with BPSD aged 60 years and above. This model 
performed over a five-year time horizon with a one-month cycle length based on a societal 
perspective. The incremental cost-effectiveness ratio was used as the estimated outcome. 
Sensitivity analyses were also conducted to demonstrate the robustness of the results.  
Results: Over 5 years, olanzapine was found to be a cost-effective therapeutic option for the 
treatment of behaviourally disturbed patients with dementia compared with risperidone, in 
Thailand from a societal perspective (ICER < THB 160,000). The model underwent 
extensive sensitivity analyses which also confirmed that olanzapine was the dominant 
strategy following the base-case findings.  
Conclusions: By comparison with risperidone, the model suggests that olanzapine can be 
regarded as cost-effective therapeutic strategy for the management of patients with 
behavioural and psychological symptoms in Thailand.  
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7.1 Introduction 
In the last decades, dementia has become a leading cause of health problems in elderly people 
worldwide due to the rapid growth of older populations (World Health Organisation 2012). 
The decline in cognitive abilities is known as the main illness of people with dementia; 
however, non-cognitive symptoms of dementia are also prominent difficulties which take 
place in parallel to cognitive deteriorations during the progressive nature of the disease of 
these people (Liperoti, Pedone and Corsonello 2008).  
Behavioural and psychological symptoms of dementia, sometimes known as neuropsychiatric 
symptoms, non-cognitive symptoms or behavioural disturbances, are major problems in 
people with dementia which frequently occur at some point during the course of their illness 
(Benoit et al. 1999, Desai and Grossberg 2001, Cerejeira, Lagarto and Mukaetova-Ladinska 
2012). These symptoms, such as agitation, aggression, psychosis, wandering, sleep 
disturbances and oppositional behaviour, lead to a significant impact on caregiver burden and 
caregiver stress over and above the functional and cognitive impairment in those patients 
(Rymer et al. 2002, Benoit et al. 2006, Hersch and Falzgraf 2007, Liperoti, Pedone and 
Corsonello 2008, Cerejeira, Lagarto and Mukaetova-Ladinska 2012, Kales, Gitlin and 
Lyketsos 2015).  
Currently, there is no cure for BPSD and no FDA-approved medications for the treatment of 
BPSD (Desai, Schwartz and Grossberg 2012, Zdanys et al. 2016). Moreover, BPSD-
associated symptoms are the most significant problems encountered in clinical practice. The 
main treatment options are focused on problematic behavioural symptoms management. The 
non-drug interventions or non-pharmacological approaches are recommended as the first 
treatment options, however, drug interventions or pharmacological approaches are applied in 
cases where patients are unsuccessful or do not respond to first-line treatments (Andrade and 
Radhakrishnan 2009, Kales, Gitlin and Lyketsos 2015).  
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Atypical antipsychotics are one class of pharmacological approaches which are favourable to 
prescribe in patients with BPSD as a first-line therapy, even though there are serious concerns 
over the safety. These drugs and their prescriptions are an off-label fashion for BPSD patients 
(Alexopoulos et al. 2005, Liperoti, Pedone and Corsonello 2008, Zec and Burkett 2008, and 
Mather and Theodore 2012). As previously stated, behavioural disturbances in patients with 
dementia have a great impact on the economic burden and health care problems of caregiving 
for these people (Kales, Gitlin and Lyketsos 2015).  
To date there are a limited number of studies conducted in health economic evaluations on 
atypical antipsychotics used in people with dementia. There are a variety of atypical 
antipsychotics, including olanzapine and risperidone, that are prescribed for patients with 
BPSD in Thailand but these are not well defined in terms of economic evaluations.  
The purpose of this chapter is to conduct a cost-utility analysis of olanzapine compared with 
risperidone, for the treatment of patients with behavioural and psychological symptoms of 
dementia in Thailand. 
 
7.2 Methods 
A model-based cost-utility analysis was performed to assess the health and economic impact 
of atypical antipsychotics, olanzapine and risperidone, in the treatment of patients with 
behavioural and psychological symptoms of dementia in Thailand.  
7.2.1 Model structure  
The existing model-based economic evaluations in dementia have been critically reviewed 
through the comprehensive literature search (see Chapter 2). The most commonly used model 
frameworks were adopted for developing in the different model characteristics. Then, a 
comparison amongst those models was conducted and justified in selecting the most 
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appropriate model for applying to the cost-utility analysis of olanzapine compared with 
risperidone in the treatment of patients with BPSD in Thailand (see Chapter 4).  
The model used in this thesis was an adaptation of a Markov model based on the FTC 
conceptual framework developed by Rive et al. (2010) to simulate the disease progression in 
patients over time. The significant concept of the model was the patients’ need for FTC. The 
definition of the FTC was based on either the dependency or the location of care, (community 
or institutions), (Rive et al. 2010). The patients’ dependency status was assessed by physical 
and functional disability. Health states of the model consisted of not requiring FTC (Pre-
FTC), FTC and death.  
In this thesis, the dependency status of patients was measured by physicians as well as the 
Activities of Daily Living (ADL) rating as assessed by the Barthel Index-Thai. The scores 
were categorised into four levels: a total dependence (score ranging from 0 to 4), a severe 
dependence (score 5-8), a moderate dependence (score 9-11), and a mild dependence (score 
12 and above (Prasat Neurological Institute 2014). Subsequently, the FTC and Pre-FTC states 
were defined by a score of 0-8 and 9 and over, respectively. 
Due to this thesis focusing on the treatment of patients with BPSD, behavioural disturbances 
associated with patients requiring atypical antipsychotics for their treatment were then 
incorporate into the health states of the model (Figure 7.1).  
Based on the model structure, all patients with BPSD were possibly starting treatment with 
one of the two available choices, (either olanzapine or risperidone), at the beginning of the 
model. Those patients were also assumed to start with the Pre-FTC state. The transition of 
patients from one health state to another state depended on the transition probabilities to 
simulate how patients progressed through the health states of the model over time. The 
possibility of transitions between health states of those patients is outlined below. 
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• From Pre-FTC, there were three possible transition states which those patients might 
move to. Some patients remained in their current heath state (Pre-FTC), whereas 
some of them transitioned to the other possible pathways of FTC and death.  
• From FTC state, some patients remained in the same state whilst others progressed to 
death. 
• Death was defined as an absorbing state.  
The disease progression was conducted over a one-month cycle length and the time horizon 
of this analysis was five years, (a total of 60 Markov cycles). These were chosen because 
they covered the chronically progressive disease and reflected the nature history of the 
disease.  
This is also in line with previous studies regarding model-based economic evaluation in 
dementia, especially Alzheimer’s disease, based on the FTC conceptual framework (Green et 
al. 2005, Rive et al. 2010, Turongkaravee et al. 2011, Rive et al. 2012). Further, Microsoft® 
Excel version 2013 was used to construct the decision-analytic model of this thesis. 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Diagram of the Markov model based on the FTC conceptual framework for 
the cost-utility analysis of olanzapine compared with risperidone 
 FTC +BPSD 
  
  Pre-FTC+ BPSD 
Death 
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7.2.2 Data inputs of the model 
The main parameters required for the developed model based on the FTC framework using 
the predictive equation to predict the time to the FTC state are outlined below.  
7.2.2.1 The estimation of transition probabilities from the not requiring FTC state (Pre-
FTC) to the FTC state 
As stated above, the formulated model in this thesis reflected the disease progression which 
was represented through three health states: Pre-FTC, FTC and, finally, death. Due to a lack 
of data associated with predicting time until patients deteriorate to a level requiring full-time 
care (FTC) in Thailand, this thesis applied a new predictive equation by Rive et al. (2010) 
which was developed based on data from the UK longitudinal epidemiological study of 117 
Pre-FTC patients with Alzheimer’s disease, LASER-AD cohort (Livingston et al. 2004), to 
calculate the length of time to FTC in the model. Further, based on the LASER-AD cohort, 
the assessment in the cohort was at baseline, at six months and then every twelve months. 
Thus, the interval probabilities of reaching the FTC state were extrapolated over a five-year 
time horizon based on the assumption as to whether the risk of transitioning to the FTC state 
was constant in each time interval.  
According to the predictive equation by Rive et al. (2010), the potential predictors for 
predicting the need for FTC were based on baseline values of cognition, (as measured by the 
Alzheimer’s Disease Assessment Scale-cognitive subscale, ADAS-cog), function, (as 
measured by the Alzheimer’s Disease Cooperate Study-Activities of Daily Living Scale total, 
ADCS-ADL), behaviour, (as measured by the neuropsychiatric inventory total, NPI-total) 
and the rates of change, (i.e. slopes), in deterioration of ADAS-cog and ADCS-ADL scores. 
To predict the time to FTC, the equations used in this model are outlined below.   
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• The equation for predicting the time to FTC 
 
𝑝𝑗 = 1 − exp (− exp (−11.1343 + 0.0330 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 − 0.0877 × 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
+ 0.0377 × 𝑁𝑃𝐼𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 + 0.8122 × 𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗)
− 2.4072 × 𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒
𝑠𝑙𝑜𝑝𝑒 (𝑗)) × exp(3.3195 × ln(𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙𝑗))) 
 
where    𝑝𝑗  was probability for the time interval j 
  𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒    was the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale at baseline 
  𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒   was the Alzheimer’s Disease Cooperative Study- 
Activities of Daily Living scale at baseline 
  𝑁𝑃𝐼𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒    was the Neuropsychiatric Inventory total score at baseline 
  𝐴𝐷𝐴𝑆 − 𝑐𝑜𝑔𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑠𝑙𝑜𝑝𝑒 (𝑗)  was the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale for the time interval j 
  𝐴𝐷𝐶𝑆 − 𝐴𝐷𝐿𝑡𝑜𝑡𝑎𝑙−𝑠𝑐𝑜𝑟𝑒𝑠𝑙𝑜𝑝𝑒 (𝑗)  was the Alzheimer’s Disease Cooperative Study 
Activities of Daily Living scale for the time interval j 
• Based on the assumption of the constant risk of FTC within each time interval, the 
estimation of the monthly transition probability to the FTC state was computed by 
 
     𝑝𝑗𝑖
𝐹𝑇𝐶 = 1 − √(1 − 𝑃𝑗
𝑙𝑒𝑛𝑔𝑡ℎ(𝑗)
) 
 
where   𝑝𝑗𝑖𝐹𝑇𝐶    was the monthly probability 
  𝑝𝑗        was the probability for the time interval j 
In addition, the calculation of the transition process from the Pre-FTC to FTC states due to 
drug treatments was based on three steps as outlined below.  
• The first step was associated with defining baseline parameters, (baseline values of 
ADAS-cog, ADCS-ADL and NPI and slopes of ADAS-cog, ADCS-ADL), in patients 
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given the standard care. The standard care was defined as either patients having no 
pharmacological therapy or background therapy with ChEIs (Rive et al. 2010).  
• At the second step, clinical effectiveness data of olanzapine and risperidone in 
dementia were derived from a critical review of published studies which ADAS-cog, 
ADCS-ADL and NPI were measured as the main clinical outcomes of such studies. 
For state-changes of the model, the probability was dependent on baseline parameters 
at the beginning and on the adopted treatment effects. Thus, the treatment effects of 
olanzapine and risperidone were adjusted to the baseline parameters of the standard 
care, providing the predictive equation parameters of each drug treatment.  
• The last step was that the predictive equation parameters of each drug were input into 
the predictive equation for calculating the interval probabilities of reaching the FTC 
state in the model.  
Baseline characteristics of patients to predict time to FTC 
The predictive equation to predict time to FTC was developed based on the LASER-AD 
cohort as this cohort was designed to be representative of the general Alzheimer’s disease 
population (Rive et al. 2010). In addition, based on the LASER-AD cohort the distribution of 
patients was 30% with mild, 40% with moderate and 30% with severe symptoms of the 
disease. Mean age of Pre-FTC patients was 79.80 years. Approximately 69% of patients in 
the Pre-FTC state were women. Further, the mean ADAS-cog score was 27.20. Hypertension 
was predominant in the patients’ medical history, (34%). The Laser-AD study also reported a 
prevalence of patients at 6 months post-baseline approximately 82% for agitation and 71% 
for psychosis (Ryu et al. 2005, Rive et al. 2010).  
According to the primary data collected in Thailand, patients with BPSD were diagnosed 
with dementia, (ICD-10: F00-F03), or Alzheimer’s disease, (G30), were included in this 
thesis (World Health Organization 2015). The cause of dementia profile of patients with 
BPSD was approximately 86.59% diagnosed with Alzheimer’s disease, 10.98% with 
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unspecified dementia and 2.44% with mixed dementia. Patient characteristics of this thesis 
were distributed to 26.83% mild, 41.46% moderate and 31.71% with severe classification of 
the disease. Associated with the Pre-FTC state, the mean age of BPSD patients was 77.54 
years and mean ADAS-cog score was 29.40. A predominant comorbidity of patients with the 
Pre-FTC was hypertension (50.93%). Additionally, in this thesis patients had a presence of 
agitation/aggression and psychosis accounting for 60.98% and 53.66%, respectively.  
When considering the prediction of time to FTC, the data inputs to the equation were based 
on assessments on all core Alzheimer’s disease domains: ADAS-cog, ADCS-ADL and NPI 
of patients at baseline. These assessments were frequently used in Alzheimer’s disease or 
dementia in several countries (Rive et al. 2010). However, ADAS-cog, ADCS-ADL and NPI 
scores were not generally used in the routine clinical practice in Thailand. For instance, the 
cognitive function was generally assessed by Thai Mental State Examination, (TMSE) or 
MMSE-Thai 2002. The “activities of living” was measured by basic activities of daily living, 
(bADL), and instrumental activities of daily living, (iADL), (Prasat Neurological Institute 
2014). Whilst an assessment of BPSD was mostly based on the ABCs approach and Four Ds 
approach (Sittironnarit 2011, Prasat Neurological Institute 2014).   
Due to a lack of data associated with baseline characteristics of patients in a Thai setting to 
exercise in the predictive equation, this model took baseline data from patients given the 
standard care in the LASER-AD study in the UK (Livingston et al. 2004). In addition, other 
reasons were considered as follows: the population of patients in this thesis were similar in 
their characteristics to the population used to develop the predictive equation by Rive et al. 
(2010) as stated above and the predictive equation was also able to apply broadly in other 
settings due to the equation being developed based on the general Alzheimer’s disease 
population (Rive et al. 2010). This was consistent with the previous economic evaluation 
study in dementia, especially Alzheimer’s disease, which used the baseline characteristics of 
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patients given the standard care from the LASER-AD study in the UK as applied to the cost-
effectiveness study in Norway (Rive et al. 2012).  
7.2.2.2 The estimation of transition probabilities of dying 
The transition probabilities between states to death in the thesis were calculated by 
multiplying the available data of the monthly probability on age-specific death, focusing on 
age 60 and over, of the general Thai population from the epidemiological data in Thailand 
(The Thai working group on burden of disease and injuries 2002) and the relative risk (RR) 
of patients dying from Alzheimer’s disease associated with each health state, (Pre-FTC and 
FTC). According to Gambassi et al. (1999), this study showed that the relative risk of patients 
dying from Alzheimer’s disease was 1.45 and 3.03 in the Pre-FTC and FTC states, 
respectively. This was in line with the cost-utility analysis of ChEIs in Alzheimer’s disease in 
Thailand that used the same method to predict the probabilities of death of patients in the 
model based on the FTC conceptual framework (Turongkaravee et al. 2011).  
There are several studies indicating an increased risk of death in the elderly atypical 
antipsychotic users (Maher et al. 2011, Ma et al. 2014); however, this was in contrast with the 
results from the study by Schneider et al. (2006). According to Schneider et al. (2006), the 
clinical trial-the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s 
disease, (CATIE-AD), a large double-blind randomised controlled trial of 421 outpatients 
with Alzheimer’s disease with psychosis, aggression or agitation and assigned to olanzapine, 
risperidone, quetiapine or placebo, reported that there were no significant differences 
amongst treatment groups compared with placebo regarding an increased risk of death. In 
addition, the study by Kales et al. (2012) conducted a retrospective study in 33,604 patients 
with dementia based on the national data of Veterans Affairs between 1999 and 2008, in the 
USA. This found that olanzapine treated patients had lower mortality rates than risperidone 
treated patients (RR 0.99, 95% CI 0.89–1.10); however, it was not statistically significant 
between two drug treatments. Thus, the assumption in this thesis with regard to transition 
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probabilities of the death of BPSD patients and being treated with olanzapine or risperidone 
was that any treatment did not reflect an increased risk of mortality. This assumption was 
consistent with the study of olanzapine versus no treatment for the treatment of agitation and 
psychosis in patients with Alzheimer’s disease (Kirbach et al. 2008). Table 7.1 shows the 
monthly probabilities of dying for the general Thai population classified by age group, 
focusing on aged 60 and over. 
Table 7.1: Monthly probabilities of dying of the general Thai population classified by 
age group (The Thai working group on the burden of disease and injuries 2002) 
Age group (years) Probability 
60-64 0.00119 
65-69 0.00175 
70-74 0.00267 
75-79  0.00423 
80-84  0.00667 
> 85  0.01000 
 
7.2.2.3 Clinical effectiveness data of olanzapine or risperidone 
The effectiveness data were derived from a critical review of published studies based on a 
comprehensive literature search from electronic database between 1994 and July 2015. 
Clinical data for treatments were also extended to the relevant clinical trials from the 
references of the literature review.  
In olanzapine and risperidone treated groups, the baseline characteristics of patients were 
adjusted with the treatment effects of both drugs derived from the clinical trials. The 
treatment effects of the model made the same assumptions in line with previous published 
pharmaco-economic studies of ChEIs and memantine models in Alzheimer’s disease (Green 
et al. 2005, Rive et al. 2010, Rive et. 2012). Thus, the model assumed that patients started 
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treatments immediately and benefits from treatments had immediate effects, resulting in 
modifying the time to progress from the Pre-FTC to FTC states of these patients. Further, 
treatment effects based on clinical trials did not evaluate the disease-modifying effects of the 
treatments on cognition and functioning (Deberdt et al. 2005, Sultzer et al. 2008). Both drugs 
were then assumed to have no effect on the modifying of disease and on changing the rate in 
cognitive function and functioning over time. Based on this assumption, the treatment effects 
of olanzapine and risperidone did not affect or alter the speed of cognitive and functional 
decline, thus parameters associated with slopes of ADAS-cog and ADCS-ADL in the 
equation were the same values in both treatment groups. These parameters were taken data 
from the baseline characteristics of patients given the standard care as previously stated.   
Consequently, treatment effects of olanzapine and risperidone considered only the changes in 
ADAS-cog, ADCS-ADL, and NPI scores. The treatment effects from the two drugs were 
implemented by deducting those scores from the baseline data of patients at the beginning of 
the decision-analytic model. This was consistent with previous studies of the economic 
evaluation of memantine based on the FTC framework using the predictive equation by Rive 
et al. (2010) to estimate the time to the FTC state (Rive et al. 2010, Rive et. 2012, Zala et al. 
2017).  
According to the literature review, the effectiveness data of olanzapine and risperidone were 
obtained mainly from two published clinical trials (Deberdt et al. 2005, Sultzer et al. 2008). 
With regard to cognitive function and functional ability, the effects of olanzapine and 
risperidone were derived from the Phase 1 outcomes, were measured as primary outcomes of 
the CATIE-AD study, a double-blind randomised controlled trial of 421 outpatients with 
Alzheimer’s disease, who had psychosis, aggression or agitation and were assigned either 
olanzapine, risperidone, quetiapine or a placebo (Sultzer et al. 2008). Based on Phase 1 
outcomes of the CATIE-AD study, at 12 weeks the changes in the cognition scores, (as 
measured by ADAS-cog), were 0.70 for olanzapine, 1.70 for risperidone and 1.30 for the 
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placebo; however, these scores were not regarded as significant differences. For ADCS-ADL 
scores, the CATIE-AD study reported that the changes showed -6.10 in olanzapine-treated 
patients, -1.10 in risperidone-treated patients and 0.50 in the placebo group (Sultzer et al. 
2008). The NPI-total scores were derived from the study by Deberdt et al. (2005), double-
blind randomised controlled trial of 496 patients with psychotic symptoms associated with 
dementia and assigned to olanzapine, risperidone or placebo. According to Deberdt et al. 
(2005), the study reported that the changes of NPI-total scores, was measured as a primary 
outcome of the treatment groups compared with the placebo group and were 0.50 in the 
olanzapine-treated group and 2.60 in the risperidone-treated group, respectively.  
In addition, the study by Leeuwen et al. (2018) suggested patients with Alzheimer’s disease 
with more severe neuropsychiatric symptoms, especially agitation, aggression, or psychosis, 
responded well to long-term antipsychotic treatment. As a result, the assumption of this 
model was that the effects of drugs were assumed to be constant over a five-year time 
horizon. 
Table 7.2 details the baseline characteristics of patients and the clinical effectiveness data of 
olanzapine and risperidone. As Table 7.3 shows, the predictive equation parameters based on 
treatment effects with olanzapine and risperidone were used in calculating the length of time 
to FTC in the model.  
Table 7.2: Summary of the baseline characteristics of patients and the clinical 
effectiveness data of olanzapine and risperidone  
Variable Baseline Olanzapine effect 
(Change in scores) 
Risperidone effect 
(Change in scores) 
Reference 
Behavioural (NPI-total) 18.54 0.50 2.60 Deberdt et al. (2005), 
Rive et al. (2010) 
Functioning (ADCS-ADL) 45.00 -6.60 -1.60 Sultzer et al. (2008), 
Rive et al. (2010) 
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Variable Baseline Olanzapine effect 
(Change in scores) 
Risperidone effect 
(Change in scores) 
Reference 
Cognition (ADAS-cog) 36.30 -0.60 0.40 Sultzer et al. (2008), 
Rive et al. (2010) 
ADAS-cog slope 0.6116 0.6116 0.6116 Rive et al. (2010) 
ADCS-ADL slope -0.7503 -0.7503 -0.7503 Rive et al. (2010) 
* (+)/ (-), improvement of clinical outcomes from the treatments, olanzapine or risperidone 
 
Table 7.3: The predictive equation parameters from treatment effects with olanzapine 
and risperidone for calculating the time to FTC in the model 
Variable Olanzapine Risperidone Reference 
Behavioural (NPI-total) 19.04 21.14 Deberdt et al. (2005), Rive et al. (2010) 
Functioning (ADCS-ADL) 38.40 43.40 Sultzer et al. (2008), Rive et al. (2010) 
Cognition (ADAS-cog) 35.70 36.70 Sultzer et al. (2008), Rive et al. (2010) 
ADAS-cog slope 0.6116 0.6116 Rive et al. (2010) 
ADCS-ADL slope -0.7503 -0.7503 Rive et al. (2010) 
 
Then, the monthly probabilities of the time to the FTC state were computed based on the 
predictive equation parameters of each treatment using the predictive equation as presented 
above. The estimated monthly probabilities time to the FTC state of both treatments, 
(olanzapine and risperidone), are shown in Table 7.4.  
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Table 7.4: Monthly transition probabilities of reaching FTC state of the treatments with 
olanzapine and risperidone  
 
7.2.2.4 Cost data of olanzapine and risperidone-treated patients with behavioural and 
psychological symptoms of dementia at each health state of the model from a societal 
perspective 
Costs of patients with BPSD and treated with olanzapine and risperidone were obtained from 
primary collected data from two hospitals: Thammasat Hospital University and Khon Kaen 
Rajanagarindra Psychiatric Hospital in Thailand using the cost questionnaire completed by 
face-to-face interviews with the outpatients and/or their caregivers. More details of the 
process of data collection and calculating costs can be seen in Chapter 5. 
In this thesis, data on cost included direct medical and direct non-medical costs from a 
societal perspective. The direct non-medical costs of patients with BPSD included informal 
care. Due to the concerns over safety and relapse of atypical antipsychotic use in patients 
with BPSD, costs associated with adverse events and relapses were also taken into account in 
the cost analysis in this thesis. Cost data were classified into the Pre-FTC and FTC states. All 
costs were expressed in the Thai currency at 2017 values (1£ =45). Cost parameters of 
olanzapine and risperidone treated patients with BPSD in the model are shown in the Table 
7.5.  
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Table 7.5: Cost parameters for the cost-utility analysis for olanzapine compared with 
risperidone in patients with BPSD 
Parameter Base-case value Source 
Mean  (SD) 
Cost estimations (THB)    
Direct medical costs     
Monthly drug costs     
  Pre-FTC, cost per month     
     Risperidone  70.51  (34.13) Collected data in a Thai setting 
     Olanzapine  939.29  (588.38) Collected data in a Thai setting 
   FTC, cost per month    
     Risperidone  76.24  (21.12) Collected data in a Thai setting 
     Olanzapine  1,271.97  (544.42) Collected data in a Thai setting 
Total direct medical costs    
   Pre-FTC, cost per month    
     Risperidone  4,324.47  (2,030.91) Collected data in a Thai setting 
     Olanzapine  4,782.94  (1,938.46) Collected data in a Thai setting 
   FTC, cost per month    
     Risperidone  5,627.54  (3,003.93) Collected data in a Thai setting 
     Olanzapine  9,905.50  (7,990.77) Collected data in a Thai setting 
Direct non-medical costs    
   Pre-FTC, cost per month    
     Risperidone  40,392.62  (14,412.45) Collected data in a Thai setting 
     Olanzapine  39,564.34  (15,404.85) Collected data in a Thai setting 
   FTC, cost per month    
     Risperidone  47,539.49  (10,245.71) Collected data in a Thai setting 
     Olanzapine  48,388.70  (18,511.68) Collected data in a Thai setting 
Total monthly costs    
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Parameter Base-case value Source 
Mean  (SD) 
   Pre-FTC, cost per month    
     Risperidone  44,717.09  (14,573.74) Collected data in a Thai setting 
     Olanzapine  44,347.28  (16,071.51) Collected data in a Thai setting 
   FTC, cost per month    
     Risperidone  53,167.03  (11,251.27) Collected data in a Thai setting 
     Olanzapine  58,294.20  (19,227.41) Collected data in a Thai setting 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
 
7.2.2.5 Health-related quality of life weights, (or utility weights), of olanzapine and 
risperidone treated patients with behavioural and psychological symptoms of dementia 
at each health state of the model 
The cross-sectional survey based on the face-to-face interviews using the EQ-5D-5L was 
conducted in the outpatients departments with BPSD patients who were being treated with 
olanzapine or risperidone at the same setting. The resulting EQ-5D-5L scores were evaluated 
using Thailand tariffs, based on time trade-off (TTO) and the Discrete Choice Experiment 
(DCE) methods, to compute and capture individual utility weights for each health state, (Pre-
FTC and FTC). More details are given previously in Chapter 6. Utility weight parameters of 
olanzapine- and risperidone-treated patients with BPSD in the model are shown in Table 7.6. 
  
 
 
 
 
 
 
 
381 
 
Table 7.6: Utility weight parameters for the cost-utility analysis for olanzapine 
compared with risperidone inpatients with BPSD 
Parameter Base-case 
value 
Source 
Mean (SD)  
Health utility weights    
   Pre-FTC, utility weights    
     Risperidone  0.46 (0.26)  Collected data in a Thai setting 
     Olanzapine  0.63 (0.30)   Collected data in a Thai setting 
   FTC, utility weights    
     Risperidone  0.12 (0.13)  Collected data in a Thai setting 
     Olanzapine  0.23 (0.22)   Collected data in a Thai setting 
 
7.2.2.6 Discount rates of the study  
A discount rate of 3% per annum was applied to both costs and health outcomes. This was 
based on the recommendation in the guideline of health technology assessment in Thailand 
(HITAP 2014).  
7.2.2.7 Data analysis 
7.2.2.7.1 Base-case analysis of the model 
At the base-case scenario, the results of the cost-utility analysis were calculated in terms of 
an incremental cost-effectiveness ratio (ICER) as measured by incremental costs, (a 
difference in costs between treatment groups), divided by incremental outcomes, (a 
difference in quality-adjusted life years, (QALYs), of both treatments). The QALYs was a 
measure of survival weighted by utility values, where the utility values indicated the 
desirability of living in each health state. Costs, including direct medical and direct non-
medical costs, were expressed in Thai currency, reporting in 2017 value, (1 £ = 45 Baht).  
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The incremental cost-effectiveness ratio (ICER) used to calculate as outlined below. 
 
                                      ICER     =   
Cost of Olanzapine - Cost of Risperidone 
QALY of Olanzapine - QALY of Risperidone
     
 
where:   ICER was an incremental cost-effectiveness ratio 
             QALY was the quality-adjusted life year 
7.2.2.7.2 Sensitivity analyses of the model 
The model underwent deterministic and probability sensitivity analyses to examine the 
robustness of the base-case results and conclusions.  
• The deterministic sensitivity analysis was performed based on the one-way 
sensitivity analysis across costs, utilities and discount rates by varying each 
parameter. Based on this method, the costs associated with each health state were 
analysed by varying between plausible extremes of data based on the primary data 
collected in a Thai setting. The utility weights were defined by varying ± 30%. In line 
with the recommendations of the guideline of health technology assessment in 
Thailand (HITAP 2014), discount rates for costs and health benefits were varied 
between 0% and 6% per annum.  
• Probabilistic sensitivity analyses, (PSA), using a Monte Carlo simulation were 
performed by varying all key parameters in a plausible range according to a pre-
defined distribution on the basis of 1,000 repetitions. Beta distributions were assigned 
to health utility weights. Gaussian distributions were applied to transition 
probabilities, whereas gamma distributions were chosen for the cost data. Based on 
this approach, the expected costs and expected number of QALYs for that 
combination of parameter values were produced. The PSA in this thesis was 
performed using Microsoft® Excel version 2013. 
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In this thesis, the cost-effectiveness acceptability curve, (CEAC) was created from 1,000 
approximations using the Monte Carlo simulation based on the net monetary benefit 
approach. At the given willingness to pay threshold, (WTP),  the cost-effectiveness 
acceptability curve provided the probability of the cost-effectiveness of the treatment of 
interest compared with the current treatment, based on the uncertainty of sampling variations 
of costs and outcomes and the uncertainty of an acceptable level of cost–effectiveness ratio of 
a decision maker. In this thesis, the willingness to pay was defined as a range between THB 0 
- 500,000. Moreover, the willingness to pay was the valuation of the health benefit in 
monetary terms. This was the maximum price at which a consumer will definitely pay for 
their health benefit (Bertram et al. 2016) (see more details in Chapter 3, section 3.5.2).  
In Thailand, the cost-effectiveness, (CE), threshold was defined at THB 160,000 per QALY 
for consideration regarding a cost-effectiveness strategy which was defined by the Sub-
committee of the NLEM of Thailand (Teerawattananon 2018). However, a range of 
willingness to pay for an additional QALY in Thailand was suggested at THB 59,000-
285,000 (valued in 2008) by Thavorncharoensap et al. (2013). Thus, these values, adjusted to 
2017 currencies by the Consumer Price Index, were also applied in this thesis to consider at 
what price society would be willing to pay to gain an additional QALY.    
 
7.3 Results 
7.3.1 Base-case results 
As Table 7.7 shows, over the 5-year time period for an evaluation based on a societal 
perspective, the total expected cost per BPSD patient receiving risperidone was THB 
1,918,257.12 and THB 2,015,958.43 for the BPSD patient receiving olanzapine. The 
incremental cost associated with the use of risperidone was lower than the use of olanzapine 
accounting for THB 97,701.31.  
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The total expected outcomes as addressed in terms of QALYs were 15.45 and 10.81 for the 
olanzapine treated patient and the risperidone treated patient, respectively. This showed that 
patients treated with olanzapine had an incremental improvement in QALYs compared with 
those treated with risperidone, (a corresponding QALY of 4.64).  
At the base-case scenario, the treatment with olanzapine in the patient with BPSD was 
associated with an ICER of THB 21,039.45 per QALY compared with risperidone treatment 
from a societal perspective. 
Table 7.7: Cost-effectiveness results in a comparison of olanzapine relative to 
risperidone 
Strategy Cost (THB*) Incremental 
cost 
Effectiveness Incremental 
effectiveness 
ICER 
Risperidone 1,918,257.12 - 10.81 -  
Olanzapine 2,015,958.43 97,701.31 15.45 4.64 21,039.45 
* Costs, THB, the year 2017 values; perspective, a societal perspective; discount rate, at 3%; 1£ = 45 Baht 
 
7.3.2 Sensitivity analyses 
7.3.2.1 One-way sensitivity analyses 
Based on the results under the base-case analysis in a comparison of olanzapine to 
risperidone, the uncertainty around the model outcome or a central value, (corresponding to 
the base case analysis), was assessed by varying each parameter, including costs, utility 
weights and discount rates.  
In this thesis, the one-way sensitivity analyses were executed from several scenarios as 
follows: costs associated with health state were varied between maximum and minimum 
values of each parameter from primary data collected in a Thai setting.  
Utilities were tested by a variance of ± 30%. A variation of discount rates was performed 
between 0% and 6% per annum. Table 7.8 shows parameters for one-way sensitivity analysis.  
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The results of the one-way sensitivity analyses in this thesis are presented by the Tornado 
diagram. Based on the diagram, the horizontal bar with the greatest spread and on the top of 
the diagram was the significant parameter having the most sensitivity and greatest influence 
on the model outcome. Whereas the horizontal bar that was the least spread and at the bottom 
of the diagram had the least sensitivity and least influence on the model outcome.   
According to Figure 7.2, with regard to cost parameters, informal care of the olanzapine-
treated patient in the FTC state had the greatest influence on the model outcome. By 
comparison with the base-case scenario, an increase in 51.72% of the informal care cost of 
olanzapine in the FTC state significantly affected a 379.81% increase in the ICER, (THB 
100,946.74 per QALY). By contrast, a 77.24% decrease in the cost of informal care of 
olanzapine in the FTC state, resulting in a decrease in the ICER accounting for 567.17%, 
(THB 98,288.75 per QALY). Other most sensitive parameters were also found in informal 
care cost of olanzapine in the Pre-FTC state. From the base-case analysis, a 100.00% 
decrease in the informal care cost of olanzapine in the Pre-FTC state, resulted in a change in 
decreasing by 531.23% of the ICER, (THB 90,726.04 per QALY). A 56.66% increase in the 
informal care cost of olanzapine in the Pre-FTC state, lead to an increase in the ICER 
accounting for 300.99%, (THB 84,363.50 per QALY). For informal care cost of risperidone 
in the Pre-FTC state, a variation of costs by a reduction of 75.08% and an increase of 49.54% 
from the base-case scenario was associated with an increased ICER accounting for 411.74%, 
(THB 107,664.36 per QALY), and a decreased ICER accounting for 271.68%, (THB 
36,118.80 per QALY), respectively.  
When considering parameters that had the least influence on the model outcome, the 
medication cost of risperidone treatment in the FTC state was found to be a significant 
parameter. By comparing with the base-case scenario, if the medication cost of risperidone 
treatment in the FTC state decreased by 30.55%, it resulted in an increase in the ICER around 
0.50%, (THB 21,144.33 per QALY). By contrast, a 38.90% increase in the medication cost 
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of risperidone treatment in the FTC state increased, leading to a decrease in the ICER 
accounting for 0.63%, (THB 20,905.89 per QALY).   
Additionally, a variation of utility weights by ± 30% found that the utility weights of 
olanzapine in the Pre-FTC state had the greatest influence on the model outcome. Based on 
the base-case scenario, a change in utility weights of olanzapine in the Pre-FTC state from 
0.63 to 0.44, (-30%), and 0.83, (+30%), was associated with an increase in 206.72% of the 
ICER, (THB 64,530.75 per QALY), and a decrease in 40.26% of the ICER, (THB 12,568.65 
per QALY), respectively. Conversely, a variation of utility weights of risperidone in the FTC 
state had the least influence on the model outcome. When comparing with the base-case 
analysis, the ICER decreased to THB 17,828.18 per QALY, (15.26% change), if the utility 
weights of risperidone in the FTC state decreased by 30%. In contrast with a 30% increase in 
the utility weights of risperidone in the FTC state, which found that the ICER had increased 
to THB 25,661.72 per QALY, (21.97% change). 
By varying discount rates, the ICER had a 3.18% increase, (THB 21,708.90 per QALY), 
from the base-case analysis if the discount rate was changed at 0% per annum. Whilst the 
ICER had decreased 3.15%, (THB 20,375.26 per QALY), from the base-case analysis if the 
discount rate was adjusted at 6% per annum. This showed that a variation of the discount 
rates had less significant impact on the ICER, accounting for 3% changed from the base-case 
analysis.  
Table 7.8: Parameter for the base-case and for sensitivity analyses of olanzapine or 
risperidone for the treatment of patients with BPSD 
Model Parameter Base-case Sensitivity Analysis 
Medication use (THB)   
Risperidone in the Pre-FTC state 70.51 26.48 to 158.85 
Risperidone in the FTC state 76.24 52.95 to 105.90 
Olanzapine in the Pre-FTC state 939.29 462.53 to 1,850.10 
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Model Parameter Base-case Sensitivity Analysis 
Olanzapine in the FTC state 1,271.97 462.53 to 2,134.80  
Comorbidity-associated costs (THB)   
Risperidone in the Pre-FTC state 4,087.41 0 to 11,700.00 
Risperidone in the FTC state 4,789.58 0 to 16,423.13 
Olanzapine in the Pre-FTC state 3,832.20 0 to 10,890.00  
Olanzapine in the FTC state 6,477.18 60.00 to 21,020.00 
Non-medical costs for OPD visits (THB)   
Risperidone in the Pre-FTC state 2,173.87 912.98 to 11,212.98 
Risperidone in the FTC state 2,433.69 1,062.98 to 4,862.98 
Olanzapine in the Pre-FTC state 1,975.05 300.00 to 3,300.00 
Olanzapine in the FTC state 2,106.62 1,012.98 to 5,460.00 
Non-medical costs for IPD visits (THB)   
Risperidone in the Pre-FTC state 2,618.66 0 to 54,489.60 
Risperidone in the FTC state 1,557.10 0 to 17,395.84 
Olanzapine in the Pre-FTC state 592.65 0 to 17,779.52 
Olanzapine in the FTC state 8,589.39 0 to 41,642.70 
Other treatments (THB)   
Risperidone in the Pre-FTC state 1,867.41 0 to 10,000.00 
Risperidone in the FTC state 3,567.29 1,200.00 to 10,000.00 
Olanzapine in the Pre-FTC state 1,161.67 0 to 5,000.00 
Olanzapine in the FTC state 3,190.91 500.00 to 9,500.00 
Costs associated with paid caregivers (THB)   
Risperidone in the Pre-FTC state 7,861.11 0 to 20,000.00 
Risperidone in the FTC state 9,382.86 4,000.00 to 15,000.00 
Olanzapine in the Pre-FTC state 6,189.67 0 to 13,000.00 
Olanzapine in the FTC state 10,800.00 6,000.00 to 18,000.00 
Informal care costs (THB)   
Risperidone in the Pre-FTC state 29,708.61 7,404.30 to 44,425.80 
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Model Parameter Base-case Sensitivity Analysis 
Risperidone in the FTC state 33,143.06 19,744.80 to 44,425.80 
Olanzapine in the Pre-FTC state 31,508.35 0 to 49,360.34 
Olanzapine in the FTC state 32,532.95 7,404.05 to 49,360.34 
Utility weights (± 30%)   
Risperidone in the Pre-FTC state 0.46 0.32 to 0.60 
Risperidone in the FTC state 0.12 0.08 to 0.16 
Olanzapine in the Pre-FTC state 0.63 0.44 to 0.82 
Olanzapine in the FTC state 0.23 0.16 to 0.30 
Discount rate (at 0% and 6%) 3% 0% to 6% 
* Cost in 2017 Thai currency (THB); 1£ = 45 Baht 
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Figure 7.2: The Tornado diagram based on the one-way sensitivity analysis of 
parameters in the model  
 
* At the base case, (or reference case): THB 21,039.45 per QALY 
7.3.2.2 Probability sensitivity analysis (PSA) 
According to Figure 7.3 associated with the cost-effectiveness plane for olanzapine versus 
risperidone, the probability sensitivity analysis showed that olanzapine was more effective 
than risperidone in 98.80% at the given willingness to pay for an additional QALY at THB 
500,000 based on 1,000 repeated random computations.  
Reference case 
care 
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Figure 7.3: Cost-effectiveness plane for olanzapine compared with risperidone based on 
1,000 PSA iterations of a willingness to pay for an additional QALY at THB 500,000  
 
 
Figure 7.4 shows the cost-effectiveness acceptability curve for the willingness to pay 
threshold for an additional QALY at THB 500,000. From the societal perspective, at a 
willingness to pay threshold of THB 0 per QALY, risperidone had a greater probability of a 
cost-effective treatment than olanzapine accounting for 73% of PSA iterations. If the 
willingness to pay was approximately THB 21,000 this showed that the probability of 
olanzapine being the cost-effectiveness treatment option for BPSD patients was only 50% 
when compared with risperidone. Where decision makers aimed to increase the willingness to 
pay threshold for an additional QALY to more than THB 21,000, olanzapine progressively 
increased the probability of being the cost-effective treatment. Conversely, the probability of 
the cost-effectiveness of risperidone was continuously decreasing as the willingness to pay 
more than THB 21,000 by decision makers increased.  
When considering the willingness to pay threshold per QALY at THB 59,885-289,275 (at 
year 2017 values) suggested for Thailand (Thavorncharoensap et al. 2013), olanzapine was 
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considered as the dominant therapeutic option for the treatment of patients with BPSD based 
on a societal perspective associated with 82.80%-98.20%.    
According to the cost-effectiveness threshold for the policy-makers in Thailand, the treatment 
option was considered to be more effective, less costly and cost effective at THB 160,000 per 
QALY, defined by the Sub-committee of the NLEM of Thailand (Teerawattananon 2018). 
The results showed that olanzapine was a cost effective treatment for patients with BPSD 
compared with risperidone from a societal perspective, accounting for 96.60%.  
Figure 7.4: Cost-effectiveness acceptability curve of willingness to pay for an additional 
QALY at THB 500,000 based on a societal perspective  
  
** WTP, willingness to pay for an additional QALY in Thai currency, (THB), 1£ = 45 Baht 
Figure 7.5 shows a cost-effectiveness acceptability curve from a healthcare perspective 
considering only direct-medical costs. This shows that risperidone had a greater probability 
of cost-effectiveness at a willingness to pay of THB 0 per QALY. However, at more than 
THB 21,867.09 per QALY of a willingness to pay, olanzapine had a greater probability of 
cost-effectiveness than the option treatment of risperidone. At a willingness to pay of THB 
500,000 per QALY, olanzapine provided the probability of a cost-effectiveness at around 
98.20% compared with risperidone.  
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Given the willingness to pay thresholds per QALY for Thailand at a range of THB 59,885-
289,275, (in year 2017 values), according to the proposal by Thavorncharoensap et al. 
(2013), olanzapine was the dominant treatment for treating of BPSD patients based on a 
healthcare perspective, accounting for 91.60%-97.80%.    
Furthermore, based on the cost-effectiveness threshold in Thailand for policy-makers, it was 
defined at THB 160,000 per QALY (Teerawattananon 2018). The results showed that 
olanzapine was a cost effective treatment for patients with BPSD compared with risperidone 
from a healthcare perspective, accounting for in 96.80%. 
Figure 7.5: Cost-effectiveness acceptability curve of willingness to pay for an additional 
QALY at THB 50,000 based on a healthcare perspective  
 
** WTP, willingness to pay for an additional QALY in Thai currency, (THB), 1£ = 45 Baht 
 
7.4 Discussion 
The analyses presented in this chapter have provided information comparing the cost-
effectiveness of olanzapine compared with risperidone for patients with behavioural and 
psychological symptoms of dementia in Thailand, using the cost-utility analysis based on the 
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decision-analytic model which had not previously been performed before in Thailand and 
Asia in general.   
From a societal perspective over a five-year time period, the results suggest that treatment of 
patients with BPSD with olanzapine is cost effective, in terms of cost per QALY gained, 
when compared with risperidone in Thailand, accounting for THB 21,039.45 per QALY 
based on the cost-effectiveness threshold at THB 160,000 per QALY in Thailand.  
To date, very few studies have assessed the economic impact of atypical antipsychotics for 
patients with BPSD. For example, in the previous study, a Markov model was constructed to 
examine the cost effectiveness of olanzapine for the treatment of agitation and psychosis in 
adults aged 65 and above with Alzheimer’s disease in the US (Kirbach et al. 2008). The study 
by Kirbach et al. (2008) reported that olanzapine was the cost-effective treatment, (ICER= 
US 13,230 per QALY), however, the comparator used for analysis was no treatment. Thus, 
the findings from the Kirbach’s study might not be directly compared with this thesis due to 
the difference in a scope of an economic evaluation. In another study, Rosenheck et al. 
(2007) conducted a cost-benefit analysis of atypical antipsychotics, (risperidone, olanzapine, 
quetiapine), compared with a placebo in Alzheimer’s disease outpatients with psychosis, 
aggression, or agitation, based on a clinical trial with nine-month follow up in the US. The 
results from Rosenheck’s study suggested the placebo group had a lower health costs 
compared with the atypical antipsychotic group, whereas the QALYs had no differences 
between treatments. By comparing the findings, it is evident that Rosenheck’s study provided 
the results in a different way from this thesis. This might be partly caused by the differences 
in medical costs and healthcare services provided between Thailand and the US as well as the 
methods conducted in both studies. Furthermore, the instrument used to assess health-related 
quality of life is different between the two studies. This thesis uses EQ-5D-5L, whereas the 
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study by Rosenheck et al. (2007) applies HUI-3. This could be associated with the 
differences in the results on the QALYs in both studies.  
Additionally, the model in this thesis is constructed by adapting from the FTC model 
framework; however, it is different from the original model (Rive et al. 2010) due to this 
thesis focuses more on patients with BPSD and requiring atypical antipsychotics for their 
treatments. In the previous study by Rive et al. (2010) the probabilities of dying derived data 
from the LASER-AD study in the UK. However, the transition probabilities of dying used in 
the thesis are estimated from the mortality rates of the available epidemiological data of the 
general Thai population, multiplied by the relative risks due to Alzheimer’s disease from a 
previous study (Gambassi et al. 1999, The Thai working group on the burden of disease and 
injuries 2002). This might lead to more accuracy and be more reflective of a data analysis 
within a Thai setting.  
According to a sensitivity analysis, the informal care costs are the significant parameters 
which have the greatest influence on the ICER. Therefore, an alteration of informal care costs 
of both treatments will result in the dramatic changes of the ICER. For instance, based on a 
comparison of olanzapine to risperidone, if the informal care cost of olanzapine in the FTC 
state increases as in a worst case scenario by THB 16,827.39 from the base-case analysis, the 
ICER is estimated to increase at THB 100,946.74 per QALY from the base-case analysis 
(ICER=THB 21,039.45/QALY). Conversely, a decrease in the informal care cost of 
olanzapine in the FTC state as in a worst case scenario, (THB 7,404.05), would lead to a 
decrease in ICER which is associated with lower costs and higher QALYs compared to 
risperidone. As a consequence, it indicates that as the informal care cost of olanzapine in the 
FTC state decreased it would be expected to see a decrease in additional costs to gain one 
QALY. Furthermore, this is in line with reporting from WHO et al (2012) that the informal 
care costs were the predominant cost of dementia in lower-and upper-income countries 
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accounting for 40-65%. Mean informal care costs per patient with BPSD in this thesis are 
THB 31,425.84 and THB 32,020.65 for the Pre-FTC and FTC state, accounting for 62.39%-
64.21% of a total cost. However, a previous study conducted in the Thai elderly with 
dementia in a Thai University hospital by Turongkaravee (2008), reported the informal care 
costs of patients with the Pre-FTC and FTC states were THB 4,814.00 and THB 25,872.00, 
respectively. Based on Turongkaravee (2008), informal care costs of both states, (Pre-FTC 
and FTC), had lower costs when compared with this thesis. This might be associated with a 
difference in time spent in patients’ care of both studies as this thesis focused on patients with 
BPSD. In addition, several studies also suggested patients with BPSD correlated with 
increasing caregiver burden (Mohamed et al 2010, Sasoni et al. 2013, Pinidbunjerdkool, 
Saengwanitch and Sithinamsuwan 2014, Reed et al. 2014, Lanctot et al. 2017). Therefore, 
this thesis is able to imply that the occurrence of BPSD was a significant factor, leading to a 
greater cost of informal care for patients with dementia.  
Furthermore, much of the informal care costs of patients with BPSD are associated with care 
inputs by caregivers and their families which have a significant influence in the societal costs 
of patients with dementia. Therefore, policy-makers should exercise or interpret the results 
with caution if this information is adopted in to the decision making process of the 
reimbursement system.  
However, when considering the information based on a healthcare perspective focusing only 
on direct medical costs, the results still show that olanzapine is the dominant treatment for 
BPSD patients compared with risperidone, accounting for THB 21,867.09 per QALY under 
the cost-effectiveness threshold at THB 160,000 per QALY. By comparing the results 
between the viewpoints of a societal perspective, (focusing on direct medical and non-
medical costs), and a healthcare perspectives, (considering only direct medical costs), the 
ICER per QALY of olanzapine versus risperidone from the healthcare perspective has a 
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higher value when compared with the societal perspective, by THB 827.64 per QALY, (THB 
21,867.09 per QALY versus THB 21,039.45 per QALY). This might be caused by direct 
non-medical costs, (such as informal care costs, paid caregivers, and other treatment costs), 
between treatments show no significant differences. Therefore, the differences in the ICERs 
per QALY between a societal and a healthcare perspective mainly depend on the differences 
in the direct medical costs of both drugs.  
When considering the utility weights by varying at ±30%, the changes in values of the Pre-
FTC state of both treatments show more subtle changes in ICER than the FTC state. The 
utility weight in the Pre-FTC state of the olanzapine treatment is the significant factor which 
is related to the greatest changes in ICERs. If the utility weight in the Pre-FTC state of 
olanzapine changes to the plausible minimum value, the ICER has increased to THB 
64,530.75 per QALY. By contrast, if it changes to the plausible maximum value, the ICER 
has decreased to THB 12,568.65 per QALY. As a consequence it implies that if the 
olanzapine-treated patient in the Pre-FTC state has a more health-related quality of life it 
would be expected to see a decrease in additional costs to gain one QALY.   
The cost-utility analysis shows that olanzapine is a cost-effective choice in the management 
of behaviourally disturbed patients with dementia. Validity and robustness of the results were 
performed by a probabilistic sensitivity analysis using the Monte Carlo simulation by 
randomly sampling each parameter according to pre-defined distribution for a total of 1,000 
iterations.  
As with any model, economic evaluation has its limitations. Firstly, the predictive equation 
used in this thesis is based on the LASER-AD study deriving from the UK population 
(Livingston et al. 2004). However, that study was designed to be representative of the general 
Alzheimer’s disease population.  
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Secondly, data relating to relapse requiring hospitalisation and relapse not requiring 
hospitalisation used to calculate the costs of patients being on olanzapine or risperidone are 
derived from studies of schizophrenia, due to a paucity of data of these drugs being used for 
the treatment of dementia patients (see more information in Chapter 5).  
Thirdly, adverse event-related costs from atypical antipsychotic drug use consider only 
constipation, falls and EPSs. An underestimation of costs from other hidden adverse events 
might occur, such as weight gain, somnolence, prolactin increase, urinary infection and 
cerebrovascular events (Deberdt et al. 2005, Schneider et al. 2006 and Ma et al. 2014).  
Finally, a further limitation is that utility data derived from a cross-sectional survey using the 
EQ-5D. This then might be associated with a limitation of the study to know how changes 
over time were due to the two drugs. Due to this limitation, the thesis might be unable to 
answer how the drugs affect the health-related quality of life or utility weights over time, how 
long patients benefit from drugs after taking them and the time until patients had 
discontinued drugs for any reason, namely lack of efficacy, intolerability and undesirable 
effects. Also, current utility weights might be due to other conditions, such as the 
improvement of co-conditions of patients.   
In conclusion, this model-based economic evaluation suggests that olanzapine is a cost-
effective treatment for patients with BPSD in Thailand when compared with risperidone, (the 
cost-effectiveness threshold at THB 160,000 per QALY). In essence, to the researcher’s best 
knowledge, this thesis is the first study to highlight and contribute new evidence on the 
analysis of the cost-effectiveness of olanzapine compared with risperidone for behavioural 
disturbances related to patients with dementia in Thailand. In addition, the findings of this 
study provide useful information for behaviourally disturbed patients with dementia and 
support to the decision making of physicians, patients, caregivers and policy makers in 
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providing improved treatments and suitably allocated resources for sufferers from 
behavioural disturbances in Thailand.  
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Chapter 8: Conclusions and recommendations for future research 
The overall aim of this thesis is to examine a cost-utility analysis of olanzapine and 
risperidone for the treatment of patients with behavioural and psychological symptoms of 
dementia, (BPSD), in Thailand. In order to achieve this aim, three objectives were devised 
which included developing the decision-analytic model for an evaluation, examining costs 
and health-related quality of life, (or utility weights), of patients with BPSD and treated with 
olanzapine or risperidone in a Thai setting and calculating the incremental cost-effectiveness 
ratio, (ICER), of olanzapine versus risperidone for behaviourally disturbed patients with 
dementia in Thailand.   
The purpose of this chapter is to describe how the aim of thesis was achieved by providing an 
overview of all chapters in the thesis. The summary of findings is provided and a contribution 
to knowledge is also highlighted. The strengths and limitations as well as the post research 
evaluation are then identified. Policy implements are also addressed. In addition, further 
research opportunities will be recommended.  
 
8.1 Overview of the thesis 
The rationale for this thesis set out in Chapter 1 documented a dearth of studies associated 
with the health economic evaluation of atypical antipsychotics for patients with BPSD, 
specifically in Thailand and Asia in general. Also, an increase in the number of people living 
with dementia which provokes a negative effect on families, communities and healthcare 
systems, across several countries, along with Thailand (World Health Organisation 2012, 
Prince et al. 2015). Non-cognitive symptoms or BPSD were common co-conditions in people 
with dementia which affects up to 90% of these people over the course of their illness. These 
symptoms were a significant trouble in dementia people more than their cognitive 
impairment, leading to a complicated management, caregiving burden, a financial burden of 
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families and healthcare and a poor quality of life of both patients and caregivers (Cerejeira, 
Lagarto and Mukaetova-Ladinska 2012).  For the BPSD management in Thailand, research 
evidence reported there were a variety of atypical antipsychotics administrated for patients 
with BPSD in the routine clinical settings; however, risperidone and olanzapine were the 
most common drugs prescribed for these patients (Chanthawong et al. 2012, Rapeepatchai 
and Promma 2015). Currently, a difference between olanzapine and risperidone is not well 
defined in terms of health economic evaluation for the treatment of patients with BPSD in 
Thailand. 
Chapter 2 details the literature review regarding definitions of dementia and BPSD, the 
BPSD management, health economic evaluations and the model-based health economic 
evaluations in dementia. The conclusion from this chapter was that there were some 
criticisms that were debatable about effectiveness and concern over adverse events associated 
with atypical antipsychotic use in people with dementia (Schneider, et al 2006, Angelini et al 
2007, Maher et al. 2011, Tempi et al. 2016); notwithstanding, it is clear that the modest 
efficacy of these drugs associated with reducing behavioural disturbances has a potential 
effect to improve of quality of life for patients and caregivers and decrease caregivers’ 
distress (Masopust, et al. 2018). The literature review also documented the very few studies 
relevant to economic evaluation on the treatment of patients with BPSD, especially atypical 
antipsychotics. To date, only two studies examined atypical antipsychotics for 
agitation/aggression and psychosis in Alzheimer’s disease. One study was a comparison of 
olanzapine to no treatment using modelling in the US (Kirbach et al. 2008), whilst another 
study conducted involved atypical antipsychotics, (risperidone, olanzapine, quetiapine), and 
placebo, (as a watchful waiting strategy), alongside a clinical trial based on the CATIE-AD 
study, in the US (Rosenheck et al. 2007). Based on this review, it allowed the thesis to 
pinpoint the gaps in the literature and defined the direction of the research study from this 
point.  
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Chapter 3 identified and developed the research design, methodology and methods of 
economic evaluation as conducted for the evaluation of the atypical antipsychotics for the 
treatment of BPSD patients in Thailand. 
Chapter 4 reports the model development based on the literature review, on model-based 
economic evaluation in dementia. The findings from this chapter yielded different models 
that were formulated from different model conceptual frameworks and then tested these 
models incorporating the key parameters. Then a comparison amongst those models was 
conducted to justify and select the most appropriate model to be adopted for an evaluation of 
olanzapine and risperidone in Thailand. This chapter answered objective number 1 of this 
thesis (see Chapter 1, section 1.3.2).  
Additionally, Chapter 5 answered objective number 2 (see Chapter 1, section 1.3.2) by 
analysing the costs of patients with BPSD and being treated with olanzapine and risperidone. 
The costs relating to these patients were categorised by cognitive function, (mild, moderate 
and severe), and dependence status, (Pre-FTC and FTC).  
Chapter 6 analysed the health-related quality of life, (or utility weight), of olanzapine- and 
risperidone-treated patients with BPSD and this answered research objective number 2 (see 
Chapter 1, section 1.3.2). The utility weights of these patients were also classified by 
cognitive function and dependence.  
Chapter 7 covers the assessment of the cost-utility analysis of olanzapine and risperidone for 
the treatment of patients with BPSD in Thailand. This chapter shows the main findings 
answering the research question, the main aim and objective number 3, (see Chapter 1, 
sections 1.3.1 and 1.3.2), of this thesis. Furthermore, based on the literature review, there is 
currently no model-based economic evaluation that undertook a comparison between 
olanzapine and risperidone for the treatment of patients with BPSD, specifically in Thailand 
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and Asia in general. Hence, the findings from this chapter have produced a new scientific 
assessment that is relevant to this field. 
 
8.2 Summary of findings of the thesis 
8.2.1 Defining the scope of the study  
This thesis was conducted to investigate the economic evaluation of atypical antipsychotic 
drug use for the treatment of outpatients with BPSD aged 60 years and above in Thailand. 
This was based on a literature review of the use of atypical antipsychotic drugs for the 
treatment of BPSD in patients with dementia. Olanzapine had been presented that it was an 
efficacy for the treatment of dementia patients with behavioural disturbances (see Chapter 2, 
section 2.4). This drug is frequently prescribed to patients experiencing BPSD in Thailand; 
however, it is more expensive than an existing atypical antipsychotic drug. Olanzapine has 
been classified in the non-National List of Essential Medicines (non-NLEM) of Thailand. 
This drug was then paid for BPSD patients as out-of-pocket expenses rather than the primary 
healthcare system, leading to a restriction of these patients to access or receive the most 
appropriate medication and having a financial impact on the households who chose to fund 
the use of the drug for the patients. Consequently, olanzapine was chosen as the treatment of 
interest in this thesis.  
8.2.2 Selection comparator 
Risperidone is an atypical antipsychotic drug approved in the NLEM and is currently in 
common use for the treatment of BPSD in Thailand. Thus, this drug was chosen as a 
comparator for an economic evaluation on the treatment of dementia patients with BPSD, in 
this thesis.  
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8.2.3 Defining the type of economic evaluation and the model framework 
A cost-utility analysis was conducted in this thesis. A decision-analytic model, known as a 
Markov model, was used to estimate the costs and outcomes regarding olanzapine compared 
with risperidone, using a one-month Markov cycle over a five-year evaluation period and 
reflecting the clinically progressive disease of behaviourally disturbed patients with 
dementia. The health states used in the model were the Pre-FTC state, the FTC state as well 
as death. The transition probability was calculated from the predictive equation to estimate 
the probability of BPSD patients in the Pre-FTC state requiring the FTC state. The study used 
three main dimensions related to the disease progression of patients with dementia, including 
cognition as measured by ADAS-cog scale, functional status as measured by ADCS-ADL 
scale and behavioural ability as measured by NPI score, which were incorporated in the 
equation. The probabilities of dying were based on the epidemiological data of the general 
Thai population as classified by age multiplied by the relative risk of mortality in patients 
with Alzheimer’s disease.  
8.2.4 Measurement of costs and health utility weights 
Since the main aim of this thesis was to evaluate the cost-effectiveness in routine setting, the 
study was conducted using a cross-sectional survey by face-to-face interviews, designed to 
gather data of costs and utility weights through the cost and the EQ-5D-5L questionnaires, in 
outpatients and/or their caregivers from Thammasat University hospital and Khon Kaen 
Rajanagarind Psychiatric hospital, in Thailand.  
For cost analysis, only direct medical and direct non-medical costs were included. The direct 
medical costs were medication costs, additional costs, hospitalised costs, additional payments 
from the patients’ healthcare insurance coverage, costs associated with comorbidity, adverse 
events-related costs and relapse-related costs. Direct non-medical costs included the patients' 
out-of-pocket expenses, informal care costs, paid caregiver costs for paying the caregivers for 
providing care to patients and costs of transportation, accommodation, and extra food for 
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patients. All costs were from a societal perspective and presented as Thai baht (THB) in 2017 
values (£1 = THB 45). The finding showed that the costs of risperidone-treated patients were 
THB 44,717.09 in the Pre-FTC state and THB 53,167.03 in the FTC state. For olanzapine-
treated patients, costs were THB 44,347.28 and THB 58,294.20 in the Pre-FTC and FTC 
states, respectively.   
In addition, the utility weights were collected based on a five-dimensional questionnaire with 
five-levels of severity in each dimension. The Thai preference weights, (tariffs or value sets), 
were used to calculate the utility weights used in this thesis. According to the findings from 
the analysis, the utility weights of risperidone-treated patients were 0.46 of the Pre-FTC state 
and 0.12 of the FTC state. Whilst the utility weights of olanzapine-treated patients were 0.63 
and 0.23 of the Pre-FTC and FTC states, respectively.   
8.2.5 Handling time in an evaluation of a cost-utility analysis 
A discount rate of 3% per annum was applied to both costs and QALYs. This rate was 
recommended by Thailand’s Health Technology Assessment guidance as well as the World 
Health Organization.  
8.2.6 Handling uncertainty of an economic evaluation 
One-way and probabilistic sensitivity analyses were performed for the parameter 
uncertainties. One-way analyses were conducted by varying the values of key parameters, 
including costs, utility weights and discount rates. Costs of drug treatments associated with 
each health state were varied between plausible extreme values of data. The utility weights of 
drug treatments associated with each health state were defined by a variance of ± 30%. The 
discount rate was varied between 0% and 6% based on the recommendation of the guideline 
of health technology assessment in Thailand (HITAP 2014).  
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For the probabilistic sensitivity analysis, Monte Carlo simulations were also undertaken with 
1,000 iterations of the model parameters according to a pre-defined distribution for additional 
testing of the robustness of the results.  
8.2.7 The cost-utility analysis of atypical antipsychotics for the treatment of patients 
with behavioural and psychological symptoms in Thailand 
To analysis the cost-effectiveness in this thesis, the main outcome measure was the cost per 
QALY gained or ICER. The results indicated olanzapine is predicted for better outcomes and 
lower costs compared to risperidone. Therefore, olanzapine may be the cost-effective 
therapeutic option for the treatment of patients with dementia and suffering with behavioural 
and psychological symptoms in Thailand (ICER < THB 160,000).  
By comparing the findings with the studies in this field, the result of this thesis is consistent 
with a previous study which conducted an economic evaluation on atypical antipsychotics in 
Alzheimer’s patients with agitation and psychosis by Kirbach et al. (2008). Kirbach and 
collegues undertook a cost-utility analysis of olanzapine versus no treatment in those 
patients, over a 13-year period or until patients died from the disease progression, based on 
the US health system perspective. Based on that study, the findings suggested that olanzapine 
was a dominant strategy for the treatment for agitation and psychosis of patients with 
Alzheimer’s disease. However, it should be noted that there are differences in comparators 
between Kirbach’s study and this thesis. Kirbach and colleagues conducted an analysis 
against no treatment, whereas this thesis compared olanzapine to risperidone. Moreover, 
parameters used in the model, the settings of the studies as well as country-specific healthcare 
systems between Kirbach’s study and this thesis are significant differences.  
Conversely, the study by Rosenheck et al. (2007), a cost-benefit analysis of atypical 
antipsychotics in a randomised trial from the follow-up of patients for nine months from an 
economic perspective, reported that total costs of treating groups with risperidone, 
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quetiapine, or olanzapine were higher than a placebo group. By the comparison of QALYs, 
there were no significant differences amongst the groups treated with atypical antipsychotics 
and a placebo. However, there are differences in the methods of the thesis, the instrument in 
measuring HRQoL, the settings of the studies as well as country-specific healthcare systems 
between Rosenheck’s study and this thesis.  
 
8.3 Contribution to Knowledge of the Thesis  
The findings of this thesis that emerged from the model development, face-to-face interviews 
examining costs and utility weights of patients with BPSD and treated with olanzapine and 
risperidone and the cost-utility analysis of atypical antipsychotics, (olanzapine and 
risperidone), have made several contributions to knowledge at different points which will 
now be outlined.  
Chapter 4 details the different models that were developed based on adaptations with one 
using the CERAD conceptual framework (Neumann et al. 1999) and two others of the FTC 
conceptual framework using a predictive equation to estimate the time until patients required 
FTC, in which one equation was developed by Caro et al. (2001) based on longitudinal 
epidemiological data (Stern et al. 1997) and the other was developed by Rive et al. (2010) 
based on longitudinal epidemiological study of LASER-AD study (Livingston et al. 2004). 
These models were then tested by incorporating key variables, including transition 
probabilities, clinical effectiveness data, costs and utility weights of olanzapine or 
risperidone. Further, costs and utility weights of patients with BPSD treated with olanzapine 
and risperidone were derived from a primary data collected in a Thai setting. A comparison 
in line with characteristics, strengths and weaknesses amongst those different models was 
also conducted. The most appropriate model was then chosen for applying further analysis of 
those BPSD patients in Thailand (Chapter 7). To the researcher’s knowledge, the findings of 
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this chapter have not been presented, certainly in the outlined literature review, in this area 
because health states of each model uniquely focused on the severity of cognitive function, 
(mild, moderate and severe), or the dependence status, (Pre-FTC and FTC), and patients with 
BPSD requiring atypical antipsychotic drugs for their treatments. This thesis also 
documented the significant characteristics as well as strengths and weaknesses of each model 
when the models were applied to patients with BPSD and being treated with atypical 
antipsychotics, as focused only on olanzapine and risperidone.  
Additionally, Chapter 5 provides a further contribution to knowledge of associated costs, 
including direct medical costs and direct non-medical costs, of patients with BPSD and being 
treated with either olanzapine or risperidone from a societal perspective. The costs were 
based on primary data collected from the actual routine clinical setting in Thailand. 
Interestingly, both relapse rates and frequent adverse events, (extrapyramidal symptoms, 
constipation and falls), due to atypical antipsychotic use in BPSD patients were also included 
for cost analyses which increases the values of the data as being as realistic as possible. 
Subsequently, the findings in this chapter represents an original contribution to knowledge 
towards establishing costs for olanzapine  and risperidone treated patients with BPSD by 
classifying these patients according to cognitive function, (mild, moderate and severe stages), 
and dependency, (Pre-FTC and FTC states). To the researcher’s knowledge, this has never 
previously been done before, specifically in Thailand or Asia in general.  
Chapter 6 also contributes to knowledge in other areas that surround the utility analyses of 
olanzapine and risperidone treated patients with BPSD. The utility weight data was also 
derived from primary collected data of those patients using the EQ-5D-5L questionnaire from 
the routine clinical setting in Thailand. These utility weights were then used in calculating the 
health outcomes, as presented in terms of QALYs. The findings also provided new 
information of utility weights of olanzapine and risperidone treated patients with BPSD 
according to a classification of patients by cognitive function and dependency as stated 
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above. To the researcher’s knowledge, these have not previously been presented before in 
Thailand or Asia in general.  
Chapter 7 has contributed to knowledge in the area of health economic evaluation of atypical 
antipsychotics, (olanzapine and risperidone), for the treatment of patients with BPSD. To the 
researcher’s knowledge, this previously has never been done before in Thailand, or Asia in 
general. The selected model based on the model development, (see Chapter 4), was 
constructed to assess the cost-effectiveness of olanzapine compared with risperidone from a 
societal perspective over a five-year time horizon. The incremental cost-effectiveness ratio 
(ICER) was calculated to indicate the dominant strategy of the BPSD treatment. The 
robustness of the results was performed based on sensitivity analyses. Therefore, the findings 
of this chapter have contributed useful information to stakeholders, namely physicians, 
patients, caregivers and policy-makers, for their decision making to manage and select the 
recommended effective treatment for sufferers with BPSD, specifically in Thailand.  
 
8.4 Policy Implications  
By conducting the cost-utility analysis, the improved understanding of evaluating atypical 
antipsychotics, (olanzapine versus risperidone), in the treatment of BPSD has implications 
for policy-makers, professionals, caregivers and people with BPSD in light of the findings of 
this thesis as outlined below.  
• For people affected by behavioural and psychological symptoms of dementia and 
their caregivers 
The impact of people with BPSD on the financial burden and quality of life is enormous for 
patient themselves and their caregivers. As the major part of costs for people with BPSD is 
direct non-medical costs, particularly informal care due to time spent in patients’ care. Stress 
is a significant problem for most caregivers who are living with and caring for BPSD 
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patients. Thus, people affected by BPSD need the recommended cost-effective treatment to 
reduce or eliminate behavioural symptoms as the condition persisted. The findings from this 
thesis have provided information for people affected by BPSD to select the best choice for 
their treatment. Then, an improvement in patients’ conditions associated with BPSD leads to 
a greater wellbeing, a better quality of life of patient themselves and their caregivers as well 
as a reduction in household financial burden associated with physician visits, hospital 
admissions, relapses, adverse events, transportation, food, accommodation, other treatments, 
paid caregivers and informal care costs. This also helps to improve the quality of life and 
reduce the distress of both patients with BPSD and their caregivers.  
• For providers in health care sectors 
To overcome the difference of access to medications for managing of BPSD, the health 
economic evaluation of treatments is used in healthcare decision making. This not only 
considers medication costs but also integrates all relevant costs and QALYs gained of 
patients with BPSD. Subsequently, the findings from this thesis have provided physicians 
and/or healthcare providers additional new information to help in deciding the prescription of 
the best choice of treatment and offers support in developing the most appropriate care and 
strategies for coping with patients with BPSD in the routine clinical setting of Thailand.  
• For policy-makers 
To maximise the benefits from spending of healthcare budget, the thesis findings may 
provide information to facilitate policy-makers in deciding whether health systems should be 
funded. It may seem reasonable that if the treatment is more cost-effective than another that 
is already funded, it should also be funded, leading to a reimbursement of patients or service 
providers if they use a cost-effective drug.  
In conclusion, for the implications to a clinical practice and policy in Thailand, this thesis 
was conducted based on the routine clinical practices in a real setting. Therefore, the results 
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are appropriate to be considered for the implementation in the treatment of BPSD sufferers in 
Thailand. Aside from that, this is also useful information contributing to the stakeholder 
knowledge in providing better management and patients’ care, allocating the constrained 
resources efficiently and preparing suitable healthcare systems for patients with BPSD in 
Thailand.  
 
8.5 Strengths and Limitations of the Research 
8.5.1 Strengths of the research 
To the researcher’s best knowledge, this is the first cost-utility analysis study to compare 
atypical antipsychotic drugs, (olanzapine versus risperidone), for the treatment of patients 
with dementia and suffering with behavioural and psychological symptoms in Thailand or 
Asia.  
This study is unique in that it includes adverse events and relapses to estimate the total cost 
analysis of atypical antipsychotics use for those patients, leading to greater accuracy of the 
economic evaluation of these drugs, for the treatment of BPSD patients in a routine clinical 
practice. In addition, all data input associated with costs and utility weights in the model are 
derived from a primary, real setting, collection source of patients with BPSD, from two 
hospitals in Thailand. Interestingly, the findings of the cost analysis from this thesis also 
introduce new information associated with cost data for patients with BPSD being on 
olanzapine or risperidone, by the classification of patients in terms of cognitive function and 
physical dependence. Similarly, utility weights associated with patients with BPSD and 
treated with olanzapine or risperidone provide unique information based on the classification 
by cognitive function and physical dependency, of olanzapine-treated and risperidone-treated 
patients with behavioural disturbances. 
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8.5.2 Limitations of the research 
In this thesis, there are some limitations identified as listed below. 
8.5.2.1 Model limitation 
It is clearly an important limitation associated with the movement from the Pre-FTC state to 
the FTC state of patients driven by the transition probability which uses a predictive equation 
based on data from the LASER-AD study in the UK due to a lack of any similar information 
available in Thailand.  
8.5.2.2 Data limitations 
Regarding data limitations, a cross-sectional study is a concern over the restriction to produce 
information associated with monitoring changes in costs and utility values of patients, 
influenced by the treatment during the disease progression over time. 
Another concern is that utility values deriving from a primary data collection are mostly rated 
by caregivers as a proxy report. However, it is essential to consider proxy-ratings instead of 
patient-ratings in this study due to most patients having cognitive impairment, resulting to the 
difficulty to respond the HRQoL measure. Thus, the interpretation of the results should be 
considered with the caution.  
Additionally, the application of the EQ-5D-5L instrument was used to measure the health 
utility values for dementia patients with behavioural disturbances in this thesis. This tool is 
not a disease-specific instrument; however, the EQ-5D-5L was adopted due to a lack of 
information of dementia-specific instruments in the Thai language. Apart from that, the main 
outcome is also measured in terms of the QALY gained which can be calculated as index 
values from the EQ-5D-5L.  
Costs associated with relapses and adverse events are included in the cost analysis in this 
study. Since atypical antipsychotics are off-label use for the treatment of symptoms related to 
dementia, there are a lack of studies of atypical antipsychotics associated with drug-induced 
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adverse events in the different dependence levels and drug-associated relapses, for the 
treatment of patients with dementia. As a result, the relapse data are adopted from studies of 
schizophrenia. Thus, the cost analysis might be an over or underestimate from the actual 
costs of patients with BPSD having risperidone or olanzapine on their prescriptions. In 
addition, the adverse events associated with costs are assumed to have similar figures in each 
health state. The adverse events in this thesis include only constipation, falls and 
extrapyramidal symptoms (EPSs), resulting to the over- or under- estimations of cost analysis 
due to other hidden adverse events from atypical antipsychotic use for BPSD patients.   
8.5.2.3 Generalisability of the research 
Generalizability is another limitation due to this thesis being specific to the healthcare system 
in Thailand. Cost and utility data are conducted by primary collected data in a Thai setting. 
Hence, the generalising or adoption of results to different circumstances should be interpreted 
or exercised with caution.  
 
8.6 Post Research Evaluation 
In this thesis, sensitivity analyses were conducted in order to assess uncertainty surrounding 
model parameters by varying parameters in 33 different scenarios across costs, utility weights 
and discount rates and all model parameters using Monte Carlo simulation of 1,000 repeated 
random computations. Based on the techniques and procedures used to assess the cost-utility 
analysis, the author is assured of the validity and robustness of the results of this thesis. If the 
thesis were to be replicated using similar procedures, it is anticipated that the researcher 
would acquire the same results. 
However, the thesis highlights probabilities of dying, costs and utility weights associated 
with patients with BPSD were based on data specifically in the Thai setting. Therefore, by 
replicating this thesis in other settings even using similar procedures, it is possibly that the 
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researcher might obtain different results. This might associated with differences in medical 
costs, characteristics of care provision from caregivers and healthcare services provided in 
different countries. 
 
8.7 Recommendations for further study 
This thesis initially contributes the cost-utility analysis of olanzapine versus risperidone for 
the treatment of patients with dementia with behavioural disturbances in Thailand. The 
analysis is based on a decision-analytic model, a Markov model, which suggests that 
olanzapine is the cost-effective option relative to risperidone. However, future research 
should examine some additional points to fill the gaps in this thesis as follows:  
• The cost and utility data may be conducted in a longitudinal assessment in order to 
evaluate the changes in costs and utility values of patients which are influenced by the 
treatment during the disease progression over time. 
• More patients should be considered leading to greater accuracy of a data analysis.  
• Although this thesis includes adverse events in the analysis of cost data of 
behaviourally disturbed patients treated with atypical antipsychotics, other adverse 
events, such as weight gain, urinary tract infection, oedema, sedation, and 
cerebrovascular events, should be considered for further study in order to increase the 
accuracy of information to help improve the implementation of routine clinical 
practice of these patients.   
• Other atypical antipsychotics, such as aripiprazole and quetiapine, and rates of 
switching of atypical antipsychotic drugs for the treatment should be considered in a 
future study, to introduce different aspects of an economic evaluation of atypical 
antipsychotic use in BPSD patients. This also leads to more precise information for 
adapting routine clinical practices.  
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• The predictive equation to calculate the time to FTC state in this thesis was developed 
from the LASER-AD study of the UK data. Therefore, a further study of the equation 
to predict length of time to the FTC state in patients with dementia should be 
developed specifically based on data from the Thai population.  
• The relative risk of dying from dementia or Alzheimer’s disease in this thesis was 
obtained from a previous study which conducted in the US. Thus, further studies 
should investigate especially in Thai patients with dementia and which would be 
more suitable for use with the Thai population.  
• Indirect costs should be included in order to have different points of view of costing 
analysis being addressed in the thesis, leading to more accuracy in the treatment of 
patients with BPSD within a realistic situation.  
• If patient-level data are available, Discrete Event Simulation (DES) should be 
considered to simulate unique demographic and clinical characteristics of individuals, 
as this approach captures data in a realistic environment and manner, resulting in 
more precise projections and computationally efficiency of an economic evaluation.  
 
8.8 Publications 
The researcher has previously published work in this area in an international peer reviewed 
journal (Thongchundee et al. 2015) (see Appendix 7). Moreover, the researcher has also 
presented a poster of elements of this work at a Sheffield Hallam University conference. 
Finally, the researcher anticipates a further four articles for publication which will be linked 
to the scope of this thesis in near future.  
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Appendix 1: Examples of search terms and keywords for literature reviews 
An explanation of search terms and keywords used in this thesis is presented as follows: / = 
Mesh Heading Exp, (Exp = exploded MeSH Heading); asterisk (*) = any group of characters, 
including no character; ti = title word; ab = abstract word; $ = one character or none; “ ” = 
phrase search; unless otherwise stated, term searched all fields.  
1. Efficacy of atypical antipsychotics for dementia 
Database: MEDLINE and PsycINFO search strategies 
1. dementia*:ti,ab. 
2. alzheimer*:ti,ab. 
3. Behavio$ral and psychological symptom* 
4. BPSD:ti,ab. 
5. neuropsychiatric* symptom*:ti,ab. 
6. or/1-5 
7. atypical antipsychotic*:ti,ab. 
8. risperidone:ti,ab. 
9. olanzapine:ti,ab. 
10. aripiprazole:ti,ab. 
11. quetiapine:ti,ab. 
12. or/6-11 
13. 6 and 12 
Database: the Cochrane Library  
1. dementia 
2. Alzheimer’s 
3. 1 and 2 
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2. Health economic evaluations of atypical antipsychotics for dementia 
Database: MEDLINE search strategy 
1. dementia*:ti,ab. 
2. alzheimer*:ti,ab. 
3. cost analysis*:ti,ab.  
4. cost effective*:ti,ab. 
5. cost utilit*:ti,ab. 
6. cost benefit*:ti,ab. 
7. atypical antipsychotic*:ti,ab. 
8. risperidone:ti,ab. 
9. olanzapine:ti,ab. 
10. quetiapine:ti,ab. 
11. aripiprazole:ti,ab. 
12. 1 or 2 
13. 3 or 4 or 5 or 6 
14. 7 or 8 or 9 or 10 or 11 
15. 12 and 13 and 14 
Database: the Centre for Reviews and Dissemination (CRD) and the National Health 
System Economic Evaluation Database (NHS EED)  
1. cost effectiveness  
2. cost benefit  
3. cost analysis 
4. #1 or #2 or #3  
5. dementia 
6. dementia.ti 
7. dementia/  
 
 
454 
 
8. Alzheimer Disease/ 
9. #6 or #7 or #8   
10. atypical antipsychotics 
11. risperidone 
12. olanzapine 
13. quetiapine 
14. aripiprazole 
15. #10 or #11 or #12 or #13 or #14  
16. #4 and #9 and #15  
The extended literature search of Health economic evaluations of atypical 
antipsychotics for dementia 
Database: MEDLINE search strategy 
1. cost*:ti,ab. 
2. finance*:ti,ab. 
3. “economic evaluation” 
4. pharmacoeconomic*:ti,ab. 
5. dementia*:ti,ab. 
6. alzheimer’s*:ti,ab. 
7. risperidone:ti,ab. 
8. risperdal:ti,ab. 
9. olanzapine:ti,ab. 
10. zyprexa:ti,ab. 
11. aripiprazole:ti,ab. 
12. abilify:ti,ab. 
13. quetiapine:ti,ab. 
14. seroquel:ti,ab. 
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15. 1 or 2 or 3 or 4 
16. 5 or 6 
17. or/7-14 
18. 15 and 16 and 17 
 
Database: the Centre for Reviews and Dissemination (CRD) and the National Health 
System Economic Evaluation Database (NHS EED)  
1. dementia  
2. alzheimer  
3. costs  
4. costing 
5. finance 
6. "economic evaluation"  
7. pharmacoeconomic 
8. risperidone or risperdal   
9. olanzapine or zyprexa  
10. aripiprazole or abilify  
11. quetiapine or seroquel  
12. #1 or #2  
13. #3 or #4 or #5 or #6 or #7  
14. #8 or #9 or #10 or #11 
15. #12 and #13 and #14  
  
3. Modelling-based economic evaluation in dementia 
Database: MEDLINE  
1. dementia*:ti,ab. 
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2. alzheimer*:ti,ab. 
3. economic model*:ti,ab. 
4. markov*:ti,ab. 
5. model economic:ti,ab. 
6. assessment of health economics in Alzheimer’s disease:ti,ab. 
7. assessment of health economics in dementia:ti,ab. 
8. AHEAD:ti,ab. 
9. CERAD:ti,ab.  
10. equation*:ti,ab. 
11. 1 or 2 
12. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
13. 11 and 12 
Database: the Centre for Reviews and Dissemination of University of York (CRD)  
1. dementia 
2. dementia:ti,ab. 
3. dementia/  
4. alzheimer disease/ 
5. vascular dementia/  
6. frontotemporal dementia/ 
7. lewy body disease/  
8. cost-benefit analysis/ 
9. cost savings/ 
10. costs and cost analysis/ 
11. health care costs/ 
12. #1 or #2 or #3 or #4 or #5 or #6 or #7 
13. #8 or #10 or #11 or #11  
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14. #12 and #13 
15. decision support techniques/ 
16. models, economic/  
17. #15 or #16 
18. #14 and #17  
4. Costing associated with dementia 
Database: MEDLINE 
1. dementia*:ti,ab. 
2. alzheimer*:ti,ab. 
3. BPSD:ti,ab. 
4. neuropsychiatric symptom*:ti,ab. 
5. bevavio$ral disturban*:ti,ab. 
6. non cognitive symptom*:ti,ab. 
7. cost*:ti,ab. 
8. 1 or 2 
9. 3 or 4 or 5 or 6 
10. 7 and 8 and 9 
  
5. Health-related Quality of Life in dementia 
Database: MEDLINE  
1. dementia*:ti,ab. 
2. alzheimer*:ti,ab. 
3. quality of life:ti,ab. 
4. health related quality of life:ti,ab. 
5. health utility* index:ti,ab. 
6. utility* index:ti,ab. 
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7. eq-5d:ti,ab. 
8. demqol:ti,ab. 
9. qol ad:ti,ab. 
10. adrql:ti,ab. 
11. Alzheimer* related quality of life:ti,ab. 
12. SF*:ti,ab. 
13. GHQ:ti,ab. 
14. activity and affect indicators of quality of life:ti,ab. 
15. cornell brown scale for quality of life:ti,ab. 
16. dementia care mapping:ti,ab. 
17. dementia quality of life:ti,ab. 
18. qualidem:ti,ab. 
19. quality of life-alzheimer*:ti,ab. 
20. qualid:ti,ab. 
21. quality of life in late stage of dementia:ti,ab. 
22. 1 or 2 
23. or/3-21 
24. 22 and 23 
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Appendix 2: The letter of collaborating organisation 
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Appendix 3: The letter of ethics approval of data collection 
● The Faculty Research Ethics Committee of Centre for Health and Social Care 
Research of Sheffield Hallam University in the UK  
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● The Human Research Ethics Committee of Thammasat University (Faculty of 
Medicine) in Thailand 
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● The Human Research Ethics Committee of Khon Kaen Rajanagarindra Psychiatric 
Hospital in Thailand 
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Appendix 4: Information sheet, consent form and costing and quality of life 
questionnaires 
● Information sheet 
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● Consent form 
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● The Costing Questionnaire 
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● The quality of life questionnaire: The European Quality of life Measure-5 Domains-5 
Levels in Thai version (EQ-5D-5L) 
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Appendix 5: Thai Mental State Examination (TMSE) 
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Appendix 6: An additional assessment associated with the improvement of 
olanzapine or risperidone for patients with behavioural and psychological 
symptoms of dementia after measuring using EQ-5D-5L at month 5 or 6 
 
Patient Treatment with risperidone Treatment with olanzapine 
1 Off risperidone Loss to follow up 
2 2 3 
3 Loss to follow up 4 
4 3 2 
5 Off risperidone Death 
6 Off risperidone 3 
7 2 4 
8 5 Off olanzapine 
9 Off risperidone 4 
10 4 Off olanzapine 
11 Off risperidone 4 
12 Death Loss to follow up 
13 4 4 
14 3 4 
15 Off risperidone 3 
16 4 4 
17 3 Off olanzapine 
18 Off risperidone 4 
19 2 5 
20 Off risperidone 4 
21 4 4 
22 Loss to follow up 4 
23 3 Off olanzapine 
24 2 4 
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Patient Treatment with risperidone Treatment with olanzapine 
25 Off risperidone 4 
26 3 4 
27 3 Off olanzapine 
28 3 4 
29 4 Off olanzapine 
30 4 4 
31 Off risperidone 4 
32 5 2 
33 3 Off olanzapine 
34 4 4 
35 Off risperidone 3 
36 3 Off olanzapine 
37 1 3 
38 3 Off olanzapine 
39 Loss to follow up 4 
40 4 3 
41 2 3 
* Levels of the improvement: 1 = not at all improved, 2 = slightly improved, 3 = moderately improved, 4 = much 
improved and 5 = extremely improved 
After measuring using EQ-5D-5L after at least five months to six months, an additional 
assessment was conducted associated with the improvement of patients with BPSD and being 
treated with either olanzapine and risperidone, based on asking those patients or their 
caregivers, by face-to-face interviews or telephone interviews, are presented as follows: 
A total of 41 patients with BPSD were using risperidone for their treatment. From these 
patients, 11 patients had stopped taking the risperidone drug. In addition, there were three 
patients of this group who were lost to follow-up in that time of assessment and a patient 
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unfortunately for their family died. The remaining 26 risperidone-treated patients rated the 
improvement on average at level 3, (moderately improved).  
For the group being treated with olanzapine there were also a total of 41 patients. Nine 
patients stopped the olanzapine treatment. Furthermore, two patients were lost to follow up 
for their appointments and unfortunately again one patient died in this group. A total of 29 
patients appraised the improvement based on the olanzapine treatment associated with level 
4, (much improved). 
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Appendix 7: Publication 
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